<SEC-DOCUMENT>0001274737-21-000044.txt : 20210511
<SEC-HEADER>0001274737-21-000044.hdr.sgml : 20210511
<ACCEPTANCE-DATETIME>20210511171043
ACCESSION NUMBER:		0001274737-21-000044
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210511
DATE AS OF CHANGE:		20210511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39049
		FILM NUMBER:		21912389

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exdx-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:dc3d5bf2-9b73-4463-aa2c-e75c744aa8d3,g:734221f7-636e-4e71-b928-4b5e730d1da3,d:dffe191f32b5442996096aa67f5e278a--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:exdx="http://www.exagen.com/20210331" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exdx-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80L2ZyYWc6ZTAyNWI3YjgxMGE0NGU1OGFmOGY2NDYwOTdiYmY2NGYvdGFibGU6NGU1YTI1M2JkNDRkNDU1OGEzYjJkNDYyOGZiMjI3YjQvdGFibGVyYW5nZTo0ZTVhMjUzYmQ0NGQ0NTU4YTNiMmQ0NjI4ZmIyMjdiNF8zLTEtMS0xLTA_e717c702-7d49-4370-9d82-52afe57f170c">0001274737</ix:nonNumeric><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80L2ZyYWc6ZTAyNWI3YjgxMGE0NGU1OGFmOGY2NDYwOTdiYmY2NGYvdGFibGU6NGU1YTI1M2JkNDRkNDU1OGEzYjJkNDYyOGZiMjI3YjQvdGFibGVyYW5nZTo0ZTVhMjUzYmQ0NGQ0NTU4YTNiMmQ0NjI4ZmIyMjdiNF80LTEtMS0xLTA_b67796b5-53c0-404f-b322-d15cdeb645ea">12-31</ix:nonNumeric><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80L2ZyYWc6ZTAyNWI3YjgxMGE0NGU1OGFmOGY2NDYwOTdiYmY2NGYvdGFibGU6NGU1YTI1M2JkNDRkNDU1OGEzYjJkNDYyOGZiMjI3YjQvdGFibGVyYW5nZTo0ZTVhMjUzYmQ0NGQ0NTU4YTNiMmQ0NjI4ZmIyMjdiNF81LTEtMS0xLTA_d10c9814-b41f-46f0-851f-3b4cbd767535">2021</ix:nonNumeric><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80L2ZyYWc6ZTAyNWI3YjgxMGE0NGU1OGFmOGY2NDYwOTdiYmY2NGYvdGFibGU6NGU1YTI1M2JkNDRkNDU1OGEzYjJkNDYyOGZiMjI3YjQvdGFibGVyYW5nZTo0ZTVhMjUzYmQ0NGQ0NTU4YTNiMmQ0NjI4ZmIyMjdiNF82LTEtMS0xLTA_80eb3699-770c-40b9-95f1-d168f20d9d51">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80L2ZyYWc6ZTAyNWI3YjgxMGE0NGU1OGFmOGY2NDYwOTdiYmY2NGYvdGFibGU6NGU1YTI1M2JkNDRkNDU1OGEzYjJkNDYyOGZiMjI3YjQvdGFibGVyYW5nZTo0ZTVhMjUzYmQ0NGQ0NTU4YTNiMmQ0NjI4ZmIyMjdiNF83LTEtMS0xLTA_747005f5-9958-4c8f-8db8-749b6b600710">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ifd4d54f913db46d989b313ea1cf7787b_D20191101-20191130" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTExOQ_943420c3-685f-4155-98c0-99295e2c5baa">P24M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exdx-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ide9030e76ecf4a9fba67cf057c17afba_I20210507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="idc581bdd73dd4021b430c6ee34ea7187_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74dfc75aad9542dabc25c6d61005effa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cbaa66b7be7474ab7a46aa220c8660a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34cf1017273f4604809f912f8b657925_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i339ea458049d4a5487ec4a446348117a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6378bff170144726a0783fd0bb36c1bb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d7ae133aa7d4c2ca916c1a2f5aaeacb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i982e06fc73cd4df1b2177274c2d432e5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57d8609b6a10413a832521fbe6add4c6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ffb13c1b9d4b6c8256e8e5e1dcd383_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6df3369140bd4cb9a9d5f8e91adac83e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0bf96da109947f599efed58bc0f90d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0c6212cfa0f4ad388b89fa71d8bc8c3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icce72bac87624a92bdbfc5d01d2d86c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b221cae4dee43a2acc22fa21886929f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i504e33597e674687b5ef22eca9e130d4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i967f443c3ab8444dbe967bcd6f7b5174_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9a4e45c10a54a7a992104de496d6574_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14ddb9d17de4c8eb2f62cc86eb0451f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaa8db75f5344e35b666cc34a12c7d9e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3322be77d6de4025839cac63f86f0243_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5194501b750d4090955a5e16b78c217c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0fc61924d3f34ca4bab8516c11208885_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7ac61c025c245af88e7397f61447e69_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d9452d5c4c42f9bb942373684d2e42_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i834f47585cfe4c7d8a215294b1923d36_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f3ffd1dd835435c94a893df6356b1b1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i187e453a33374a7797711f58bcc14b7f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8a62a0ccfd34fca91b61d270f96dbfd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65a7a857be764806adc1eb00dcc35517_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id13f474ddf0d441ba77566815923f88a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i782e358e46694beb9624e9aa3ed858ea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i701b3c86d5b74909bf2e8bf593384649_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c299e56192b4127a3e3d90a1847d6f1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i023127e7d06344128078f124e3501be0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4184a1eb75de41ce9509149528c2c0aa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia721771017024f3f9f0c91f7b23abe19_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14c0363cf9954703ba1f808170614d1e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae6bedc762044534a4143ad3d0409cf0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1454a0a0df9044c6b9f918a3859fbdb2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ab1dd3b4a245ce9165116eabdb5ff9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76abec2d56de47129071a1dd6c7b2acb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1509c8e8724f4915b96a65425f3d99ee_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i905e56813efc44a0997851f5274917d7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2d9d310c7f94750b20d74e6de87c94a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c286444d4974baf83c59a97267301ea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if67771cd955c4c85bf332d7c2b0097d8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dd0a205cd3249ccb82b12ae5f6c2929_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ef52e13fcc4ac290fb3f3f17fc1d8e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib134284be93446ceb5f659fddbb92851_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic717b41edf9f4ff48d0b9b2e8087ccf9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035a93a2bf2f4d91913f3d26706f1810_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3f2c6ac308c4ed4a5dac4b72e609986_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>exdx:unit</xbrli:measure></xbrli:unit><xbrli:context id="i00bf9e1bcaa041139ea4e7b5f25c4a6e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccf1ab5f053e4f769295776a4596ca23_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bc7c41756524ddd9cc16ef0ee800e1b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8c4a64accf64f4e8d3c6f1c85c45656_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i545c29e8f1ac444a9fd4436eb738bd53_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie01b6015e94e40b18dbc9c1af60a487e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b7dc429b4b47a4a086f500297ae4f5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c36c4109874e448199eb8e55ebd4dc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id50b7c2e8d494f8c946e330ed5574198_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a1bd4a29ec4f84888bbc4981057e5b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8a1d1023b6a4f4db7161e28f63e8578_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib430868217a64c48beccdf7a906cd385_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56ebd098dbb0414199e0a1f304311104_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed20d5e060644a197e27c3b20c2b130_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide582e20a1564092a1d4f74f3cce4c9c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e1e4c97623d4b02a76aab4a8cd9dfc1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exdx:segment</xbrli:measure></xbrli:unit><xbrli:context id="icc9a7f02a64d485784bba6b218e085da_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib68a12746a0a43778d411a0e71f850e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e89c10b517a40da817bf9dd7fadec65_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if96214d4c6e24fdb959ba168df6a8af4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718a9b57c44f43859f8f20ce6569fbb6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87b062212901454892bd5210a1dbcd07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4a67b72dfa84dba92b35b0b41b493e2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0e64a9b4c5140059a5acbc43d92843a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84fefc5a1ec94437b3ba22e7b5a8b9da_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeea39a95a634c1f8fae5c44cf640d7a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea8e8125271042c2bd42020d228a5c4b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7261f22c88a04977b74b69ed970fe446_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49816a32de1a4847a965a660b298f0a0_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79bb007a0e4b4e11ad37da79ccacc407_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:CapitalRoyaltyPartnersIILPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9225dd725d3041c3897811c47544cbeb_D20181207-20181207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-07</xbrli:startDate><xbrli:endDate>2018-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic99585e2b612446894f42dbc14e98bc3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62c7962700564e34b08a1b062a8fb73a_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd4d54f913db46d989b313ea1cf7787b_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9517d690925b44e1b66094ac282a2fb8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a1d3210812c4ec99a01bc62b58c261b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe724be62e54f5e98c97114c1b16b4c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb1da3cc014a47988102c4a5fbfcdf4a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5600c9592fb46b690a5bc52e4c34fc2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i786adb20b67b40bfb36498bdace13f68_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibef5d76e001f48ab9c9f255b50909153_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51edebd2dc964c65960284e7a29563ad_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc8c434620fc4d7fa5e5804d5459e9c8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9300102ead9949fa9aa89415fe805f2a_D20210401-20210511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i526a9a0b5afe4cc1874bdb70a537e2e7_D20210401-20210511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf438e067e0e490e8bd11c8a8dfb7428_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d19acf05fd481bbbf64336028dc9c3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c9e78b389424e3ba420f778fc2889d9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d467b35645c46a0bc2317ac4c2edca0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf259d6549974c23a1e93dd4e55b13cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97ff3388db6d405984fbd5a85da92d27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f9e0cbbdb764f8195a783d55722eb00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98fb6a4c5e334327ad489b104eeff646_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fe73e79f1c549a483f3917d929c8e40_D20201110-20201110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-10</xbrli:startDate><xbrli:endDate>2020-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc1bb719e1074fdebd679404c35cd358_D20210325-20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ff8c067c394119ba0c56e9d82ededc_I20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c19a7a2bfad4edd8ddd7b2557ae3114_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i350d91760ddf4160af25d20cd8d9b448_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafc3772ba3454fac8749b13340ee0e47_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaea87b8242ef4b51bfab54bca764763b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i246430710e7b464984f4d6c04203b925_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb31a3a85da44447bf660e6e7ba47571_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c847c7e24b747288c96c2df35a0d98f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9740e39188bc48939564a399602a85af_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i205b83f91058431aacdac5b60d121b3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f7571bc1a6842eea4966067cef12287_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if56d5f147a234f47a5c286cd55a8ab8d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e686b941754a318cfceeff5fffc858_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb431306073e41619a17523f2b2e4c23_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b8c82dfa9c441afb9faca3a14a0e8c3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c0b8637038f4e0485961f9c7baa5391_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2512bb71fe984f9f8a14d808494366bf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id44b1e4210bc4a58b1886b02e42edda2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05daa2aed2c447f9b2aaf190a27f3d81_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i713b0e54a4ca43bfb3140d1b4aff6cd1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414d38c16c134af097eb843d3bb15bc4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbf102bb294e439ca5afd862c3fe6335_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idffe191f32b5442996096aa67f5e278a_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M184NA_1f0b1f23-6999-4d7a-aeb7-9f9f7b89e010">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Mark One) </span></div><div><span style="font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:115%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:2.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.026%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6ZWE1OWE5M2E5YTYwNDQ4MThmY2NlYzBkZWIzZTA1MzMvdGFibGVyYW5nZTplYTU5YTkzYTlhNjA0NDgxOGZjY2VjMGRlYjNlMDUzM18wLTAtMS0xLTA_690bc495-5a8a-4954-b7c0-10630a421ea3">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the quarterly period ended <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6ZWE1OWE5M2E5YTYwNDQ4MThmY2NlYzBkZWIzZTA1MzMvdGFibGVyYW5nZTplYTU5YTkzYTlhNjA0NDgxOGZjY2VjMGRlYjNlMDUzM18xLTAtMS0xLTAvdGV4dHJlZ2lvbjphNjY3Y2YxNGI4NmU0MDFlODg5MGU1NDBiOGFjMzNlM18zNg_74c58d09-6108-4468-b8ea-69f1c6cbc7bb">March&#160;31, 2021</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6ZWE1OWE5M2E5YTYwNDQ4MThmY2NlYzBkZWIzZTA1MzMvdGFibGVyYW5nZTplYTU5YTkzYTlhNjA0NDgxOGZjY2VjMGRlYjNlMDUzM18yLTAtMS0xLTA_dcb20ba0-d50f-49fc-9e92-d61cf8d0799c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Commission File Number: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M18xMzA_639943c5-53b2-46bb-812b-2901597e2e03">001-39049</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M18xMzQ_a996082c-c9a1-4112-b387-19c08b85ffa1">EXAGEN INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:0.1%"></td><td style="width:1.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MTkxYWFkZDYwMGJlNGQ5M2JmNzhjZTI5MmYxZDcwODEvdGFibGVyYW5nZToxOTFhYWRkNjAwYmU0ZDkzYmY3OGNlMjkyZjFkNzA4MV8wLTAtMS0xLTA_a0b54eeb-052b-4e13-9fa1-1e1c3f1e63f9">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MTkxYWFkZDYwMGJlNGQ5M2JmNzhjZTI5MmYxZDcwODEvdGFibGVyYW5nZToxOTFhYWRkNjAwYmU0ZDkzYmY3OGNlMjkyZjFkNzA4MV8wLTYtMS0xLTA_003a185d-8978-4673-9805-32c1e140e6bb">20-0434866</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MTkxYWFkZDYwMGJlNGQ5M2JmNzhjZTI5MmYxZDcwODEvdGFibGVyYW5nZToxOTFhYWRkNjAwYmU0ZDkzYmY3OGNlMjkyZjFkNzA4MV8zLTEtMS0xLTA_353131e6-7ac9-4498-8586-1011d0e05ffa">1261 Liberty Way</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MTkxYWFkZDYwMGJlNGQ5M2JmNzhjZTI5MmYxZDcwODEvdGFibGVyYW5nZToxOTFhYWRkNjAwYmU0ZDkzYmY3OGNlMjkyZjFkNzA4MV80LTEtMS0xLTA_070cf835-2607-4ca3-9ca0-ae6e1908a1ed">Vista,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MTkxYWFkZDYwMGJlNGQ5M2JmNzhjZTI5MmYxZDcwODEvdGFibGVyYW5nZToxOTFhYWRkNjAwYmU0ZDkzYmY3OGNlMjkyZjFkNzA4MV80LTItMS0xLTA_e8177e15-9f1c-4628-8cb2-4d8b6762b838">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MTkxYWFkZDYwMGJlNGQ5M2JmNzhjZTI5MmYxZDcwODEvdGFibGVyYW5nZToxOTFhYWRkNjAwYmU0ZDkzYmY3OGNlMjkyZjFkNzA4MV80LTYtMS0xLTA_0147b121-72f5-4f9d-b62d-610daf4c8130">92081</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.766%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MzlmNjVmNDBiNzZiNDA5OGI2NjU5ZmYwYWM0YWE0MmEvdGFibGVyYW5nZTozOWY2NWY0MGI3NmI0MDk4YjY2NTlmZjBhYzRhYTQyYV8wLTAtMS0xLTA_e9964966-66d0-404f-81e3-ba0fee7b3ce9">(760)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MzlmNjVmNDBiNzZiNDA5OGI2NjU5ZmYwYWM0YWE0MmEvdGFibGVyYW5nZTozOWY2NWY0MGI3NmI0MDk4YjY2NTlmZjBhYzRhYTQyYV8wLTEtMS0xLTA_f2531936-e76c-443e-b6ce-2c0d469e3b16">560-1501</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant's Telephone Number, Including Area Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:35.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.962%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MzQ2MjRhZDk0M2ZjNGJkZGJlYjFhNzY0YzE2NzUxZjkvdGFibGVyYW5nZTozNDYyNGFkOTQzZmM0YmRkYmViMWE3NjRjMTY3NTFmOV8xLTAtMS0xLTA_48b5e9ec-0318-4d5a-90e8-9192ed835707">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MzQ2MjRhZDk0M2ZjNGJkZGJlYjFhNzY0YzE2NzUxZjkvdGFibGVyYW5nZTozNDYyNGFkOTQzZmM0YmRkYmViMWE3NjRjMTY3NTFmOV8xLTItMS0xLTA_d5657030-71be-482a-8c87-3669c53f48bf">XGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MzQ2MjRhZDk0M2ZjNGJkZGJlYjFhNzY0YzE2NzUxZjkvdGFibGVyYW5nZTozNDYyNGFkOTQzZmM0YmRkYmViMWE3NjRjMTY3NTFmOV8xLTQtMS0xLTA_abd56325-f213-4dcc-ba85-49c41799423e">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M182MDM_1b8b7f49-03a4-4b69-8451-7f6feedc40c9">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M185MDU_06495b7f-1656-4a94-bf1b-b14baa3ba892">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:20.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6Mzk1NGEzMzYzNGFjNDUxZTlhMDkwYTM3MDY2NDZkZDcvdGFibGVyYW5nZTozOTU0YTMzNjM0YWM0NTFlOWEwOTBhMzcwNjY0NmRkN18yLTAtMS0xLTA_0a395365-d1f7-4586-a01f-101a68730a42">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6Mzk1NGEzMzYzNGFjNDUxZTlhMDkwYTM3MDY2NDZkZDcvdGFibGVyYW5nZTozOTU0YTMzNjM0YWM0NTFlOWEwOTBhMzcwNjY0NmRkN18yLTQtMS0xLTA_130baf7e-3044-45df-b2c0-a790fb41fb9e">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6Mzk1NGEzMzYzNGFjNDUxZTlhMDkwYTM3MDY2NDZkZDcvdGFibGVyYW5nZTozOTU0YTMzNjM0YWM0NTFlOWEwOTBhMzcwNjY0NmRkN180LTQtMS0xLTA_4152a543-9c56-4a33-8c0b-60555df009e1">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Securities Act&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M18xNTM5_5e31cb8f-9ff1-417f-bd63-6a00d353610f">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M18xNjU5_a7e60e1b-6182-459e-9032-a6f2239d3b40">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares of common stock outstanding as of the close of business on May&#160;7, 2021 was <ix:nonFraction unitRef="shares" contextRef="ide9030e76ecf4a9fba67cf057c17afba_I20210507" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M18xNzQ2_fa8126a8-8141-4c81-a7b7-c5140a52c235">16,928,278</ix:nonFraction>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idffe191f32b5442996096aa67f5e278a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_13">Condensed Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_16">Condensed Balance Sheets as of March 31, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_19">Condensed Statements of Operations for the Three Months ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_22">Condensed Statements of Stockholders' Equity for the Three Months ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_25">Condensed Statements of Cash Flows for the Three Months ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_28">Notes to Unaudited Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_64">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_64">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_79">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_79">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_82">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_82">30</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_88">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_88">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_91">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_91">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_94">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_94">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_97">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_97">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_100">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_100">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_103">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_103">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_106">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_106">35</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_109">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idffe191f32b5442996096aa67f5e278a_109">36</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="idffe191f32b5442996096aa67f5e278a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_13"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I. Financial Information</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Condensed Financial Statements</span></div><div id="idffe191f32b5442996096aa67f5e278a_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNC00LTEtMS0w_035cceaa-a444-4370-b461-364bf972f22a">118,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNC02LTEtMS0w_b950158c-c2df-4faf-a29b-fe0f5b5c9d28">57,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNS00LTEtMS0w_5ed4fe2b-2e63-4c1d-8c70-6726c33f6516">8,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNS02LTEtMS0w_e7dfe626-872a-42ef-ae1d-b9c4e78dd59c">8,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNi00LTEtMS0w_1930151b-171e-4253-9c9e-879804c8be13">3,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNi02LTEtMS0w_d9fc2edf-43ef-4075-ab82-bc019d23849c">4,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNy00LTEtMS0w_476c5eed-39ce-4f3d-bc99-dda53d497bdc">129,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNy02LTEtMS0w_bcb29a03-9537-42aa-b6ee-25a1d2020a11">70,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfOC00LTEtMS0w_48414c0e-7fb7-405f-a871-f01b080c3552">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfOC02LTEtMS0w_ce495af6-ec56-424d-b5b7-a420fe482f6a">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfOS00LTEtMS0w_63f4a12a-6aab-4f45-858f-ea1d6b499353">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfOS02LTEtMS0w_ec0f7ce8-06cf-4a1c-bb9b-0afad0c2b5b1">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTAtNC0xLTEtMA_09c89d53-7089-480d-aedb-87dcce8fc43a">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTAtNi0xLTEtMA_30b7678c-3643-4f93-bc1e-80f74f9e9005">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTEtNC0xLTEtMA_40afe4cf-3382-46b6-a7b8-b8f7c1e13cf3">137,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTEtNi0xLTEtMA_01f48b5f-773d-448f-9c97-ba314eefcf92">78,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTQtNC0xLTEtMA_432c3b81-171f-4170-b4c9-7e3ad0fc860b">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTQtNi0xLTEtMA_3536dbe1-853b-4aae-856d-4c2877e9a781">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTUtNC0xLTEtMA_e192623e-d6a3-4a7a-be57-be86d6d7c52f">5,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTUtNi0xLTEtMA_c7a284ef-12ac-4343-9fd9-95b8ea99d342">5,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTctNC0xLTEtMA_785328a2-bf40-4cf3-bf35-cc689b61b5a4">7,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTctNi0xLTEtMA_a14ea70d-5111-4f31-ae35-feb57157f576">8,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTgtNC0xLTEtMA_20761bf6-c3b1-43c9-9f9e-519c81f993c9">26,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTgtNi0xLTEtMA_2159f3ad-9933-4348-9252-80676fd58226">26,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjAtNC0xLTEtMA_ee95b45d-b272-40c5-aeeb-f2c44b90f5c5">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjAtNi0xLTEtMA_4a7cb1b3-4b98-406a-94e9-7038db9d4fe9">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjEtNC0xLTEtMA_e37605a4-5d02-4f56-aaf6-6c64793c4fb3">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjEtNi0xLTEtMA_66ecb717-a151-45b3-80bd-f2ba98165f33">948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjItNC0xLTEtMA_ea7033f7-e019-4683-85a3-5ca345a2dfaa">36,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjItNi0xLTEtMA_980bdb73-bed9-45ea-8ff9-1c0cd6dbabe6">36,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjMtNC0xLTEtMA_0476a057-413e-4b9e-9e45-3b24943014ed"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjMtNi0xLTEtMA_e2a677ac-06e5-4304-b08c-edfdd870efe8"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzIx_b072b05a-9fe0-4016-98c6-ece7760de2c0"><ix:nonFraction unitRef="usdPerShare" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzIx_f4ff17ec-bd43-4ddb-a5fd-5a651b4eefc1">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzM1_b736ce25-ca89-4c3e-a2f2-124e2e04fc2f"><ix:nonFraction unitRef="shares" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzM1_d4834439-80a1-44fb-bb63-27c859b3697c">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzU3_1006d159-0cad-45c9-a97f-ba2b07778abb"><ix:nonFraction unitRef="shares" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzU3_1327319c-c7d8-4b51-83c0-f3990e1d847d"><ix:nonFraction unitRef="shares" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzU3_3c4b2a3b-d842-4eed-9809-f5aad3ddd736"><ix:nonFraction unitRef="shares" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzU3_bb78c9a7-2e43-426b-9659-81a4c99d4203">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at March&#160;31, 2021 and December 31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtNC0xLTEtMA_74c63ac8-4f8e-46df-a7a6-a7a9d4cd6a0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtNi0xLTEtMA_feee8381-b6e1-4036-a861-a8348401204f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzE4_0fe55bd2-c2f4-4800-b66e-cd48c15dc9d5"><ix:nonFraction unitRef="usdPerShare" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzE4_1ea3ce9f-7a15-428c-9a29-2e825af99e24">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzMy_668b541b-f843-4e17-9b39-3e2452d94686"><ix:nonFraction unitRef="shares" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzMy_d54a13b9-ff81-48c9-8c94-3735ef5258af">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzgy_ede2dbd8-ec0e-4757-aa82-16ebdc4d4802"><ix:nonFraction unitRef="shares" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzgy_f82ef43c-47e9-4b1f-be3a-77dc53993ed3">16,925,680</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzg5_144121db-23ff-459f-9512-fbe814a540ad"><ix:nonFraction unitRef="shares" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzg5_e11352c8-346c-4edc-bc09-97729922c23a">12,652,308</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctNC0xLTEtMA_c2c2745e-8c62-4f09-90cc-7fc62608e651">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctNi0xLTEtMA_557919f9-3f5f-4318-9458-ce068ef4db81">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjgtNC0xLTEtMA_c91be3bb-30a4-45be-910f-10b2dff5e918">288,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjgtNi0xLTEtMA_d64af3ee-c0cb-4cd0-bc3a-a0a63de8071b">223,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjktNC0xLTEtMA_ba894114-d769-41de-abf6-6155531050ec">187,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjktNi0xLTEtMA_d59cb93b-03c0-4ef4-966c-66ba05917062">181,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMzAtNC0xLTEtMA_5b4c7c48-3d1d-41c5-88b5-7a5c62559516">101,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMzAtNi0xLTEtMA_23568b4b-6167-401e-bcbc-ac8a3d2e1b5b">41,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMzEtNC0xLTEtMA_828e2a6a-26f5-4dbd-822e-98955cfabca5">137,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMzEtNi0xLTEtMA_d1419be9-e907-4119-892f-0763595ff650">78,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="idffe191f32b5442996096aa67f5e278a_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Condensed Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMy0yLTEtMS0w_221a90dc-f389-433c-9c4a-9e48c0b1be97">10,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMy00LTEtMS0w_49300834-081e-4bdf-a025-7b87cb876fcb">9,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfNS0yLTEtMS0w_b0defe58-a964-443b-b986-1c0636030620">4,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfNS00LTEtMS0w_1eadd5cb-305f-472e-8ec0-03d002bc5084">4,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfNi0yLTEtMS0w_e5c80890-ba1b-4d4b-98c1-2ae0259440eb">10,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfNi00LTEtMS0w_391961fa-b8c6-4533-97d8-de3900d54c84">9,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfNy0yLTEtMS0w_98bbe8cc-e312-41bd-a94c-1e9a542a394d">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfNy00LTEtMS0w_bc20b943-fc7e-4189-be73-6e54cebd1c8f">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTAtMi0xLTEtMA_39998fd9-5bd7-4fbc-b2ec-650f6b2b7aea">16,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTAtNC0xLTEtMA_991a6d97-31a7-4f86-9f0b-3419185835e0">14,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTEtMi0xLTEtMA_9ebdba5f-27a9-4da4-8211-c12815f8be13">5,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTEtNC0xLTEtMA_655f025c-13d7-4911-be5b-ad7e263ebf92">5,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTItMi0xLTEtMA_b34220b1-ee91-4570-874f-34b134211be8">645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTItNC0xLTEtMA_be0097da-762b-4343-9de3-b7d4f21136ba">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTQtMi0xLTEtMA_55379f09-b07f-408c-8b68-1a3068937d96">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTQtNC0xLTEtMA_027991b9-4b06-42e4-8a7e-224e44c0e20b">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTUtMi0xLTEtMA_4c7831ee-0abd-4862-a9e4-dfadbaf13d61">6,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTUtNC0xLTEtMA_641dcda2-1554-4a0d-b54a-cb3990bd8585">5,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTYtMi0xLTEtMA_36ae5d1a-0ebb-4311-9196-615822d3e8ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTYtNC0xLTEtMA_7b1fe556-34fe-4083-a5a4-5f5aed1e1619">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTctMi0xLTEtMA_856e0317-479f-48e9-87bf-3adbd8ec92e3">6,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTctNC0xLTEtMA_90bb43f7-707d-409b-bdcb-bcdb6bccabec">5,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMjEtMi0xLTEtMA_2e97007c-d247-4dd6-9ffa-11480f4ac4fe">0.48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMjEtNC0xLTEtMA_fdfe049b-57de-48aa-9c27-9d769d27950a">0.44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of shares used to compute net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMjItMi0xLTEtMA_fc8d6154-7d8b-4a79-9a44-3f8fd6f5f237">12,943,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMjItNC0xLTEtMA_5e0fb54c-882d-4e91-a9c3-f2a5322af466">12,595,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="idffe191f32b5442996096aa67f5e278a_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Unaudited Condensed Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7cbaa66b7be7474ab7a46aa220c8660a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMi0yLTEtMS0zNA_bf5ccd06-33f7-4c0e-a7cb-5a4689c050a1">12,652,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cbaa66b7be7474ab7a46aa220c8660a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMi00LTEtMS0zNA_6fe012b2-c16a-4e21-8801-1bac39d49ca7">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34cf1017273f4604809f912f8b657925_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMi02LTEtMS0zNA_7d37ccb4-91a2-4b8c-934a-85e6e706797c">223,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i339ea458049d4a5487ec4a446348117a_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMi04LTEtMS0zNA_1bf90445-b2b4-4f22-a643-f2ad391ead6c">181,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMi0xMC0xLTEtMzQ_85ced39d-9fa9-4fed-9cd3-31d8f9ac1f24">41,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock in public offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="exdx:StockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy0wLTEtMS0xNjg4L3RleHRyZWdpb246NjMyOTIxYjU4MjgxNDUwNDg5Y2ZhMThmYTQ2ZWEyMWJfMTA5OTUxMTYyNzg1MQ_d02ae006-3c56-4a50-a3a8-5ed290f635d0">4,435</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6378bff170144726a0783fd0bb36c1bb_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy0yLTEtMS0zNjc_920a5a87-b14e-4be7-a9a0-80270362234f">4,255,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6378bff170144726a0783fd0bb36c1bb_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy00LTEtMS0zNzE_d210a31b-8b50-418d-8565-a47deb0be9d1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7ae133aa7d4c2ca916c1a2f5aaeacb_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy02LTEtMS0zNzU_5b41726d-6003-423a-b2a5-f3dcbb437dd7">64,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy0xMC0xLTEtNjU_b0881b39-9e3f-4cb1-b96d-0b6c7005d73b">64,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6378bff170144726a0783fd0bb36c1bb_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy0yLTEtMS0zNA_988e0e0e-61e3-4e13-83c5-6864a4f34df1">3,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7ae133aa7d4c2ca916c1a2f5aaeacb_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy02LTEtMS0zNA_673eae83-5774-45a0-8bc1-26b758f81113">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy0xMC0xLTEtMzQ_e539e9d6-6b30-48b3-bcc5-da7e21f53e13">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6378bff170144726a0783fd0bb36c1bb_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNS0yLTEtMS0zNjc_664af82e-7b7e-4774-874e-c628ae9f4b5d">14,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7ae133aa7d4c2ca916c1a2f5aaeacb_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNS02LTEtMS0zNzU_501a67ae-a238-47a2-b202-3fb9f14c1644">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNS0xMC0xLTEtNjU_773840be-34a4-4c3b-aa24-d5d102da6b03">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7ae133aa7d4c2ca916c1a2f5aaeacb_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNC02LTEtMS0zNA_6aa18692-9852-49aa-bbe7-449fca1ce86f">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNC0xMC0xLTEtMzQ_740f18d1-a908-4736-ac84-35939c7d2317">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i982e06fc73cd4df1b2177274c2d432e5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNi04LTEtMS0zNA_71cc7c63-7291-45eb-b204-c9d7b50a8a09">6,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNi0xMC0xLTEtMzQ_821de086-11a8-4fb7-b32e-a0107e509fe3">6,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57d8609b6a10413a832521fbe6add4c6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNy0yLTEtMS0zNA_dc2468c3-b6ba-4cfa-8ce1-0ab50f2ed361">16,925,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d8609b6a10413a832521fbe6add4c6_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNy00LTEtMS0zNA_6629414f-2713-4e01-8c29-8eb755a453e5">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ffb13c1b9d4b6c8256e8e5e1dcd383_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNy02LTEtMS0zNA_83e6c2e1-e751-438b-9083-591165ead299">288,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6df3369140bd4cb9a9d5f8e91adac83e_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNy04LTEtMS0zNA_c4e2bb4b-1e69-4e31-b15f-1b8835bb10ee">187,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNy0xMC0xLTEtMzQ_e799f309-1677-4ef3-81cc-404b261cbdb9">101,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0bf96da109947f599efed58bc0f90d9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMi0yLTEtMS0w_0a59b7e2-6d59-495b-b519-35b94fc4eef4">12,560,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0bf96da109947f599efed58bc0f90d9_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMi00LTEtMS0w_59b636c8-9a4e-4613-ba3a-1d79ce381e8e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0c6212cfa0f4ad388b89fa71d8bc8c3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMi02LTEtMS0w_29394b68-229d-4587-a48b-9c3de1845154">220,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icce72bac87624a92bdbfc5d01d2d86c1_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMi04LTEtMS0w_004d66a5-c65c-4571-b047-a1e2d29c5b7a">164,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b221cae4dee43a2acc22fa21886929f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMi0xMC0xLTEtMA_06d038c3-0586-4cb0-80d9-ed897f1ead97">55,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i504e33597e674687b5ef22eca9e130d4_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMy0yLTEtMS0w_ba624ab7-a040-4ec3-940d-115336440f7d">43,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i967f443c3ab8444dbe967bcd6f7b5174_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMy02LTEtMS0w_70899d7c-9ce1-4373-989e-089192325fee">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMy0xMC0xLTEtMA_4fb32fc0-c4e4-4bf7-9891-e2aa18d35f5f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i967f443c3ab8444dbe967bcd6f7b5174_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNC02LTEtMS0w_b38d59a1-a3fd-4792-a171-9f49befd2de6">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNC0xMC0xLTEtMA_5a27c60e-7005-48ee-8099-2f76fa74a810">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net exercise of common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i504e33597e674687b5ef22eca9e130d4_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNS0yLTEtMS0w_649d2a99-41bf-431e-be03-b53d81263e02">22,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNS0xMC0xLTEtMA_fc0a65cf-6e5b-4535-a50e-671de1d0d289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9a4e45c10a54a7a992104de496d6574_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNi04LTEtMS0w_ec4db218-074e-4de8-8064-975a46831f87">5,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNi0xMC0xLTEtMA_92099b96-0fb1-4170-849f-b76fcd08dc51">5,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March&#160;31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia14ddb9d17de4c8eb2f62cc86eb0451f_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNy0yLTEtMS0w_e7e97a79-5591-44fa-912e-b1a373814672">12,627,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14ddb9d17de4c8eb2f62cc86eb0451f_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNy00LTEtMS0w_0816f30d-78e1-4729-b97e-a82215b0e23d">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa8db75f5344e35b666cc34a12c7d9e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNy02LTEtMS0w_93852018-54eb-42e7-b538-a5fbe725b6ac">220,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3322be77d6de4025839cac63f86f0243_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNy04LTEtMS0w_ec2d7c80-65b2-4123-a2ea-ae305e5b99ed">170,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5194501b750d4090955a5e16b78c217c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNy0xMC0xLTEtMA_7f9f26b5-0667-457d-ab49-cd37d9f2700a">50,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="idffe191f32b5442996096aa67f5e278a_25"></div><hr style="page-break-after:always"/><div style="min-height:24.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Unaudited Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNC02LTEtMS0w_1b05014e-7f82-48ca-a653-e5f2896f134e">6,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNC04LTEtMS0w_31b3f44d-9eee-4482-adce-d550407fda09">5,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNi02LTEtMS0w_4768c95d-ab6c-4363-866d-1a026114cfda">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNi04LTEtMS0w_51c98853-81a1-47af-9cc1-1445599ace48">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNy02LTEtMS0w_10828e28-e17b-4334-95b8-2576a957bace">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNy04LTEtMS0w_56032c2f-674b-4ad6-8a68-59122f4593df">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfOC02LTEtMS0w_5235202e-4880-4749-aa0e-a7644f4938a5">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfOC04LTEtMS0w_d54e4234-3f24-4172-afeb-21e4b3926c41">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTAtNi0xLTEtMA_cca59a31-e245-4ce2-a674-bcaa7787d521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTAtOC0xLTEtMA_d53db411-1ced-4e61-b2fc-c935a88c6cda">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTItNi0xLTEtMA_750156fe-d990-40ed-9596-8b6f2b3102cd">912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTItOC0xLTEtMA_d560f452-c347-4f3b-9808-3d2b22c10dbe">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTQtNi0xLTEtMA_55951b54-0889-40f3-9cef-fa925f538d8f">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTQtOC0xLTEtMA_d5f7a26c-30eb-4618-96d4-a58f4d0453c3">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTUtNi0xLTEtMA_2cfaf22b-0167-4b50-ac0e-7a9219013edc">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" sign="-" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTUtOC0xLTEtMA_edaf1938-cb87-417c-a801-b9507993218d">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTYtNi0xLTEtMA_be2afbae-40cf-4e75-8948-986d61edebcd">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTYtOC0xLTEtMA_6bc263f7-40e2-42c9-8553-b6d6f4c218a0">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTctNi0xLTEtMA_85cf803e-d5eb-44af-a38c-7b5f2b010ee2">792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTctOC0xLTEtMA_b3784aef-7d7b-4a47-b712-29175236121a">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTgtNi0xLTEtMA_835c65f4-ba97-4244-8b98-0dfc70edcaa0">317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTgtOC0xLTEtMA_03ee8647-c45f-4ef5-bc1a-f64fcb0a9f58">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjAtNi0xLTEtMA_1acad6ea-3689-4a9f-9fce-502d27226686">4,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjAtOC0xLTEtMA_19f06527-7376-45f5-bb32-5b7bd0b16736">3,301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjItNi0xLTEtMA_a75b88df-796d-41a9-9179-149b5ba78ec9">167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjItOC0xLTEtMA_40f89807-0058-4bb2-8b1c-c9bcd30c5831">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjYtNi0xLTEtMA_2dc5bef9-7e49-4eca-8eb8-e1b3d915a131">167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjYtOC0xLTEtMA_9cfe026c-999c-4847-aad9-5cbe30ae4cce">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjgtNi0xLTEtMA_0b6083f9-7b1e-4c1c-8815-fba8032ab33c">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjgtOC0xLTEtMA_b4188b8e-26af-47b5-8ecc-3898b82e115e">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from common stock issued under Employee Stock Purchase Pan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjktNi0xLTEtMA_c080b5f3-f7cf-4865-b7f2-0beb8ed197aa">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjktOC0xLTEtMA_5451f723-39db-4a55-be9b-e62cee38252b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payment on capital lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMzEtNi0xLTEtMA_4b9fbc7e-bd33-4dda-9ada-b4449fc8ab33">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMzEtOC0xLTEtMA_ff04320c-842e-4f2c-82c1-a751ff8e5066">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock in public offering, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMzUtNi0xLTEtODc_536dff7c-afab-41eb-9b72-4adc6ccfc086">69,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMzUtOC0xLTEtODM_13d59ed8-07d8-4a94-b769-11996cb7ab29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of issuance costs related to public offering</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMzYtNi0xLTEtMjg3NA_6f064150-96f8-43ca-9e14-43df981bc850">4,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMzYtOC0xLTEtMjg3NA_565cbb06-5f05-4d75-bd46-319051cfea0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDAtNi0xLTEtMA_fac7f737-dc92-430b-adad-198ba73adaa2">65,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDAtOC0xLTEtMA_3d7ccadd-f972-4d6e-88ab-76b11c6d31c9">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDEtNi0xLTEtMA_1e7486e9-1e83-49f8-b224-b5e73b443fc7">60,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDEtOC0xLTEtMA_f64794fa-6d30-483d-87d8-2d980e7b2cb0">3,436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDItNi0xLTEtMA_0e9d638e-c4e6-4aa1-9515-bb8ab78906eb">57,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b221cae4dee43a2acc22fa21886929f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDItOC0xLTEtMA_0ce85d3c-c9ee-45d5-a307-9dd887417632">72,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDMtNi0xLTEtMA_cd3d2894-429c-4ca3-bda3-5658285578d9">118,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5194501b750d4090955a5e16b78c217c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDMtOC0xLTEtMA_6bd95658-b551-48c6-bbc5-2cee5956dfb7">68,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDUtNi0xLTEtMA_38cd809d-bf93-4319-b3c0-b08f33ca707f">439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDUtOC0xLTEtMA_68c06645-4c6d-41c6-ac1a-fa16900dc98c">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment purchased under capital lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="exdx:EquipmentPurchasedUnderCapitalLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDgtNi0xLTEtMA_704345b5-9931-4e1c-aff2-0e50f5bf72ce">384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="exdx:EquipmentPurchasedUnderCapitalLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDgtOC0xLTEtMA_9895dbdd-75f1-41e0-9682-82d98c6922d3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs incurred, but not paid, in connection with capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNTAtNi0xLTEtMA_5d8d26d2-21c2-46df-8b77-5d1881f4c1d9">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNTAtOC0xLTEtMA_61d45864-1e02-4978-bb8b-9165abcb09f2">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs included in accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNTMtNi0xLTEtMA_194f9ac3-b2a7-435e-ae6f-31c075a80391">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNTMtOC0xLTEtMA_0323d176-1c55-4890-aedc-fe6c800ceea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred offering costs reclassified to equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="exdx:DeferredOfferingCostsReclassifiedToEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNTUtNi0xLTEtMTU4Nw_bdf79530-42cc-4120-a227-e262a0b1ddba">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="exdx:DeferredOfferingCostsReclassifiedToEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNTUtOC0xLTEtMTU4Nw_5ee876c2-30f4-4eb7-9323-a844635bcff6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="idffe191f32b5442996096aa67f5e278a_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_31"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zMS9mcmFnOjM3YmRhZmYxMGQyMDQwMzU5YmVhMmIxZjc2ZGIzMWJmL3RleHRyZWdpb246MzdiZGFmZjEwZDIwNDAzNTliZWEyYjFmNzZkYjMxYmZfMjU2NA_2de3aee8-f286-4430-9d7b-da054a73db99" continuedAt="i4c12ec5681824cf19f4a71aa22cfb1b8" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i4c12ec5681824cf19f4a71aa22cfb1b8"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exagen Inc. (the Company) is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At March&#160;31, 2021, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zMS9mcmFnOjM3YmRhZmYxMGQyMDQwMzU5YmVhMmIxZjc2ZGIzMWJmL3RleHRyZWdpb246MzdiZGFmZjEwZDIwNDAzNTliZWEyYjFmNzZkYjMxYmZfMTAxMQ_ec4cc064-ed87-44af-92c4-3bd363f8a086">118.1</ix:nonFraction> million and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zMS9mcmFnOjM3YmRhZmYxMGQyMDQwMzU5YmVhMmIxZjc2ZGIzMWJmL3RleHRyZWdpb246MzdiZGFmZjEwZDIwNDAzNTliZWEyYjFmNzZkYjMxYmZfMTA0OA_0ca11d32-ce75-4e89-a6b7-ee65c38589b8">187.5</ix:nonFraction> million. Since inception, the Company has financed its operations primarily through a combination of equity financings of common stock and private placements of preferred securities, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div></ix:continuation><div id="idffe191f32b5442996096aa67f5e278a_34"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzU_7117a360-13ab-4f6d-a2cf-ba999ad9d4b7" continuedAt="id4db6ef796954a76ad99a989ef346073" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="id4db6ef796954a76ad99a989ef346073" continuedAt="i8ce81c9000d4462dbbc99ccef9adbec2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed balance sheet as of March&#160;31, 2021, the condensed statements of operations and the condensed statements of stockholders' equity for the three months ended March&#160;31, 2021 and 2020 and cash flows for the three months ended March&#160;31, 2021 and 2020 and the related footnote disclosure are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments, necessary for the fair presentation of the Company's financial position as of March&#160;31, 2021 and its results of operations for the three month periods presented. The results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December 31, 2020, included in its Annual Report on Form 10-K filed with the SEC on March 16, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8ce81c9000d4462dbbc99ccef9adbec2" continuedAt="id749392bb42048f4b69b78e2e065d88d"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill) and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNjY_90d7cd5d-3be3-41d2-90a7-bbb829091868" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzY_b1476be1-4c5d-4389-9dbb-0d2e6cd37b4c" continuedAt="i09df7323507945a2b27dbb8a04dbdcfb" escape="true">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</ix:nonNumeric></span></div><ix:continuation id="i09df7323507945a2b27dbb8a04dbdcfb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0fc61924d3f34ca4bab8516c11208885_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfMy0yLTEtMS0w_4da1a9b8-d2c9-469e-89f1-3bf5eb00d633">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7ac61c025c245af88e7397f61447e69_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfMy00LTEtMS0w_8150a560-d070-4b84-94bd-74b51c31000b">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21d9452d5c4c42f9bb942373684d2e42_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfNS0yLTEtMS0w_960a8c97-6efb-404c-b4ce-c995cde701fa">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i834f47585cfe4c7d8a215294b1923d36_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfNS00LTEtMS0w_0e4bee87-687d-4a02-a64f-64bea083dcd9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f3ffd1dd835435c94a893df6356b1b1_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfNi0yLTEtMS0w_97b97cb8-8de5-4d01-92f5-3efb91003c75">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i187e453a33374a7797711f58bcc14b7f_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfNi00LTEtMS0w_d83e25fb-aa2c-48e5-8d70-b93ec8017a4f">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8a62a0ccfd34fca91b61d270f96dbfd_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfNy00LTEtMS0w_7517399d-e073-42c8-bf7d-8aa00e9d2eb4">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65a7a857be764806adc1eb00dcc35517_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjZjM2E5YWRlYjM4NjQzMzg4ZGM3NGM4MDZmNTJiZWI2L3RhYmxlcmFuZ2U6NmMzYTlhZGViMzg2NDMzODhkYzc0YzgwNmY1MmJlYjZfMy00LTEtMS0w_fd6a3d03-9aac-4ba8-8cf9-d8a0d2a6aff6">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id13f474ddf0d441ba77566815923f88a_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjZjM2E5YWRlYjM4NjQzMzg4ZGM3NGM4MDZmNTJiZWI2L3RhYmxlcmFuZ2U6NmMzYTlhZGViMzg2NDMzODhkYzc0YzgwNmY1MmJlYjZfMy02LTEtMS0w_b8175739-2a10-406d-bb52-93b7dda74032">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i782e358e46694beb9624e9aa3ed858ea_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjZjM2E5YWRlYjM4NjQzMzg4ZGM3NGM4MDZmNTJiZWI2L3RhYmxlcmFuZ2U6NmMzYTlhZGViMzg2NDMzODhkYzc0YzgwNmY1MmJlYjZfNS00LTEtMS0w_23830b58-c9c4-4e5f-aa62-fb8a41ba352c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i701b3c86d5b74909bf2e8bf593384649_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjZjM2E5YWRlYjM4NjQzMzg4ZGM3NGM4MDZmNTJiZWI2L3RhYmxlcmFuZ2U6NmMzYTlhZGViMzg2NDMzODhkYzc0YzgwNmY1MmJlYjZfNS02LTEtMS0w_d2f679fe-3afe-4c1c-8e78-1a91f2b234fe">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, approximately <ix:nonFraction unitRef="number" contextRef="i2c299e56192b4127a3e3d90a1847d6f1_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzgzMw_e01a8157-3527-4c8a-871e-935ce0b51e9f">81</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i023127e7d06344128078f124e3501be0_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0MQ_3bd1f408-a19e-4b2f-b41a-24682fbf5804">83</ix:nonFraction>%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on key suppliers for certain laboratory materials. For the three months ended March&#160;31, 2021 and 2020, approximately <ix:nonFraction unitRef="number" contextRef="i4184a1eb75de41ce9509149528c2c0aa_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfNDE4OQ_8fe99d3c-f322-461b-93d3-b04284df2377">98</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia721771017024f3f9f0c91f7b23abe19_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfNDE5Ng_415559f4-4020-49cb-9187-04f3b62701bf">96</ix:nonFraction>%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNjc_90656f09-e998-4907-9499-962ff859f771" continuedAt="i66dc8437a5634004946b91fbd619283b" escape="true">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id749392bb42048f4b69b78e2e065d88d" continuedAt="i43c22eba3d4340459530371c60b16650"><ix:continuation id="i66dc8437a5634004946b91fbd619283b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c0363cf9954703ba1f808170614d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfMy0yLTEtMS0w_75097fc6-08b0-4aa7-b3df-ac8c042a50d3">6,027</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6bedc762044534a4143ad3d0409cf0_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfMy00LTEtMS0w_df98076d-3141-4948-beb8-e381fc3ca3d3">6,062</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1454a0a0df9044c6b9f918a3859fbdb2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNC0yLTEtMS0w_1127d739-6749-44e1-9efe-0fe20e3cb652">2,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ab1dd3b4a245ce9165116eabdb5ff9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNC00LTEtMS0w_09b0c4cd-8336-4f05-976e-a01d1b128067">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76abec2d56de47129071a1dd6c7b2acb_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNS0yLTEtMS0w_31186eb3-fd79-4f22-8bed-af56d0b000df">1,965</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1509c8e8724f4915b96a65425f3d99ee_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNS00LTEtMS0w_fa1ad752-9a3e-4dae-a449-466d532487b0">1,082</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905e56813efc44a0997851f5274917d7_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNi0yLTEtMS0w_ea142478-6092-4d22-a0d0-e318cfa41a0b">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d9d310c7f94750b20d74e6de87c94a_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNi00LTEtMS0w_30356c52-5f61-4380-bf54-33025dddea95">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c286444d4974baf83c59a97267301ea_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNy0yLTEtMS0w_27003074-c00d-4a71-a7df-8ac1955c4855">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67771cd955c4c85bf332d7c2b0097d8_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNy00LTEtMS0w_d1124cd9-213f-4f43-99e8-9690c22d5787">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfOC0yLTEtMS0w_5304296b-dcfc-4396-a646-e94f5cb6643b">10,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfOC00LTEtMS0w_a55905c2-69e0-4efe-ad7d-abb0d46ee2d9">9,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay that is immaterial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODE_9cb497cf-88fd-4f00-9727-3b597a7217f8" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODI_1c870f71-c410-49dc-8da3-db6bf8abc573" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $<ix:nonFraction unitRef="usd" contextRef="i1dd0a205cd3249ccb82b12ae5f6c2929_I20161231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfNjkwNA_5f79eb90-e190-4864-bd83-1301caa1f650">0.1</ix:nonFraction> million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzE_43e9fd3d-ca94-456c-958e-38e7f8a794ff" continuedAt="i670d1ec3637f4728a9e6dc779da6fba4" escape="true"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzE_6bbca675-6309-4829-ba34-1cc7155eb9fc" continuedAt="i8e989f16cbf54b5780348e27dbfc663e" escape="true">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i43c22eba3d4340459530371c60b16650" continuedAt="i891e2dac65074b5a80b7c046333627a8"><div><ix:continuation id="i670d1ec3637f4728a9e6dc779da6fba4"><ix:continuation id="i8e989f16cbf54b5780348e27dbfc663e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjgyMzcyY2ZmY2JjZTQxMjliYTkzODA2MDk2N2Q3ZTI1L3RhYmxlcmFuZ2U6ODIzNzJjZmZjYmNlNDEyOWJhOTM4MDYwOTY3ZDdlMjVfMi00LTEtMS0w_da686ddf-0303-4c7d-b69a-5d1988facbdc">118,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjgyMzcyY2ZmY2JjZTQxMjliYTkzODA2MDk2N2Q3ZTI1L3RhYmxlcmFuZ2U6ODIzNzJjZmZjYmNlNDEyOWJhOTM4MDYwOTY3ZDdlMjVfMi02LTEtMS0w_0101872a-c397-44a7-849a-12c6edb8d167">57,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjgyMzcyY2ZmY2JjZTQxMjliYTkzODA2MDk2N2Q3ZTI1L3RhYmxlcmFuZ2U6ODIzNzJjZmZjYmNlNDEyOWJhOTM4MDYwOTY3ZDdlMjVfMy00LTEtMS0w_07c8838d-858e-4960-b637-cbbb67dbc486">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjgyMzcyY2ZmY2JjZTQxMjliYTkzODA2MDk2N2Q3ZTI1L3RhYmxlcmFuZ2U6ODIzNzJjZmZjYmNlNDEyOWJhOTM4MDYwOTY3ZDdlMjVfMy02LTEtMS0w_2e45ffe3-4917-4db0-9018-fc147bc26094">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjgyMzcyY2ZmY2JjZTQxMjliYTkzODA2MDk2N2Q3ZTI1L3RhYmxlcmFuZ2U6ODIzNzJjZmZjYmNlNDEyOWJhOTM4MDYwOTY3ZDdlMjVfNC00LTEtMS0w_7c5ba74e-0d4e-4323-8d08-5f4bec860895">118,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjgyMzcyY2ZmY2JjZTQxMjliYTkzODA2MDk2N2Q3ZTI1L3RhYmxlcmFuZ2U6ODIzNzJjZmZjYmNlNDEyOWJhOTM4MDYwOTY3ZDdlMjVfNC02LTEtMS0w_623cb57f-019c-4a83-b658-45b6e62caec5">57,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzI_d7bb340f-d8cf-4422-8387-feb24945257c" escape="true"><div style="margin-top:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payors) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Promotion Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a co-promotion agreement (the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. The Company is responsible for the costs associated with its sales force over the course of such co-promotion. Janssen is responsible for all other aspects of the commercialization of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company is entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over a predetermined baseline. For quarter ended March&#160;31, 2020, the tiered promotion fee ranged from $<ix:nonFraction unitRef="usd" contextRef="ic2ef52e13fcc4ac290fb3f3f17fc1d8e_I20200331" decimals="0" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTA1ODM_d2233032-ebc5-4e62-b7b2-76552d5111b7">750</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="ib134284be93446ceb5f659fddbb92851_I20200331" decimals="0" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTA1ODk_b3670654-444e-4bdd-88eb-71fee2b24492">1,250</ix:nonFraction> per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020, the Janssen Agreement was amended (June Amended Janssen Agreement) to adjust the predetermined average baseline for the third and fourth quarters of 2020, and for each of the third and fourth quarters of 2020, the Company received a minimum promotion fee of $<ix:nonFraction unitRef="usd" contextRef="ic717b41edf9f4ff48d0b9b2e8087ccf9_I20200930" decimals="-5" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMTY4Mw_220ed7fc-6c3f-4498-bef1-4aa188b49e4e"><ix:nonFraction unitRef="usd" contextRef="i035a93a2bf2f4d91913f3d26706f1810_I20201231" decimals="-5" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMTY4Mw_a229be02-f156-47c2-aa9f-e62ba9e9927c">0.3</ix:nonFraction></ix:nonFraction>&#160;million and the fee was capped at <ix:nonFraction unitRef="number" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzg_2f96277e-4afd-44b1-87df-145f58fd6a0f"><ix:nonFraction unitRef="number" contextRef="ic3f2c6ac308c4ed4a5dac4b72e609986_I20200930" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzg_ec9f38e1-8745-4c37-bb03-1cf14ebafdd9">5</ix:nonFraction></ix:nonFraction>% above the adjusted predetermined baseline. In December 2020, the Janssen Agreement was further amended. The Janssen Agreement, as amended in June 2020 and December 2020 is collectively referred to as the Amended Janssen Agreement. In accordance with the Amended Janssen Agreement, the predetermined average baseline for prescribed units for the quarters ending December 31, 2020, March 31, 2021 and June 30, 2021, was adjusted to approximately <ix:nonFraction unitRef="unit" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPrescribedUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ2NA_8e59301d-0216-4ed1-98ac-a11bc8490ce4">28,750</ix:nonFraction> prescribed units per quarter, subject to adjustment under certain circumstances. For the first and second quarter of 2021, the Company will be entitled to an amended tiered promotion fee ranging from $<ix:nonFraction unitRef="usd" contextRef="i00bf9e1bcaa041139ea4e7b5f25c4a6e_I20210630" decimals="-2" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ3Mg_1fcae933-2b06-4cd3-a926-555ce1652be1"><ix:nonFraction unitRef="usd" contextRef="iccf1ab5f053e4f769295776a4596ca23_I20210331" decimals="-2" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ3Mg_76cb585f-9ecd-4244-b9f4-5dc445c311e7">500</ix:nonFraction></ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i4bc7c41756524ddd9cc16ef0ee800e1b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ3OA_853de476-e1fc-42b6-b574-ff9c00d92225"><ix:nonFraction unitRef="usd" contextRef="i4bc7c41756524ddd9cc16ef0ee800e1b_I20210630" decimals="-2" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ3OA_fa474880-2de2-4d8c-b0b6-7c99ba0501e9">1,000</ix:nonFraction></ix:nonFraction> per prescription based on the incremental increase in total prescribed units. Pursuant to the Amended Janssen Agreement, for the first and second quarters of 2021, the Company will receive a minimum promotion fee of $<ix:nonFraction unitRef="usd" contextRef="i00bf9e1bcaa041139ea4e7b5f25c4a6e_I20210630" decimals="-5" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMTY1NA_01cd4c51-8bf0-446f-8d4c-223d779b940a"><ix:nonFraction unitRef="usd" contextRef="iccf1ab5f053e4f769295776a4596ca23_I20210331" decimals="-5" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMTY1NA_06e694a0-3649-4b46-adc5-acda84eb96a8">0.3</ix:nonFraction></ix:nonFraction>&#160;million and the fee will be capped at <ix:nonFraction unitRef="number" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ4Ng_2f56e5d8-798f-4539-bcbc-0e4fc630c670"><ix:nonFraction unitRef="number" contextRef="ia8c4a64accf64f4e8d3c6f1c85c45656_I20210630" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ4Ng_dd2e8a34-c32f-402b-8ab0-86efa38f169c">10</ix:nonFraction></ix:nonFraction>% above the adjusted predetermined baseline. The quarterly tiered promotion fee for the remaining term of the Janssen Promotion Agreement beginning on July 1, 2021 will revert to the terms set forth in the Janssen Agreement prior to amendment, with no minimum promotion fee and no cap on predetermined baseline units. In addition, during the term of the Janssen Agreement, the Company is restricted </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i891e2dac65074b5a80b7c046333627a8" continuedAt="i3b722c71b69a40648472e25bbd6f64bc"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from promoting any other biologic or Janus kinase inhibitor, or JAK inhibitor, used for treatment of indications covered by the agreement without first obtaining Janssen's written consent. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Janssen Agreement expires on December 31, 2021, unless extended by the Company for an additional <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:durmonth" name="exdx:CoPromotionAgreementRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMjA2Ng_b1e75479-72e2-48de-b24e-586ea45d5885">12</ix:nonNumeric> months upon <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:durday" name="exdx:CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMjA4MQ_983d33b9-fd50-40ff-a328-b5ea5b5e77ae">180</ix:nonNumeric> days written notice prior to the end of the current term. If the Company elects to extend the term, the predetermined baseline for 2022 will be subject to future agreement by the Company and Janssen. Janssen may terminate the Amended Janssen Agreement at any time for any reason upon <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" format="ixt-sec:durday" name="exdx:CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMjA5MA_eb8bc4bc-1011-421c-b541-aff0471bf084">30</ix:nonNumeric> days' notice to the Company, and the Company may terminate the Amended Janssen Agreement for any reason at the end of any calendar quarter upon 30 days' notice to Janssen. Either party may terminate the Amended Janssen Agreement in the event of the other party's default of any of its material obligations under the agreement if such default remains uncured for a specified period of time following receipt of written notice of such default.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations relating to sales and co-promotion services for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a series of single performance obligations since Janssen simultaneously receives and consumes benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations is based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the agreement is cancelable. The Company recognized co-promotion revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i545c29e8f1ac444a9fd4436eb738bd53_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTI4OTI_bb71fe43-ace5-48ef-b58f-7357be984bba">0.3</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="ie01b6015e94e40b18dbc9c1af60a487e_D20200101-20200331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTI5MDc_89f59b35-ad9b-4cdd-91f1-ba35bfb9b4d9">no</ix:nonFraction> co-promotion revenue during the three months ended March&#160;31, 2021 and 2020, respectively. The related expenses for marketing SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are included in selling, general and administrative expenses and are expensed as incurred.</span></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODM_8053057b-0bfc-4310-9f51-a606df2d2288" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODQ_e8c7200f-a10d-4390-b6af-2df29ed251a5" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTM4MTQ_cc242423-377b-45f7-80b7-2e37ded103d4">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTM4Mjk_20b262cb-87e1-4739-a6ed-19c2bbf125a5">0.4</ix:nonFraction> million for the three months ended March&#160;31, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i51b7dc429b4b47a4a086f500297ae4f5_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTQyODE_4c7a372d-654f-48e9-a114-cf1e36d759a9">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i83c36c4109874e448199eb8e55ebd4dc_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTA5OTUxMTY1NzAwMQ_2b342701-8973-4775-baf6-abe5881141d6">0.4</ix:nonFraction> million for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:EmployeeStockOwnershipPlanESOPPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODU_2567a114-7e95-44c8-a829-2d0a8cb6d6b2" continuedAt="ic7cfbb5e43b144a7b873ed50dd0e420c" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the employee stock purchase plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was <ix:nonFraction unitRef="number" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ5MA_4bcf1579-58be-4f76-b2a3-b87b9aa0412e">zero</ix:nonFraction>, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest annually from the grant date in four equal installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy RSUs upon vesting. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3b722c71b69a40648472e25bbd6f64bc" continuedAt="i05e172b7eb16471c909c253d4d9c7a45"><ix:continuation id="ic7cfbb5e43b144a7b873ed50dd0e420c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, the Company awarded <ix:nonFraction unitRef="shares" contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTA5OTUxMTY1OTQzNQ_98ff4cd0-3975-433f-b215-c37bd3d8c2d9">185,000</ix:nonFraction> RSUs to certain employees, all of which are outstanding and unvested as of March&#160;31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.</span></div></ix:continuation><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzM_922fcba0-e03b-4220-8417-2d3529bc18b3" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzk_0615f730-f9eb-411e-976d-b6c1f1a6caac" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan and shares of the Company's common stock pursuant to Employee Stock Purchase Plan. For the three months ended March&#160;31, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzQ_a6b388a8-e439-4ccd-a1e4-6dc0ecaf9a6d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.669%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id50b7c2e8d494f8c946e330ed5574198_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNC0yLTEtMS0w_98706730-32d3-42b8-933f-2d216969c92c">426,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8a1bd4a29ec4f84888bbc4981057e5b_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNC00LTEtMS0w_46fd5e16-4a7a-43f3-b7fb-aba2527a7c1d">436,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8a1d1023b6a4f4db7161e28f63e8578_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNS0yLTEtMS0w_7c658bc9-8c0c-4df3-8f5e-787c8c875643">2,041,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib430868217a64c48beccdf7a906cd385_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNS00LTEtMS0w_843ec17d-788e-47eb-a915-f2c42e2f8cf3">1,630,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56ebd098dbb0414199e0a1f304311104_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNi0yLTEtMS0yODA0_378f65ce-5daa-4087-a4e8-b7eb8c905918">185,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ed20d5e060644a197e27c3b20c2b130_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNi00LTEtMS0yODA4_f1246f88-e7a5-4cda-894a-e9dad057048c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide582e20a1564092a1d4f74f3cce4c9c_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNi0yLTEtMS0zNTc_7ac6294c-bfd9-41f0-87c5-b277ae171857">2,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e1e4c97623d4b02a76aab4a8cd9dfc1_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNi00LTEtMS0zNTc_c1518fbe-c046-4775-a14a-69ff669c7dcb">2,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNi0yLTEtMS0w_c05e3441-0e56-4df3-bfd4-fbd5516565ec">2,656,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNi00LTEtMS0w_eb7fdcd0-8b15-4aab-8d7d-48ff164d7e86">2,068,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODA_751f44ae-a349-4767-bf3f-82b2969341f1" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, <ix:nonFraction unitRef="segment" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTgyNTY_3671274c-1011-497b-bf66-9d751106cbac">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODY_6f6e6e08-ad81-4c8f-bc4a-f479bd238a1f" continuedAt="i4899f08018d14fda8ab32378401448cf" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i05e172b7eb16471c909c253d4d9c7a45"><ix:continuation id="i4899f08018d14fda8ab32378401448cf"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.</span></div></ix:continuation></ix:continuation><div id="idffe191f32b5442996096aa67f5e278a_37"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfNzcy_9835da39-427a-49b6-bdf0-3aa9f5a96c54" continuedAt="i500fca55f8984095b9b7ae5f5d1ecd6d" escape="true">Other Financial Information</ix:nonNumeric></span></div><ix:continuation id="i500fca55f8984095b9b7ae5f5d1ecd6d" continuedAt="ib58563880bdd4e69ac17ef280cf270bf"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfNzcz_087720dd-7422-4e3b-be10-6cd974876d28" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfMS0yLTEtMS0w_73d53010-3b9b-4a0e-be96-6534e37ab94e">921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfMS00LTEtMS0w_c827a5ad-f398-403d-8e65-0b74efd6c891">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfMi0yLTEtMS0w_395d5d1f-ae3c-42c5-b4cf-66bf1389f901">65</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfMi00LTEtMS0w_11f38206-23d4-43d9-9436-50c49f2ac884">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="exdx:PrepaidMaintenanceAndInsuranceContracts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfMy0yLTEtMS0w_c30cacd0-c71c-4618-8d4e-a94a0f86610a">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="exdx:PrepaidMaintenanceAndInsuranceContracts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfMy00LTEtMS0w_ccab32c6-aca7-4ceb-bd02-79fc2cf43392">2,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfNC0yLTEtMS0w_22717133-a635-47b4-86cc-c301f9b5adf2">220</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfNC00LTEtMS0w_cab55dff-bd45-4b13-8302-63e1ecd6746b">659</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfNS0yLTEtMS0w_dff02f01-f806-4c50-94bf-759eec535831">3,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfNS00LTEtMS0w_397bf31e-9d5b-4974-bf63-34b2c844892f">4,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfNzc0_87d7500f-d5df-4422-95dd-c67987c016db" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc9a7f02a64d485784bba6b218e085da_I20210331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfMS0yLTEtMS0w_4fca6b2c-f999-4971-8013-66b8eb47d04b">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68a12746a0a43778d411a0e71f850e4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfMS00LTEtMS0w_19983469-2925-411c-b20a-5e4aa5fb1809">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e89c10b517a40da817bf9dd7fadec65_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfMi0yLTEtMS0w_a9169f0f-fdf8-40c5-a616-5c8557362d43">3,148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96214d4c6e24fdb959ba168df6a8af4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfMi00LTEtMS0w_7928ff6d-f31e-4e02-b0bd-ae0106748794">2,679</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i718a9b57c44f43859f8f20ce6569fbb6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfMy0yLTEtMS0w_dff5b519-78c7-4287-aabb-f3875b21a392">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87b062212901454892bd5210a1dbcd07_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfMy00LTEtMS0w_13a3f9b2-4f19-44ec-b482-88de4609fd60">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a67b72dfa84dba92b35b0b41b493e2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNC0yLTEtMS0w_14573c6d-287a-4b23-a693-59122b48f756">1,073</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0e64a9b4c5140059a5acbc43d92843a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNC00LTEtMS0w_45e43a9a-fa23-498c-9bb1-bb61438150b9">1,072</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84fefc5a1ec94437b3ba22e7b5a8b9da_I20210331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNS0yLTEtMS0w_5d798b85-c949-40f6-96f8-b7824ba3ee3c">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeea39a95a634c1f8fae5c44cf640d7a_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNS00LTEtMS0w_8e8f451d-848a-460a-9fe7-3a66125aece8">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNi0yLTEtMS0w_1238e784-14a8-4dd5-b284-02a314f7bda0">5,506</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNi00LTEtMS0w_6fe7d078-6e59-4c21-8e37-28dd94ba5e7b">5,043</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNy0yLTEtMS0w_9d95108b-f648-4a98-907e-c38887e62317">3,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNy00LTEtMS0w_171f5cc6-dbb7-4d24-83db-34c1c672a444">2,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfOC0yLTEtMS0w_0adb60f5-a5ea-438f-b02b-fc93f984fb84">2,378</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfOC00LTEtMS0w_72e99bbe-6d39-44a5-b008-58c709dff7bb">2,102</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib58563880bdd4e69ac17ef280cf270bf"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended March&#160;31, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfMzU5_ba5a55ff-01ba-4469-9a28-d29398c26c0f">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfMTA5OTUxMTYyODY1MQ_6d3bbb23-ddfe-4880-a046-33d2f23f7133">0.1</ix:nonFraction> million, respectively. At March&#160;31, 2021 and December 31, 2020, the gross book value of assets under capital lease was $<ix:nonFraction unitRef="usd" contextRef="iea8e8125271042c2bd42020d228a5c4b_I20210331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfNTQy_a6cd3ef6-d299-47db-be7e-c4d55f4f3f2f">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7261f22c88a04977b74b69ed970fe446_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfNTU3_e506b70a-0a9f-4c30-9921-df5037366cfa">1.2</ix:nonFraction> million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfNzcw_2bdbc174-1724-41ca-b077-1f2d04774f78" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfMS0yLTEtMS0w_3ae23467-0c69-454a-8cd8-9b85e6fba8c7">3,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfMS00LTEtMS0w_1967a7cf-d363-4e85-add6-16eeb9cec522">3,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfMy0yLTEtMS0w_f5cade37-a333-4cc3-a3d3-90c5ec6e4e41">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfMy00LTEtMS0w_15badcbb-b5ef-4198-982f-5a13b3ced5a7">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNC0yLTEtMS0w_e4a4e212-f01d-48f7-9d4a-fd72c4fbd48d">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNC00LTEtMS0w_d1055da1-5607-4b8a-9bc5-da5d291d4aa4">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNS0yLTEtMS0w_22b0d019-9204-4ca6-b99d-6e23335894be">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNS00LTEtMS0w_1e005c24-e6ff-4e54-b72e-d6ae87ae85e0">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNi0yLTEtMS0w_7af06e42-540b-42dc-8346-8d8ecc395546">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNi00LTEtMS0w_4c8b8246-781a-4301-b95e-21754da9086a">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="us-gaap:CapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNy0yLTEtMS0w_cec2499e-0250-4a54-a872-2bf7fd1c52a0">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="us-gaap:CapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNy00LTEtMS0w_7774b049-bb27-4a38-a999-93d1dc46287e">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfOC0yLTEtMS0w_f2f76493-5771-4a34-954b-f6118a1527e1">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfOC00LTEtMS0w_0cda0dec-1202-48bd-b9e4-dcf8700865d0">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfOS0yLTEtMS0w_d8a3f4f6-4e41-481a-af24-bd98cc6b57c7">5,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfOS00LTEtMS0w_620f8b91-690d-4a5d-b3ef-5c0c10905030">5,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_40"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfNTQ4MA_347aef17-c653-449e-992e-fdc1fa4c8103" continuedAt="i0ac17afacc4f4e9881ecc38ae4a3e116" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="i0ac17afacc4f4e9881ecc38ae4a3e116" continuedAt="i7e882196dfad4a9b83cbc485f20484bd"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Term Loan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $<ix:nonFraction unitRef="usd" contextRef="i49816a32de1a4847a965a660b298f0a0_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTk3_3db558e7-2597-48cb-b4b2-de9a057616a6">20.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i79bb007a0e4b4e11ad37da79ccacc407_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMjAx_e06f01ea-1c55-47d7-9ce8-0cbbe5492216">17.8</ix:nonFraction> million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $<ix:nonFraction unitRef="usd" contextRef="i9225dd725d3041c3897811c47544cbeb_D20181207-20181207" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMzg1_79ff06f1-0bf9-442f-bdec-e23d10447471">5.0</ix:nonFraction> million under the 2017 Term Loan. At March&#160;31, 2021, <ix:nonFraction unitRef="usd" contextRef="ic99585e2b612446894f42dbc14e98bc3_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfNDIx_8863637a-a8e4-4cab-9753-3bce108608e2">no</ix:nonFraction> additional amounts remain available to borrow under the 2017 Term Loan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company executed the First Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the Loan Amendment is <ix:nonFraction unitRef="number" contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfNjgx_bf6506c9-7cc7-410e-817d-f90edb321aa7">8.5</ix:nonFraction>%, of which <ix:nonFraction unitRef="number" contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130" decimals="INF" name="exdx:DebtInstrumentStatedInterestRatePaidInKind" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfNjk0_5e896f91-c28e-4dbf-9b15-93bb71bbfdee">2.0</ix:nonFraction>% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2022, after which interest accrues at an annual rate of <ix:nonFraction unitRef="number" contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfODM2_bf6506c9-7cc7-410e-817d-f90edb321aa7">8.5</ix:nonFraction>%. The Company has estimated the effective interest rate of this loan to be approximately <ix:nonFraction unitRef="number" contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130" decimals="2" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfOTI3_f43637e3-ad1e-430a-b48b-8a2016af0c4b">10</ix:nonFraction>%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the Loan Amendment will be repaid in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTExOQ_943420c3-685f-4155-98c0-99295e2c5baa">twenty-four</span> equal monthly installments commencing in December 2022. Upon repayment of the final installment under the Loan Amendment, the Company is required to pay an additional fee of $<ix:nonFraction unitRef="usd" contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTI5Ng_02e0784f-5adf-49ce-860a-7de3085ff470">1.0</ix:nonFraction> million. This obligation is being accreted into interest expense over the term of Loan Amendment using the effective interest method. For each of the three months ended March&#160;31, 2021 and 2020, the Company issued PIK Loans totaling $<ix:nonFraction unitRef="usd" contextRef="i9517d690925b44e1b66094ac282a2fb8_D20200101-20200331" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTUwMw_554116f6-c467-48c4-afc5-f5e9bf50f002"><ix:nonFraction unitRef="usd" contextRef="i6a1d3210812c4ec99a01bc62b58c261b_D20210101-20210331" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTUwMw_d18da14a-9f71-4cd6-9c41-a2586b8689de">0.1</ix:nonFraction></ix:nonFraction> million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Amendment requires a prepayment premium of <ix:nonFraction unitRef="number" contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130" decimals="INF" name="exdx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTc3Mw_2a2ec724-e50b-4ef7-aa01-90aec6d1f970">3</ix:nonFraction>% of the aggregate outstanding principal. The prepayment premium decreases by <ix:nonFraction unitRef="number" contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130" decimals="INF" name="exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTg1Mg_1fb3b944-7f0a-4489-b66a-02fef41696cb">1</ix:nonFraction>% during each subsequent twelve-month period after November&#160;19, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7e882196dfad4a9b83cbc485f20484bd"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $<ix:nonFraction unitRef="usd" contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130" decimals="-5" name="exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMzQ5NQ_6c948477-bd79-4998-99bc-8bba9e16c963">2.0</ix:nonFraction> million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the Company was in compliance with all covenants of the Loan Amendment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the Loan Amendment covenants, the repayment of the Loan Amendment may be accelerated, and the applicable interest rate will be increased by <ix:nonFraction unitRef="number" contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130" decimals="INF" name="exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfNDg5Ng_852abd0a-cc3a-4ec2-84de-a29e8c2240f0">4.0</ix:nonFraction>% until the default is cured. Although repayment of the Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Minimum Payments on the Outstanding Borrowings</span></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfNTQ4MQ_d86e3352-aa46-42c6-a6f5-4b8dfecd2e6c" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfMS0yLTEtMS0w_b397554c-684a-4b34-a2e2-a60095e58a53">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfMi0yLTEtMS0w_66628342-8c6f-4265-8f0e-9559df380fb2">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfMy0yLTEtMS0w_a44a8f3e-6aba-4d65-b759-7463a0cb81b2">15,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfNC0yLTEtMS0w_27c20f67-0044-40dc-9f1b-a16eead9964a">14,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfNS0yLTEtMS0yNTc4_7814d569-b24c-4a37-b521-b627dcd7e2d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="exdx:LongTermDebtIncludingUndiscountedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfNi0yLTEtMS0w_db18bd09-04a8-4017-8c3e-8e9a414ebb48">34,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfOC0yLTEtMS0w_920e3a47-ec44-4442-bb17-74498e12fed0">273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="exdx:LongTermDebtUndiscountedInterestAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfOS0yLTEtMS0w_7645a47c-bfe2-4b56-b061-f5598688f453">7,084</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfMTAtMi0xLTEtMA_489c370f-5364-436e-acb6-acdf40261967">26,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_43"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMzYzMw_27f1cb5b-a54e-4184-8b38-1a3ee0a8608b" continuedAt="i5844a4f327a140569b4224b86548e392" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i5844a4f327a140569b4224b86548e392" continuedAt="icbc7ff28c09a42a0a2e9ed996409175b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the Company leases office and laboratory space in Vista, California, under leases that expire in January 2026, with an option to extend a portion of the lease for an additional <ix:nonNumeric contextRef="iffe724be62e54f5e98c97114c1b16b4c_D20210101-20210331" format="ixt-sec:duryear" name="exdx:OperatingLeasesRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMjM5_f964e250-c145-4eb8-8b2d-c4f4cf995fbb">5</ix:nonNumeric>-year period. In addition, the Company also leases additional office space in Vista, California, under a lease that expires in January 2026 with an option to extend the lease for an additional <ix:nonNumeric contextRef="ibb1da3cc014a47988102c4a5fbfcdf4a_D20210101-20210331" format="ixt-sec:duryear" name="exdx:OperatingLeasesRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfNDM0_162a6d84-7de6-4e4a-9ae0-ddc63804e643">5</ix:nonNumeric>-year period. The Company's lease payments under each of these leases are subject to escalation clauses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, rent expense was $<ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfNTk4_40a3450c-e923-4cda-b409-8282c1976096">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfNjEz_d9ae15bc-5a88-4da3-9809-5d91e3137f5a">0.1</ix:nonFraction> million, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related liabilities</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icbc7ff28c09a42a0a2e9ed996409175b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. As of March&#160;31, 2021 and December 31, 2020, the remaining milestone obligation is for an additional $<ix:nonFraction unitRef="usd" contextRef="ie5600c9592fb46b690a5bc52e4c34fc2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="exdx:MilestoneObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTI4OQ_1a6257fe-0bbe-42b0-90dd-26582d644243"><ix:nonFraction unitRef="usd" contextRef="i786adb20b67b40bfb36498bdace13f68_I20210331" decimals="-5" format="ixt:numdotdecimal" name="exdx:MilestoneObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTI4OQ_e91c1ca7-dbb5-4704-9396-a468011d7b37">2.0</ix:nonFraction></ix:nonFraction> million payment due to Prometheus Laboratories, Inc. (Prometheus) for which the fair value was determined to be <ix:nonFraction unitRef="usd" contextRef="i786adb20b67b40bfb36498bdace13f68_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="exdx:MilestoneContingencyFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTM5Ng_033fddd0-6a8f-4f5d-8676-da1392becae0"><ix:nonFraction unitRef="usd" contextRef="ie5600c9592fb46b690a5bc52e4c34fc2_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="exdx:MilestoneContingencyFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTM5Ng_06794f50-4920-47d6-80d8-a8258d4ca6a3">zero</ix:nonFraction></ix:nonFraction> at March&#160;31, 2021 and December 31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has ongoing royalty payment obligations on net sales of products which incorporate certain acquired technologies of <ix:nonFraction unitRef="number" contextRef="ibef5d76e001f48ab9c9f255b50909153_I20210331" decimals="3" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTU2NA_71611ece-7799-4cb0-9e5a-e8dbd058063a">2.5</ix:nonFraction>%. Future royalties payable under these arrangements are limited to the lesser of an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i786adb20b67b40bfb36498bdace13f68_I20210331" decimals="-5" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTA5OTUxMTYzMTUzMA_8caa87de-d54c-47e1-b6a8-2807dc78a9a9">1.2</ix:nonFraction> million (including an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i786adb20b67b40bfb36498bdace13f68_I20210331" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdvancePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTcxMw_c0ddbcd1-0e3e-49b7-bfb5-7110c8761625">100,000</ix:nonFraction>) or the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments on net sales of products which incorporate licensed technology, as defined, ranging from <ix:nonFraction unitRef="number" contextRef="i51edebd2dc964c65960284e7a29563ad_I20210331" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMjExNQ_4864b859-fcc8-466b-8e18-f6854a2d1eba">2.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ifc8c434620fc4d7fa5e5804d5459e9c8_I20210331" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMjEyMQ_d73b761b-a9b9-41f9-8899-a73111a732bf">3.0</ix:nonFraction>%. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the first quarter of 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute, or AHN, to obtain an exclusive license to AHN's patent rights in certain inventions, or the AGN Patent Rights, in May 2021, pursuant to which the Company is required to pay AHN an initial license fee of $<ix:nonFraction unitRef="usd" contextRef="i9300102ead9949fa9aa89415fe805f2a_D20210401-20210511" decimals="-5" name="exdx:LicenseAgreementInitialLicenseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTA5OTUxMTYzMjM4NQ_3a2163de-9f9a-4285-a3c3-cc7f93a49860">0.4</ix:nonFraction> million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-5" name="us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMjQzMw_fba91400-4ba0-4425-899e-8b0038bbc7b6">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMjQ0OA_ab964233-0aac-4a77-a072-be2c17db0de5">6.0</ix:nonFraction> million for the years ended December 31, 2021 and 2022, respectively, with a <ix:nonFraction unitRef="number" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="2" name="exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTA5OTUxMTYzMTU1NQ_71455018-afd7-42bd-80b4-1ff61a4849b3">15</ix:nonFraction>% annual increase thereafter through the year ended December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the first quarter 2021, the Company entered into a master research collaboration agreement with AHN in May 2021, pursuant to which the Company is required to pay AGN a collaboration fee of $<ix:nonFraction unitRef="usd" contextRef="i526a9a0b5afe4cc1874bdb70a537e2e7_D20210401-20210511" decimals="-5" name="exdx:CollaborationAgreementAnnualCollaborationFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTA5OTUxMTYzMzE2OQ_266254dd-0047-48e7-b8e2-2c3d50ec6ba6">0.4</ix:nonFraction> million for each year during the initial term of the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payors and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or of which of the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities.</span></div></ix:continuation><div id="idffe191f32b5442996096aa67f5e278a_46"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RleHRyZWdpb246YTM5NjZhZjU2YWVlNDcxOWE3NTZiZTA2NzE1YWFjNTFfMzAw_0be4c285-55d7-4ce8-b565-48439228dd2d" continuedAt="ic7df4336bda64ef0aaf57f966b5824c0" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic7df4336bda64ef0aaf57f966b5824c0" continuedAt="i1d6e22be966e48429e71ec83b1c82088"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RleHRyZWdpb246YTM5NjZhZjU2YWVlNDcxOWE3NTZiZTA2NzE1YWFjNTFfMzAx_6127e6ba-ca73-43b2-891e-3341a3166b7d" continuedAt="ie0c5572d04fa4bad9f5adacffd4db3b4" escape="true">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1d6e22be966e48429e71ec83b1c82088" continuedAt="i8c68c993cbc54c36b864bd06977ebac0"><ix:continuation id="ie0c5572d04fa4bad9f5adacffd4db3b4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf438e067e0e490e8bd11c8a8dfb7428_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOjA3YTI1YWE5MGVjYzRhNTI4MTRiNDRkZTE1MzNkNDJmL3RhYmxlcmFuZ2U6MDdhMjVhYTkwZWNjNGE1MjgxNGI0NGRlMTUzM2Q0MmZfMy0yLTEtMS0w_475bdecd-fc91-49ab-b36d-e18a2ac04c8e">107,983</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d19acf05fd481bbbf64336028dc9c3_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOjA3YTI1YWE5MGVjYzRhNTI4MTRiNDRkZTE1MzNkNDJmL3RhYmxlcmFuZ2U6MDdhMjVhYTkwZWNjNGE1MjgxNGI0NGRlMTUzM2Q0MmZfMy00LTEtMS0w_d5cc4d1d-43a6-4f39-9631-c42882e531fa">107,983</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9e78b389424e3ba420f778fc2889d9_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOjA3YTI1YWE5MGVjYzRhNTI4MTRiNDRkZTE1MzNkNDJmL3RhYmxlcmFuZ2U6MDdhMjVhYTkwZWNjNGE1MjgxNGI0NGRlMTUzM2Q0MmZfMy02LTEtMS0w_1407035c-b2b6-41c1-8fcd-833bae9d59cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d467b35645c46a0bc2317ac4c2edca0_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOjA3YTI1YWE5MGVjYzRhNTI4MTRiNDRkZTE1MzNkNDJmL3RhYmxlcmFuZ2U6MDdhMjVhYTkwZWNjNGE1MjgxNGI0NGRlMTUzM2Q0MmZfMy04LTEtMS0w_3c1a2eee-3e6e-45ef-89ee-febe813944c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf259d6549974c23a1e93dd4e55b13cc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOmIxZTdjMTA1OTIwMTQ4ZTQ4NDZmMmNjNjE3ZjgyNjZkL3RhYmxlcmFuZ2U6YjFlN2MxMDU5MjAxNDhlNDg0NmYyY2M2MTdmODI2NmRfMy0yLTEtMS0w_adbc33f7-3072-4873-9c85-48bc50657913">34,507</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97ff3388db6d405984fbd5a85da92d27_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOmIxZTdjMTA1OTIwMTQ4ZTQ4NDZmMmNjNjE3ZjgyNjZkL3RhYmxlcmFuZ2U6YjFlN2MxMDU5MjAxNDhlNDg0NmYyY2M2MTdmODI2NmRfMy00LTEtMS0w_19c50990-ba83-4810-b183-0b632b6b539c">34,507</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e0cbbdb764f8195a783d55722eb00_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOmIxZTdjMTA1OTIwMTQ4ZTQ4NDZmMmNjNjE3ZjgyNjZkL3RhYmxlcmFuZ2U6YjFlN2MxMDU5MjAxNDhlNDg0NmYyY2M2MTdmODI2NmRfMy02LTEtMS0w_eae0f768-cd52-474f-8974-97d0bf2c2501">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98fb6a4c5e334327ad489b104eeff646_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOmIxZTdjMTA1OTIwMTQ4ZTQ4NDZmMmNjNjE3ZjgyNjZkL3RhYmxlcmFuZ2U6YjFlN2MxMDU5MjAxNDhlNDg0NmYyY2M2MTdmODI2NmRfMy04LTEtMS0w_37645b10-695b-4941-8692-2ba04843d3d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8c68c993cbc54c36b864bd06977ebac0">The fair value of the Company's money market funds is based on quoted market prices.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div id="idffe191f32b5442996096aa67f5e278a_52"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTI3OQ_db252bda-9b1a-424e-b2e4-e6fa2f70b6e7" continuedAt="i89cc5ed21ec845f1a0fc567a34e2ca80" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i89cc5ed21ec845f1a0fc567a34e2ca80"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2020, the Company filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $<ix:nonFraction unitRef="shares" contextRef="i2fe73e79f1c549a483f3917d929c8e40_D20201110-20201110" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTA5OTUxMTYzMTYxNw_d00382a8-5cff-4744-9a1e-0cd76d82f0f1">150.0</ix:nonFraction> million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="icc1bb719e1074fdebd679404c35cd358_D20210325-20210325" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTA5OTUxMTYyOTE4MA_f7d98627-33b9-4097-95bc-2b75ab5e099d">4,255,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i74ff8c067c394119ba0c56e9d82ededc_I20210325" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTA5OTUxMTYyOTI0MQ_7e970ac4-e740-4d38-b062-ee683707a45d">16.25</ix:nonFraction> per share. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="icc1bb719e1074fdebd679404c35cd358_D20210325-20210325" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTA5OTUxMTYyOTM3Mg_29c4a772-dad7-4fca-a1e6-16e7ca00c306">64.7</ix:nonFraction> million, after deducting underwriting discounts and commissions and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i74ff8c067c394119ba0c56e9d82ededc_I20210325" decimals="-5" name="exdx:StockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTA5OTUxMTYyOTQ1Nw_458feb86-cc3a-4a96-97aa-cd188c9fd87f">4.4</ix:nonFraction> million. The shares were registered pursuant to the Company's Shelf Registration Statement discussed above. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Warrants</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTI4MA_a3ea7015-e7d5-4819-b4d1-8e392bd900be" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of March&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c19a7a2bfad4edd8ddd7b2557ae3114_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfMS0xLTEtMS0w_de775313-c111-4a84-978f-44d600cae211">252,798</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c19a7a2bfad4edd8ddd7b2557ae3114_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfMS0zLTEtMS0w_bfbd14e6-dbce-48d3-9e05-1f2907920246">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i350d91760ddf4160af25d20cd8d9b448_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfMi0xLTEtMS0w_0dc2c0d7-0218-449b-bade-54af48c40765">69,176</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i350d91760ddf4160af25d20cd8d9b448_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfMi0zLTEtMS0w_743315f8-4e5a-4062-af55-410f7f7f0cbb">1.84</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafc3772ba3454fac8749b13340ee0e47_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfMy0xLTEtMS0w_010c2b7c-4c4e-4cc1-8ef4-0dd183a93eeb">131</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iafc3772ba3454fac8749b13340ee0e47_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfMy0zLTEtMS0w_7856f4b2-b98e-43c5-8f11-b07decfc3ad6">1.84</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaea87b8242ef4b51bfab54bca764763b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfNC0xLTEtMS0w_dcb9689e-9c09-44d8-822f-61e914bc9f69">83,778</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaea87b8242ef4b51bfab54bca764763b_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfNC0zLTEtMS0w_a280ce6b-60c4-4310-beba-e58107db8d62">14.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i246430710e7b464984f4d6c04203b925_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfNS0xLTEtMS0w_218a5081-de0b-46ea-a530-7b5f0d953ca3">20,944</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i246430710e7b464984f4d6c04203b925_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfNS0zLTEtMS0w_e5f6e16f-67b8-4462-ad34-cd3e85e44813">14.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfNi0xLTEtMS0w_73105143-f060-4e4a-8757-c23c8d9d7d98">426,827</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_55"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTc4NA_fa9ea043-5d29-436b-96e2-d3d61df66949" continuedAt="i0581be7b923b4bc0a1923a371060f958" escape="true">Stock Option Plan</ix:nonNumeric></span></div><ix:continuation id="i0581be7b923b4bc0a1923a371060f958" continuedAt="i6632d3ed166f4886b598b70a64a1b17e"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Incentive Award Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Incentive Award Plan (the 2019 Plan). Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire <ix:nonNumeric contextRef="ifb31a3a85da44447bf660e6e7ba47571_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfNzQx_b913a2f4-f582-42a7-8f34-9fc0c57ab8df">ten years</ix:nonNumeric> after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally <ix:nonNumeric contextRef="ifb31a3a85da44447bf660e6e7ba47571_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfODc2_14ce64d1-e543-4272-b5bf-8ae1999f8b60">four years</ix:nonNumeric> from the date of grant. As of March&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i2c847c7e24b747288c96c2df35a0d98f_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfOTEz_d48a02ea-cefd-4692-9c9d-50ac867b93e3">1,391,215</ix:nonFraction> shares remained available for future awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6632d3ed166f4886b598b70a64a1b17e" continuedAt="i4726ef94fe0446329c26570158241e55"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the Employee Stock Purchase Plan (the ESPP). The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i9740e39188bc48939564a399602a85af_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMTMxMw_76dccde2-aaeb-4a88-8748-9f325c7ea362">20</ix:nonFraction>% of their eligible compensation. As of March&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i9740e39188bc48939564a399602a85af_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMTQ0NQ_9e7c2b4d-e910-43de-ba1b-a41e57f8192c">345,493</ix:nonFraction> shares remained available for issuance under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTc4MQ_8ecbee46-4e5b-443e-9c0f-326bdb3013c9" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i205b83f91058431aacdac5b60d121b3b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMS0yLTEtMS0w_96d8d1e8-3f51-4bb2-9c1f-d2476d8e34c8">1,975,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i205b83f91058431aacdac5b60d121b3b_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMS00LTEtMS0w_5576bbe0-a72a-4fd3-99c0-c8d475a2b915">11.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f7571bc1a6842eea4966067cef12287_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMS02LTEtMS0w_224a9f41-996a-4ece-9e8a-dbb21854436f">8.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205b83f91058431aacdac5b60d121b3b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMS04LTEtMS0w_3206487d-759d-4874-95e8-9c9bfc4ab6a1">6,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMi0yLTEtMS0w_e484f961-9220-4f23-8574-e8de45b1ecf0">88,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMi00LTEtMS0w_9499c7fe-be4b-44fb-b239-0f0af987abae">18.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMy0yLTEtMS0w_7e2f50e8-e3aa-4a81-8fcc-03e4a3e479f4">3,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMy00LTEtMS0w_e5aba6a7-65ed-42aa-9171-e99857fcddd3">12.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNC0yLTEtMS0w_d7e107c0-92eb-48c0-8d54-0c1015c9eff0">17,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNC00LTEtMS0w_e84e36b1-740d-4d1b-8851-270a50f64062">12.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNS0yLTEtMS0w_8c0f8cb6-c665-4031-a96f-5ff875cde974">2,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNS00LTEtMS0w_04827d84-a76b-40c1-a757-48453f89eac8">29.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNi0yLTEtMS0w_89316ac6-8b74-496f-a9f4-d2f2c3931466">2,041,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNi00LTEtMS0w_e011913e-a458-4f09-9269-ff35fa019859">12.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNi02LTEtMS0w_33f8ce3d-c9d3-43ee-9f0d-2749d941e26f">8.54</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNi04LTEtMS0w_b2d01d7f-2720-4fcb-bec5-c7a8b6fb96cb">13,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNy0yLTEtMS0w_89e97478-1999-4f59-a814-bdfd2551de22">2,041,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNy00LTEtMS0w_5e545ca2-1387-4025-90d4-1aebff2e8c25">12.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNy02LTEtMS0w_4e46c56c-d252-4688-bf41-0c9e931e7cba">8.54</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNy04LTEtMS0w_06e2efd0-c89d-434d-afe9-e7a51b4159b8">13,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfOC0yLTEtMS0w_54aaac00-f66e-40d7-9f1c-d1870b4bb70c">665,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfOC00LTEtMS0w_6edf2094-c831-4914-8fb1-aa71bef76279">9.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfOC02LTEtMS0w_4a6d734e-552c-4b75-a2af-7a93ca650bae">8.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfOC04LTEtMS0w_eb4f8fa5-d6ef-4405-b779-7935963f64a2">6,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. As of March&#160;31, 2021, total unrecognized compensation cost related to option awards was $<ix:nonFraction unitRef="usd" contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMzI3Mg_ab3ee84b-bac9-4fcf-92b2-63a552662759">8.8</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMzQxNQ_be73fedc-702f-4c4a-aea5-f7c2b8af116b">2.6</ix:nonNumeric>&#160;years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMzg0ODI5MDcwMjM0OA_3973ff7a-6d1c-4887-963d-d8543d7cd4b3" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74e686b941754a318cfceeff5fffc858_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMS0yLTEtMS03NjU_f3c587c2-9dba-48d5-8917-8c2ce48606ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i74e686b941754a318cfceeff5fffc858_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMS00LTEtMS03NjU_fcc375f0-44f1-4881-b987-1f8d0f2f4cec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e686b941754a318cfceeff5fffc858_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMS04LTEtMS03NjU_9a9ee1ff-6f85-4a2f-9c9d-031ffc4c0d08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMi0yLTEtMS03NjU_904a54f2-d14f-4cb4-8923-593bd4f4dd61">185,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMi00LTEtMS03NjU_03cff8af-12a5-4e3b-8e07-aadaabccb266">18.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMy0yLTEtMS03NjU_38c91d0d-f126-4611-80d1-c19502105f25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMy00LTEtMS03NjU_e4a16b62-909f-49f0-8de1-5687c58bc5d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfNC0yLTEtMS03NjU_f63b08f8-27d2-4879-99b0-49984f2d7641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfNC00LTEtMS03NjU_3fb0466c-8134-47db-9139-65e7913a3653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb431306073e41619a17523f2b2e4c23_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfNi0yLTEtMS03NjU_562725a7-a4c4-43ba-a36a-4c62fce04cc3">185,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb431306073e41619a17523f2b2e4c23_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfNi00LTEtMS03NjU_3bc11ab8-97af-4775-ac3d-05376f1c003a">18.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb431306073e41619a17523f2b2e4c23_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfNi04LTEtMS03NjU_3f5c75d1-f5c0-44f2-b5d3-a75afb1ed12f">3,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March&#160;31, 2021, the Company awarded <ix:nonFraction unitRef="shares" contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMjk2OA_98ff4cd0-3975-433f-b215-c37bd3d8c2d9">185,000</ix:nonFraction> RSUs at a weighted-average grant date fair value per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzNDk3MQ_ff8b4432-e123-4904-bd69-885b76847dfb">18.20</ix:nonFraction> to certain employees, all of which are outstanding and unvested as of March&#160;31, 2021. As of March&#160;31, 2021, total unrecognized compensation cost related to restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="idb431306073e41619a17523f2b2e4c23_I20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMzc4MQ_705395b1-edca-4d85-b235-66220f6ae053">3.3</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMzkyMg_646e612b-89f5-42fb-a6c0-7ce92b2be490">3.9</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTc4Mg_fca7cf0d-f412-4b39-901a-81f3a3ad8147" continuedAt="i56f6675ec22d463db234093be975f5e2" escape="true">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4726ef94fe0446329c26570158241e55"><div><ix:continuation id="i56f6675ec22d463db234093be975f5e2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfMi0yLTEtMS0wL3RleHRyZWdpb246NDIxZjgxMGJlOTMwNDk2Mjg1Yjk3MDZmNDBiODdhMjlfNA_082724a6-b20c-4689-84ac-125b1e352831">84</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfMi00LTEtMS0wL3RleHRyZWdpb246NzI4NGFiMGUxNDZlNGRlYWE3MTk1Y2YzNDM1ZjNhNTZfMTA5OTUxMTYyNzc4Mw_3cb4e51e-5607-4fb8-adce-77b5efaf93ec">47</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfMi00LTEtMS0wL3RleHRyZWdpb246NzI4NGFiMGUxNDZlNGRlYWE3MTk1Y2YzNDM1ZjNhNTZfMTA5OTUxMTYyNzc5MA_7d5b1576-d299-42d8-8ad7-14f2c4e8372e">50</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfMy0yLTEtMS0wL3RleHRyZWdpb246MjcxZGZmMWUyNTljNDg0NjkwNGFhYjE2MmY1NTc5ZDdfNA_9c689ee8-09f0-4678-b3a7-3a3ac78aedbe">0.8</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfMy00LTEtMS0wL3RleHRyZWdpb246YTBiMzNkZTc0YjBhNDE5Mzk0OGIxNTNjNTMxN2ZlZmZfMTA5OTUxMTYyNzc4Mg_9c5d4460-2b55-46e9-a5a4-bea94c13e6ba">0.6</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfMy00LTEtMS0wL3RleHRyZWdpb246YTBiMzNkZTc0YjBhNDE5Mzk0OGIxNTNjNTMxN2ZlZmZfMTA5OTUxMTYyNzc4OA_db5920dd-a7be-487d-acea-b9c149de88aa">1.7</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfNC0yLTEtMS0w_86d5fc86-d79d-414c-aac9-ac490f5ed907">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfNC00LTEtMS0w_ed537c13-0a53-4bfe-a9ae-f5b6a8dcf2df">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfNS0yLTEtMS0wL3RleHRyZWdpb246MTNiZmNhNDhlNGIwNDIzY2JiZjI4MzFjZmNhODZmNTZfNA_3465b02d-da1f-474b-a291-54f7da9b4281">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfNS00LTEtMS0wL3RleHRyZWdpb246NGQxNTAxZDcwN2IzNGQxZWFiODk5MWQ0MDI3MTViYTNfMTA5OTUxMTYyNzc4Ng_ccc9c390-c76e-4754-a7d0-36013592baea">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMzg0ODI5MDcwMjM0Nw_15f1e12b-96f9-4df1-a4d8-565a8916a281" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b8c82dfa9c441afb9faca3a14a0e8c3_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfMi0yLTEtMS02MjY_39e25baa-9029-44f5-864e-e7b17895609a">60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c0b8637038f4e0485961f9c7baa5391_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfMi00LTEtMS02MjY_da077daf-0f22-4092-886e-31d2475c2456">58</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b8c82dfa9c441afb9faca3a14a0e8c3_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfMy0yLTEtMS02MjY_8f92c356-523f-44dc-b1db-c108d318289d">0.1</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c0b8637038f4e0485961f9c7baa5391_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfMy00LTEtMS02MjY_476c8ea7-2f7a-43c9-9526-6b757f9f8c2a">1.1</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b8c82dfa9c441afb9faca3a14a0e8c3_D20210101-20210331" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfNC0yLTEtMS02MjY_a8175f21-b4d7-4b3d-9da6-6b52e44a4ffc">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c0b8637038f4e0485961f9c7baa5391_D20200101-20200331" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfNC00LTEtMS02MjY_c966a320-9bf5-434e-a467-f5acac4c2526">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b8c82dfa9c441afb9faca3a14a0e8c3_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfNS0yLTEtMS02MjY_2c5d3432-7b8c-4839-a8c0-cd41d3efbb80">0.50</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c0b8637038f4e0485961f9c7baa5391_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfNS00LTEtMS02MjY_a7a0851a-7c13-418f-be66-bacefc2647c8">0.50</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for the ESPP was immaterial for the three months ended March&#160;31, 2021 and 2020. As of March&#160;31, 2021, total unrecognized compensation cost related to stock purchase rights granted under the ESPP $<ix:nonFraction unitRef="usd" contextRef="i9740e39188bc48939564a399602a85af_I20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzNDI4NA_19158832-3fca-4bb4-9b8b-2da468919867">0.1</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="i2b8c82dfa9c441afb9faca3a14a0e8c3_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzNDQyMw_21bfdb75-4451-4662-9403-f2e25b65a58e">0.4</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTc4Mw_79a90f1a-aded-4467-b53e-28fbda39eb53" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2512bb71fe984f9f8a14d808494366bf_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfMi0yLTEtMS0w_e56033c3-717d-4146-91af-0e5121add8f9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id44b1e4210bc4a58b1886b02e42edda2_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfMi00LTEtMS0w_823005bc-f500-44cd-9df0-9bddd38643b5">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05daa2aed2c447f9b2aaf190a27f3d81_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfMy0yLTEtMS0w_ebe05368-5f80-4604-9f52-cacfd14727eb">791</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i713b0e54a4ca43bfb3140d1b4aff6cd1_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfMy00LTEtMS0w_19416b2a-031d-4731-9d29-a32a0310bf1e">422</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414d38c16c134af097eb843d3bb15bc4_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfNC0yLTEtMS0w_8bb13fbd-dfe1-4b87-a9cc-a8793cf8bed5">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf102bb294e439ca5afd862c3fe6335_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfNC00LTEtMS0w_d23d5647-9406-4f4c-ac5e-a33dcc796af4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfNS0yLTEtMS0w_6f040a2b-2946-47bf-984f-816d4f86ab9d">912</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfNS00LTEtMS0w_035304f2-d093-4382-b373-baf79d2ff0f3">431</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_61"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV82MS9mcmFnOjU0ZTJjY2M0MTY5NzQ2NTZhYTM0ZmNiNmU4YTc5NDI2L3RleHRyZWdpb246NTRlMmNjYzQxNjk3NDY1NmFhMzRmY2I2ZThhNzk0MjZfNjg3Nw_bf6ca7ed-8afc-49ba-9ed4-c5d2cc6ccf10" continuedAt="icfc4c62845734c0884b9e4c5a799b3eb" escape="true">COVID-19</ix:nonNumeric></span></div><ix:continuation id="icfc4c62845734c0884b9e4c5a799b3eb" continuedAt="ic27e8720e432462ca0c54709a229c849"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, due to the worldwide COVID-19 pandemic, the Company experienced a reduction in patient test volumes, delays in patient enrollment in ongoing and planned clinical studies, and delays in the procurement of its testing supplies. In response to the pandemic, the Company has curtailed non-essential employee travel, equipped employees with the ability to work remotely with the exception of clinical laboratory employees, and reduced marketing spend and employee headcount. The full extent to which the COVID-19 pandemic will directly or indirectly continue to impact the Company's business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional and international markets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. The CARES Act did not have a material impact on the Company's effective tax rate or income tax provision for the three months ended March 31, 2020. Under the Tax Cuts and Jobs Act (TCJA), NOLs generated post TCJA were allowed to be carried forward indefinitely but were only allowed to offset 80% of taxable income. As a result of the CARES Act and the change to permit NOLs generated in taxable years 2018, 2019 and 2020 to offset 100% of taxable income, the Company released valuation allowance </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic27e8720e432462ca0c54709a229c849"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">against its deferred tax assets in the amount of $<ix:nonFraction unitRef="usd" contextRef="i5194501b750d4090955a5e16b78c217c_I20200331" decimals="-5" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV82MS9mcmFnOjU0ZTJjY2M0MTY5NzQ2NTZhYTM0ZmNiNmU4YTc5NDI2L3RleHRyZWdpb246NTRlMmNjYzQxNjk3NDY1NmFhMzRmY2I2ZThhNzk0MjZfNTA1Nw_b50afc7a-af0c-4e71-b6fb-9ffa9823e911">0.1</ix:nonFraction> million. The release of valuation allowance resulted in a discrete tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV82MS9mcmFnOjU0ZTJjY2M0MTY5NzQ2NTZhYTM0ZmNiNmU4YTc5NDI2L3RleHRyZWdpb246NTRlMmNjYzQxNjk3NDY1NmFhMzRmY2I2ZThhNzk0MjZfNTE0Mg_cf3c654f-5275-47e7-9711-f47b195ef73d">0.1</ix:nonFraction>&#160;million in the first quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law. It provides additional COVID-19 focused relief and extends certain provisions of the CARES Act. At this time, the Company does not believe that the Consolidated Appropriations Act, 2021 has a material impact on its financial statements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="idffe191f32b5442996096aa67f5e278a_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with the unaudited condensed financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and notes thereto for the year ended December 31, 2020 included in our Annual Report on Form 10-K for the year ended December 31, 2020, as amended.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Looking Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and other parts of this quarterly report contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this quarterly report, including statements regarding our future results of operations and financial position, business strategy, the impact of the COVID-19 pandemic, current and future product offerings, reimbursement and coverage, our ability to implement an integrated testing and therapeutics strategy, the expected benefits from our partnerships or promotion arrangements with third-parties, research and development costs, timing and likelihood of success and plans and objectives of management for future operations, are forward-looking statements. These statements are often identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; or &#8220;continue,&#8221; and similar expressions or variations. The forward-looking statements in this quarterly report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, operating results, business strategy, and short-term and long-term business operations and objectives. These forward-looking statements speak only as of the date of this quarterly report and are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A, &#8220;Risk Factors.&#8221; The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand, several of which are based on our proprietary CB-CAPs technology. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE, and rheumatoid arthritis, or RA. Our strategy includes leveraging our portfolio of testing products to market therapeutics through our sales channel, targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing products and therapeutics positions us to offer targeted solutions to rheumatologists and, ultimately, better serve patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently market 10 testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. Our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD, enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of CTDs and other related diseases with overlapping symptoms. We commercially launched AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD in 2012 and revenue from this product comprised 81% and 83% of our revenue for the three months ended March&#160;31, 2021 and 2020, respectively. There is an unmet need for rheumatologists to add clarity in their CTD clinical evaluation, and we believe there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our portfolio of testing products to establish partnerships with leading pharmaceutical companies, academic research centers and patient advocacy organizations. In December 2018 we entered into the co-promotion agreement, or the Janssen Agreement, with Janssen Biotech, Inc., or Janssen, to exclusively promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in order to advance our integrated testing and therapeutics strategy and we began direct promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in January 2019. Our SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> promotion efforts contributed approximately $0.3 million and no revenue for the three months ended March&#160;31, 2021 and 2020, respectively, with our quarterly tiered promotion fee based on the incremental increase in total prescribed units above a predetermined average baseline. See "-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen Promotion Agreement" below for additional terms of the agreement. We also have agreements with GlaxoSmithKline plc., or GSK, Covance Inc. and Parexel, among others, that leverage our testing products and/or the information generated from such tests. We provide GSK, a leader in lupus therapeutics, our test result data to provide market insight into and help increase awareness of the benefits of early and accurate diagnosis of SLE and lupus nephritis, and monitoring disease activity. We partner with academic research centers and patient advocacy organizations, such as Brigham and Women's Hospital, Hospital for Special Surgery, Duke University and Emory University as well as the Lupus Foundation of America, to help improve the quality of life for people affected by autoimmune diseases through programs of research, education, support and advocacy. We plan to pursue additional strategic partnerships that are synergistic with our evolving portfolio of testing products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tests in our approximately 10,000 square foot clinical laboratory, which is certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, by the Centers for Medicare and Medicaid Services, or CMS, and accredited by the College of American Pathologists, or CAP, and located in Vista, California. Our laboratory is certified for performance of high-complexity testing by CMS in accordance with CLIA. We are approved to offer our products in all 50 states. Our clinical laboratory reports all AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing product results within five business days. In the second half of 2021, we expect to begin the conversion of approximately 8,000 square feet of warehouse space into additional clinical laboratory and research and development facility space, which is expected to be completed in the first half of 2022. The expansion of our clinical laboratory and research and development facility are expected to allow us to enhance our testing capacity and improve efficiencies as well as allow us to develop molecular and multiomic capabilities and advance our product pipeline, including support of development of tests for fibromyalgia, RA, thrombosis and lupus nephritis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products using our specialized sales force. As of March&#160;31, 2021, we have a sales force of 60 representatives covering a total of 63 territories. Unlike many diagnostic sales forces that are trained only to understand the comparative benefits of their tests, the specialized backgrounds of our sales force coupled with our comprehensive training enables our sales representatives to interpret results from our de-identified patient test reports and provide unique insights in a highly tailored discussion with rheumatologists. Our integrated testing and therapeutics strategy results in a unique opportunity to promote and sell targeted therapies in patient focused sales calls with rheumatologists, including those with whom we have a longstanding relationship and history using our portfolio of testing products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement for our testing services comes from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare, and patients. Reimbursement rates vary by product and payor. We continue to focus on expanding coverage among existing contracted rheumatologists and to achieve coverage with commercial payors, laboratory benefit managers and evidence review organizations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception we have devoted substantially all our efforts developing and marketing products for the diagnosis, prognosis and monitoring of autoimmune diseases. Although our revenue has increased sequentially year over year, we have never been profitable and, as of March&#160;31, 2021 we had an accumulated deficit of $187.5&#160;million. We incurred net losses of $6.2&#160;million and $5.6 million for the three months ended March&#160;31, 2021 and 2020, respectively. We expect to continue to incur operating losses in the near term as our operating expenses will increase to support the growth of our business, as well as additional costs associated with being a public company. We have funded our operations primarily through equity and debt financings and revenue from sales of our products. We completed our initial public offering, or IPO, in September 2019, raising net proceeds from the offering of approximately $50.4 million, net of underwriting discounts, commissions and other offering expenses, for aggregate expenses of approximately $7.5 million. In March 2021, we completed a public offering of 4,255,000 shares of our common stock at a public offering price of $16.25 per share. Net proceeds from the offering were approximately $64.7 million, net of underwriting discounts and commissions and offering costs of $4.4 million. As of March&#160;31, 2021, we had $118.1&#160;million of cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current COVID-19 worldwide pandemic has presented substantial public health challenges and is affecting our employees, patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions are taking actions in an effort to slow the spread of COVID-19, including issuing varying forms of "stay-at-home" orders, restricting business functions outside of one's home, restricting gatherings, restricting travel, and mandating social distancing and face coverings. Certain jurisdictions have begun a phased re-opening, although the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential to return to prior restrictions remains if there are increases in new COVID-19 cases in the future. Even in areas where "stay-at-home" restrictions have been lifted and the number of COVID-19 cases have declined, many individuals remain cautious about resuming activities such as preventative-care medical visits. As a result of COVID-19 related limitations and reordering of priorities across the U.S. healthcare system, a reduction in patient flow occurred and our test volumes began to decrease in the second half of March 2020 and we experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD volume decrease of approximately 5% in the year ended December 31, 2020 as compared to 2019. We substantially recovered to pre-COVID-19 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered in the fourth quarter 2020. For the three months ended March&#160;31, 2021 as compared to the same period in 2020, we experienced a AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test volume increase of approximately 7%. However, the continued spread of COVID-19 may adversely affect testing volumes in future periods, the extent of which is highly uncertain. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe there are several other important factors that have impacted, and that we expect will impact our operating performance and results of operations, including shutdowns of our facilities and operations as well as those of our suppliers and courier services, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, as well as our inability to achieve volume-based pricing discounts with our key suppliers and absorb fixed laboratory expenses. For example, we have experienced delays in patient enrollment for ongoing and planned clinical studies involving our tests, which may delay or prevent launch of future test products. We have also experienced delays in procurement of our testing supplies due to suppliers rationing testing supplies and prioritizing COVID-19 testing in the first quarter of 2021, which may continue into the future, and our partners, including Janssen, may also experience a disruption in their ability to readily obtain supply. Our sales force has been, and for an extended period of time may continue to be limited to their in-person interactions with healthcare providers, and therefore, also limited their ability to engage in various types of healthcare provider education activities. Healthcare providers and patients have canceled or delayed scheduling, and for an extended period of time may continue to cancel or delay scheduling, standard wellness visits and other non-emergency appointments and procedures, contributing to a decline in orders of our testing products. The portion of our workforce which has been working remotely in an effort to reduce the spread of COVID-19, may be infected from the virus or otherwise distracted. We may also face increased competition for laboratory employees due to the increased demand in the industry for such personnel. We may inaccurately estimate the duration or severity of the COVID-19 pandemic, which could cause us to misalign our staffing, spending, activities and precautionary measures with market current or future market conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we initially curtailed non-essential travel and have equipped most of our employees with the ability to work remotely with the exception of our clinical laboratory employees, and implemented measures to protect the health of our employees and to support the functionality of our clinical laboratory, such as providing personal protective equipment (including face masks or shields) and maintaining social distancing. In addition, in the second quarter of 2020, our sales force recommenced certain field-based interactions and scaled marketing spend, although access to healthcare providers remains limited and the use of virtual sales tools has increased. From March 2020 through December 31, 2020, as a result of the COVID-19 pandemic, we terminated our temporary employees and 18 full-time employees, which included three employees at the vice president level. The full extent of which the COVID-19 pandemic will directly or indirectly continue to impact our business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets.</span></div><div style="margin-top:12pt"><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Our Performance</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of COVID-19, we believe there are several important factors that have impacted, and that we expect will impact, our operating performance and results of operations, including:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Continued Adoption of Our Testing Products.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Since the launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD in 2012 and through March&#160;31, 2021, we have delivered over 516,000 of these tests. Through the first quarter of 2021, 29,029 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests were delivered, representing approximately 7% growth over the same period in 2020. The number of ordering healthcare providers in the first quarter of 2021 was a record 1,763, representing an approximate 4% increase over the same period in 2020, and we had a record 659 adopting healthcare </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">providers (defined as those who previously prescribed at least 11 diagnostic tests in the corresponding period) compared to 582 in the same period in 2020. A high percentage of adopting healthcare providers continue to order tests in subsequent quarters, as approximately 99% of adopting healthcare providers from the fourth quarter of 2020 ordered at least one diagnostic test in the first quarter of 2021. Revenue growth for our testing products will depend on our ability to continue to expand our base of ordering healthcare providers and increase our penetration with existing healthcare providers.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Reimbursement for Our Testing Products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payors, including both commercial and government payors such as Medicare. Payment from third-party payors differs depending on whether we have entered into a contract with the payors as a "participating provider" or do not have a contract and are considered a "non-participating provider." Payors will often reimburse non-participating providers, if at all, at a lower amount than participating providers. We have received a substantial portion of our revenue from a limited number of third-party commercial payors, most of which have not contracted with us to be a participating provider. Historically, we have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payors have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications.&#160;If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payors, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, retrospective reimbursement adjustments can negatively impact our revenue and cause our financial results to fluctuate.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;We began promoting SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States under the Janssen Agreement in January 2019. Our SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promotion efforts contributed approximately $0.3 million and no revenue for the three months ended March&#160;31, 2021 and 2020, respectively. We may continue to encounter difficulties in successfully promoting SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and generating significant revenue under the Janssen Agreement. Our ability to effectively promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will require us to be successful in a range of activities, including creating demand for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through our own sales activities as well as those of Janssen. In interest of supporting these efforts we plan to continue to evaluate the reach and frequency of our sales force and the dedication of time and resources to supporting the co-promotion efforts of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to other aspects of our business. We expect to encounter difficulties being able to maintain meaningful co-promotion revenue based on sales over the predetermined baseline in 2021 and we may not be successful in materially increasing market share, potentially resulting in the recognition of the minimum promotion fee of $0.3 million in the second quarter of 2021, which would cause us to continue to rely on our existing testing products to drive revenue growth. Additionally, there is no minimum promotion fee for the second half of 2021. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Development of Additional Testing Products.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We rely on sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test to generate the significant majority of our revenue. We expect to continue to invest in research and development in order to develop additional testing products and expect these costs to increase. Our success in developing new testing products will be important in our efforts to grow our business by expanding the potential market for our testing products and diversifying our sources of revenue.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Maintain Meaningful Margin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;We realized an increase to our gross margins beginning in the first quarter of 2020 following the expiration of a 10% annual royalty on our CB-CAPs technology. We believe we are well positioned to maintain meaningful margin through a continued focus on increasing operating leverage through the implementation of certain internal initiatives, such as conducting additional validation and reimbursement oriented clinical studies to facilitate payor coverage of our testing products, capitalizing on our growing reagent purchasing to negotiate improved volume-based pricing and automation in our clinical laboratory to reduce material and labor costs. However, our efforts to maintain a meaningful margin may be partially offset by our ability to generate meaningful co-promotion revenue in 2021.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Timing of Our Research and Development Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Our spending on experiments and clinical studies may vary substantially from quarter to quarter. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. The timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are obtained in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results. We conduct clinical studies to validate our new testing products, as well as ongoing clinical and outcome studies to further expand the published evidence to support our commercialized AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products. Spending on research and development for both experiments and studies may vary significantly by quarter depending on the timing of these various expenses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">How We Recognize Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;We record revenue on an accrual basis based on our estimate of the amount that will be ultimately realized for each test upon delivery based on a historical analysis of amounts collected by test and by payor. Changes to such estimates may increase or decrease revenue recognized in future periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. We discuss many of these risks, uncertainties and other factors in the section entitled "Risk Factors."</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Janssen Promotion Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into the Janssen Agreement, under which we are responsible for the costs associated with our sales force in promoting SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. Janssen is responsible for all other costs associated with our promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Janssen Agreement. In exchange for our sales and co-promotional services, we are entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over a predetermined baseline. For the quarter ended March&#160;31, 2020, the tiered promotion fee ranged from $750 to $1,250 per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020 we amended the Janssen Agreement, to adjust the predetermined average baseline for total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to approximately 26,000 prescribed units per quarter. For each of the third and fourth quarters of 2020, we received a minimum promotion fee of $0.3 million and the fee was be capped at 5% above the adjusted predetermined baseline. In December 2020, we further amended the Janssen Agreement, pursuant to which the predetermined average baseline for total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the quarters ending December 31, 2020, March 31, 2021 and June 30, 2021, was adjusted to approximately 28,750 prescribed units per quarter, subject to further adjustment under certain circumstances. For the first and second quarter of 2021, we will be entitled to an amended quarterly tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over the predetermined baseline. Pursuant to the Amended Janssen Agreement, for each of the first and second quarters of 2021, we will receive a minimum promotion fee of $0.3 million and the fee will be capped at 10% above the adjusted predetermined baseline. The quarterly tiered promotion fee for the remaining term of the Amended Janssen Agreement beginning on July 1, 2021 will revert to the terms set forth in the Janssen Agreement prior to the amendment, with no minimum promotion fee and no cap on predetermined baseline units. The Janssen Agreement expires on December 31, 2021, unless extended by us for an additional 12 months upon 180 days written notice prior to the end of the current term. If we elect to extend the term, the predetermined baseline for 2022 will be subject to future agreement by us and Janssen. Janssen may terminate the Janssen Agreement at any time for any reason upon 30 days' notice to us, and we may terminate the Janssen Agreement for any reason at the end of any calendar quarter upon 30 days' notice to Janssen. Either party may terminate the Janssen Agreement in the event of the other party's default of any of its material obligations under the agreement if such default remains uncured for a specified period of time following receipt of written notice of such default.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximately $0.3 million and no revenue for the three months ended March&#160;31, 2021 and 2020, respectively, for our promotional efforts under the Janssen Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our experience to date, we expect some seasonal variations in our financial results due to a variety of factors, such as the year-end holiday period and other major holidays, vacation patterns of both patients and healthcare providers, including medical conferences, climate and weather conditions in our markets, seasonal conditions that may affect medical practices and provider activity, including for example influenza outbreaks that may reduce the percentage of patients that can be seen, and other factors relating to the timing of patient benefit changes, as well as patient deductibles and co-insurance limits.</span></div><div id="idffe191f32b5442996096aa67f5e278a_73"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have derived nearly all of our revenue from the sale of our testing products, most of which is attributable to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test. We primarily market our testing products to rheumatologists in the United States. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rheumatologists who order our testing products and to whom results are reported are generally not responsible for payment for these products. The parties that pay for these services, or payors, consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e. hospitals, other laboratories, etc.), and patient self-pay. Our service is completed upon the delivery of test results to the prescribing rheumatologists which triggers billing for the service.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We record revenue on an accrual basis based on our estimate of the amount that will be ultimately realized for each test upon delivery based on a historical analysis of amounts collected by test and by payor. These assessments require significant judgment by management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase our revenue will depend on our ability to further penetrate the market for our current and future testing products, and increase our reimbursement and collection rates for tests delivered, as well as our ability to continue to generate meaningful co-promotion revenue. We expect to encounter difficulties promoting SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above the predetermined baseline potentially resulting in us receiving the minimum promotion fee of $0.3 million in the second quarter of 2021. Additionally, there is no minimum promotion fee for the second half of 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, we substantially recovered to pre-COVID-19 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered in the fourth quarter of 2020. However, the continued spread of COVID-19 may adversely affect testing volumes in future periods, the extent of which is highly uncertain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue represents the expenses associated with obtaining and testing patient specimens. The components of our costs of revenue include materials costs, direct labor, equipment and infrastructure expenses associated with testing specimens, shipping charges to transport specimens, blood specimen collections fees, royalties, depreciation and allocated overhead, including rent and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each payor, commercial third-party, government, or individual, reimburses us at different amounts. These differences can be significant. As a result, our costs of revenue as a percentage of revenue may vary significantly from period to period due to the composition of payors for each month's billings.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming future testing volumes are not negatively impacted by the spread of COVID-19, we expect that our costs of revenue will increase in absolute dollars as the number of tests we perform increases. However, we expect that the cost per test will decrease over time due to volume discounts on materials and shipping costs and other volume efficiencies we may gain as the number of tests we perform increases. As discussed above, the continued spread of COVID-19 may adversely affect testing volumes which may result in an increase in cost per test due to our inability to realize volume efficiencies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist of personnel costs, including stock-based compensation expense, direct marketing expenses, accounting and legal expenses, consulting costs, and allocated overhead including rent, information technology, depreciation and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our selling, general and administrative expenses will increase in absolute dollars in 2021 as compared to 2020, as we continue to evaluate the reach and frequency of our sales and sales support functions, expected additions to headcount and increases for personnel costs, including stock-based compensation. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs incurred to develop our technology, testing products and product candidates, collect clinical specimens and conduct clinical studies to develop and support our testing products and product candidates. These costs consist of personnel costs, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">studies and allocated overhead including rent and utilities. We expense all research and development costs in the periods in which they are incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses will increase in absolute dollars in 2021 as compared to 2020, as we continue to invest in research and development activities related to our existing testing products and product candidates, including the expansion of our clinical research and development facility, expected additions to headcount and increases for personnel costs, including stock-based compensation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of cash and non-cash interest expense associated with our financing arrangements, including the borrowings under our amended loan and security agreement with Innovatus Life Sciences Lending Fund I, LP, or Innovatus. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect interest expense to remain consistent in 2021 as compared to 2020, and remain consistent thereafter until 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, consists primarily of interest income earned on our cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes include federal and state income taxes in the United States.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_76"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited, in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,805&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,221)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(631)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,209)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,681)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,209)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,563)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(646)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $1.0&#160;million, or 10.5%, for the three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020, primarily due to an increase in the number of diagnostic tests delivered resulting in part from volume reductions experienced in late March 2020 as a result of the COVID-19 pandemic. The number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests, which accounted for 81% and 83% of revenue in the three months ended March&#160;31, 2021 and 2020, respectively, increased to 29,029 tests delivered in the three months ended March&#160;31, 2021 compared to 27,126 tests delivered in the same 2020 period. The adoption of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test by rheumatologists for the three months ended March&#160;31, 2021 increased to 1,763 ordering healthcare providers as compared to 1,692 ordering healthcare providers in the same 2020 period. In addition, revenue from the co-promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased to approximately $0.3 million during the three months ended March&#160;31, 2021 compared to no co-promotion revenue during the three months ended March&#160;31, 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue increased $0.2 million, or 3.7%, for the three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020. This increase was primarily due to increased direct costs such as materials and supplies, labor and shipping and handling associated with the increase in test volume in 2021 compared to 2020, partially offset by decreased royalty costs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $0.4&#160;million, or 4.3%, for the three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020. This increase was primarily due to an increase of $0.4 million of employee related expenses, including stock-based compensation and recruitment expenses, and increases related to insurance expenses of $0.1 million and legal expenses of $0.1 million, partially offset by decreases in audit and professional services of $0.1 million and marketing expenses of $0.1 million. The first quarter of 2020 included one-time restructuring charges of approximately $0.2 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $0.8 million for the three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020. This increase was primarily due to an increase of $0.4 million of employee related expenses, including stock-based compensation and recruitment expenses, and an increase related to clinical study expenses of $0.4 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense remained consistent for the three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, decreased $0.2 million for the three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020. The decrease was primarily driven by lower money market interest rates in 2021 compared to 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit decreased $0.1 million for the three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020 due to a change in tax law under the CARES Act enacted in 2020 that resulted in an income tax benefit during the three months ended March&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception. For the three months ended March&#160;31, 2021 and 2020, we incurred a net loss of $6.2 million and $5.6&#160;million, respectively, and we expect to incur additional losses and increased operating expenses in future periods. As of March&#160;31, 2021, we had an accumulated deficit of $187.5&#160;million. To date, we have generated only limited revenue, and we may never achieve revenue sufficient to offset our expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the date of our IPO in September 2019, our operations were financed primarily from sales of our common stock and redeemable convertible preferred stock and borrowings under various debt financings. In September 2019, we completed our IPO and received net proceeds of approximately $50.4 million, net of underwriting discounts, commissions and other offering expenses, for aggregate expenses of approximately $7.5 million. On November 10, 2020, we filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020. In March 2021, we completed a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">public offering of 4,255,000 shares of our common stock at a public offering price of $16.25 per share, which shares were sold under the Shelf Registration Statement. Net proceeds from the offering were approximately $64.7 million, net of underwriting discounts and commissions and other offering expenses of $4.4 million. As of March&#160;31, 2021, we had $118.1&#160;million of cash and cash equivalents. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in cash and money market funds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we entered into the loan and security agreement with Innovatus under which we immediately drew down $20.0&#160;million. In December 2018, we borrowed an additional $5.0&#160;million under the loan agreement. In November 2019, we amended the loan and security agreement with Innovatus, which we collectively refer to as the Amended Loan Agreement. Pursuant to the Amended Loan Agreement, the loan term is for five years with a final maturity date of November 2024. The Amended Loan Agreement accrues interest at an annual rate of 8.5%, of which 2.0%, during the first 36 months, will be treated as paid in-kind interest. Paid in-kind interest is added to the principal balance each period. After the initial 36 months of the loan, the entire 8.5% will be paid in cash at the end of each period. On or after the first anniversary of the Loan Amendment, but before the second anniversary of the Loan Amendment, we may, at our option, prepay the term loan borrowings by paying the lender a prepayment premium. Prepayment before the second anniversary of the Loan Amendment may only occur for specified reasons in the Amended Loan Agreement. The prepayment premium decreases by 1% during each subsequent twelve-month period after the first anniversary of the Loan Amendment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Amended Loan Agreement are secured by a security interest in substantially all of our assets, including our intellectual property. The Amended Loan Agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to maintain certain levels of minimum liquidity of $2.0&#160;million and achieve certain minimum amounts of revenue, and limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The consequences of failing to achieve the performance covenant will be cured if, within sixty days of failing to achieve the performance covenant, we issue additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. At March&#160;31, 2021, we were in compliance with all covenants of the Amended Loan Agreement. In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the loan and security agreement with Innovatus in November 2017, we issued the lender a seven-year warrant to purchase 15,384,615 shares of our Series&#160;F redeemable convertible preferred stock at an exercise price of $0.078&#160;per share, and in December 2018, in connection with the additional $5.0 million borrowed under the loan and security agreement, we issued to the lender a seven-year warrant to purchase 3,846,154 shares of our Series F redeemable convertible preferred stock at an exercise price of $0.078 per share. In connection with the completion of our IPO in September 2019, the warrants were automatically converted into warrants exercisable for an aggregate of 104,722 shares of common stock at an exercise price of $14.32.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we received $0.7 million of funding under the CARES Act Provider Relief Fund, subject to our agreement to comply with the Department of Health &amp; Human Services', or HHS, standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support healthcare-related expenses or lost revenue attributable to COVID-19.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash are to fund our operations as we continue to grow our business. We expect to continue to incur operating losses in the near term as our operating expenses will be increased to support the growth of our business. We expect that our costs of revenue, selling, general and administrative expenses, and research and development expenses will continue to increase as we increase our test volume, expand our marketing efforts and increase our internal sales force to drive increased adoption of and reimbursement for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products, promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, prepare to commercialize new testing products, continue our research and development efforts and further develop our product pipeline. We believe we have sufficient laboratory capacity to support increased test volume. We expect to make significant investments for laboratory equipment and capital expenditures in the near term related to our laboratory facilities and expansion of research capabilities, including an investment to convert </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately 8,000 square feet of warehouse space into additional clinical laboratory and research and development facility space, which is expected to be completed in the first half of 2022. The expansion of our clinical laboratory and research development facility are expected to allow us to enhance our testing capacity and improve efficiencies as well as allow us to develop molecular and multiomic capabilities and advance our product pipeline, including support of development of tests for fibromyalgia, RA, thrombosis and lupus nephritis. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our near- and longer-term liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business, including payments we may be required to make upon the achievement of previously negotiated milestones associated with intellectual property we have licensed, payments related to non-cancelable purchase obligations with one supplier for reagents, payments related to our principal and interest under our long term borrowing arrangements, payments for operating leases related to our office and laboratory space in Vista, California and payments for capital leases related to our laboratory equipment. Based on our current business plan, we believe that our existing cash and cash equivalents and our anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12&#160;months from the date of this filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimate of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business, including challenges resulting from social distancing and stay-at home orders through a reduction in testing volumes;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain and grow sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for our testing products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in working capital;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation studies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the additional costs we may incur as a result of operating as a public company;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with our promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including the expansion of our sales capabilities, and the extent and timing of generating revenue from such promotion; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we establish additional partnerships or in-license, acquire or invest in complementary businesses or products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate revenue to support our costs structure, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. If additional funding is required or desired, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all, or that we will generate sufficient cash from operations to adequately fund our operating needs or achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion plans or commercialization efforts. Doing so will likely have an unfavorable effect on our ability to execute on our business plan and could have a negative impact on our relationships with parties such as Janssen. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,312)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,301)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,436)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2021 was $4.3 million and primarily resulted from our net loss of $6.2 million adjusted for non-cash charges of $1.3 million related to stock-based compensation, depreciation, amortization and non-cash interest and changes in our net operating assets of $0.6&#160;million primarily related to net decreases in prepaid expenses and other current assets and accounts receivable, net, partially offset by net decreases in accounts payables and accrued and other current liabilities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2020 was $3.3&#160;million and primarily resulted from our net loss of $5.6&#160;million adjusted for non-cash charges of $0.6&#160;million related to depreciation, amortization, stock-based compensation and non-cash interest. The net cash in operating activities were partially offset by changes in our net operating assets of $1.6&#160;million primarily related to net increases in accounts payable and accrued and other current liabilities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended March&#160;31, 2021 and March&#160;31, 2020 was $0.2&#160;million and $0.1&#160;million, respectively, and was due to net purchases of property and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2021 was $65.1 million primarily resulting from the net proceeds received from our public offering in March 2021 of $65.0 million and proceeds from Employee Stock Purchase Plan purchases, partially offset by principal payments on capital lease obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used by financing activities for the three months ended March&#160;31, 2020 was $0.1&#160;million and primarily resulted from principal payments on capital lease obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Management Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and any such differences may be material. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our critical accounting policies, please see the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Significant Management Estimates" contained in the Annual Report on Form 10-K for the year ended December 31, 2020, as amended. There have been no significant changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2021 as compared to the critical accounting policies and estimates disclosed in Management&#8217;s </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discussion and Analysis of Financial Condition and Operations included in the Annual Report on Form 10-K for the year ended December 31, 2020, as amended, other than as set forth in Note 2 to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 2 to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q for a summary of changes in significant accounting policies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented we did not have, nor do we currently have any off-balance sheet arrangements, as defined under the rules and regulations of the SEC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an "emerging growth company." The JOBS Act permits an "emerging growth company" such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our audited financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act, which such fifth anniversary will occur in 2024. However, if certain events occur prior to the end of such five-year period, including if we become a "large accelerated filer" as defined in Rule&#160;12b-2 under the Exchange Act, our annual gross revenues exceed $1.07&#160;billion or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.</span></div><div id="idffe191f32b5442996096aa67f5e278a_79"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_82"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this quarterly report, the effectiveness of our disclosure controls </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of March&#160;31, 2021, our disclosure controls and procedures were effective at the reasonable assurance level. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during the three months ended March&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_85"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div style="text-align:center"><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_88"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently not a party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="idffe191f32b5442996096aa67f5e278a_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors disclosed in Part I, Item 1A, "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2020, as amended, other than changes to the risk factors set forth below:</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Strategy </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business is subject to risks arising from epidemic diseases, such as the global pandemic of the COVID-19 coronavirus.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current COVID-19 worldwide pandemic has presented substantial public health challenges and is affecting our employees, patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions are taking actions in an effort to slow the spread of COVID-19, including issuing varying forms of "stay-at-home" orders, restricting business functions outside of one's home, restricting gatherings, restricting travel, and mandating social distancing and face coverings. Certain jurisdictions have begun a phased re-opening, although the potential to return to prior restrictions remains if there are increases in new COVID-19 cases in the future. Even in areas where "stay-at-home" restrictions have been lifted and the number of COVID-19 cases have declined, many individuals remain cautious about resuming activities such as preventative-care medical visits. A pandemic, including COVID-19 or other public health epidemic, poses the risk that we or our employees, contractors, suppliers, third-party shipping carries, government and third-party payors and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. As a result of COVID-19 related limitations and reordering of priorities across the U.S. healthcare system, a reduction in patient flow occurred and our test volumes began to decrease in the second half of March 2020 and we experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD volume decrease of approximately 5% in the year ended December 31, 2020 as compared to 2019. We substantially recovered to pre-COVID-19 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests delivered in the fourth quarter 2020. For the three months ended March&#160;31, 2021 as compared to the same period in 2020, we experienced a AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD volume increase of approximately 7%. However, the continued spread of COVID-19 may adversely affect testing volumes in future periods, the extent of which is highly uncertain. Healthcare providers and patients have canceled or delayed scheduling, and for an extended period of time may continue to cancel or delay scheduling, standard wellness visits and other non-emergency appointments and procedures, contributing to a decline in orders of our testing products. The economic downturn may also result in closures of the practices of our primary customers. As it relates to our promotion efforts of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we may experience decreased demand for or discontinued treatment with SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from patients who are infected by COVID-19 or who may be at higher risk of infection if it is determined that such patients should minimize exposure to immunosuppressant therapies. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we believe there are several other important factors that have impacted, and that we expect will impact our operating performance and results of operations, including shutdowns of our facilities and operations as well as those of our suppliers and courier services, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, as well as our inability to achieve or re-negotiate volume-based discounts with our key suppliers and to absorb fixed laboratory expenses. For example, we have experienced delays in patient enrollment for ongoing and planned clinical studies involving our tests, which may delay or prevent launch of future test products. Our sales force has been, and for an extended period of time may continue to be limited to their in-person interactions with healthcare providers, and therefore, also limited their ability to engage in various types of healthcare provider education activities. The portion of our workforce which has been working remotely in an effort to reduce the spread of COVID-19, may be infected from the virus or otherwise distracted. We have also experienced delays in procurement of our testing supplies due to suppliers rationing testing supplies and prioritizing COVID-19 testing in the first quarter of 2021, which may continue into the future, and our partners, including Janssen, may also experience a disruption in their ability to readily obtain supply. We may also face increased competition for laboratory employees due to the increased demand in the industry for such personnel. We may inaccurately estimate the duration or severity of the COVID-19 pandemic, which could cause us to misalign our staffing, spending, activities and precautionary measures with market current or future market conditions.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our laboratory operations, including laboratory employees and medical directors, may be subject to closure or shut down, either due to the spread of the disease within these individuals, or as part of a larger scale government </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">recommendation or mandate. Any disruption in our laboratory operations would have a material adverse effect on our business and would impede our ability to process tests in a timely manner, or at all.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The occurrence of any of the foregoing events could have a material adverse effect on our business, financial condition and results of operations. The COVID-19 pandemic and mitigation measures have had and may continue to have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital on a timely basis or at all. The extent to which the COVID-19 pandemic impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact. COVID-19 may also have the effect of heightening many of the other risks described in this section and in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020, as amended.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will continue to devote considerable resources to the research and development of our planned future testing products and enhancements to our current testing products. We may not be able to develop testing products with the clinical utility necessary to be useful and commercially successful. There are certain products for which a commercial launch would trigger additional payment obligations to licensors of the technology. In these cases, if the economic projections of the product do not outweigh the additional obligations, we may not launch these products. In order to develop and commercialize testing products, we need to: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expend significant funds to conduct substantial research and development; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conduct successful validation studies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our laboratory processes to accommodate different tests; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">achieve and maintain required regulatory certifications; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our infrastructure to be able to analyze increasingly large amounts of data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">build the commercial infrastructure to market and sell new testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our testing product development process involves a high degree of risk and may take several years. Our testing product development efforts may fail for many reasons, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to identify additional biomarkers to incorporate into our testing products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure or sub-optimal performance of the testing product at the research or development stage;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining patient consent inclusive of genetic analysis;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty in accessing archival patient blood specimens, especially specimens with known clinical results; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure of clinical validation studies to support the effectiveness of the test. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a testing product candidate or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating potential revenue from a new testing product and our ability to invest in other products in our pipeline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the second half of 2021, we expect to begin the conversion of approximately 8,000 square feet of warehouse space into an additional clinical laboratory and research and development facility space in order to develop molecular and multiomic capabilities. We have not yet developed any molecular or multiomic testing products nor do we have experience developing and integrating molecular biomarkers into new or existing testing products, and we may never be successful doing so in the future. As a result, there is considerable risk that the expansion of our clinical laboratory and research and development facility may not lead to the development of additional testing products that generate meaningful revenue. Further, as we begin to expand our clinical laboratory and research and development facility in order to develop molecular and multiomic capabilities, we expect to need to make significant investments in key personnel and highly trained scientists with relevant experience to handle the increased operations and development of molecular biomarkers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as we develop testing products, we will have to make significant investments in product development, marketing and selling resources. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the testing product or product feature that was the subject of the clinical study, which could harm our business. Additionally, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Developing new testing products and enhancements to our existing technologies is expensive and time consuming, and there is no assurance that such activities will result in significant new marketable testing products, enhancements to our current technologies, design improvements, cost savings, revenue or other expected benefits. If we spend significant resources on research and development and are unable to generate an adequate return on our investment or divert resources away from other, more attractive growth opportunities, our business and results of operations may be materially and adversely affected. </span></div><div><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_94"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2019, the SEC declared effective our registration statement on Form S-1 (File No. 333-233446), as amended, filed in connection with our IPO. At the closing of the offering on September 23, 2019, we issued and sold 4,140,00 shares of our common stock at the initial public offering price to the public of $14.00 per share, which included the exercise in full of the underwriters&#8217; option to purchase additional shares. We received gross proceeds from the IPO of $58.0 million, before deducting underwriting discounts, commissions and other offering expenses, which resulted in net proceeds of approximately $50.4 million and offering-related transaction costs of approximately $7.5 million. Cowen and Company, LLC, Cantor Fitzgerald &amp; Co and William Blair &amp; Company, L.L.C. acted as joint book-running managers for the offering. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, we have used approximately $21.1 million of the proceeds from our IPO primarily related to selling and marketing activities. There has been no material change in the planned use of such proceeds from that described in the final Prospectus filed by us with the SEC on September 20, 2019.</span></div><div style="text-align:center"><span><br/></span></div><div id="idffe191f32b5442996096aa67f5e278a_97"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="idffe191f32b5442996096aa67f5e278a_100"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="idffe191f32b5442996096aa67f5e278a_103"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="idffe191f32b5442996096aa67f5e278a_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Filing Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519252366/d769261dex31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/23/2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000017/ex31-amendedandrestatedbyl.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/22/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex41.htm">Specimen stock certificate evidencing the shares of common stock.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, dated July  12, 2019, by and among the Registrant and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex43.htm">Amended and Restated Stockholders&#8217; Agreement, dated July 12, 2019, by and among the Registrant and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex44.htm">Form of Common Stock Purchase Warrant issued to investors by the Registrant in connection with private placement financings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex105-formofrsuagreement20.htm">Form of Restricted Stock Unit Agreement under Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex1034-amend1to1221liberty.htm">First Amendment to Standard Industrial/Commercial Single-Tenant Lease, dated January 6, 2021, by and between Liberty Vista and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex1046-executivecicseveran.htm">Executive Change in Control Severance Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn311-33121.htm">Certificate of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn312-33121.htm">Certificate of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn321-33121.htm">Certifications Pursuant to U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">* &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="idffe191f32b5442996096aa67f5e278a_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:52.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXAGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May&#160;11, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Fortunato Ron Rocca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May&#160;11, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kamal Adawi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>xgn311-33121.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic15e140b9a164bb8b0cc93fd865cf046_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, Fortunato Ron Rocca, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Quarterly Report on Form 10-Q of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;11, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>xgn312-33121.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i18ba4e5ea7df44a2a4b8410054ecc6b0_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, Kamal Adawi, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Quarterly Report on Form 10-Q of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;11, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>xgn321-33121.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i99fdd05aabda430f95ca85881506630e_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:201%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying quarterly report on Form 10-Q of the Company for the quarterly period ended March&#160;31, 2021 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; May&#160;11, 2021</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:20pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying quarterly report on Form 10-Q of the Company for the quarterly period ended March&#160;31, 2021 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; May&#160;11, 2021</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:20pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>exdx-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:dc3d5bf2-9b73-4463-aa2c-e75c744aa8d3,g:734221f7-636e-4e71-b928-4b5e730d1da3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exdx="http://www.exagen.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exagen.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.exagen.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://www.exagen.com/role/CondensedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofOperations" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations">
        <link:definition>1003004 - Statement - Unaudited Condensed Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofStockholdersEquity" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Unaudited Condensed Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofStockholdersEquityParenthetical" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical">
        <link:definition>1005006 - Statement - Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedStatementsofCashFlows" roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Unaudited Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.exagen.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.exagen.com/role/OrganizationDetails">
        <link:definition>2402401 - Disclosure - Organization - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSecuritiesDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.exagen.com/role/OtherFinancialInformation">
        <link:definition>2111103 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.exagen.com/role/OtherFinancialInformationTables">
        <link:definition>2312302 - Disclosure - Other Financial Information - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPrepaidexpensesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails">
        <link:definition>2413407 - Disclosure - Other Financial Information - Prepaid expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPropertyandequipmentDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails">
        <link:definition>2414408 - Disclosure - Other Financial Information - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationNarrativeDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails">
        <link:definition>2415409 - Disclosure - Other Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails">
        <link:definition>2416410 - Disclosure - Other Financial Information - Accrued and other current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.exagen.com/role/Borrowings">
        <link:definition>2117104 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.exagen.com/role/BorrowingsTables">
        <link:definition>2318303 - Disclosure - Borrowings - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails">
        <link:definition>2419411 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsFutureminimumpaymentsDetails" roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails">
        <link:definition>2420412 - Disclosure - Borrowings - Future minimum payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.exagen.com/role/CommitmentandContingencies">
        <link:definition>2121105 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesNarrativeDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails">
        <link:definition>2422413 - Disclosure - Commitment and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exagen.com/role/FairValueMeasurements">
        <link:definition>2123106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exagen.com/role/FairValueMeasurementsTables">
        <link:definition>2324304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails">
        <link:definition>2425414 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exagen.com/role/StockholdersEquity">
        <link:definition>2126107 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.exagen.com/role/StockholdersEquityTables">
        <link:definition>2327305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2428415 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.exagen.com/role/StockholdersEquityDetails">
        <link:definition>2429416 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlan" roleURI="http://www.exagen.com/role/StockOptionPlan">
        <link:definition>2130108 - Disclosure - Stock Option Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanTables" roleURI="http://www.exagen.com/role/StockOptionPlanTables">
        <link:definition>2331306 - Disclosure - Stock Option Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanNarrativeDetails" roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails">
        <link:definition>2432417 - Disclosure - Stock Option Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockOptionActivityDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails">
        <link:definition>2433418 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanRestrictedStockUnitsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails">
        <link:definition>2434419 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanFairValueAssumptionsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails">
        <link:definition>2435420 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockBasedCompensationExpenseDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails">
        <link:definition>2436421 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Covid19" roleURI="http://www.exagen.com/role/Covid19">
        <link:definition>2137109 - Disclosure - Covid-19</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Covid19Details" roleURI="http://www.exagen.com/role/Covid19Details">
        <link:definition>2438422 - Disclosure - Covid-19 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" abstract="false" name="DeferredOfferingCostsIncludedWithinCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AccruedPurchaseGoodsAndServicesCurrent" abstract="false" name="AccruedPurchaseGoodsAndServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_JanssenSIMPONIMember" abstract="true" name="JanssenSIMPONIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_IncentiveAwardPlan2019Member" abstract="true" name="IncentiveAwardPlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_HealthcareInsurersMember" abstract="true" name="HealthcareInsurersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPromotionFeePerPrescription" abstract="false" name="JointVentureQuarterlyPromotionFeePerPrescription" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationJan192026Member" abstract="true" name="ExpirationJan192026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" abstract="false" name="DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" abstract="false" name="DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_CoPromotionAgreementRenewalTerm" abstract="false" name="CoPromotionAgreementRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_LongTermDebtIncludingUndiscountedInterest" abstract="false" name="LongTermDebtIncludingUndiscountedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_MilestoneContingencyFairValueDisclosure" abstract="false" name="MilestoneContingencyFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_StockIssuanceCosts" abstract="false" name="StockIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" abstract="false" name="PurchaseObligationAnnualIncreaseInCommitmentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm" abstract="false" name="CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_CollaborationAgreementAnnualCollaborationFee" abstract="false" name="CollaborationAgreementAnnualCollaborationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PrepaidMaintenanceAndInsuranceContracts" abstract="false" name="PrepaidMaintenanceAndInsuranceContracts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_BlueShieldMember" abstract="true" name="BlueShieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_PrometheusLaboratoriesIncMember" abstract="true" name="PrometheusLaboratoriesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPrescribedUnits" abstract="false" name="JointVentureQuarterlyPrescribedUnits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_ClientMember" abstract="true" name="ClientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_ExpirationMar312026Member" abstract="true" name="ExpirationMar312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_RoyaltyObligationPercentageOfSales" abstract="false" name="RoyaltyObligationPercentageOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_EquipmentPurchasedUnderCapitalLease" abstract="false" name="EquipmentPurchasedUnderCapitalLease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeAxis" abstract="true" name="RentalPropertyByTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exdx_CapitalRoyaltyPartnersIILPMember" abstract="true" name="CapitalRoyaltyPartnersIILPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeDomain" abstract="true" name="RentalPropertyByTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exdx_ExpirationSep72024Member" abstract="true" name="ExpirationSep72024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" abstract="false" name="JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_DebtInstrumentStatedInterestRatePaidInKind" abstract="false" name="DebtInstrumentStatedInterestRatePaidInKind" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_OfficeMember" abstract="true" name="OfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_LongTermDebtUndiscountedInterestAmount" abstract="false" name="LongTermDebtUndiscountedInterestAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_Term2017Member" abstract="true" name="Term2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_OperatingLeasesRenewalTerm" abstract="false" name="OperatingLeasesRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_ReceivableBenchmarkMember" abstract="true" name="ReceivableBenchmarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_UnitedHealthcareMember" abstract="true" name="UnitedHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement" abstract="false" name="CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPromotionFee" abstract="false" name="JointVentureQuarterlyPromotionFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationApr12026Member" abstract="true" name="ExpirationApr12026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_LicenseAgreementInitialLicenseFee" abstract="false" name="LicenseAgreementInitialLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_InnovatusLifeSciencesLendingFundMember" abstract="true" name="InnovatusLifeSciencesLendingFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_AdvancePayment" abstract="false" name="AdvancePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AccruedLiabilitiesClinicalStudyCurrent" abstract="false" name="AccruedLiabilitiesClinicalStudyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AssetsUnderCapitalLeaseMember" abstract="true" name="AssetsUnderCapitalLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_DeferredOfferingCostsReclassifiedToEquity" abstract="false" name="DeferredOfferingCostsReclassifiedToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_Government1Member" abstract="true" name="Government1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentPaidInKindLoansIssued" abstract="false" name="DebtInstrumentPaidInKindLoansIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationDec72025Member" abstract="true" name="ExpirationDec72025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exdx_MilestoneObligation" abstract="false" name="MilestoneObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_AVISECTDTestMember" abstract="true" name="AVISECTDTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_AlleghenyHealthNetworkResearchInstituteMember" abstract="true" name="AlleghenyHealthNetworkResearchInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>exdx-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:dc3d5bf2-9b73-4463-aa2c-e75c744aa8d3,g:734221f7-636e-4e71-b928-4b5e730d1da3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20210331.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="exdx-20210331.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f54e6a77-8ffd-42b2-b4f4-368248268fad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_cf625b2c-64bf-4074-95f8-c69cc0461ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f54e6a77-8ffd-42b2-b4f4-368248268fad" xlink:to="loc_us-gaap_PreferredStockValue_cf625b2c-64bf-4074-95f8-c69cc0461ca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_67ac1c99-d3bb-4a66-91ad-b27c20ac0066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f54e6a77-8ffd-42b2-b4f4-368248268fad" xlink:to="loc_us-gaap_AdditionalPaidInCapital_67ac1c99-d3bb-4a66-91ad-b27c20ac0066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1bc979be-509f-4038-b431-dbdfca133cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f54e6a77-8ffd-42b2-b4f4-368248268fad" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1bc979be-509f-4038-b431-dbdfca133cd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_41794b39-b393-40b7-8216-cc1f0021d656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f54e6a77-8ffd-42b2-b4f4-368248268fad" xlink:to="loc_us-gaap_CommonStockValue_41794b39-b393-40b7-8216-cc1f0021d656" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bd642d67-2a0b-43de-9e40-4cf33ae802a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7032479-1918-4246-8e4c-df4f85eaf35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bd642d67-2a0b-43de-9e40-4cf33ae802a7" xlink:to="loc_us-gaap_StockholdersEquity_a7032479-1918-4246-8e4c-df4f85eaf35e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_40f9582b-5a6f-47bc-bbdb-42cefcb509d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bd642d67-2a0b-43de-9e40-4cf33ae802a7" xlink:to="loc_us-gaap_Liabilities_40f9582b-5a6f-47bc-bbdb-42cefcb509d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2ae03fec-f7e6-43a9-ac97-1030f2f267f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bd642d67-2a0b-43de-9e40-4cf33ae802a7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2ae03fec-f7e6-43a9-ac97-1030f2f267f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3ca82793-7d88-4a00-8f00-be1c91b50dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_dcc73e2e-0ebb-4ead-a89f-d3618fa1f7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3ca82793-7d88-4a00-8f00-be1c91b50dc5" xlink:to="loc_us-gaap_AccountsPayableCurrent_dcc73e2e-0ebb-4ead-a89f-d3618fa1f7f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3a9552f9-d1f3-4a8b-af4f-d782cb159c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3ca82793-7d88-4a00-8f00-be1c91b50dc5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3a9552f9-d1f3-4a8b-af4f-d782cb159c66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a2416341-45fa-45a3-8404-dcd618304fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3b787d0-5fd8-4d15-8fd8-6c39f20f33db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a2416341-45fa-45a3-8404-dcd618304fc1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3b787d0-5fd8-4d15-8fd8-6c39f20f33db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_70d8b690-62be-43af-9779-0647ae7f8812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a2416341-45fa-45a3-8404-dcd618304fc1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_70d8b690-62be-43af-9779-0647ae7f8812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_226f8a1f-6b04-4412-8655-34e7b784a6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a2416341-45fa-45a3-8404-dcd618304fc1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_226f8a1f-6b04-4412-8655-34e7b784a6f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c4272ff0-0e24-41e1-9966-4ed0767cad4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a2416341-45fa-45a3-8404-dcd618304fc1" xlink:to="loc_us-gaap_LiabilitiesCurrent_c4272ff0-0e24-41e1-9966-4ed0767cad4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_33ae5b17-3d9d-4063-b34f-4cf3b9e5fde8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_40542769-03e1-42eb-bafa-1ff9c8977096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_33ae5b17-3d9d-4063-b34f-4cf3b9e5fde8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_40542769-03e1-42eb-bafa-1ff9c8977096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3e78d54a-0742-4b41-9a26-091012fe2a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_33ae5b17-3d9d-4063-b34f-4cf3b9e5fde8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3e78d54a-0742-4b41-9a26-091012fe2a0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_db3d5e90-00b8-4ebc-a856-ad223d581da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_33ae5b17-3d9d-4063-b34f-4cf3b9e5fde8" xlink:to="loc_us-gaap_AssetsCurrent_db3d5e90-00b8-4ebc-a856-ad223d581da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_37a3da58-425c-4a31-ae56-ede714e0f062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_33ae5b17-3d9d-4063-b34f-4cf3b9e5fde8" xlink:to="loc_us-gaap_Goodwill_37a3da58-425c-4a31-ae56-ede714e0f062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4c2ee088-9f6e-41fd-9098-ca6fca73116b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1b57fac-38c2-4f88-9e18-6880306723cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c2ee088-9f6e-41fd-9098-ca6fca73116b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1b57fac-38c2-4f88-9e18-6880306723cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0a86cc0e-5482-41e3-9900-6efa86b55fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c2ee088-9f6e-41fd-9098-ca6fca73116b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0a86cc0e-5482-41e3-9900-6efa86b55fc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_5030547e-0975-4e3f-ba0c-069ab7dd3354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c2ee088-9f6e-41fd-9098-ca6fca73116b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_5030547e-0975-4e3f-ba0c-069ab7dd3354" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20210331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="simple" xlink:href="exdx-20210331.xsd#UnauditedCondensedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_77785dbe-daa7-4fbf-aaad-8cc4bb5df3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ad822b3d-b2e5-4049-9e75-cec77664ac76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_77785dbe-daa7-4fbf-aaad-8cc4bb5df3df" xlink:to="loc_us-gaap_InterestExpense_ad822b3d-b2e5-4049-9e75-cec77664ac76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_75f42ac9-0440-493d-b581-c89643e2db7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_77785dbe-daa7-4fbf-aaad-8cc4bb5df3df" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_75f42ac9-0440-493d-b581-c89643e2db7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9722708e-61e5-47bb-bea9-72b06f3dfeeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_77785dbe-daa7-4fbf-aaad-8cc4bb5df3df" xlink:to="loc_us-gaap_OperatingIncomeLoss_9722708e-61e5-47bb-bea9-72b06f3dfeeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cda01b4b-4549-4ecf-8201-07f71b010b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_32cc1950-c38e-4070-9455-772aec159610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_19915b46-96a7-44fd-8bd2-88af10ebb4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_32cc1950-c38e-4070-9455-772aec159610" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_19915b46-96a7-44fd-8bd2-88af10ebb4a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d5582454-b0e2-4560-9216-a9200f172226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_32cc1950-c38e-4070-9455-772aec159610" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d5582454-b0e2-4560-9216-a9200f172226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_479f5bed-5508-4d2d-b4e8-615a98e40584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_32cc1950-c38e-4070-9455-772aec159610" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_479f5bed-5508-4d2d-b4e8-615a98e40584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f61445f-e9d9-4bb5-b74d-dfb3446d96c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_d17abb88-d34d-421c-9147-5ac95c7afe7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2f61445f-e9d9-4bb5-b74d-dfb3446d96c3" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_d17abb88-d34d-421c-9147-5ac95c7afe7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_671ea6fc-00e7-48e7-ade4-80bb17b77379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2f61445f-e9d9-4bb5-b74d-dfb3446d96c3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_671ea6fc-00e7-48e7-ade4-80bb17b77379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0849ae3c-8b6b-435a-b597-38dbf54d1683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_54db3126-fd0a-48c9-93c8-dc5d5e9beb36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0849ae3c-8b6b-435a-b597-38dbf54d1683" xlink:to="loc_us-gaap_CostsAndExpenses_54db3126-fd0a-48c9-93c8-dc5d5e9beb36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_02751f81-7804-4874-b6e6-294de7bcb7de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0849ae3c-8b6b-435a-b597-38dbf54d1683" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_02751f81-7804-4874-b6e6-294de7bcb7de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20210331.xsd#UnauditedCondensedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="exdx-20210331.xsd#UnauditedCondensedStatementsofStockholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20210331.xsd#UnauditedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d843cfa0-d7e1-4c21-ba6d-913e444dbb04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_83c396e7-da67-471d-8e70-a519a87bc550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d843cfa0-d7e1-4c21-ba6d-913e444dbb04" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_83c396e7-da67-471d-8e70-a519a87bc550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef145379-403d-4e54-8b02-df69c564b5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c6d88c56-54c8-415f-af8b-34ec7fba3c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef145379-403d-4e54-8b02-df69c564b5e8" xlink:to="loc_us-gaap_ShareBasedCompensation_c6d88c56-54c8-415f-af8b-34ec7fba3c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_f07b6d36-7981-4849-80f2-fa36a923d2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef145379-403d-4e54-8b02-df69c564b5e8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_f07b6d36-7981-4849-80f2-fa36a923d2bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_940668ee-1402-495f-a364-660d82e64acb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef145379-403d-4e54-8b02-df69c564b5e8" xlink:to="loc_us-gaap_NetIncomeLoss_940668ee-1402-495f-a364-660d82e64acb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0223d618-71dd-4edb-a746-91df17931052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef145379-403d-4e54-8b02-df69c564b5e8" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0223d618-71dd-4edb-a746-91df17931052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d6868630-b67b-48eb-a6b5-0eb8aa435854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef145379-403d-4e54-8b02-df69c564b5e8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d6868630-b67b-48eb-a6b5-0eb8aa435854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e76957c8-975a-48f5-b73b-aa4c4cfb9f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef145379-403d-4e54-8b02-df69c564b5e8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e76957c8-975a-48f5-b73b-aa4c4cfb9f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5824258e-a117-4634-b59c-795c5ae36424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef145379-403d-4e54-8b02-df69c564b5e8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5824258e-a117-4634-b59c-795c5ae36424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_edf05d0b-a40f-408d-b191-db3f677a227c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef145379-403d-4e54-8b02-df69c564b5e8" xlink:to="loc_us-gaap_PaidInKindInterest_edf05d0b-a40f-408d-b191-db3f677a227c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_cabfb1b9-5177-48a9-93a1-8b59a0d9eb67" xlink:href="exdx-20210331.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef145379-403d-4e54-8b02-df69c564b5e8" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_cabfb1b9-5177-48a9-93a1-8b59a0d9eb67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6029be49-b34c-4840-b6ee-dc6787203edd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef145379-403d-4e54-8b02-df69c564b5e8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6029be49-b34c-4840-b6ee-dc6787203edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_a69e11c4-db9a-4c20-abc7-021dc1986578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef145379-403d-4e54-8b02-df69c564b5e8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_a69e11c4-db9a-4c20-abc7-021dc1986578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0fafc87e-6c34-4c8b-b6aa-1caa4ea1689e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5eb84b5-ccc0-45f3-a6b2-f7582b2ed1e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0fafc87e-6c34-4c8b-b6aa-1caa4ea1689e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5eb84b5-ccc0-45f3-a6b2-f7582b2ed1e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32018d7c-84d0-41e5-87bb-d52f72b05593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0fafc87e-6c34-4c8b-b6aa-1caa4ea1689e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32018d7c-84d0-41e5-87bb-d52f72b05593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e599de4-74bc-4ce7-8cae-2a3cca7b3460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0fafc87e-6c34-4c8b-b6aa-1caa4ea1689e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e599de4-74bc-4ce7-8cae-2a3cca7b3460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0e7d5b92-69ce-4572-8114-08e1d0beb0b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5f43c8bb-012f-49ba-9b32-bcd80b11e4a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0e7d5b92-69ce-4572-8114-08e1d0beb0b5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5f43c8bb-012f-49ba-9b32-bcd80b11e4a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_01ba4872-916b-471d-8a9b-3cdee5b54629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0e7d5b92-69ce-4572-8114-08e1d0beb0b5" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_01ba4872-916b-471d-8a9b-3cdee5b54629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_42211e7d-032b-4e2d-aa5d-de523d00f366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0e7d5b92-69ce-4572-8114-08e1d0beb0b5" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_42211e7d-032b-4e2d-aa5d-de523d00f366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4d0c007f-d983-423b-8a8f-45b63f715ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0e7d5b92-69ce-4572-8114-08e1d0beb0b5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4d0c007f-d983-423b-8a8f-45b63f715ccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_222d1ff1-a4cf-4b67-b654-b66349659e29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0e7d5b92-69ce-4572-8114-08e1d0beb0b5" xlink:to="loc_us-gaap_ProceedsFromStockPlans_222d1ff1-a4cf-4b67-b654-b66349659e29" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Organization" xlink:type="simple" xlink:href="exdx-20210331.xsd#Organization"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/Organization" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_395411dd-c3df-435e-a157-ab7082631648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_01256be5-7320-47b6-a711-69843b61ed8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_395411dd-c3df-435e-a157-ab7082631648" xlink:to="loc_us-gaap_RestrictedCash_01256be5-7320-47b6-a711-69843b61ed8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b02c072-8507-4737-9779-16cff948cffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_395411dd-c3df-435e-a157-ab7082631648" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b02c072-8507-4737-9779-16cff948cffd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformation"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e0e731cb-8253-4631-aca6-5186fa1cad69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_4edeadac-4e7b-4d1c-82bb-41bf49821dbe" xlink:href="exdx-20210331.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e0e731cb-8253-4631-aca6-5186fa1cad69" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_4edeadac-4e7b-4d1c-82bb-41bf49821dbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_204179b5-50f7-4e45-bda9-d7ecf33854c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e0e731cb-8253-4631-aca6-5186fa1cad69" xlink:to="loc_us-gaap_PrepaidRoyalties_204179b5-50f7-4e45-bda9-d7ecf33854c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_417f6438-9d78-4473-a06e-6eecfd894cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e0e731cb-8253-4631-aca6-5186fa1cad69" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_417f6438-9d78-4473-a06e-6eecfd894cc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_db5905ef-1ee0-42fa-94fc-de6ff657a100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e0e731cb-8253-4631-aca6-5186fa1cad69" xlink:to="loc_us-gaap_OtherAssetsCurrent_db5905ef-1ee0-42fa-94fc-de6ff657a100" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2632b8a0-c83f-4344-998d-e5d04dfb94f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3d0d8ccc-6921-483b-ae86-6c643e3cc3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2632b8a0-c83f-4344-998d-e5d04dfb94f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3d0d8ccc-6921-483b-ae86-6c643e3cc3ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_232731f0-3938-43cf-b6e6-f0b5082dbed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2632b8a0-c83f-4344-998d-e5d04dfb94f6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_232731f0-3938-43cf-b6e6-f0b5082dbed4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cc18a24c-d696-47ee-b793-a174c63da072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_c98a37c0-738e-43f2-ad24-0c14860a17b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cc18a24c-d696-47ee-b793-a174c63da072" xlink:to="loc_us-gaap_AccruedSalariesCurrent_c98a37c0-738e-43f2-ad24-0c14860a17b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_6e970265-e2d1-42c2-9fdf-4e1d63130527" xlink:href="exdx-20210331.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cc18a24c-d696-47ee-b793-a174c63da072" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_6e970265-e2d1-42c2-9fdf-4e1d63130527" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_20596418-e4dd-4db5-bdc3-a2df0066e855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cc18a24c-d696-47ee-b793-a174c63da072" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_20596418-e4dd-4db5-bdc3-a2df0066e855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_8599d119-c0ee-4f83-94a4-6365f29b2310" xlink:href="exdx-20210331.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cc18a24c-d696-47ee-b793-a174c63da072" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_8599d119-c0ee-4f83-94a4-6365f29b2310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_481dbdd2-40fb-4334-8ecf-06d4d5523360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cc18a24c-d696-47ee-b793-a174c63da072" xlink:to="loc_us-gaap_InterestPayableCurrent_481dbdd2-40fb-4334-8ecf-06d4d5523360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_98fa3259-4ae0-4b8c-8f23-dfb27221eb06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cc18a24c-d696-47ee-b793-a174c63da072" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_98fa3259-4ae0-4b8c-8f23-dfb27221eb06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a4ef87e1-e178-4b51-83d7-d802a5371f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cc18a24c-d696-47ee-b793-a174c63da072" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a4ef87e1-e178-4b51-83d7-d802a5371f07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Borrowings" xlink:type="simple" xlink:href="exdx-20210331.xsd#Borrowings"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/Borrowings" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#BorrowingsTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#BorrowingsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c18325e8-90fb-4fec-8d6b-4a5d1ed3470c" xlink:href="exdx-20210331.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2c80b720-3b46-4f80-b4aa-2e3d4006b0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c18325e8-90fb-4fec-8d6b-4a5d1ed3470c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2c80b720-3b46-4f80-b4aa-2e3d4006b0ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1c40a441-e4bd-4857-bdbd-0735ad0ee50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c18325e8-90fb-4fec-8d6b-4a5d1ed3470c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1c40a441-e4bd-4857-bdbd-0735ad0ee50b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8471df31-4ba9-44f0-9137-da95b860f8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c18325e8-90fb-4fec-8d6b-4a5d1ed3470c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8471df31-4ba9-44f0-9137-da95b860f8f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b481f76a-eb0a-4af5-9369-29958f0d1218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c18325e8-90fb-4fec-8d6b-4a5d1ed3470c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b481f76a-eb0a-4af5-9369-29958f0d1218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ed7ee24b-7b77-4231-92d2-fcfd1724ef62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c18325e8-90fb-4fec-8d6b-4a5d1ed3470c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ed7ee24b-7b77-4231-92d2-fcfd1724ef62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1ae88329-b2ab-458a-924c-d83266ce188d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ddae79c8-ffdb-464f-9262-28c6207bbdb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ae88329-b2ab-458a-924c-d83266ce188d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ddae79c8-ffdb-464f-9262-28c6207bbdb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_114a02ea-8e76-4642-acfe-fac0f2f87741" xlink:href="exdx-20210331.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ae88329-b2ab-458a-924c-d83266ce188d" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_114a02ea-8e76-4642-acfe-fac0f2f87741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_581838ca-56d1-4e9c-a643-222d923276ff" xlink:href="exdx-20210331.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ae88329-b2ab-458a-924c-d83266ce188d" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_581838ca-56d1-4e9c-a643-222d923276ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="exdx-20210331.xsd#CommitmentandContingencies"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exdx-20210331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlan"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19" xlink:type="simple" xlink:href="exdx-20210331.xsd#Covid19"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/Covid19" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19Details" xlink:type="simple" xlink:href="exdx-20210331.xsd#Covid19Details"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/Covid19Details" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>exdx-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:dc3d5bf2-9b73-4463-aa2c-e75c744aa8d3,g:734221f7-636e-4e71-b928-4b5e730d1da3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20210331.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended" id="if4f4f8ec30e543768c13fdb97f9eb79b_Cover"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="exdx-20210331.xsd#CondensedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="extended" id="i9b520752908441caa019090f91ca7794_CondensedBalanceSheets"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20210331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended" id="ic465522bb14e4017bf7b40947fa1dbcc_CondensedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="simple" xlink:href="exdx-20210331.xsd#UnauditedCondensedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="extended" id="ic909f37073f449babd82bb421ea71603_UnauditedCondensedStatementsofOperations"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20210331.xsd#UnauditedCondensedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="extended" id="i18250bacc1554ebab83b770a75f80b6d_UnauditedCondensedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_de870855-8c49-4e00-82c9-d58592d68cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de870855-8c49-4e00-82c9-d58592d68cc9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1763ca86-1368-4648-b593-de3fb861327b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1763ca86-1368-4648-b593-de3fb861327b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c4ac80f0-19f5-453b-8869-6e4981f594cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockholdersEquity_c4ac80f0-19f5-453b-8869-6e4981f594cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_323cba86-0e75-4c9b-ab1f-a2201f01b3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_323cba86-0e75-4c9b-ab1f-a2201f01b3b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fd6fa41c-b1d3-44df-995b-280909e2073c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fd6fa41c-b1d3-44df-995b-280909e2073c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ea5a6951-09ee-4c9c-86b0-688e6ac0a0e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ea5a6951-09ee-4c9c-86b0-688e6ac0a0e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b795b87f-32b8-41af-9514-179ee54d592e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b795b87f-32b8-41af-9514-179ee54d592e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ab1e9c9d-be7e-493f-a342-33e8b8ff593c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ab1e9c9d-be7e-493f-a342-33e8b8ff593c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0d7a7a0b-a992-43d4-b682-dd23f0132705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0d7a7a0b-a992-43d4-b682-dd23f0132705" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d4af276-9c29-470f-86ff-bd7563e58a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d4af276-9c29-470f-86ff-bd7563e58a8a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_a93cdf7b-a356-4107-85fb-dc135447c739" xlink:href="exdx-20210331.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_a93cdf7b-a356-4107-85fb-dc135447c739" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_0d910c72-e7a5-4907-897a-8748bcc40269" xlink:href="exdx-20210331.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_0d910c72-e7a5-4907-897a-8748bcc40269" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_20c6715a-258e-46a2-acfb-952a8718cb36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_NetIncomeLoss_20c6715a-258e-46a2-acfb-952a8718cb36" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ebe80311-cb9f-4be1-bb3c-0829bdaf5650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d2a12e29-d92b-4833-803d-2e00de77afcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4e6d5096-5939-4faa-bffe-64451952dc4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_de870855-8c49-4e00-82c9-d58592d68cc9" xlink:to="loc_us-gaap_StatementTable_4e6d5096-5939-4faa-bffe-64451952dc4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d865850d-e3ea-4ac1-9b07-9d2ee38d9dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4e6d5096-5939-4faa-bffe-64451952dc4d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d865850d-e3ea-4ac1-9b07-9d2ee38d9dd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d865850d-e3ea-4ac1-9b07-9d2ee38d9dd0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d865850d-e3ea-4ac1-9b07-9d2ee38d9dd0" xlink:to="loc_us-gaap_EquityComponentDomain_d865850d-e3ea-4ac1-9b07-9d2ee38d9dd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb1c0405-cb24-453a-a8b2-d68cc9e3e9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d865850d-e3ea-4ac1-9b07-9d2ee38d9dd0" xlink:to="loc_us-gaap_EquityComponentDomain_cb1c0405-cb24-453a-a8b2-d68cc9e3e9e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fd6c6953-99a6-4261-aebd-5088d7c9d19d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb1c0405-cb24-453a-a8b2-d68cc9e3e9e6" xlink:to="loc_us-gaap_CommonStockMember_fd6c6953-99a6-4261-aebd-5088d7c9d19d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1d116188-19e7-4d6b-9ae5-027d70b41567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb1c0405-cb24-453a-a8b2-d68cc9e3e9e6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1d116188-19e7-4d6b-9ae5-027d70b41567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_53b97187-3df3-4df7-84ae-71b69db84302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cb1c0405-cb24-453a-a8b2-d68cc9e3e9e6" xlink:to="loc_us-gaap_RetainedEarningsMember_53b97187-3df3-4df7-84ae-71b69db84302" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="exdx-20210331.xsd#UnauditedCondensedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="iec762197ece94738b4cbce8345a27911_UnauditedCondensedStatementsofStockholdersEquityParenthetical"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20210331.xsd#UnauditedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="extended" id="ic6f567f4349a48528b1daa32470d7c7b_UnauditedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Organization" xlink:type="simple" xlink:href="exdx-20210331.xsd#Organization"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Organization" xlink:type="extended" id="ifd87d5d888de4de6a88a1e12c0314fe5_Organization"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended" id="i8dfa20bc0fef4eaca42d74fc2714e69d_OrganizationDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i0e80692e5cc04d45b56a4f02a5ddc3c0_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i06588ae35e454c0585fa4d6baa1c6425_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="ie58396efa108432bafc7d3b4de246279_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended" id="i8c46a21ef2e94480ab76d6b5dda8a6ee_SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d6ee2c77-14a6-4497-b089-0fde024dbb63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_26fd5484-f184-4634-9405-9c3e5994c69d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d6ee2c77-14a6-4497-b089-0fde024dbb63" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_26fd5484-f184-4634-9405-9c3e5994c69d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f333425b-7582-4765-9b65-3956f652aefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d6ee2c77-14a6-4497-b089-0fde024dbb63" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f333425b-7582-4765-9b65-3956f652aefe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_df4419ea-3710-4486-880e-8991681a573e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f333425b-7582-4765-9b65-3956f652aefe" xlink:to="loc_srt_MajorCustomersAxis_df4419ea-3710-4486-880e-8991681a573e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_df4419ea-3710-4486-880e-8991681a573e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_df4419ea-3710-4486-880e-8991681a573e" xlink:to="loc_srt_NameOfMajorCustomerDomain_df4419ea-3710-4486-880e-8991681a573e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_df4419ea-3710-4486-880e-8991681a573e" xlink:to="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_d7e40818-0109-4469-a0d0-bef9344bcf3d" xlink:href="exdx-20210331.xsd#exdx_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:to="loc_exdx_MedicareMember_d7e40818-0109-4469-a0d0-bef9344bcf3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_8bb33029-5fc2-4be0-9365-35b1d4092dcd" xlink:href="exdx-20210331.xsd#exdx_BlueShieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:to="loc_exdx_BlueShieldMember_8bb33029-5fc2-4be0-9365-35b1d4092dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_8d23804f-1624-45cb-846f-f18bd9f14630" xlink:href="exdx-20210331.xsd#exdx_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:to="loc_exdx_MedicareAdvantageMember_8d23804f-1624-45cb-846f-f18bd9f14630" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_8adf0725-2734-4c9d-b084-584774a36fb9" xlink:href="exdx-20210331.xsd#exdx_UnitedHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:to="loc_exdx_UnitedHealthcareMember_8adf0725-2734-4c9d-b084-584774a36fb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_7ea270f6-2315-497c-8fd4-3229a7b515f9" xlink:href="exdx-20210331.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:to="loc_exdx_JanssenSIMPONIMember_7ea270f6-2315-497c-8fd4-3229a7b515f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_256a1389-b02a-4f5d-9ed7-ea3a4834cb73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f333425b-7582-4765-9b65-3956f652aefe" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_256a1389-b02a-4f5d-9ed7-ea3a4834cb73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_256a1389-b02a-4f5d-9ed7-ea3a4834cb73_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_256a1389-b02a-4f5d-9ed7-ea3a4834cb73" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_256a1389-b02a-4f5d-9ed7-ea3a4834cb73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_786cb627-1c34-4fa4-b44f-1079a34c1972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_256a1389-b02a-4f5d-9ed7-ea3a4834cb73" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_786cb627-1c34-4fa4-b44f-1079a34c1972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6631eca1-9562-4625-89e3-ea7aa408c382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_786cb627-1c34-4fa4-b44f-1079a34c1972" xlink:to="loc_us-gaap_SalesRevenueNetMember_6631eca1-9562-4625-89e3-ea7aa408c382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember_54227168-2064-44f7-9666-dadc6baf64be" xlink:href="exdx-20210331.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_786cb627-1c34-4fa4-b44f-1079a34c1972" xlink:to="loc_exdx_ReceivableBenchmarkMember_54227168-2064-44f7-9666-dadc6baf64be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_edb2fcaf-5d18-4728-b1ee-a48f1ac92c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f333425b-7582-4765-9b65-3956f652aefe" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_edb2fcaf-5d18-4728-b1ee-a48f1ac92c1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_edb2fcaf-5d18-4728-b1ee-a48f1ac92c1b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_edb2fcaf-5d18-4728-b1ee-a48f1ac92c1b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_edb2fcaf-5d18-4728-b1ee-a48f1ac92c1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c65735ef-4b6b-4bd7-8dc0-d341fd39c367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_edb2fcaf-5d18-4728-b1ee-a48f1ac92c1b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c65735ef-4b6b-4bd7-8dc0-d341fd39c367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4fe7f5ea-0d1a-4550-8548-d63366e4e642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c65735ef-4b6b-4bd7-8dc0-d341fd39c367" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4fe7f5ea-0d1a-4550-8548-d63366e4e642" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i1126ee262c09423e8121c4c7cf929ebd_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_92016878-d1a8-4e91-9fc2-bbeb0dadde1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_92016878-d1a8-4e91-9fc2-bbeb0dadde1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_065c9814-3488-4a15-923b-7421bc7ff79e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_RestrictedCash_065c9814-3488-4a15-923b-7421bc7ff79e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_26c9eb08-e08b-41b7-9792-2314cb3df74b" xlink:href="exdx-20210331.xsd#exdx_JointVentureQuarterlyPromotionFeePerPrescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_26c9eb08-e08b-41b7-9792-2314cb3df74b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFee_75572ff6-b68b-4bde-b853-0bd71d5a8ba0" xlink:href="exdx-20210331.xsd#exdx_JointVentureQuarterlyPromotionFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFee_75572ff6-b68b-4bde-b853-0bd71d5a8ba0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_75e7b251-cd80-4651-8074-782c7fbd711d" xlink:href="exdx-20210331.xsd#exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_75e7b251-cd80-4651-8074-782c7fbd711d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPrescribedUnits_291fcf80-6dcd-4d36-9c58-56418a5188a0" xlink:href="exdx-20210331.xsd#exdx_JointVentureQuarterlyPrescribedUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_JointVentureQuarterlyPrescribedUnits_291fcf80-6dcd-4d36-9c58-56418a5188a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoPromotionAgreementRenewalTerm_c219f160-a824-4f92-ad7e-24bb8f82f684" xlink:href="exdx-20210331.xsd#exdx_CoPromotionAgreementRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_CoPromotionAgreementRenewalTerm_c219f160-a824-4f92-ad7e-24bb8f82f684" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm_091afee8-c14d-42b3-b853-f6cee738c55a" xlink:href="exdx-20210331.xsd#exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm_091afee8-c14d-42b3-b853-f6cee738c55a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement_ba3a97bf-92eb-4088-926b-55a1f7a20cf6" xlink:href="exdx-20210331.xsd#exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement_ba3a97bf-92eb-4088-926b-55a1f7a20cf6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3b3b3852-142d-4484-ace3-21d479a3d763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3b3b3852-142d-4484-ace3-21d479a3d763" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_f4de2739-a2b3-47c7-b870-6ffbe383a0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_AdvertisingExpense_f4de2739-a2b3-47c7-b870-6ffbe383a0d6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_c25cfe6b-6400-418e-b470-8346e003c3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_CostOfRevenue_c25cfe6b-6400-418e-b470-8346e003c3e9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ed10c30c-1f15-4469-9bcd-ab815095469c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ed10c30c-1f15-4469-9bcd-ab815095469c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_deb5f4e6-afdc-4e0a-8edb-6489d28669fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_deb5f4e6-afdc-4e0a-8edb-6489d28669fe" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_52c21482-f7aa-4e97-bde6-5a4b22e25e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_NumberOfOperatingSegments_52c21482-f7aa-4e97-bde6-5a4b22e25e8b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_75fda264-2750-425d-90ab-597a2bbc18d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_75fda264-2750-425d-90ab-597a2bbc18d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_75fda264-2750-425d-90ab-597a2bbc18d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_75fda264-2750-425d-90ab-597a2bbc18d7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_75fda264-2750-425d-90ab-597a2bbc18d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_120244c4-2058-4ce7-8709-7dcf22878d44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_75fda264-2750-425d-90ab-597a2bbc18d7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_120244c4-2058-4ce7-8709-7dcf22878d44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_805aa40e-ceba-4b30-b7cd-68e8077bd4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_120244c4-2058-4ce7-8709-7dcf22878d44" xlink:to="loc_us-gaap_SalesRevenueNetMember_805aa40e-ceba-4b30-b7cd-68e8077bd4a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0132908a-3088-482d-8bbd-152cf08bf6ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0132908a-3088-482d-8bbd-152cf08bf6ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0132908a-3088-482d-8bbd-152cf08bf6ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0132908a-3088-482d-8bbd-152cf08bf6ec" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0132908a-3088-482d-8bbd-152cf08bf6ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_98adc483-e514-436b-b1dc-8eab51e00ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0132908a-3088-482d-8bbd-152cf08bf6ec" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_98adc483-e514-436b-b1dc-8eab51e00ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_873f7fbb-d37f-458c-82fb-4aa77b415e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_98adc483-e514-436b-b1dc-8eab51e00ec8" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_873f7fbb-d37f-458c-82fb-4aa77b415e99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_e1d3875f-8bb3-4e9d-92e8-8e82fda207c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_98adc483-e514-436b-b1dc-8eab51e00ec8" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_e1d3875f-8bb3-4e9d-92e8-8e82fda207c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6ea3348c-9f9d-40e4-82ec-ed9b716c5ecc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_srt_ProductOrServiceAxis_6ea3348c-9f9d-40e4-82ec-ed9b716c5ecc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ea3348c-9f9d-40e4-82ec-ed9b716c5ecc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6ea3348c-9f9d-40e4-82ec-ed9b716c5ecc" xlink:to="loc_srt_ProductsAndServicesDomain_6ea3348c-9f9d-40e4-82ec-ed9b716c5ecc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06b45fd1-5d6b-468b-a24b-678d47cb92fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6ea3348c-9f9d-40e4-82ec-ed9b716c5ecc" xlink:to="loc_srt_ProductsAndServicesDomain_06b45fd1-5d6b-468b-a24b-678d47cb92fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_a9d7bb4e-654e-4f04-8fa6-027e4dbf3e84" xlink:href="exdx-20210331.xsd#exdx_AVISECTDTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06b45fd1-5d6b-468b-a24b-678d47cb92fb" xlink:to="loc_exdx_AVISECTDTestMember_a9d7bb4e-654e-4f04-8fa6-027e4dbf3e84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_a840337d-6c8c-415b-9dca-133fd63c5df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06b45fd1-5d6b-468b-a24b-678d47cb92fb" xlink:to="loc_us-gaap_ShippingAndHandlingMember_a840337d-6c8c-415b-9dca-133fd63c5df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_02fa08d4-8060-4ae1-ac87-1769908adac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_02fa08d4-8060-4ae1-ac87-1769908adac3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_02fa08d4-8060-4ae1-ac87-1769908adac3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_02fa08d4-8060-4ae1-ac87-1769908adac3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_02fa08d4-8060-4ae1-ac87-1769908adac3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5db5c150-9448-45cd-b6d1-3fef7e70a66c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_02fa08d4-8060-4ae1-ac87-1769908adac3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5db5c150-9448-45cd-b6d1-3fef7e70a66c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_2f35a7ac-d8b7-44c6-95e8-63ab14575298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5db5c150-9448-45cd-b6d1-3fef7e70a66c" xlink:to="loc_us-gaap_OtherAssetsMember_2f35a7ac-d8b7-44c6-95e8-63ab14575298" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b765e289-991e-4c0f-bb05-f761aa5d72a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_srt_RangeAxis_b765e289-991e-4c0f-bb05-f761aa5d72a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b765e289-991e-4c0f-bb05-f761aa5d72a4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b765e289-991e-4c0f-bb05-f761aa5d72a4" xlink:to="loc_srt_RangeMember_b765e289-991e-4c0f-bb05-f761aa5d72a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f6dd7db-3165-4264-9093-9a502692c5f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b765e289-991e-4c0f-bb05-f761aa5d72a4" xlink:to="loc_srt_RangeMember_2f6dd7db-3165-4264-9093-9a502692c5f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_329881fd-e2e8-4534-b762-ade77d1946e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2f6dd7db-3165-4264-9093-9a502692c5f3" xlink:to="loc_srt_MinimumMember_329881fd-e2e8-4534-b762-ade77d1946e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e1c2fdb3-9bd2-4736-9821-84a567dd38bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2f6dd7db-3165-4264-9093-9a502692c5f3" xlink:to="loc_srt_MaximumMember_e1c2fdb3-9bd2-4736-9821-84a567dd38bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_caa9c97a-24a8-4042-bd74-cc19cde553e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_srt_StatementScenarioAxis_caa9c97a-24a8-4042-bd74-cc19cde553e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_caa9c97a-24a8-4042-bd74-cc19cde553e8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_caa9c97a-24a8-4042-bd74-cc19cde553e8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_caa9c97a-24a8-4042-bd74-cc19cde553e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a57b51f3-ac15-4de8-aa97-6abdcf47e9e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_caa9c97a-24a8-4042-bd74-cc19cde553e8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a57b51f3-ac15-4de8-aa97-6abdcf47e9e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_26a99010-ff05-4111-a30b-370dd57d26cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a57b51f3-ac15-4de8-aa97-6abdcf47e9e7" xlink:to="loc_srt_ScenarioForecastMember_26a99010-ff05-4111-a30b-370dd57d26cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_495fc463-7712-4064-accb-65207424583d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_srt_CounterpartyNameAxis_495fc463-7712-4064-accb-65207424583d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495fc463-7712-4064-accb-65207424583d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_495fc463-7712-4064-accb-65207424583d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495fc463-7712-4064-accb-65207424583d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bc5db9a-bec2-47dd-88d7-f97b5b16d8e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_495fc463-7712-4064-accb-65207424583d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bc5db9a-bec2-47dd-88d7-f97b5b16d8e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_1017663a-2bfd-4e6c-8143-9edae7dbc394" xlink:href="exdx-20210331.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bc5db9a-bec2-47dd-88d7-f97b5b16d8e3" xlink:to="loc_exdx_JanssenSIMPONIMember_1017663a-2bfd-4e6c-8143-9edae7dbc394" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e05cc84e-b9c4-45ba-b9b7-1ac828287531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_us-gaap_AwardTypeAxis_e05cc84e-b9c4-45ba-b9b7-1ac828287531" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e05cc84e-b9c4-45ba-b9b7-1ac828287531_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e05cc84e-b9c4-45ba-b9b7-1ac828287531" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e05cc84e-b9c4-45ba-b9b7-1ac828287531_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6564859-3e63-4d7d-94ae-df12f03daf23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e05cc84e-b9c4-45ba-b9b7-1ac828287531" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6564859-3e63-4d7d-94ae-df12f03daf23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_42e1e797-85e9-4cf1-9925-7aa91a435539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6564859-3e63-4d7d-94ae-df12f03daf23" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_42e1e797-85e9-4cf1-9925-7aa91a435539" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended" id="i2ec77a59e3404133b97ea90e4f1265ee_SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b94a3103-c2e1-4641-b6b1-5f824af1b27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_625a6adf-b40c-42ef-b19c-259f68f0f3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b94a3103-c2e1-4641-b6b1-5f824af1b27b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_625a6adf-b40c-42ef-b19c-259f68f0f3cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_57d4fa30-b5f0-4b9a-9562-a3ebc6519386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b94a3103-c2e1-4641-b6b1-5f824af1b27b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_57d4fa30-b5f0-4b9a-9562-a3ebc6519386" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a2ac9faf-e465-400a-b005-c83ad2c03306" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57d4fa30-b5f0-4b9a-9562-a3ebc6519386" xlink:to="loc_srt_MajorCustomersAxis_a2ac9faf-e465-400a-b005-c83ad2c03306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a2ac9faf-e465-400a-b005-c83ad2c03306_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a2ac9faf-e465-400a-b005-c83ad2c03306" xlink:to="loc_srt_NameOfMajorCustomerDomain_a2ac9faf-e465-400a-b005-c83ad2c03306_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a2ac9faf-e465-400a-b005-c83ad2c03306" xlink:to="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember_6000cda1-d025-41b3-93aa-72c0c8be4c17" xlink:href="exdx-20210331.xsd#exdx_HealthcareInsurersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:to="loc_exdx_HealthcareInsurersMember_6000cda1-d025-41b3-93aa-72c0c8be4c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_b587e40a-bcd3-4437-8df4-6ae0f9d4c17c" xlink:href="exdx-20210331.xsd#exdx_Government1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:to="loc_exdx_Government1Member_b587e40a-bcd3-4437-8df4-6ae0f9d4c17c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_f14029a2-4d12-4cab-bd62-d06e7273218e" xlink:href="exdx-20210331.xsd#exdx_ClientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:to="loc_exdx_ClientMember_f14029a2-4d12-4cab-bd62-d06e7273218e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_f2f4e875-1654-47b6-8ea6-340faef45593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:to="loc_us-gaap_OtherCustomerMember_f2f4e875-1654-47b6-8ea6-340faef45593" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_f7cac0f5-3d3b-472f-a3a3-3d0be9c0274a" xlink:href="exdx-20210331.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:to="loc_exdx_JanssenSIMPONIMember_f7cac0f5-3d3b-472f-a3a3-3d0be9c0274a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended" id="iff6fea425d98477e9ae46ab2e7f57c81_SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended" id="i0fbbdb8d41434147887bfbc73d8ffb7f_SummaryofSignificantAccountingPoliciesSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f6b77f1e-ce00-4107-a710-d866571ae6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46676862-f616-452f-ae3d-f838487030bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6b77f1e-ce00-4107-a710-d866571ae6d1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46676862-f616-452f-ae3d-f838487030bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_61149811-358a-43bc-96c6-d86b1e81aef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6b77f1e-ce00-4107-a710-d866571ae6d1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_61149811-358a-43bc-96c6-d86b1e81aef5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a3fef21a-dd60-4e64-a64e-7172872049d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_61149811-358a-43bc-96c6-d86b1e81aef5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a3fef21a-dd60-4e64-a64e-7172872049d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a3fef21a-dd60-4e64-a64e-7172872049d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a3fef21a-dd60-4e64-a64e-7172872049d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a3fef21a-dd60-4e64-a64e-7172872049d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b128bcb9-afa2-401b-acde-78fc818a002c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a3fef21a-dd60-4e64-a64e-7172872049d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b128bcb9-afa2-401b-acde-78fc818a002c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_88ec831e-9eb9-4b2f-830e-0721bd31f88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b128bcb9-afa2-401b-acde-78fc818a002c" xlink:to="loc_us-gaap_WarrantMember_88ec831e-9eb9-4b2f-830e-0721bd31f88c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_1d370a24-b700-49d1-ab1b-132d6de8de4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b128bcb9-afa2-401b-acde-78fc818a002c" xlink:to="loc_us-gaap_StockOptionMember_1d370a24-b700-49d1-ab1b-132d6de8de4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_885d7161-a6a7-4a95-b29a-7eb37c497c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b128bcb9-afa2-401b-acde-78fc818a002c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_885d7161-a6a7-4a95-b29a-7eb37c497c8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e14bb96b-81e3-4031-917e-fae423efdd9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b128bcb9-afa2-401b-acde-78fc818a002c" xlink:to="loc_us-gaap_EmployeeStockMember_e14bb96b-81e3-4031-917e-fae423efdd9e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformation"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="extended" id="i95f46f79182b4fe19bf7c7eb8bcc8dd7_OtherFinancialInformation"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended" id="if90bea9bda2a4cc69c944d6209a154cc_OtherFinancialInformationTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended" id="iad3bb87a42724343827d8f96196ab8f2_OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended" id="i4076c776b09643299abc95136aa01b3e_OtherFinancialInformationPropertyandequipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_189ed879-714e-449b-a91b-d9557f6be94a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a8f17e55-c602-45e0-8607-46f28c585368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_189ed879-714e-449b-a91b-d9557f6be94a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a8f17e55-c602-45e0-8607-46f28c585368" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_31329079-dd87-429e-9799-8ccd08d97229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_189ed879-714e-449b-a91b-d9557f6be94a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_31329079-dd87-429e-9799-8ccd08d97229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c454ff7f-9729-4446-8e99-7e29aa5b39ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_189ed879-714e-449b-a91b-d9557f6be94a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c454ff7f-9729-4446-8e99-7e29aa5b39ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f47ebcd8-bb94-48c5-8377-d8980cf6c630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_189ed879-714e-449b-a91b-d9557f6be94a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f47ebcd8-bb94-48c5-8377-d8980cf6c630" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_df9424e9-a23c-43f4-a4f5-7dcc73b4c325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f47ebcd8-bb94-48c5-8377-d8980cf6c630" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_df9424e9-a23c-43f4-a4f5-7dcc73b4c325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df9424e9-a23c-43f4-a4f5-7dcc73b4c325_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_df9424e9-a23c-43f4-a4f5-7dcc73b4c325" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df9424e9-a23c-43f4-a4f5-7dcc73b4c325_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_df9424e9-a23c-43f4-a4f5-7dcc73b4c325" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5d52bd16-341b-4619-b019-4bd0a0f2bec5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5d52bd16-341b-4619-b019-4bd0a0f2bec5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_f4d53f86-5b4c-49a8-82b0-b3b585dfda2b" xlink:href="exdx-20210331.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:to="loc_exdx_LaboratoryEquipmentMember_f4d53f86-5b4c-49a8-82b0-b3b585dfda2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_196b34a4-adbe-406b-ab1f-22b83d3b403e" xlink:href="exdx-20210331.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_196b34a4-adbe-406b-ab1f-22b83d3b403e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4caa131f-fe4d-42fa-9991-d1d2cdab653a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4caa131f-fe4d-42fa-9991-d1d2cdab653a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_a7f2e15f-3778-4cb3-bfd3-83604d12e19f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:to="loc_us-gaap_ConstructionInProgressMember_a7f2e15f-3778-4cb3-bfd3-83604d12e19f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended" id="ia3953c58bc2d4ade967b800fd5b77839_OtherFinancialInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3c28a922-22f3-49f6-b7cd-600e212824aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ce576a5b-256a-42b1-a47a-f2b97a309f02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3c28a922-22f3-49f6-b7cd-600e212824aa" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ce576a5b-256a-42b1-a47a-f2b97a309f02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_dc8f3236-ad7f-4b9f-88cd-8088b0180d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3c28a922-22f3-49f6-b7cd-600e212824aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_dc8f3236-ad7f-4b9f-88cd-8088b0180d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_13702d2d-9f9e-433d-8cc6-78a2664ddd3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3c28a922-22f3-49f6-b7cd-600e212824aa" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_13702d2d-9f9e-433d-8cc6-78a2664ddd3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0290eb54-13c1-417d-9194-2a3b2af55e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_13702d2d-9f9e-433d-8cc6-78a2664ddd3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0290eb54-13c1-417d-9194-2a3b2af55e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0290eb54-13c1-417d-9194-2a3b2af55e38_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0290eb54-13c1-417d-9194-2a3b2af55e38" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0290eb54-13c1-417d-9194-2a3b2af55e38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4e7d229-1b14-4145-a541-590a87379c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0290eb54-13c1-417d-9194-2a3b2af55e38" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4e7d229-1b14-4145-a541-590a87379c2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember_0581bc12-439d-49d6-9994-48b704dc5436" xlink:href="exdx-20210331.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4e7d229-1b14-4145-a541-590a87379c2a" xlink:to="loc_exdx_AssetsUnderCapitalLeaseMember_0581bc12-439d-49d6-9994-48b704dc5436" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="extended" id="i92ca1ec3ec014c21bc5c43ba035e09a2_OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Borrowings" xlink:type="simple" xlink:href="exdx-20210331.xsd#Borrowings"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Borrowings" xlink:type="extended" id="i5aba66431063482ea99414308a6f114c_Borrowings"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#BorrowingsTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended" id="id079960f1b1349baadf727abb6b8ac16_BorrowingsTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i2ef02002012f4e5c81e823bc2c30308d_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_611233b9-ec78-4e39-9cd2-04d034825820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_611233b9-ec78-4e39-9cd2-04d034825820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9cb5b8e7-87b2-40f4-a13d-4a8fdf83867b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9cb5b8e7-87b2-40f4-a13d-4a8fdf83867b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0fbb5d76-a4fe-4476-9d3a-afdd2faf4efb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0fbb5d76-a4fe-4476-9d3a-afdd2faf4efb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_77e77e22-7502-4488-a20f-ce60a95fce6d" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_77e77e22-7502-4488-a20f-ce60a95fce6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5e8ded89-887c-444b-990e-fe8c81cee8fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5e8ded89-887c-444b-990e-fe8c81cee8fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_00248636-eddf-4687-819e-341ba31bec8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_DebtInstrumentTerm_00248636-eddf-4687-819e-341ba31bec8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_48096845-2aa9-4d7c-b28b-a76e026742e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_48096845-2aa9-4d7c-b28b-a76e026742e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_2833e15f-5756-441d-9ff9-d9211af1da31" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_2833e15f-5756-441d-9ff9-d9211af1da31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_8c6bc9fe-640b-4da2-a2c6-5db48712d016" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_8c6bc9fe-640b-4da2-a2c6-5db48712d016" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_6bf78129-b8b8-43d1-af09-d8956fdcf9d3" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_6bf78129-b8b8-43d1-af09-d8956fdcf9d3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_cb0969c5-63eb-429b-8d71-3f036d4ea44f" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_cb0969c5-63eb-429b-8d71-3f036d4ea44f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_21331193-32c5-4318-b920-545d41e605c0" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_21331193-32c5-4318-b920-545d41e605c0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c9092b99-117c-4c6f-acac-66d0a0b5873d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_DebtInstrumentTable_c9092b99-117c-4c6f-acac-66d0a0b5873d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7f99fba0-57d2-4e9c-bd18-21655bdefb02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c9092b99-117c-4c6f-acac-66d0a0b5873d" xlink:to="loc_us-gaap_DebtInstrumentAxis_7f99fba0-57d2-4e9c-bd18-21655bdefb02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7f99fba0-57d2-4e9c-bd18-21655bdefb02_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7f99fba0-57d2-4e9c-bd18-21655bdefb02" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7f99fba0-57d2-4e9c-bd18-21655bdefb02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7a81553-5434-4164-b907-37face57be81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7f99fba0-57d2-4e9c-bd18-21655bdefb02" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7a81553-5434-4164-b907-37face57be81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_139b202d-1393-4561-9e4c-931f6ef0f6c2" xlink:href="exdx-20210331.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7a81553-5434-4164-b907-37face57be81" xlink:to="loc_exdx_Term2017Member_139b202d-1393-4561-9e4c-931f6ef0f6c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_10461eb9-17dc-4b48-aad0-67f8943e2959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c9092b99-117c-4c6f-acac-66d0a0b5873d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_10461eb9-17dc-4b48-aad0-67f8943e2959" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_10461eb9-17dc-4b48-aad0-67f8943e2959_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_10461eb9-17dc-4b48-aad0-67f8943e2959" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_10461eb9-17dc-4b48-aad0-67f8943e2959_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bec2f939-35ef-42b0-800b-b6e64bb19fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_10461eb9-17dc-4b48-aad0-67f8943e2959" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bec2f939-35ef-42b0-800b-b6e64bb19fea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_f8405168-f4f3-4950-83cb-06e2a3192431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bec2f939-35ef-42b0-800b-b6e64bb19fea" xlink:to="loc_us-gaap_LoansPayableMember_f8405168-f4f3-4950-83cb-06e2a3192431" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_65c161eb-97aa-4258-9c35-a8635ad17f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bec2f939-35ef-42b0-800b-b6e64bb19fea" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_65c161eb-97aa-4258-9c35-a8635ad17f8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_bff274b5-cfad-420d-90e4-b6a3262288a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c9092b99-117c-4c6f-acac-66d0a0b5873d" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_bff274b5-cfad-420d-90e4-b6a3262288a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_bff274b5-cfad-420d-90e4-b6a3262288a0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_bff274b5-cfad-420d-90e4-b6a3262288a0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_bff274b5-cfad-420d-90e4-b6a3262288a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_7940e180-2637-489e-9293-e1c654681b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_bff274b5-cfad-420d-90e4-b6a3262288a0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_7940e180-2637-489e-9293-e1c654681b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_20d89637-6e3e-4e2d-814f-7917dd945ec9" xlink:href="exdx-20210331.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7940e180-2637-489e-9293-e1c654681b67" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_20d89637-6e3e-4e2d-814f-7917dd945ec9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember_d49d9448-4a3b-45ce-8cc1-883b9a63c4a9" xlink:href="exdx-20210331.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7940e180-2637-489e-9293-e1c654681b67" xlink:to="loc_exdx_CapitalRoyaltyPartnersIILPMember_d49d9448-4a3b-45ce-8cc1-883b9a63c4a9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended" id="ia8ba111d682841d59901a1c234ccdff8_BorrowingsFutureminimumpaymentsDetails"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="exdx-20210331.xsd#CommitmentandContingencies"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="extended" id="i66188e3df6a6428fa3ca7868167c196a_CommitmentandContingencies"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended" id="i2db30542e11948d292f4dae10fa7ceb1_CommitmentandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeasesRenewalTerm_0feceb8a-72e2-41a7-8ed4-60b4d8ad820c" xlink:href="exdx-20210331.xsd#exdx_OperatingLeasesRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_OperatingLeasesRenewalTerm_0feceb8a-72e2-41a7-8ed4-60b4d8ad820c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_fd812f31-2a5b-40bc-9739-61e0dfa29664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_us-gaap_LeaseAndRentalExpense_fd812f31-2a5b-40bc-9739-61e0dfa29664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation_20071798-d95c-4d7b-ac9c-a4c04f312ad6" xlink:href="exdx-20210331.xsd#exdx_MilestoneObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_MilestoneObligation_20071798-d95c-4d7b-ac9c-a4c04f312ad6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneContingencyFairValueDisclosure_75734cca-b25a-46d3-a181-c9cdb5aed3fd" xlink:href="exdx-20210331.xsd#exdx_MilestoneContingencyFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_MilestoneContingencyFairValueDisclosure_75734cca-b25a-46d3-a181-c9cdb5aed3fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_18bf6cc6-2ab9-48a6-b9ce-e08e323aa1fd" xlink:href="exdx-20210331.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_18bf6cc6-2ab9-48a6-b9ce-e08e323aa1fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_f329bbf1-d2f9-4fe4-846b-2f485a1f7a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_f329bbf1-d2f9-4fe4-846b-2f485a1f7a0d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_3e6bf6e8-ce70-4943-bf4f-ae77e0408882" xlink:href="exdx-20210331.xsd#exdx_AdvancePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_AdvancePayment_3e6bf6e8-ce70-4943-bf4f-ae77e0408882" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementInitialLicenseFee_442f4d76-c9bd-40cd-9341-c00b7c3b8efe" xlink:href="exdx-20210331.xsd#exdx_LicenseAgreementInitialLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_LicenseAgreementInitialLicenseFee_442f4d76-c9bd-40cd-9341-c00b7c3b8efe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0ec6075c-604b-48aa-afcf-0e634ee1ec9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0ec6075c-604b-48aa-afcf-0e634ee1ec9d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_527a8a52-f113-447c-a506-7043e6756fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_527a8a52-f113-447c-a506-7043e6756fe6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_6238f988-330a-42d4-85bb-f19dd2adda6e" xlink:href="exdx-20210331.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_6238f988-330a-42d4-85bb-f19dd2adda6e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_2ea82a67-226b-4701-afc0-271f75d55f89" xlink:href="exdx-20210331.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_2ea82a67-226b-4701-afc0-271f75d55f89" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_329604b1-50ce-4b61-9e5d-a73f863e66bb" xlink:href="exdx-20210331.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:to="loc_exdx_RentalPropertyByTypeAxis_329604b1-50ce-4b61-9e5d-a73f863e66bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_329604b1-50ce-4b61-9e5d-a73f863e66bb_default" xlink:href="exdx-20210331.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exdx_RentalPropertyByTypeAxis_329604b1-50ce-4b61-9e5d-a73f863e66bb" xlink:to="loc_exdx_RentalPropertyByTypeDomain_329604b1-50ce-4b61-9e5d-a73f863e66bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_4d0cfa54-051d-440b-9127-1c496c449c4d" xlink:href="exdx-20210331.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exdx_RentalPropertyByTypeAxis_329604b1-50ce-4b61-9e5d-a73f863e66bb" xlink:to="loc_exdx_RentalPropertyByTypeDomain_4d0cfa54-051d-440b-9127-1c496c449c4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_2bb8735a-91c2-42cd-a08a-2de7beda21df" xlink:href="exdx-20210331.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_4d0cfa54-051d-440b-9127-1c496c449c4d" xlink:to="loc_exdx_OfficeAndLaboratoryMember_2bb8735a-91c2-42cd-a08a-2de7beda21df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_41d841c3-6d10-443c-ae9d-3f1dfe108865" xlink:href="exdx-20210331.xsd#exdx_OfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_4d0cfa54-051d-440b-9127-1c496c449c4d" xlink:to="loc_exdx_OfficeMember_41d841c3-6d10-443c-ae9d-3f1dfe108865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e77a7157-f86a-4df8-89ce-1c4d33f2134f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:to="loc_srt_CounterpartyNameAxis_e77a7157-f86a-4df8-89ce-1c4d33f2134f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e77a7157-f86a-4df8-89ce-1c4d33f2134f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e77a7157-f86a-4df8-89ce-1c4d33f2134f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e77a7157-f86a-4df8-89ce-1c4d33f2134f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a7b2319-9faf-4ce8-b5b0-23c9b8460a09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e77a7157-f86a-4df8-89ce-1c4d33f2134f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a7b2319-9faf-4ce8-b5b0-23c9b8460a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_888a5d90-8af5-48ce-a5c6-2141d50b062d" xlink:href="exdx-20210331.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a7b2319-9faf-4ce8-b5b0-23c9b8460a09" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_888a5d90-8af5-48ce-a5c6-2141d50b062d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_6f0e348b-f499-4169-a27f-699ff9d1beb4" xlink:href="exdx-20210331.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a7b2319-9faf-4ce8-b5b0-23c9b8460a09" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_6f0e348b-f499-4169-a27f-699ff9d1beb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a4c656d3-49d5-4005-88e7-0470cb8733b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:to="loc_srt_RangeAxis_a4c656d3-49d5-4005-88e7-0470cb8733b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a4c656d3-49d5-4005-88e7-0470cb8733b7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a4c656d3-49d5-4005-88e7-0470cb8733b7" xlink:to="loc_srt_RangeMember_a4c656d3-49d5-4005-88e7-0470cb8733b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eef99c26-135d-4199-a8f4-b08bbfe00d95" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a4c656d3-49d5-4005-88e7-0470cb8733b7" xlink:to="loc_srt_RangeMember_eef99c26-135d-4199-a8f4-b08bbfe00d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_01d0950b-d1ab-4db2-bb0b-323e3909c516" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eef99c26-135d-4199-a8f4-b08bbfe00d95" xlink:to="loc_srt_MinimumMember_01d0950b-d1ab-4db2-bb0b-323e3909c516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0cc2c0db-07e9-4497-8f89-8a43297390b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eef99c26-135d-4199-a8f4-b08bbfe00d95" xlink:to="loc_srt_MaximumMember_0cc2c0db-07e9-4497-8f89-8a43297390b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_285fa607-f0fb-4fee-ac5a-cfe11e7050b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_285fa607-f0fb-4fee-ac5a-cfe11e7050b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_285fa607-f0fb-4fee-ac5a-cfe11e7050b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_285fa607-f0fb-4fee-ac5a-cfe11e7050b4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_285fa607-f0fb-4fee-ac5a-cfe11e7050b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6d4e3062-522d-47d3-8547-762ff63ddafa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_285fa607-f0fb-4fee-ac5a-cfe11e7050b4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6d4e3062-522d-47d3-8547-762ff63ddafa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_bf03a504-ff64-430b-8640-9a2556ceb37a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6d4e3062-522d-47d3-8547-762ff63ddafa" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_bf03a504-ff64-430b-8640-9a2556ceb37a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4e79dddf-d7de-47a1-b22f-f981e3c790b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4e79dddf-d7de-47a1-b22f-f981e3c790b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4e79dddf-d7de-47a1-b22f-f981e3c790b1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4e79dddf-d7de-47a1-b22f-f981e3c790b1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4e79dddf-d7de-47a1-b22f-f981e3c790b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_93013d02-ba49-4f80-9300-39ef9a50b199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4e79dddf-d7de-47a1-b22f-f981e3c790b1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_93013d02-ba49-4f80-9300-39ef9a50b199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_79b23381-d8c5-4b8c-a5eb-ba2b44c21e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_93013d02-ba49-4f80-9300-39ef9a50b199" xlink:to="loc_us-gaap_SubsequentEventMember_79b23381-d8c5-4b8c-a5eb-ba2b44c21e8a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exdx-20210331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurements" xlink:type="extended" id="i64b806354c8e461ab3b3977cbb6b9a37_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i7eee3ccdbb8b416397484d313ac3b897_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="iea7be054c400444c8716dfc9cb1bb3d2_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_929f446f-7e57-41d0-9f8c-59e7e4b6be80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_c4a91a2a-184f-4dd8-bfa5-8fea3cee9bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_929f446f-7e57-41d0-9f8c-59e7e4b6be80" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_c4a91a2a-184f-4dd8-bfa5-8fea3cee9bff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8d197903-7a58-4c7c-ab98-528c41989a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c4a91a2a-184f-4dd8-bfa5-8fea3cee9bff" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8d197903-7a58-4c7c-ab98-528c41989a08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3cab5e24-fce2-4f59-8cd8-3954d1f392b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_929f446f-7e57-41d0-9f8c-59e7e4b6be80" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3cab5e24-fce2-4f59-8cd8-3954d1f392b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ba99eb9-a88f-486c-95b6-545d00bebcd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3cab5e24-fce2-4f59-8cd8-3954d1f392b5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ba99eb9-a88f-486c-95b6-545d00bebcd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5ba99eb9-a88f-486c-95b6-545d00bebcd5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ba99eb9-a88f-486c-95b6-545d00bebcd5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5ba99eb9-a88f-486c-95b6-545d00bebcd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c93e455e-2cb7-42a6-8306-682bcd43bff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ba99eb9-a88f-486c-95b6-545d00bebcd5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c93e455e-2cb7-42a6-8306-682bcd43bff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7ee753b5-0f63-48d8-959d-9bf89e09e7e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c93e455e-2cb7-42a6-8306-682bcd43bff0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7ee753b5-0f63-48d8-959d-9bf89e09e7e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbfbc2c-934f-404b-b426-77cca6de233e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3cab5e24-fce2-4f59-8cd8-3954d1f392b5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbfbc2c-934f-404b-b426-77cca6de233e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0cbfbc2c-934f-404b-b426-77cca6de233e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbfbc2c-934f-404b-b426-77cca6de233e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0cbfbc2c-934f-404b-b426-77cca6de233e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbcd4ab5-8b0f-45d0-8747-f281127446cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbfbc2c-934f-404b-b426-77cca6de233e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbcd4ab5-8b0f-45d0-8747-f281127446cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_983e2cba-2db8-46de-82ed-aad9aa76a704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbcd4ab5-8b0f-45d0-8747-f281127446cc" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_983e2cba-2db8-46de-82ed-aad9aa76a704" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_725fc744-1634-4e3a-b970-b2c4842b5f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbcd4ab5-8b0f-45d0-8747-f281127446cc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_725fc744-1634-4e3a-b970-b2c4842b5f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9e3d663d-3cdc-4d1b-91bb-f73366eb6236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbcd4ab5-8b0f-45d0-8747-f281127446cc" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9e3d663d-3cdc-4d1b-91bb-f73366eb6236" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d4addde0-6b35-4429-b7b1-f1d54a3d8a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3cab5e24-fce2-4f59-8cd8-3954d1f392b5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d4addde0-6b35-4429-b7b1-f1d54a3d8a0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4addde0-6b35-4429-b7b1-f1d54a3d8a0a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d4addde0-6b35-4429-b7b1-f1d54a3d8a0a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4addde0-6b35-4429-b7b1-f1d54a3d8a0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4d7b57c-96dd-43ac-9199-628987a13767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d4addde0-6b35-4429-b7b1-f1d54a3d8a0a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4d7b57c-96dd-43ac-9199-628987a13767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_450ddaa7-2295-4710-b105-3f7e20f0b87f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4d7b57c-96dd-43ac-9199-628987a13767" xlink:to="loc_us-gaap_MoneyMarketFundsMember_450ddaa7-2295-4710-b105-3f7e20f0b87f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquity" xlink:type="extended" id="ifd6a27e4a8d448da973de5007233d885_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="extended" id="ie639a77a680e47adb8d4788c052c55d9_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i28d88adcc647436b8e633b05f7a8c1b3_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d437dd2d-c8b9-48ad-8a63-d805a9960bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9cf38510-42dc-48d9-aa8d-17010c286c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d437dd2d-c8b9-48ad-8a63-d805a9960bd2" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9cf38510-42dc-48d9-aa8d-17010c286c40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_546b3656-5d95-46a4-8dd5-8cce77a16ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d437dd2d-c8b9-48ad-8a63-d805a9960bd2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_546b3656-5d95-46a4-8dd5-8cce77a16ec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6946a51e-8a59-4afc-b26d-0433ce54147c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d437dd2d-c8b9-48ad-8a63-d805a9960bd2" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6946a51e-8a59-4afc-b26d-0433ce54147c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_46a15ab9-4e52-44b3-9fe5-998b8a8fe4d2" xlink:href="exdx-20210331.xsd#exdx_StockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d437dd2d-c8b9-48ad-8a63-d805a9960bd2" xlink:to="loc_exdx_StockIssuanceCosts_46a15ab9-4e52-44b3-9fe5-998b8a8fe4d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_10bddc64-29ca-4c56-a467-135ad1627665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d437dd2d-c8b9-48ad-8a63-d805a9960bd2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_10bddc64-29ca-4c56-a467-135ad1627665" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_861e6b9e-81f8-4f3a-be26-d65c29a17438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10bddc64-29ca-4c56-a467-135ad1627665" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_861e6b9e-81f8-4f3a-be26-d65c29a17438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_861e6b9e-81f8-4f3a-be26-d65c29a17438_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_861e6b9e-81f8-4f3a-be26-d65c29a17438" xlink:to="loc_us-gaap_EquityComponentDomain_861e6b9e-81f8-4f3a-be26-d65c29a17438_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_413fb7f0-3107-45ec-92d4-e7f3af3c7681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_861e6b9e-81f8-4f3a-be26-d65c29a17438" xlink:to="loc_us-gaap_EquityComponentDomain_413fb7f0-3107-45ec-92d4-e7f3af3c7681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1c988cef-0d05-45a0-b40e-57bb3dfacacd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_413fb7f0-3107-45ec-92d4-e7f3af3c7681" xlink:to="loc_us-gaap_CommonStockMember_1c988cef-0d05-45a0-b40e-57bb3dfacacd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e48394ed-df39-4087-82ec-bcd9e460c346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10bddc64-29ca-4c56-a467-135ad1627665" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e48394ed-df39-4087-82ec-bcd9e460c346" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e48394ed-df39-4087-82ec-bcd9e460c346_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e48394ed-df39-4087-82ec-bcd9e460c346" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e48394ed-df39-4087-82ec-bcd9e460c346_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b4a969a8-097d-4d27-aa63-fdd1714ca462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e48394ed-df39-4087-82ec-bcd9e460c346" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b4a969a8-097d-4d27-aa63-fdd1714ca462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_a23c9d05-6b8b-4781-9933-804011d11458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b4a969a8-097d-4d27-aa63-fdd1714ca462" xlink:to="loc_us-gaap_IPOMember_a23c9d05-6b8b-4781-9933-804011d11458" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="extended" id="if749937c501540e99c482ecc37df0f91_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ca59669e-dc28-4d97-a63e-43388343daec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1b2b2bdf-9438-49fc-a9c1-46bac74f674e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca59669e-dc28-4d97-a63e-43388343daec" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1b2b2bdf-9438-49fc-a9c1-46bac74f674e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_583fcd17-f9d2-4e63-8075-05d9d4afd45b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca59669e-dc28-4d97-a63e-43388343daec" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_583fcd17-f9d2-4e63-8075-05d9d4afd45b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ad5c3372-10e6-4360-9406-190f0b865109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca59669e-dc28-4d97-a63e-43388343daec" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ad5c3372-10e6-4360-9406-190f0b865109" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5fb4063c-c274-4189-ae6b-5988f0fef2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ad5c3372-10e6-4360-9406-190f0b865109" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5fb4063c-c274-4189-ae6b-5988f0fef2ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5fb4063c-c274-4189-ae6b-5988f0fef2ae_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5fb4063c-c274-4189-ae6b-5988f0fef2ae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5fb4063c-c274-4189-ae6b-5988f0fef2ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5fb4063c-c274-4189-ae6b-5988f0fef2ae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_aae82934-45b5-4f7e-88b0-525b1d9a50a9" xlink:href="exdx-20210331.xsd#exdx_ExpirationJan192026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:to="loc_exdx_ExpirationJan192026Member_aae82934-45b5-4f7e-88b0-525b1d9a50a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_c000e4e7-fe05-40a9-9c50-702d77502cad" xlink:href="exdx-20210331.xsd#exdx_ExpirationMar312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:to="loc_exdx_ExpirationMar312026Member_c000e4e7-fe05-40a9-9c50-702d77502cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_cf18756f-6469-4081-a217-0afaee515b25" xlink:href="exdx-20210331.xsd#exdx_ExpirationApr12026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:to="loc_exdx_ExpirationApr12026Member_cf18756f-6469-4081-a217-0afaee515b25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_f6c61bb3-53e3-41cd-81e2-3e3853cb04df" xlink:href="exdx-20210331.xsd#exdx_ExpirationSep72024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:to="loc_exdx_ExpirationSep72024Member_f6c61bb3-53e3-41cd-81e2-3e3853cb04df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_924b56f4-27fe-4d34-bfa4-2822282ce70d" xlink:href="exdx-20210331.xsd#exdx_ExpirationDec72025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:to="loc_exdx_ExpirationDec72025Member_924b56f4-27fe-4d34-bfa4-2822282ce70d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlan"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended" id="i3776f4ebfddf4d9cacdbaffef329c793_StockOptionPlan"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended" id="ie614128701404f498c8d99e42a219791_StockOptionPlanTables"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended" id="i7ebb6704462a4ed29f9a203a9dd25a7d_StockOptionPlanNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_849e2e24-f906-4ce2-8672-a6cf004a3b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_849e2e24-f906-4ce2-8672-a6cf004a3b15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_254faa9b-3981-495a-af2a-79937e12a70d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_254faa9b-3981-495a-af2a-79937e12a70d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5d6e913-ed4a-4820-b95f-a0c3b04eea1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5d6e913-ed4a-4820-b95f-a0c3b04eea1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_51a25402-38b8-43d1-a6e7-a275ca4f7d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_51a25402-38b8-43d1-a6e7-a275ca4f7d34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62e1c759-2aba-435b-9593-8ec7b33a6a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62e1c759-2aba-435b-9593-8ec7b33a6a2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b08cc5e-1165-4068-bb41-790312cd4c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b08cc5e-1165-4068-bb41-790312cd4c3b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f73b8ea-4658-4ed7-ab4b-dc20a22a1591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f73b8ea-4658-4ed7-ab4b-dc20a22a1591" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e24fe90-9c71-46a0-afaf-28df9ca3b16d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e24fe90-9c71-46a0-afaf-28df9ca3b16d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45f5d055-43fa-40e1-bfd3-5198bd1d0268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45f5d055-43fa-40e1-bfd3-5198bd1d0268" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4717a25d-b3cd-4e38-98ba-d5ce34ab04c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45f5d055-43fa-40e1-bfd3-5198bd1d0268" xlink:to="loc_us-gaap_PlanNameAxis_4717a25d-b3cd-4e38-98ba-d5ce34ab04c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4717a25d-b3cd-4e38-98ba-d5ce34ab04c0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4717a25d-b3cd-4e38-98ba-d5ce34ab04c0" xlink:to="loc_us-gaap_PlanNameDomain_4717a25d-b3cd-4e38-98ba-d5ce34ab04c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2f49080a-ea75-425a-af41-5cd48e5dd910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4717a25d-b3cd-4e38-98ba-d5ce34ab04c0" xlink:to="loc_us-gaap_PlanNameDomain_2f49080a-ea75-425a-af41-5cd48e5dd910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_4f3a4454-f312-4780-aefa-b25b183520fa" xlink:href="exdx-20210331.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2f49080a-ea75-425a-af41-5cd48e5dd910" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_4f3a4454-f312-4780-aefa-b25b183520fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_072d08d1-93f4-4ac5-8b29-f7041c0998ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45f5d055-43fa-40e1-bfd3-5198bd1d0268" xlink:to="loc_us-gaap_AwardTypeAxis_072d08d1-93f4-4ac5-8b29-f7041c0998ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_072d08d1-93f4-4ac5-8b29-f7041c0998ea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_072d08d1-93f4-4ac5-8b29-f7041c0998ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_072d08d1-93f4-4ac5-8b29-f7041c0998ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b329f750-c870-48a4-a206-405f2a37b546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_072d08d1-93f4-4ac5-8b29-f7041c0998ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b329f750-c870-48a4-a206-405f2a37b546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b42d5bb7-25cc-45d1-a05c-c030673dee55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b329f750-c870-48a4-a206-405f2a37b546" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b42d5bb7-25cc-45d1-a05c-c030673dee55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e914fc13-31b1-42da-8942-fe5651f3d4a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b329f750-c870-48a4-a206-405f2a37b546" xlink:to="loc_us-gaap_EmployeeStockMember_e914fc13-31b1-42da-8942-fe5651f3d4a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_902a7dd8-d016-4911-9e17-aa4adbc8e4b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b329f750-c870-48a4-a206-405f2a37b546" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_902a7dd8-d016-4911-9e17-aa4adbc8e4b8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended" id="i3f4665324fd54351a9ab99d79b92a8a9_StockOptionPlanStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9cd8eaf2-a12e-4c5a-bd41-226c2d637933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9cd8eaf2-a12e-4c5a-bd41-226c2d637933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_334d3483-cc3c-4213-a848-b87432bd1808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_334d3483-cc3c-4213-a848-b87432bd1808" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9f4aee95-0e41-4ec7-8f2b-f883146f3b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9f4aee95-0e41-4ec7-8f2b-f883146f3b79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_dbcf561d-7fbc-48aa-9314-5fa99a1f2133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_dbcf561d-7fbc-48aa-9314-5fa99a1f2133" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_113fbe25-8a49-4f00-9f13-f7cc7526e2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_113fbe25-8a49-4f00-9f13-f7cc7526e2b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_84911549-fe43-4b50-9fb8-1a7aa61d0893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e0078158-b6ab-44d3-8acc-9c218a55b048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e0078158-b6ab-44d3-8acc-9c218a55b048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5dceeda2-35e6-4da3-8bea-2e871e70a938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5dceeda2-35e6-4da3-8bea-2e871e70a938" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b597449b-f7cd-4a84-8ee9-b33b5607fe48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b597449b-f7cd-4a84-8ee9-b33b5607fe48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5496591b-8bc1-48ae-9f0c-ded3c1da7149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5496591b-8bc1-48ae-9f0c-ded3c1da7149" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_793274c3-96a4-49f6-b5de-fa4262b337be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_793274c3-96a4-49f6-b5de-fa4262b337be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0da8c531-ae29-4df7-aae1-04c8e2d0b8ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_26dbc36d-5d2b-419f-853f-db010effa121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_26dbc36d-5d2b-419f-853f-db010effa121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_357195ea-21b2-4287-8c7a-926fa14b4a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_357195ea-21b2-4287-8c7a-926fa14b4a82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1d6885fb-76d6-4555-9431-f64119bf02be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1d6885fb-76d6-4555-9431-f64119bf02be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dd36fd5b-1fbb-4dea-8c71-744d8429e110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dd36fd5b-1fbb-4dea-8c71-744d8429e110" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a9026350-60fc-439b-86c8-0e093478b5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a9026350-60fc-439b-86c8-0e093478b5ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_fffcd094-a55b-41b3-8681-9b9ce043a322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_fffcd094-a55b-41b3-8681-9b9ce043a322" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d5452068-6b16-490c-a4a2-41eaa55f788a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d5452068-6b16-490c-a4a2-41eaa55f788a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_b4f01ba1-48de-4443-a9ac-613ad3170ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_b4f01ba1-48de-4443-a9ac-613ad3170ad1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_546d50d6-b9e4-409d-9f3d-2a28f6ea8b26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_546d50d6-b9e4-409d-9f3d-2a28f6ea8b26" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1d4b4aee-125a-42e5-a2ce-336d840a7330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1d4b4aee-125a-42e5-a2ce-336d840a7330" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80b9feb-3449-40b0-8101-d47f7918e43d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80b9feb-3449-40b0-8101-d47f7918e43d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4629ecc3-ab74-49fa-b136-de8825066981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80b9feb-3449-40b0-8101-d47f7918e43d" xlink:to="loc_us-gaap_AwardTypeAxis_4629ecc3-ab74-49fa-b136-de8825066981" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4629ecc3-ab74-49fa-b136-de8825066981_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4629ecc3-ab74-49fa-b136-de8825066981" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4629ecc3-ab74-49fa-b136-de8825066981_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f451c903-72c7-468a-9a46-53749b2d42ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4629ecc3-ab74-49fa-b136-de8825066981" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f451c903-72c7-468a-9a46-53749b2d42ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9e3c74da-ff79-4cc4-b0ae-799e9b8e82ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f451c903-72c7-468a-9a46-53749b2d42ec" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9e3c74da-ff79-4cc4-b0ae-799e9b8e82ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended" id="i146c5bc1962941748c255539e0da30dd_StockOptionPlanRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac9f7d2b-7bbd-487a-ae30-c7c0aa3d5b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac9f7d2b-7bbd-487a-ae30-c7c0aa3d5b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c4950569-f9b3-47bf-951f-bffac538504b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c4950569-f9b3-47bf-951f-bffac538504b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_988c7e09-cbc9-491d-b142-0d432531cd16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_988c7e09-cbc9-491d-b142-0d432531cd16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b5cbdfd0-3442-4ee6-aa80-a08d6fbe1599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b5cbdfd0-3442-4ee6-aa80-a08d6fbe1599" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1d9db37f-8b68-4de4-8d0b-4707daf9ddb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1d9db37f-8b68-4de4-8d0b-4707daf9ddb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_97fc83dd-ec0f-4d82-80da-90aec6769b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac9f7d2b-7bbd-487a-ae30-c7c0aa3d5b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a10e3710-281a-4616-8a80-cf3bfde7a7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a10e3710-281a-4616-8a80-cf3bfde7a7e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e369fbe5-9a8b-4abe-8f88-823467ea97fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e369fbe5-9a8b-4abe-8f88-823467ea97fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ef57d1a5-6660-4657-a7f3-1c1dffc77c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ef57d1a5-6660-4657-a7f3-1c1dffc77c1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3f360d86-3428-4515-bdf2-0fea91b4a6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3f360d86-3428-4515-bdf2-0fea91b4a6d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8e039f3c-da4d-460d-a4cf-45869d945af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_1c776417-6448-4795-8492-e65a8d2a9128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac9f7d2b-7bbd-487a-ae30-c7c0aa3d5b1c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_1c776417-6448-4795-8492-e65a8d2a9128" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_671e2be1-949d-43ad-8427-4e35b98d05ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_1c776417-6448-4795-8492-e65a8d2a9128" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_671e2be1-949d-43ad-8427-4e35b98d05ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0025d20-a46f-4b00-b33b-544e3d4420f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac9f7d2b-7bbd-487a-ae30-c7c0aa3d5b1c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0025d20-a46f-4b00-b33b-544e3d4420f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ef948970-d091-4704-86a2-c08b4faa4a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0025d20-a46f-4b00-b33b-544e3d4420f8" xlink:to="loc_us-gaap_AwardTypeAxis_ef948970-d091-4704-86a2-c08b4faa4a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef948970-d091-4704-86a2-c08b4faa4a84_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ef948970-d091-4704-86a2-c08b4faa4a84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef948970-d091-4704-86a2-c08b4faa4a84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_168e6aec-62b0-4d10-a300-d071bc810437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ef948970-d091-4704-86a2-c08b4faa4a84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_168e6aec-62b0-4d10-a300-d071bc810437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0f9c3dcb-4b92-47b9-b530-8ce0980e9bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_168e6aec-62b0-4d10-a300-d071bc810437" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0f9c3dcb-4b92-47b9-b530-8ce0980e9bc2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended" id="i646b8fdf77eb4fdfbc5375014d108c11_StockOptionPlanFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dabc1a5b-3b55-4555-9b4a-381b8d01b87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dabc1a5b-3b55-4555-9b4a-381b8d01b87a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_292319bd-2560-435f-a9d9-497fec1e97ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_292319bd-2560-435f-a9d9-497fec1e97ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_83f90c14-ea6f-4868-9524-69968342df13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_83f90c14-ea6f-4868-9524-69968342df13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5f87a0ce-c1db-4c85-b6a4-90e133e18c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5f87a0ce-c1db-4c85-b6a4-90e133e18c34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_099b581b-a376-42a3-8c52-73cac9143b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_099b581b-a376-42a3-8c52-73cac9143b0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4cf978ce-32f3-4a90-a20f-8309c9da7aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4cf978ce-32f3-4a90-a20f-8309c9da7aa4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5f508da9-9d3d-4f57-bfcd-57f48c757621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5f508da9-9d3d-4f57-bfcd-57f48c757621" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fd79fda2-2c4e-4770-8667-c5f2453e275b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fd79fda2-2c4e-4770-8667-c5f2453e275b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1b3bfc5-09e2-462a-8768-d3f9abd05312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1b3bfc5-09e2-462a-8768-d3f9abd05312" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8e36805b-4608-4d82-9260-36149e3576d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1b3bfc5-09e2-462a-8768-d3f9abd05312" xlink:to="loc_us-gaap_AwardTypeAxis_8e36805b-4608-4d82-9260-36149e3576d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e36805b-4608-4d82-9260-36149e3576d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8e36805b-4608-4d82-9260-36149e3576d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e36805b-4608-4d82-9260-36149e3576d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_341f3f0d-148e-48ef-8f6f-b0654c1263e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8e36805b-4608-4d82-9260-36149e3576d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_341f3f0d-148e-48ef-8f6f-b0654c1263e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_77567ccc-38b2-4b04-8891-95e43e4cd684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_341f3f0d-148e-48ef-8f6f-b0654c1263e1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_77567ccc-38b2-4b04-8891-95e43e4cd684" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7fc244bb-3f36-4777-aa5e-b4d2bd1af333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_341f3f0d-148e-48ef-8f6f-b0654c1263e1" xlink:to="loc_us-gaap_EmployeeStockMember_7fc244bb-3f36-4777-aa5e-b4d2bd1af333" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended" id="i7d75419d2a5e45658020bb3d8a9abf6c_StockOptionPlanStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f7655c-f8d1-47d5-a1a4-ccec9a47e511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4296aca2-7b28-48de-aa6c-55ef9f4b1cdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f7655c-f8d1-47d5-a1a4-ccec9a47e511" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4296aca2-7b28-48de-aa6c-55ef9f4b1cdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05d98d30-dead-4e25-bb10-f4d039818fba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f7655c-f8d1-47d5-a1a4-ccec9a47e511" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05d98d30-dead-4e25-bb10-f4d039818fba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_760662bd-0260-4728-9b2d-332c5eac5054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05d98d30-dead-4e25-bb10-f4d039818fba" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_760662bd-0260-4728-9b2d-332c5eac5054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_760662bd-0260-4728-9b2d-332c5eac5054_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_760662bd-0260-4728-9b2d-332c5eac5054" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_760662bd-0260-4728-9b2d-332c5eac5054_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_18ee7456-3714-437d-a15f-318f458e6d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_760662bd-0260-4728-9b2d-332c5eac5054" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_18ee7456-3714-437d-a15f-318f458e6d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d3d804ce-a4d2-4850-8365-ecd75c48f392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_18ee7456-3714-437d-a15f-318f458e6d3c" xlink:to="loc_us-gaap_CostOfSalesMember_d3d804ce-a4d2-4850-8365-ecd75c48f392" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22a6879a-be32-40a4-b99b-ab08616f8cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_18ee7456-3714-437d-a15f-318f458e6d3c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22a6879a-be32-40a4-b99b-ab08616f8cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9cfcfd34-2086-47e3-a047-b65e2a76fd0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_18ee7456-3714-437d-a15f-318f458e6d3c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9cfcfd34-2086-47e3-a047-b65e2a76fd0b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19" xlink:type="simple" xlink:href="exdx-20210331.xsd#Covid19"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Covid19" xlink:type="extended" id="i9f8e332a01d94d10b039665a262c0105_Covid19"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19Details" xlink:type="simple" xlink:href="exdx-20210331.xsd#Covid19Details"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Covid19Details" xlink:type="extended" id="id12b660222944d4d88428f2811d812e8_Covid19Details"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>exdx-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:dc3d5bf2-9b73-4463-aa2c-e75c744aa8d3,g:734221f7-636e-4e71-b928-4b5e730d1da3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7260ede4-3fad-4e28-b8ff-72c354445bb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1df1ab17-5138-4299-aa2c-1f75b9f7c669_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6dacc63d-560a-4264-90c4-b731a708ad4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b24c1694-3734-490e-a079-109b99e73293_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3047ba44-b907-40a3-b616-7bab5a640c29_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a1604e52-85b6-4d82-90fe-d77bfac8b8d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7a9c55a6-aad4-4eba-b636-889938504061_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_5f136049-66bb-4605-afde-5fce06a9e2cf_terseLabel_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_label_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund [Member]</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_documentation_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:href="exdx-20210331.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:to="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0e404c9f-ae03-47a9-bde9-5722b5d1d388_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards released/ Weighted-Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_73d18e01-7448-48cb-a711-7c8298f9de31_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_df3c7401-4c7a-4817-9986-bb9d1ba6a0b4_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis" xlink:href="exdx-20210331.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeAxis" xlink:to="lab_exdx_RentalPropertyByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7bd4c65f-72bc-4bf9-b69f-dad128293118_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5a65986c-c1d7-4611-bae5-8a416491396a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da87acb9-a8a3-41dd-92ee-b051250e64b8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e76a2a7e-f651-419b-b2e2-c328aed70ef6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_e40a465a-924f-4203-bf39-1fe93706f2f4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7259d8ea-8afe-43ca-8787-9cf238373238_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_398bfe45-7f80-4da8-b587-f9b46755fee2_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covid-19</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure [Text Block]</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:href="exdx-20210331.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_45f7a6d3-8400-4c35-a289-8966437e9cb0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_76fad17a-2efb-4b1f-8559-e05307d7548b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_BlueShieldMember_caeca5a9-4daf-4f24-bb43-728472305712_terseLabel_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:label id="lab_exdx_BlueShieldMember_label_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield [Member]</link:label>
    <link:label id="lab_exdx_BlueShieldMember_documentation_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember" xlink:href="exdx-20210331.xsd#exdx_BlueShieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_BlueShieldMember" xlink:to="lab_exdx_BlueShieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a7fc7f0e-4726-410b-b3a7-b57a97aaff38_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCustomerMember_87299f9b-9438-4ba5-b905-e9520078be87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCustomerMember_label_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCustomerMember" xlink:to="lab_us-gaap_OtherCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_103e959b-0402-477a-876e-f48a5819c1dd_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_640224ac-1ccb-4ded-a5d3-80ad16099b7e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December&#160;31, 2020 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_57a2ff6c-a4c1-4287-8ee4-ef34519ad3eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, March&#160;31, 2021 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_7f9f8492-7461-4ad1-b74a-cfeec69cd3e6_terseLabel_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation, percent of net sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_label_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_documentation_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:href="exdx-20210331.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:to="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_07999b76-2e16-4583-8083-c162a9e0235f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ec885b6d-9ffe-4a74-b357-06c488199823_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_abaa0a1f-2355-4ecb-83e7-4640c5385b8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c0a5db0d-5a86-4f53-9db6-063414573c92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_d1b772a3-4bde-4cde-a16f-4ef2b2076308_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture&#160;and&#160;fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b4d30184-4766-4563-be55-850ea1d9a8e7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_140a3d04-38c0-4749-af60-464821ab5b37_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_c04b3b2b-84fe-468e-a177-406e18084726_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issued under Employee Stock Purchase Pan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a2757d79-0c73-49a5-aaf8-ecd9dd056f76_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_788f8bcf-fdce-4022-ab0d-04f4b4c6eb0a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_13ee7ed4-c8d8-4c8b-8bba-c3828ccad4d6_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:href="exdx-20210331.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ec5a45ca-33d4-43cc-8505-4dbab0b134bb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_db2870f6-2c68-47f3-9226-3ed23f38a2ee_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_496b5957-4ca8-4172-8a71-81c82d27dc65_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20071d56-1d53-4183-a1bc-dead0f90ef11_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc9f2ef9-bcf6-4373-83b1-970508f1e0e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, March&#160;31, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_aa853a33-56d0-4175-b622-f848ced36bf3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ab2c0407-72b4-4555-bcc6-c947e3890751_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_b47b8841-1943-4e8d-93b4-aee3b9df3904_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeasesRenewalTerm_57f88689-2fdf-4769-9116-4af717cd065c_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_exdx_OperatingLeasesRenewalTerm_label_en-US" xlink:label="lab_exdx_OperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Renewal Term</link:label>
    <link:label id="lab_exdx_OperatingLeasesRenewalTerm_documentation_en-US" xlink:label="lab_exdx_OperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeasesRenewalTerm" xlink:href="exdx-20210331.xsd#exdx_OperatingLeasesRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeasesRenewalTerm" xlink:to="lab_exdx_OperatingLeasesRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d41a4668-3175-480c-8b4e-063c704ede71_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at March&#160;31, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_46f07eb6-c8b3-47cf-a80f-3bac0e9a7368_terseLabel_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchases of goods and services</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_label_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:href="exdx-20210331.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:to="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ef9a943d-2758-4773-9c72-a9b54cee0ed2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_cd7bafc5-df1b-45fc-9c13-21852a8c49d1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b1456cc9-ae96-499b-b079-bd747695aeda_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_0fdd9508-e574-4ce6-983d-56a93dadb830_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain" xlink:href="exdx-20210331.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeDomain" xlink:to="lab_exdx_RentalPropertyByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2955044c-d66e-4cac-87ef-6012d6aea298_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_30823ae2-f517-4ad1-9e70-5a82a858b251_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_e1f4f8c9-d6f4-4d08-9e03-adb70e8fab20_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind loans issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_label_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:to="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_cf457fdf-2016-4e4e-8560-cb549c1b7267_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_e8bfaa78-3479-48d8-99c5-69f1136c9feb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationSep72024Member_e9c0f1d3-c3eb-49e5-9bec-0c6a1f5362cc_terseLabel_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration September 7, 2024</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_label_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 7, 2024 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_documentation_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 7, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member" xlink:href="exdx-20210331.xsd#exdx_ExpirationSep72024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationSep72024Member" xlink:to="lab_exdx_ExpirationSep72024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_174d9e59-a3f3-462e-9e82-301ff03bd4a2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_119f171e-ddba-49bb-9c1c-5665dc343596_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d73e214e-25d4-4e4b-b17e-f7804ac9a3c0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFee_6cf8c20a-9c7b-4e3d-9490-087325c3f0da_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture, quarterly promotion fee</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFee_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFee_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFee" xlink:href="exdx-20210331.xsd#exdx_JointVentureQuarterlyPromotionFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPromotionFee" xlink:to="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_409969d0-f14a-449a-a745-6dce1de59186_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1c5551b7-a235-44b4-8939-53b186da9fc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_e566af6f-28f2-43e3-b0b3-9a923e3e4941_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeMember_c82a3e13-e022-498a-9294-7c364ccb639f_terseLabel_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:label id="lab_exdx_OfficeMember_label_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office [Member]</link:label>
    <link:label id="lab_exdx_OfficeMember_documentation_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember" xlink:href="exdx-20210331.xsd#exdx_OfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeMember" xlink:to="lab_exdx_OfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_3b8d1038-5ce1-47e7-8bd8-cd26a71f5db3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_16d6a7db-587f-42ee-83f7-dfdc580099e4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationMar312026Member_6e2e54ff-1a02-4c42-9133-5bfe19d3b3fc_terseLabel_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration March 31, 2026</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_label_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member" xlink:href="exdx-20210331.xsd#exdx_ExpirationMar312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationMar312026Member" xlink:to="lab_exdx_ExpirationMar312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LicenseAgreementInitialLicenseFee_73c28be1-4ddd-4816-8186-35114ad1e462_terseLabel_en-US" xlink:label="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial license fee</link:label>
    <link:label id="lab_exdx_LicenseAgreementInitialLicenseFee_label_en-US" xlink:label="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial License Fee</link:label>
    <link:label id="lab_exdx_LicenseAgreementInitialLicenseFee_documentation_en-US" xlink:label="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial License Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementInitialLicenseFee" xlink:href="exdx-20210331.xsd#exdx_LicenseAgreementInitialLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LicenseAgreementInitialLicenseFee" xlink:to="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e5ee1b5a-2002-4dcf-a5ab-f4087cc7bdda_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d279c3ca-1bd1-4f6e-bd33-2baed4aa7e98_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4ccab578-5a22-4401-b149-716664f3505a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_be79fb11-afef-420b-97b8-c3e124f5a632_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_61ec02ef-6e48-42ae-87b2-25c6e466a3f9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_e3b2d199-63b0-4624-93d8-4ae34f23b289_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0c16c2a0-786d-474c-a167-94543beed1be_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_31ad5bff-35ab-4b09-8cef-f2b52eabb4a9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_64afbe68-302c-4e50-9279-0a127b5058d7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareMember_280e34eb-5361-4b73-8ace-7c646826c415_terseLabel_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_exdx_MedicareMember_label_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_exdx_MedicareMember_documentation_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember" xlink:href="exdx-20210331.xsd#exdx_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareMember" xlink:to="lab_exdx_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ee191043-33dc-4c66-b0bd-f28b2bb51cda_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1ac92609-20d0-4543-b405-851a57f8b3be_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f7906c6f-b06d-4434-bf8b-503a48271ee6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_589b3a8d-7bc4-492f-980d-4fee5d976133_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_c81d31fb-d5ab-4ef6-9154-a22779e9ad49_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock in public offering, gross</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_ed1f9b9d-8da2-402f-a2e6-154654ea440a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e7adf286-3e79-43f3-93ab-6c7016990d1d_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_462ea89b-e0a0-4158-aabc-495ebf89bcbe_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_9f34cb0d-ca9f-44fa-8e5f-591b677f4ee7_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture quarterly promotion fee cap</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:href="exdx-20210331.xsd#exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:to="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationDec72025Member_2208f874-1997-42c7-8b8d-8615f1eed62f_terseLabel_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration December 7, 2025</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_label_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_documentation_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member" xlink:href="exdx-20210331.xsd#exdx_ExpirationDec72025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationDec72025Member" xlink:to="lab_exdx_ExpirationDec72025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_82eb276c-42a4-4403-9457-ab84183e45b6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d48084f9-a5b2-4f6a-b91d-596e93d3f490_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that remain available for future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_55267e83-ab8d-41a1-a781-28c20343abab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e4b88450-4405-4c5b-8fcd-0985c9afdd0e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_8c33f152-a78d-4cf4-83e3-878b1df6f317_negatedLabel_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_label_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_documentation_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:href="exdx-20210331.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:to="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_9c81d2f2-5998-4eb6-a169-bb30ee8134ab_terseLabel_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_label_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark [Member]</link:label>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_documentation_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember" xlink:href="exdx-20210331.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ReceivableBenchmarkMember" xlink:to="lab_exdx_ReceivableBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_584b7ec3-d5f3-4679-b4e1-f57ef53969cc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6844cb53-0a42-496f-91bb-7739809f7002_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f593265c-a04a-4eda-a07c-cd4f8c9e49d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0583ab3c-78cd-499c-9cb6-2aaf8d0c437e_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_UnitedHealthcareMember_65b33762-8d52-4949-b83a-cbf86d18d8db_terseLabel_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_label_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare [Member]</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_documentation_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember" xlink:href="exdx-20210331.xsd#exdx_UnitedHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_UnitedHealthcareMember" xlink:to="lab_exdx_UnitedHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d2b87216-5c25-41aa-8770-5acbf2b581e8_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred, but not paid, in connection with capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_7445b741-d35b-43c5-96f9-809ae2845005_terseLabel_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment purchased under capital lease obligations</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_label_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Capital Lease</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_documentation_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Capital Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderCapitalLease" xlink:href="exdx-20210331.xsd#exdx_EquipmentPurchasedUnderCapitalLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentPurchasedUnderCapitalLease" xlink:to="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_64b180d1-87f7-49a8-a751-3302ca9da844_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ae206d6d-3a55-41c1-8ae1-30d1ceeaf21d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_066b01b7-6e8b-4ff9-8a56-9fb5ab66622a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23d925b2-74b4-4060-a656-4506f383a440_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_9d9a4207-1901-421a-8d84-52e7cebca98c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9eb8d791-b901-4050-8b57-5da96c223c5d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_503ad04f-143d-4df6-a82a-3fd1d3aaa58c_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c3774f25-b2da-477d-9969-f226652f6f54_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_d727f01e-d4d3-48ea-8ac2-35e5c764e48b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_71eb31a1-a39d-4de0-8105-f588b17a682d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses table</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_325e22e3-a005-41f2-83b6-0b0f29831a86_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_4d407066-3036-47a9-9ecd-3faead11b612_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_dd0b2e3d-dcdd-4b90-bfae-e080c4610bf2_terseLabel_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_label_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc. [Member]</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_documentation_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember" xlink:href="exdx-20210331.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrometheusLaboratoriesIncMember" xlink:to="lab_exdx_PrometheusLaboratoriesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4ae23dcd-3a41-4b02-94eb-f061de8fea68_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock in public offering, net of issuance costs of $4,435</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9452f2c4-d2da-4117-9808-8f900d05dec2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0915db01-201f-47e2-aa9c-cf4a94b1df99_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_36278d3b-f1ec-4e0a-b30e-331104c95c53_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_2cbacee8-76d2-4bea-b59b-cad7bf3a39cf_terseLabel_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Award Plan</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_label_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019 [Member]</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_documentation_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member" xlink:href="exdx-20210331.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncentiveAwardPlan2019Member" xlink:to="lab_exdx_IncentiveAwardPlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_efd28d68-9ec7-47e1-b7de-a8051cac4143_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c50d1929-883f-4c79-8b10-49c0398651b0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dc6a934c-7126-474a-9eb2-4d0b1e8147de_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, March&#160;31, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f6f9825c-8a9c-4081-9a59-72353c96a471_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5816e4c6-8274-4800-9e92-cf962d0de7e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_abe0c742-1d2e-45a5-b3b1-5a65ebfaef60_negatedLabel_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_label_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_documentation_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:href="exdx-20210331.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:to="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_81fd3007-83d5-4481-82dc-f32e694aabc8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4491311d-166d-47be-8396-d514289fd630_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_51270e97-1deb-474e-b9a3-88a106141d2e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_b78b26da-2910-41f4-a3f6-c634bf3c371f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_4851c33d-5f15-4731-abba-efbdaf5e8e92_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risk and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_d4feb004-d494-4c9e-acea-eb5ed045a2ad_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1f7857f1-b912-4fea-8fb5-cadc4aafd1c5_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering, net</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_abcf42f9-c559-4ceb-a8ef-6a5f51c39199_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_8c2ac93f-d8b6-4c80-b34b-93ee530d7281_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_58a95571-ace5-4e8f-97ee-e7824498d25d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_8d97b869-5077-4274-bc2d-1281d4612e3d_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind, interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_label_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:to="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22a64b28-91ea-48fc-89e5-01a77f36eb67_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, cost not yet recognized, remaining weighted average vesting period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d6972854-98a9-4954-81a6-8ee97dd76de0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_72e8f765-27bd-4de1-a1f4-1ca2a1290b74_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash items:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_caa59460-1a6c-4844-ac86-03a134eac0b2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_229d08e4-3471-4590-b958-939e56d47508_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ff65bd2e-5094-4dd3-875e-529760fcf3b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_33b7bbd0-8a18-4ade-8fe7-095fa2379812_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_e53a20bb-fc3a-4dde-a99f-f75b94671246_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d11a27b1-c8a6-4307-9f10-f04862a9a8ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_7859bffc-77a7-49f5-a31b-ac8376b763a0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_232ccb0a-6fdc-44e0-8f03-2c036c48a6e4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital lease obligations, current portion</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_5dc06093-551e-4351-b027-b2cc4b4df7b6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0c658614-48c8-4310-8814-8d44e81652b9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_a2c754d3-6818-4947-a5a2-73d2c998a21a_terseLabel_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid maintenance and insurance contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_label_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_documentation_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:href="exdx-20210331.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:to="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_b4ce3de1-8e60-4732-b24f-1c895eca5d29_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:to="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ca99e7cd-7fa3-42b7-ad6d-0b31e355142a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_6e266028-5fd9-4f6c-b182-95ddd330204f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_30259939-8dc2-41b3-b9e5-b7583bfded0b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa2607f-e262-4f18-9deb-dd4656c2d006_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cf8eb67f-b9aa-4b0a-940c-9997d3b9ab50_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1ffd2916-efd9-4dfc-aad3-a2e4f1c0b456_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d22b9e35-2f52-4bb0-be72-204b22966539_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_4cf82c17-90af-44e5-8b2f-dd8939e1644e_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_7a660a49-03ea-409e-9058-d05f1678dfc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, March&#160;31, 2021, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_108cc286-243a-4a92-a205-bb0c2188bfd7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_1ef2a6ec-6804-4a77-aa9b-60c2960542ed_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_f79e0313-9cc8-46ee-a9a1-1972905facb7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPrescribedUnits_a4988e3f-3df2-43c8-8205-6a8f4e5e5714_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPrescribedUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture, number of units prescribed quarterly</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPrescribedUnits_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPrescribedUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Prescribed Units</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPrescribedUnits_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPrescribedUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Prescribed Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPrescribedUnits" xlink:href="exdx-20210331.xsd#exdx_JointVentureQuarterlyPrescribedUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPrescribedUnits" xlink:to="lab_exdx_JointVentureQuarterlyPrescribedUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d821d9bc-0f47-49b3-ab76-9bd510cff2f4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ef34f549-d36b-4310-b6ad-e4cc5a6be512_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, March&#160;31, 2021, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9581bb2f-2106-4210-9fcb-98d5a340b355_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c88a5f7d-cbc0-47ef-8567-6e6b316c1977_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_59c16051-7106-4cba-9f1f-10d9c69c5086_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_HealthcareInsurersMember_60c3382a-2076-41a5-b0bb-17e8bec9de3f_terseLabel_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare insurers</link:label>
    <link:label id="lab_exdx_HealthcareInsurersMember_label_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers [Member]</link:label>
    <link:label id="lab_exdx_HealthcareInsurersMember_documentation_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember" xlink:href="exdx-20210331.xsd#exdx_HealthcareInsurersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_HealthcareInsurersMember" xlink:to="lab_exdx_HealthcareInsurersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_d1bb9788-0dac-48ba-8707-0e7296827b24_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_54e84fe3-95bd-4dd9-8cc8-af628327d72b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2d049039-69f8-4bb2-9e73-45f5b0a3e5fd_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_00b783eb-cbb4-453e-a417-7d81b3dd32e9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_a61976ce-8ec0-4ee6-89ff-fd717217954a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_e179fa28-a4b3-4518-9ac4-f739bfc70a65_terseLabel_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory [Member]</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember" xlink:href="exdx-20210331.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeAndLaboratoryMember" xlink:to="lab_exdx_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_83e1b88e-4b22-4675-9013-4704e2a1046b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_5aa42fed-4bec-435b-9f7f-b25fcbcedcbf_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_c10022fa-24c7-472a-9cee-9a122dafecca_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_586bd23e-1cb2-467c-8f45-fa77eba30960_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_840144e1-af4a-4343-a4ed-8653d14ce894_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_55271c5a-1006-403b-8cdd-6ccf4ac10694_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_25b9639b-808e-4eff-bcc8-0db526ad594c_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:href="exdx-20210331.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4e3defd7-32c3-4c24-8819-a89e34126f6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_09f59925-e5e9-49be-a422-5ed8ceb93b65_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9557b180-902f-4a33-a848-707d21cd95b7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_53e5e838-fe8f-43ce-96c5-2a57df0f415a_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_df523a64-0ba0-4faf-a3fe-fe6480c18b71_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0fb67fca-ee23-4d40-8937-0f38c60e37e6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_fa5da599-02f6-46e2-b4d6-399ff604e0af_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_6c22f8cd-7b41-407e-b428-2384abfd25dd_terseLabel_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:href="exdx-20210331.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription_ed50cf74-556a-4ba0-badf-714ba49831ef_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture, quarterly promotion fee per prescription</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee Per Prescription</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee Per Prescription</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:href="exdx-20210331.xsd#exdx_JointVentureQuarterlyPromotionFeePerPrescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:to="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_dc69b5f3-c7ec-46c7-a013-649c4d85c760_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_dc547e17-058d-4181-8d06-4a9b687745d5_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_1341694a-656f-4da2-a8dc-32b390c08bd2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_f851bda8-fc05-458e-8d5e-5641002874f0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6b2b224e-0e0e-4af5-94c3-43ff4e23d10f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_f2ddf230-f898-468d-ae5c-919a08c26428_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_27e6dc3e-c471-4c1c-b5b4-c06986e4e3b7_terseLabel_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_label_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute [Member]</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_documentation_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:href="exdx-20210331.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:to="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_ba72e688-8cb7-4109-80b6-0e591fdba20b_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ec1aeff9-aff2-4413-9ea9-4f213f9195b6_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total borrowings, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Term2017Member_954fc97b-2e4d-478f-899c-4ba8e2a9a586_terseLabel_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term loan</link:label>
    <link:label id="lab_exdx_Term2017Member_label_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017 [Member]</link:label>
    <link:label id="lab_exdx_Term2017Member_documentation_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member" xlink:href="exdx-20210331.xsd#exdx_Term2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Term2017Member" xlink:to="lab_exdx_Term2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReorganizationsAbstract_label_en-US" xlink:label="lab_us-gaap_ReorganizationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reorganizations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReorganizationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReorganizationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReorganizationsAbstract" xlink:to="lab_us-gaap_ReorganizationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_b19af505-8725-42bb-b821-024bdc0df07d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ac1090ab-f4b0-4bad-bd31-d6edc4947384_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_128ff051-5e71-43cd-a4b8-678e374fc89f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_82edb3a7-3dae-4d55-929a-b47607e0df90_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5e74c542-2ee3-4735-82d5-caa7cd871671_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoPromotionAgreementRenewalTerm_a5bb3807-c9fd-4251-bae3-ddbb94f553b2_terseLabel_en-US" xlink:label="lab_exdx_CoPromotionAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion agreement, renewal term</link:label>
    <link:label id="lab_exdx_CoPromotionAgreementRenewalTerm_label_en-US" xlink:label="lab_exdx_CoPromotionAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Promotion Agreement, Renewal Term</link:label>
    <link:label id="lab_exdx_CoPromotionAgreementRenewalTerm_documentation_en-US" xlink:label="lab_exdx_CoPromotionAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Promotion Agreement, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoPromotionAgreementRenewalTerm" xlink:href="exdx-20210331.xsd#exdx_CoPromotionAgreementRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoPromotionAgreementRenewalTerm" xlink:to="lab_exdx_CoPromotionAgreementRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7c0a88b8-02e8-4565-8332-822cd9a34514_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e0f49dd9-5238-423c-adc9-7e5a3755a99c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_6e787553-6fcd-4c96-b2db-0306bf9cd4c5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_854fb428-e6de-4307-8c55-f2e4e29079dd_terseLabel_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets under capital lease</link:label>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_label_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Under Capital Lease [Member]</link:label>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_documentation_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Under Capital Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember" xlink:href="exdx-20210331.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AssetsUnderCapitalLeaseMember" xlink:to="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0b23536e-84e1-4df1-92ec-388b19b63e98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards canceled/Weighted-Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9548f593-5e7b-4223-9f2a-d3ff5990428f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions, Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_7eab40b8-be7f-4679-a8b5-17205e4ac304_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_40cfd1c6-e785-47af-a5dc-005a6dac36f8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9953b25f-2030-44cc-9a1d-99f1ce203258_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_67ea779f-4eca-422a-a71b-0fbe561e3dad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_bac773a1-4e61-492a-a310-34bdabff335c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ff816ae9-bd6c-409a-b146-4bb9e7f4b005_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3400c13a-b173-436f-aa9f-9ecfcf865642_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_5c3b4336-59da-410f-a934-8e16a6460736_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_fdd3b8d3-69c6-46c7-b163-c679fc380ece_terseLabel_en-US" xlink:label="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_label_en-US" xlink:label="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included within Current Liabilities</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_documentation_en-US" xlink:label="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included within Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:href="exdx-20210331.xsd#exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:to="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_498a0bc0-98b4-436c-bd70-0d4a3f164aa2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_ea8e26cb-5ffb-4c67-b26e-ba5f86ebb5b0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_bc8eaeeb-773f-4c30-a45d-37f38e728516_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6b620826-d10b-40af-a1ee-b6b48ef1346c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_75868ddb-b963-4864-8a2f-38b3e55856eb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_81f34737-6f85-42f7-85f3-6792ab23c954_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, fee incurred upon payment of final installment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8ee6940a-6651-40de-ab54-fea4fe6f9f7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, March&#160;31, 2021 (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_6b31f6e1-9a51-4671-82c9-f27261e0a5ac_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and Marketing Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_96c354da-0731-4851-b7cd-d8d30cd7aec5_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ad7f8f1-524d-4126-a561-2c62e84533c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_5be06f03-ab14-425b-8ac5-7e19caf54cd7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid in-kind note</link:label>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_label_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:to="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_00be1046-365e-42b6-ad27-b0f50d79778c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4fdfa8a0-79ff-43e4-91e2-6ec27429d07e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_fee195f4-aefd-4613-932c-d60772b7d62b_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, to be paid remainder of fiscal year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_bf430343-931a-4893-b1e2-7195ccb3ff9a_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7f7e739a-f93a-44af-afec-dcb6f0c7393b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_725b44d7-4178-4df4-af3d-1c170fb531ff_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_fa07e62e-36df-4013-9de1-6001b1de4af2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_435469b9-4e31-4e58-a7e8-d6041ca5a578_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9198e700-4c4b-4e7b-9736-160fc2204c48_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_56be24b7-f16a-4dbf-8f3f-ca5fa9f677be_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0e82bf49-3917-4e4c-ab03-916326f44989_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_44eff90e-4eaf-41d7-a6d3-f6b65fa2b56f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_4f9edd25-d2a8-4fc7-8c1b-d71250436ffe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_64b20011-5417-4c7d-b7d2-e03f889b998c_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_3f710385-2928-4ab0-a610-89e612f2d9f9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_8cff339f-ddcc-40c7-8700-3c729e2b4a67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions, Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_36d906a2-5826-45f1-ab03-5947c832985b_terseLabel_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP</link:label>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_label_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP [Member]</link:label>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_documentation_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember" xlink:href="exdx-20210331.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CapitalRoyaltyPartnersIILPMember" xlink:to="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_d6dda38c-9f80-4838-b22e-9b45e4971cfe_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, minimum unrestricted cash balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:to="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_46d5cd8e-b981-4daa-b7a8-42e54f6f71cd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued to purchase redeemable convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_8aab70c1-0bf6-4f0e-b87b-d736460a632e_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f6a7de13-fe42-4408-9ba8-cb123c43f7aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_74f2ab41-6139-4a7e-b50d-b6291bdfe42a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic&#160;testing&#160;supplies</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_36567011-3df6-49a3-8c1b-4bb71f1d4f65_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6e8eefda-ebc3-453c-9524-c00b28a76019_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7c2a4b53-becb-40b1-b08a-48985a23f416_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_b420fe1a-026f-4c72-8d9d-a4b1b3c9e1c0_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a8cf8818-c92c-458d-98ab-66ac834703d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, March&#160;31, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Government1Member_0aca500d-c061-4026-8fcc-53b5b5a9ee2e_terseLabel_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government</link:label>
    <link:label id="lab_exdx_Government1Member_label_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government1 [Member]</link:label>
    <link:label id="lab_exdx_Government1Member_documentation_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member" xlink:href="exdx-20210331.xsd#exdx_Government1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Government1Member" xlink:to="lab_exdx_Government1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd7f094f-163a-48bf-a7bd-5db36a2b342f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_bc07be84-a843-4124-a636-7b44e205111d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f34becef-e64b-49bf-9ef0-52b36cde704a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2eac9190-7428-45a2-968f-eb41792fb7f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d248d4e4-5e08-4179-853c-9cad1a9411ea_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ffb056e5-c8e5-4aac-89e5-802969acec0b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_35b775be-aff1-4cb2-b24e-14e39e7cc266_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_4ce37844-48d3-48c9-9a4c-d4a59e786d23_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan repayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8b64490-74de-4e61-890c-cffec8b3e57e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_58f43dfd-5512-4af4-8e6d-8e26f5b42f6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_32d23926-d28b-4cf5-bed5-eeef134289f2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_6dbd65fc-f394-4556-80bc-2a0d99bdd5ed_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a0a7b99d-96d2-4e36-9c7e-a48fdd6ed77f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_5ce7e70a-e0c9-4b16-9b21-80b7025e0234_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7cf46b20-c2d9-4fa6-8afa-b50819a92bb9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized at March&#160;31, 2021 and December 31, 2020; 16,925,680 and 12,652,308 shares issued and outstanding at March&#160;31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_b1719e7a-d774-46e0-8474-0d7e4988f569_terseLabel_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_label_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:href="exdx-20210331.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:to="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_daca3de6-5c95-4567-962d-f39973769a15_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_37fd9074-e680-492b-9bef-c329f080be72_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_b56cf1bf-4cd5-41de-8647-d86ea1f785dc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in public offering, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRoyalties_3cbaacca-557a-4fb4-bd17-8ab96d29b883_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid product royalties</link:label>
    <link:label id="lab_us-gaap_PrepaidRoyalties_label_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRoyalties" xlink:to="lab_us-gaap_PrepaidRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_3f1968a9-237c-4bcd-9536-bc14b169b08d_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payment on capital lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_648457b7-6d05-4eed-ab55-17fa10a12468_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_968d7148-f495-48c5-91c8-3761755de601_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_87c1b4ed-a6a1-45c6-b389-bd5e5688c869_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_49761ee5-b8e3-4c2c-8d87-d15b608f394e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareAdvantageMember_1bfe427b-3861-43b6-8d48-acacd37b0795_terseLabel_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_label_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember" xlink:href="exdx-20210331.xsd#exdx_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareAdvantageMember" xlink:to="lab_exdx_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_78417379-2e9d-429c-8e5a-42c56757b17c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5f31a9e4-ca24-4140-96f2-4244a8fe32c1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c861e759-6f49-4725-b77a-e1c5b4f11a66_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings-non-current portion, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_13f8c603-436f-415d-96ba-f6ecff5c2b94_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, prepayment premium percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f2c1b765-bac3-4a66-b6f9-036e987d1f8d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0357fe0a-069e-48a8-95ea-1cc207b23d0b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2fc57801-ecb2-4a78-b0dc-fa5337a84e2d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_cdb1c303-d78b-466f-8694-c0bb3784e33c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7ce3fc24-ef8c-43ec-ab05-c1717b1b14d6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_26e47437-02ff-41f3-a3f3-f504c3dea6ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of issuance costs related to public offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_8c15a86a-6a9c-4ad9-8d9a-3388a1f0d614_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_75095087-0091-4666-b203-f693b6afc04e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_12a62a46-5930-426b-8d92-09bd7ec2f9a3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_91fb1109-4c1f-49e7-ba97-52af5e64b833_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_62edc141-3caf-43cb-bc95-cf3c999a5dab_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1b2a5f47-9f52-48ec-9ac5-773629f957b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_36d3581c-abd6-4041-8f24-7385c0f60fe4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_edad838f-8a18-47df-ad45-1f3014aed291_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee payroll deduction percentage</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MilestoneObligation_38391387-c49e-469b-81b2-89d85a7a7f3a_terseLabel_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining milestone obligation</link:label>
    <link:label id="lab_exdx_MilestoneObligation_label_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Obligation</link:label>
    <link:label id="lab_exdx_MilestoneObligation_documentation_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation" xlink:href="exdx-20210331.xsd#exdx_MilestoneObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MilestoneObligation" xlink:to="lab_exdx_MilestoneObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_97c8d40a-0015-4343-94cc-50fb7cd4a6ed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_53000870-fec3-4533-b046-541a8f2ced30_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdvancePayment_e695f08f-e188-4de5-bd10-4fb053df24f2_terseLabel_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance royalties payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_label_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_documentation_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment" xlink:href="exdx-20210331.xsd#exdx_AdvancePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdvancePayment" xlink:to="lab_exdx_AdvancePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0ab04ccb-4492-4d63-9fe3-8290bdf1e9ed_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm_47494747-2a7e-44e4-8994-aa0ea2020c51_terseLabel_en-US" xlink:label="lab_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Promotion Agreement, Period Before Current Expiration To Extend Term</link:label>
    <link:label id="lab_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm_label_en-US" xlink:label="lab_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Promotion Agreement, Period Before Current Expiration To Extend Term</link:label>
    <link:label id="lab_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm_documentation_en-US" xlink:label="lab_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Promotion Agreement, Period Before Current Expiration To Extend Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm" xlink:href="exdx-20210331.xsd#exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm" xlink:to="lab_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_a0feb8ae-bda9-4637-809a-9f70a6f7f5b2_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_84e9c340-bc63-41e4-b445-4e6198ef1451_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6a4e0891-0d56-4bb5-ba9c-b73009f9c8b8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9fd68fd1-ce91-475d-8aa5-f15dd0597039_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_60ea270f-c01f-4d65-8dc0-c2dcdb1625f4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_6e15f16f-2a39-4ba2-99d7-eb175faaf8c4_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7b05b728-268d-433c-b6bb-4ae604c6752c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JanssenSIMPONIMember_1739d27f-56dc-4233-ab9c-2978867ced6f_terseLabel_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI)</link:label>
    <link:label id="lab_exdx_JanssenSIMPONIMember_label_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI) [Member]</link:label>
    <link:label id="lab_exdx_JanssenSIMPONIMember_documentation_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember" xlink:href="exdx-20210331.xsd#exdx_JanssenSIMPONIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JanssenSIMPONIMember" xlink:to="lab_exdx_JanssenSIMPONIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_90594786-4060-4a33-8b03-2705b9228337_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_356a8555-0a20-4e19-9a19-759aed59afbf_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3e6a4514-4193-4599-9c3a-ad43a2ce36bd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9491a389-8580-439b-8036-928658e93f14_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement_f4901f39-3056-47e1-9e47-14290c33d9c9_terseLabel_en-US" xlink:label="lab_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion, number of days' noticed required to give to terminate agreement</link:label>
    <link:label id="lab_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement_label_en-US" xlink:label="lab_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Promotion Agreement, Number Of Days' Notice To Terminate Agreement</link:label>
    <link:label id="lab_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement_documentation_en-US" xlink:label="lab_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Promotion Agreement, Number Of Days' Notice To Terminate Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement" xlink:href="exdx-20210331.xsd#exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement" xlink:to="lab_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AVISECTDTestMember_71a5d8ef-83fe-4018-b986-0d0140fec6a3_terseLabel_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_label_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test [Member]</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_documentation_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember" xlink:href="exdx-20210331.xsd#exdx_AVISECTDTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AVISECTDTestMember" xlink:to="lab_exdx_AVISECTDTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_5e50370b-acd8-466b-83c5-e4a0f71c0505_terseLabel_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember" xlink:href="exdx-20210331.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LaboratoryEquipmentMember" xlink:to="lab_exdx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_fb921da0-6d9f-48e2-9a38-6ea40c3b0cc1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_134368e9-0a64-4ac6-90a3-da7a48986440_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4d0f063b-f068-4a1d-be8b-88f113c54247_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationJan192026Member_828310fe-2a69-4982-9cda-27c73e448544_terseLabel_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration January 19, 2026</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_label_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member" xlink:href="exdx-20210331.xsd#exdx_ExpirationJan192026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationJan192026Member" xlink:to="lab_exdx_ExpirationJan192026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4e93b0bd-afd5-4669-adae-dc7684d0e004_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_34343c10-0285-4be7-98e9-3795053db86d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2c784e72-9a76-4591-9aa4-91185aee51ee_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_199afaac-939f-43f0-8b3c-d77709d0b125_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, annual reduction in prepayment penalty percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_82f009b0-24d9-4bce-a1a6-11b3a818f04c_terseLabel_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical study activity</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_label_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:href="exdx-20210331.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:to="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_41881a4d-02cb-4c14-a534-d0a9ff974ae2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_28cfc852-6d29-46ae-b04c-215e487b0bbc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_861db3f1-75d3-48d9-a1b4-de6d26fc32ee_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, increase to interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:to="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5291586c-60de-4726-9124-f2a1cb2b6815_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4c14da22-5acd-4c37-ac8d-b947f0b12a8a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4547f347-10e6-4c6e-80e7-1282d74788ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-cash Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_51e9130a-cfca-451f-8f28-7827d12bfe64_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_da64227d-f6e7-4f18-bd27-4a1d00f44f46_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_f55a7b44-1c5c-441f-91dd-ba5d805ce2f5_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d4f637c-50e1-4511-ba87-e0845e0995dc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_fc5eeca3-96cb-4973-801e-4b0edada0846_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum royalty commitment</link:label>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_label_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_264d8cd2-2684-40f0-8b94-8c0b5f201144_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_30bf9eb4-0ca8-4451-89ce-181b5140e10d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClientMember_ba795dd5-193e-40d6-b1f0-022fa8671e19_terseLabel_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:label id="lab_exdx_ClientMember_label_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client [Member]</link:label>
    <link:label id="lab_exdx_ClientMember_documentation_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember" xlink:href="exdx-20210331.xsd#exdx_ClientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClientMember" xlink:to="lab_exdx_ClientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_fee784f2-3b59-4e24-b4c8-be80b1ac1914_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_06b8c1d4-56f0-4484-bce8-6ee0e3f42348_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, income tax benefit</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:href="exdx-20210331.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c5dec786-d8df-4590-bc72-5a3bad35b9e7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock in public offering, net of issuance costs of $4,435 (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2b6c46fc-0551-42af-a081-ef7cb66b15ec_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_c9f1d8ec-8d9f-4678-b214-eae57b5f3fcc_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_95556e73-fd2b-44e2-b6a1-c3fff03fe9d9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f11c3211-fb7c-40a8-8cfe-94ad88010372_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_badf2d42-adc1-4816-b02a-915b71a9270e_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_f290d788-cb88-4e6d-9613-74c82d788c0c_terseLabel_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in purchase commitments</link:label>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_label_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Annual Increase In Commitment, Percentage</link:label>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_documentation_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Annual Increase In Commitment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:href="exdx-20210331.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:to="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e466b880-df45-477e-a6ad-cb8aa19488d6_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bc35b842-9df8-4a16-aadc-7d12a0123214_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ceebe09-162d-48e4-9765-ff7d82df4c89_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bd64cf04-8589-47e2-9c15-85a329435d1e_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredOfferingCostsReclassifiedToEquity_f7dbb024-51d2-4e18-bbb5-9532d3c46ac2_terseLabel_en-US" xlink:label="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs reclassified to equity</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsReclassifiedToEquity_label_en-US" xlink:label="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Reclassified to Equity</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsReclassifiedToEquity_documentation_en-US" xlink:label="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Reclassified to Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:href="exdx-20210331.xsd#exdx_DeferredOfferingCostsReclassifiedToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:to="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3ce8633f-68dc-482d-9a4d-83ec98d4286d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_2b887956-07e6-462b-a9e0-06fd1fd76291_totalLabel_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_label_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_documentation_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:href="exdx-20210331.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:to="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6ec50595-e4f1-4ef9-b32c-fa995a84989a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_db77e346-2e44-42a6-b22f-d4d7abb8ae2f_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_label_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:href="exdx-20210331.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:to="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract" xlink:href="exdx-20210331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OtherFinancialInformationAbstract" xlink:to="lab_exdx_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_79b63e00-1f03-4ab3-afad-93217df59e80_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_18730ed5-07fa-46af-9e46-9c6462d5ad3b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_d883f939-3ad0-46c3-bc6f-69a6dd6c53a2_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_20b3c672-f4d8-4a80-a7c1-aa9ce9528030_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_34fd5c89-1c44-412c-81d5-23932304e6d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_8af505d9-9ce8-49a1-947c-45bfbd1ffd0f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1e1ceeb7-8fb9-4de3-a7f0-f136321fa950_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_33f5dd15-b629-4294-bfd2-7de6f5aa4e86_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_655d86cb-8aee-42f2-90ca-a8a25008efa4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_4b72efdf-87f7-4139-b490-61cacc8ae890_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_645b8080-cdad-4f0a-ab8b-05fa9bdc26e5_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d990efe6-eaea-4731-a9c0-604a3c3329f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d45bd09d-aef8-4a08-b4c6-4d2bc376d31d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6093bc73-9a4f-4094-850b-5120cdccc94b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_bd58c88d-827d-4319-82ab-7351dd190b8c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba3492e6-4334-4150-9d41-780737de81b8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6014a646-00ff-4dac-9a92-203c9f3ceb0a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73705274-cfdc-40f5-a69c-ee79b6b78e97_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_6b250607-7013-4e8e-83a7-e0e442ed8b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e276096e-95a4-4aba-8d7b-e6ade1dbe43f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6f5a5ef3-5673-41a4-ad30-a60398e7fe2e_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_adb6861b-ae26-4e79-82ec-5430d81a3767_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ca71f59a-d005-4dd1-82e7-201ca59caf71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_12a5095a-fb2c-4713-b8f3-5737d5ea3040_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f90573d3-77a3-485f-b6fe-b864e91abd09_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0a5d4d18-b6d3-44f2-a8e3-36493fa07575_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_675b288b-81bd-4e01-8937-dfc1382c5ba4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationApr12026Member_74704685-7a87-4806-95b5-2c90a2b05ac1_terseLabel_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration April 1, 2026</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_label_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member" xlink:href="exdx-20210331.xsd#exdx_ExpirationApr12026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationApr12026Member" xlink:to="lab_exdx_ExpirationApr12026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3920fc49-3e12-4472-b625-937d46998319_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eaf7535c-9dea-4f90-a6ce-f1b051bcdd96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_61566747-45cd-4f98-b09f-87f4f7393de4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c1fea796-c3e4-4cbb-bd98-70e99eb492c6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_349dc5c6-76ac-4fc6-b353-16915bf44de2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_abe34584-e8ae-4761-838a-66a35c705237_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, due in year one</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_195d7304-d2ef-4add-9f4a-2d837481295b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_45176867-743f-444b-a320-0eda66974084_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_21bcb1ce-b674-4e1f-aa85-6504288048b3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuanceCosts_cdcd2017-c6f9-4d99-a2b3-009914679efa_verboseLabel_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_27712db5-dc85-4488-a922-7a25b3757fb5_terseLabel_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated offering expenses for aggregate expenses</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_label_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_documentation_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts" xlink:href="exdx-20210331.xsd#exdx_StockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuanceCosts" xlink:to="lab_exdx_StockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4b22e2be-5e2d-4d46-b616-07ae3dbcc67e_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_525adf02-025a-47dd-b72c-dbc02d3466be_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8cb59ab4-3f58-4427-944c-26b50430a52d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c67f4530-1740-41c7-ad7d-1274add4eb4f_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1642a8ae-71bd-4799-9859-6f804fddbed3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103d8aeb-a531-4f20-82db-9b4ecce02d90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_81ecda02-2404-4e17-b8af-5315c6589b95_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MilestoneContingencyFairValueDisclosure_e5c7f078-dd38-49ac-a6a0-6eb64a734e2d_terseLabel_en-US" xlink:label="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining milestone obligation, fair value</link:label>
    <link:label id="lab_exdx_MilestoneContingencyFairValueDisclosure_label_en-US" xlink:label="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Contingency, Fair Value Disclosure</link:label>
    <link:label id="lab_exdx_MilestoneContingencyFairValueDisclosure_documentation_en-US" xlink:label="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Contingency, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneContingencyFairValueDisclosure" xlink:href="exdx-20210331.xsd#exdx_MilestoneContingencyFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MilestoneContingencyFairValueDisclosure" xlink:to="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_20d3c0a7-5709-4198-b514-bf743052c1be_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of common stock warrants</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:href="exdx-20210331.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4f90dfc1-cfc0-42a4-8d2a-5c790d6913da_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5e6221b8-bc32-4dbf-a3de-04329191eef2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_28916e75-7fc2-4dce-ac73-0eb844413a25_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d5c19518-a3e3-4d0b-90a5-3e4006ce1f7f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4915710f-8c45-4f03-8342-b62a2757d413_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_16b0892b-8ca2-4c19-9011-86d309a9b278_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, March&#160;31, 2021, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_b0a9d718-af62-4496-9d7a-7030fed37695_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_fcfb34eb-a578-4f01-99ed-209b9a671a8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d3a0d346-5c9d-4eb3-9172-8c30914e695b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted; Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_fcbc845d-b3e9-4608-b102-7a826557dc56_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>exdx-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:dc3d5bf2-9b73-4463-aa2c-e75c744aa8d3,g:734221f7-636e-4e71-b928-4b5e730d1da3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20210331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b1798c91-0e14-4fda-8fb0-3c7851ff08ad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_DocumentType_b1798c91-0e14-4fda-8fb0-3c7851ff08ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5cebcbf2-4f06-400b-bcd7-8e3f16b4a48d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_DocumentQuarterlyReport_5cebcbf2-4f06-400b-bcd7-8e3f16b4a48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bf3b3d2c-2f76-493e-bfe5-ef01a3baf743" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_DocumentPeriodEndDate_bf3b3d2c-2f76-493e-bfe5-ef01a3baf743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7fc03bb5-9647-40da-90b8-b30d2e280bfc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_DocumentTransitionReport_7fc03bb5-9647-40da-90b8-b30d2e280bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4b951c97-ddfe-4742-a25d-bfc383782611" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityFileNumber_4b951c97-ddfe-4742-a25d-bfc383782611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_34df4962-c680-4119-8be2-5d212f01dbd5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityRegistrantName_34df4962-c680-4119-8be2-5d212f01dbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_858365fa-2b60-4447-b23a-7ed1cc3274c8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_858365fa-2b60-4447-b23a-7ed1cc3274c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_392d5a58-f6bc-4c6f-a8f9-c33cb6066fdd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityTaxIdentificationNumber_392d5a58-f6bc-4c6f-a8f9-c33cb6066fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4b7b091c-a70d-433d-bf14-b0e669123289" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityAddressAddressLine1_4b7b091c-a70d-433d-bf14-b0e669123289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e315e6ed-17a9-445b-a109-17509aeac687" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityAddressCityOrTown_e315e6ed-17a9-445b-a109-17509aeac687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1e2faebe-dfa4-4027-84f1-cac74db0ffb1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityAddressStateOrProvince_1e2faebe-dfa4-4027-84f1-cac74db0ffb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8475e0c8-8a40-4555-975f-65b9c400f4f8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityAddressPostalZipCode_8475e0c8-8a40-4555-975f-65b9c400f4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_15b3a741-73c2-4da8-a292-e9de25db3599" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_CityAreaCode_15b3a741-73c2-4da8-a292-e9de25db3599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0bcad2d5-09ec-4cba-862a-732e261154db" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_LocalPhoneNumber_0bcad2d5-09ec-4cba-862a-732e261154db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6ab7f962-1266-4d95-9dec-1ecf12eef56b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_Security12bTitle_6ab7f962-1266-4d95-9dec-1ecf12eef56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f231d3bf-87af-44f2-bb41-63570ffb9623" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_TradingSymbol_f231d3bf-87af-44f2-bb41-63570ffb9623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_72dfac5f-413a-4eff-89b2-15519e2b2bee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_SecurityExchangeName_72dfac5f-413a-4eff-89b2-15519e2b2bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0b273fe5-52b7-478f-add7-8ad20ccd8689" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityCurrentReportingStatus_0b273fe5-52b7-478f-add7-8ad20ccd8689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b6ff6bb7-626b-48e6-ab9c-51f97a316fc0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityInteractiveDataCurrent_b6ff6bb7-626b-48e6-ab9c-51f97a316fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3bab64fd-ef0f-4dc6-bb81-332cebca1242" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityFilerCategory_3bab64fd-ef0f-4dc6-bb81-332cebca1242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_50aa2ad7-3d86-4094-aaac-673e762f2fed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntitySmallBusiness_50aa2ad7-3d86-4094-aaac-673e762f2fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_79fb726c-77aa-4065-b673-14eb4a57f864" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityEmergingGrowthCompany_79fb726c-77aa-4065-b673-14eb4a57f864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_488e4d5e-8065-471d-8b29-b95edaf9922a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityExTransitionPeriod_488e4d5e-8065-471d-8b29-b95edaf9922a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b235f7ea-a148-4644-9500-724ab3ae5c64" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityShellCompany_b235f7ea-a148-4644-9500-724ab3ae5c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_24797a16-e05a-43d5-9532-f70a7230cda5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_24797a16-e05a-43d5-9532-f70a7230cda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6558c5bf-d79a-4b43-9c4c-e225cf9d0a72" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_EntityCentralIndexKey_6558c5bf-d79a-4b43-9c4c-e225cf9d0a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6a4e772f-d261-4d1f-b14c-4e6be65c9a1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_CurrentFiscalYearEndDate_6a4e772f-d261-4d1f-b14c-4e6be65c9a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f9b2f5b9-ed30-41af-8032-0d168f734931" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_DocumentFiscalYearFocus_f9b2f5b9-ed30-41af-8032-0d168f734931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_406f91a6-e526-4a3d-a956-a0c388eb73a8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_406f91a6-e526-4a3d-a956-a0c388eb73a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1921c3cf-faf4-4360-bb7e-1213955732e6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d363c3e1-893c-44d9-9bb4-707265c7afe3" xlink:to="loc_dei_AmendmentFlag_1921c3cf-faf4-4360-bb7e-1213955732e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="exdx-20210331.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4081f5ea-b009-40d0-85c8-99cee2844c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d205ea42-f3b3-40f2-a3aa-583166309b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4081f5ea-b009-40d0-85c8-99cee2844c9f" xlink:to="loc_us-gaap_AssetsAbstract_d205ea42-f3b3-40f2-a3aa-583166309b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c4679cc3-efa0-41be-9b50-a16c60697a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d205ea42-f3b3-40f2-a3aa-583166309b81" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c4679cc3-efa0-41be-9b50-a16c60697a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1173923-8bd3-47a2-b637-9a9ac30151c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c4679cc3-efa0-41be-9b50-a16c60697a45" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1173923-8bd3-47a2-b637-9a9ac30151c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f7b61453-1688-445a-b2ba-c0d7affb0650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c4679cc3-efa0-41be-9b50-a16c60697a45" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f7b61453-1688-445a-b2ba-c0d7affb0650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_155dab2f-0f2b-4440-b837-ef096eb13049" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c4679cc3-efa0-41be-9b50-a16c60697a45" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_155dab2f-0f2b-4440-b837-ef096eb13049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5ae7e773-319c-4da1-be2b-b992dfb13037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c4679cc3-efa0-41be-9b50-a16c60697a45" xlink:to="loc_us-gaap_AssetsCurrent_5ae7e773-319c-4da1-be2b-b992dfb13037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_207796f5-6fa3-48e7-a2c6-718c912116b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d205ea42-f3b3-40f2-a3aa-583166309b81" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_207796f5-6fa3-48e7-a2c6-718c912116b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_31d1b8bc-8e7b-4ddf-a09d-9ba1c92d8cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d205ea42-f3b3-40f2-a3aa-583166309b81" xlink:to="loc_us-gaap_Goodwill_31d1b8bc-8e7b-4ddf-a09d-9ba1c92d8cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_123846ed-be6b-4a5f-b7cf-f96ff6d65106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d205ea42-f3b3-40f2-a3aa-583166309b81" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_123846ed-be6b-4a5f-b7cf-f96ff6d65106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_467b9a87-d7af-40b9-ab0c-40cdf731e152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d205ea42-f3b3-40f2-a3aa-583166309b81" xlink:to="loc_us-gaap_Assets_467b9a87-d7af-40b9-ab0c-40cdf731e152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_334aaf24-7439-4280-9b75-54b5a52401d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4081f5ea-b009-40d0-85c8-99cee2844c9f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_334aaf24-7439-4280-9b75-54b5a52401d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4874b35e-724a-46dd-bde7-bcab4ac20fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_334aaf24-7439-4280-9b75-54b5a52401d1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4874b35e-724a-46dd-bde7-bcab4ac20fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_75d3d63f-98f0-4a9c-999c-8a45e4b49fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4874b35e-724a-46dd-bde7-bcab4ac20fb8" xlink:to="loc_us-gaap_AccountsPayableCurrent_75d3d63f-98f0-4a9c-999c-8a45e4b49fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c1666cba-725c-461c-91dd-8d9048428a95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4874b35e-724a-46dd-bde7-bcab4ac20fb8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c1666cba-725c-461c-91dd-8d9048428a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e332f105-32d6-442c-a0cc-2ab0b870ad4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4874b35e-724a-46dd-bde7-bcab4ac20fb8" xlink:to="loc_us-gaap_LiabilitiesCurrent_e332f105-32d6-442c-a0cc-2ab0b870ad4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6a07908e-6d4f-4ae9-a2ba-d0ea016b3c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_334aaf24-7439-4280-9b75-54b5a52401d1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6a07908e-6d4f-4ae9-a2ba-d0ea016b3c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_aa597e30-6be0-47f2-bfc7-ca8053cfebf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_334aaf24-7439-4280-9b75-54b5a52401d1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_aa597e30-6be0-47f2-bfc7-ca8053cfebf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a95e4327-5097-49b5-a1e1-c2b3fdaf6d70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_334aaf24-7439-4280-9b75-54b5a52401d1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a95e4327-5097-49b5-a1e1-c2b3fdaf6d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_917eccd1-19a1-4131-9cc1-e20665599f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_334aaf24-7439-4280-9b75-54b5a52401d1" xlink:to="loc_us-gaap_Liabilities_917eccd1-19a1-4131-9cc1-e20665599f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_46f660e9-1a97-47a0-861d-0249fb1b6a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_334aaf24-7439-4280-9b75-54b5a52401d1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_46f660e9-1a97-47a0-861d-0249fb1b6a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6ff939ab-8f2d-4193-b37f-0f6926ec1fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_334aaf24-7439-4280-9b75-54b5a52401d1" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6ff939ab-8f2d-4193-b37f-0f6926ec1fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bb0218a7-d360-4fac-92b9-b4885ed3073d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ff939ab-8f2d-4193-b37f-0f6926ec1fb4" xlink:to="loc_us-gaap_PreferredStockValue_bb0218a7-d360-4fac-92b9-b4885ed3073d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ac52d7f2-4043-4f82-b57f-9937ca3f30dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ff939ab-8f2d-4193-b37f-0f6926ec1fb4" xlink:to="loc_us-gaap_CommonStockValue_ac52d7f2-4043-4f82-b57f-9937ca3f30dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e3868dea-5687-468c-beb4-bcc75e6c2d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ff939ab-8f2d-4193-b37f-0f6926ec1fb4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e3868dea-5687-468c-beb4-bcc75e6c2d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89c759c5-cb6d-449c-a152-6593b424a7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ff939ab-8f2d-4193-b37f-0f6926ec1fb4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89c759c5-cb6d-449c-a152-6593b424a7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_54c4063c-3c45-4673-a358-9ec0317196d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ff939ab-8f2d-4193-b37f-0f6926ec1fb4" xlink:to="loc_us-gaap_StockholdersEquity_54c4063c-3c45-4673-a358-9ec0317196d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a331e7d4-1108-46be-a014-b8afd45d5c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_334aaf24-7439-4280-9b75-54b5a52401d1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a331e7d4-1108-46be-a014-b8afd45d5c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20210331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a0b13ded-11fb-4528-894f-027387daa4d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_35e2b2fe-a19c-47a3-ba7d-49b26a344703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a0b13ded-11fb-4528-894f-027387daa4d7" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_35e2b2fe-a19c-47a3-ba7d-49b26a344703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a83ef93c-3d5e-4134-a7a1-d21d95f4723e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_35e2b2fe-a19c-47a3-ba7d-49b26a344703" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a83ef93c-3d5e-4134-a7a1-d21d95f4723e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_55262e4b-e7d1-4f29-ba41-e7c7ee4c9b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_35e2b2fe-a19c-47a3-ba7d-49b26a344703" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_55262e4b-e7d1-4f29-ba41-e7c7ee4c9b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2aac8524-34d0-47c8-af49-e503bfa36802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_35e2b2fe-a19c-47a3-ba7d-49b26a344703" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2aac8524-34d0-47c8-af49-e503bfa36802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_39756340-e44d-483a-bb5e-5293a85328e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_35e2b2fe-a19c-47a3-ba7d-49b26a344703" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_39756340-e44d-483a-bb5e-5293a85328e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_88d2fbca-9444-49d4-9162-8b7f00c4defd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a0b13ded-11fb-4528-894f-027387daa4d7" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_88d2fbca-9444-49d4-9162-8b7f00c4defd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ae5669d6-1fe7-4502-a1e6-cb882246f7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_88d2fbca-9444-49d4-9162-8b7f00c4defd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ae5669d6-1fe7-4502-a1e6-cb882246f7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_77719cf3-bd1f-436c-8dad-9a035fa9c6e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_88d2fbca-9444-49d4-9162-8b7f00c4defd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_77719cf3-bd1f-436c-8dad-9a035fa9c6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5729f346-9db1-4c10-a721-cff25da25b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_88d2fbca-9444-49d4-9162-8b7f00c4defd" xlink:to="loc_us-gaap_CommonStockSharesIssued_5729f346-9db1-4c10-a721-cff25da25b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6481616e-9add-474f-9f12-940f1ef8111a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_88d2fbca-9444-49d4-9162-8b7f00c4defd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6481616e-9add-474f-9f12-940f1ef8111a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="simple" xlink:href="exdx-20210331.xsd#UnauditedCondensedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_33cbff83-2d09-4c44-baf2-bfd8ecd245dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2713ae05-d73e-416d-924c-0c5023b3db18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_33cbff83-2d09-4c44-baf2-bfd8ecd245dc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2713ae05-d73e-416d-924c-0c5023b3db18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d8adb823-0a6f-4e4e-bd56-71dbfaae40ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_33cbff83-2d09-4c44-baf2-bfd8ecd245dc" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d8adb823-0a6f-4e4e-bd56-71dbfaae40ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d514da04-43ab-4e1e-90de-f16f7771a35c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d8adb823-0a6f-4e4e-bd56-71dbfaae40ee" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d514da04-43ab-4e1e-90de-f16f7771a35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_64a72c36-faff-40c4-a069-ba9e05431e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d8adb823-0a6f-4e4e-bd56-71dbfaae40ee" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_64a72c36-faff-40c4-a069-ba9e05431e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d2f6b5fe-dc35-4987-a0a7-28bc2ef67ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d8adb823-0a6f-4e4e-bd56-71dbfaae40ee" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d2f6b5fe-dc35-4987-a0a7-28bc2ef67ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_103e7573-e4f4-48b5-a108-a1ab65411150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d8adb823-0a6f-4e4e-bd56-71dbfaae40ee" xlink:to="loc_us-gaap_CostsAndExpenses_103e7573-e4f4-48b5-a108-a1ab65411150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a489e969-f4f4-4010-b5cd-59f022252834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_33cbff83-2d09-4c44-baf2-bfd8ecd245dc" xlink:to="loc_us-gaap_OperatingIncomeLoss_a489e969-f4f4-4010-b5cd-59f022252834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ebcf4ff1-26a1-47c0-a618-a41afe6bee76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_33cbff83-2d09-4c44-baf2-bfd8ecd245dc" xlink:to="loc_us-gaap_InterestExpense_ebcf4ff1-26a1-47c0-a618-a41afe6bee76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_dad116da-e3ae-425b-977c-6bf5f0782719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_33cbff83-2d09-4c44-baf2-bfd8ecd245dc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_dad116da-e3ae-425b-977c-6bf5f0782719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_f2132c95-c567-4b5c-a16a-27d78f2b15a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_33cbff83-2d09-4c44-baf2-bfd8ecd245dc" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_f2132c95-c567-4b5c-a16a-27d78f2b15a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b1cd2719-c0a2-4241-968a-8b57d54e3e78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_33cbff83-2d09-4c44-baf2-bfd8ecd245dc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b1cd2719-c0a2-4241-968a-8b57d54e3e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_43a78dab-1200-40b7-95ef-7193a65030f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_33cbff83-2d09-4c44-baf2-bfd8ecd245dc" xlink:to="loc_us-gaap_NetIncomeLoss_43a78dab-1200-40b7-95ef-7193a65030f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_d2772c5c-b20e-4f7d-b76a-7cabc84609c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_33cbff83-2d09-4c44-baf2-bfd8ecd245dc" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_d2772c5c-b20e-4f7d-b76a-7cabc84609c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a454909b-f327-46c1-9100-171a757ebc94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_33cbff83-2d09-4c44-baf2-bfd8ecd245dc" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a454909b-f327-46c1-9100-171a757ebc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20210331.xsd#UnauditedCondensedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b2bc8b0a-4d81-4570-897d-715a1763810f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4e6d5096-5939-4faa-bffe-64451952dc4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b2bc8b0a-4d81-4570-897d-715a1763810f" xlink:to="loc_us-gaap_StatementTable_4e6d5096-5939-4faa-bffe-64451952dc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d865850d-e3ea-4ac1-9b07-9d2ee38d9dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4e6d5096-5939-4faa-bffe-64451952dc4d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d865850d-e3ea-4ac1-9b07-9d2ee38d9dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb1c0405-cb24-453a-a8b2-d68cc9e3e9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d865850d-e3ea-4ac1-9b07-9d2ee38d9dd0" xlink:to="loc_us-gaap_EquityComponentDomain_cb1c0405-cb24-453a-a8b2-d68cc9e3e9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fd6c6953-99a6-4261-aebd-5088d7c9d19d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb1c0405-cb24-453a-a8b2-d68cc9e3e9e6" xlink:to="loc_us-gaap_CommonStockMember_fd6c6953-99a6-4261-aebd-5088d7c9d19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1d116188-19e7-4d6b-9ae5-027d70b41567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb1c0405-cb24-453a-a8b2-d68cc9e3e9e6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1d116188-19e7-4d6b-9ae5-027d70b41567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_53b97187-3df3-4df7-84ae-71b69db84302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cb1c0405-cb24-453a-a8b2-d68cc9e3e9e6" xlink:to="loc_us-gaap_RetainedEarningsMember_53b97187-3df3-4df7-84ae-71b69db84302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_de870855-8c49-4e00-82c9-d58592d68cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4e6d5096-5939-4faa-bffe-64451952dc4d" xlink:to="loc_us-gaap_StatementLineItems_de870855-8c49-4e00-82c9-d58592d68cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de870855-8c49-4e00-82c9-d58592d68cc9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1763ca86-1368-4648-b593-de3fb861327b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1763ca86-1368-4648-b593-de3fb861327b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c4ac80f0-19f5-453b-8869-6e4981f594cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockholdersEquity_c4ac80f0-19f5-453b-8869-6e4981f594cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_323cba86-0e75-4c9b-ab1f-a2201f01b3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_323cba86-0e75-4c9b-ab1f-a2201f01b3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fd6fa41c-b1d3-44df-995b-280909e2073c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fd6fa41c-b1d3-44df-995b-280909e2073c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ea5a6951-09ee-4c9c-86b0-688e6ac0a0e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ea5a6951-09ee-4c9c-86b0-688e6ac0a0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b795b87f-32b8-41af-9514-179ee54d592e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b795b87f-32b8-41af-9514-179ee54d592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ab1e9c9d-be7e-493f-a342-33e8b8ff593c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ab1e9c9d-be7e-493f-a342-33e8b8ff593c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0d7a7a0b-a992-43d4-b682-dd23f0132705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0d7a7a0b-a992-43d4-b682-dd23f0132705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d4af276-9c29-470f-86ff-bd7563e58a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d4af276-9c29-470f-86ff-bd7563e58a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_a93cdf7b-a356-4107-85fb-dc135447c739" xlink:href="exdx-20210331.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_a93cdf7b-a356-4107-85fb-dc135447c739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_0d910c72-e7a5-4907-897a-8748bcc40269" xlink:href="exdx-20210331.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_0d910c72-e7a5-4907-897a-8748bcc40269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_20c6715a-258e-46a2-acfb-952a8718cb36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_NetIncomeLoss_20c6715a-258e-46a2-acfb-952a8718cb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ebe80311-cb9f-4be1-bb3c-0829bdaf5650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ebe80311-cb9f-4be1-bb3c-0829bdaf5650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d2a12e29-d92b-4833-803d-2e00de77afcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_128588ef-169f-4868-bbbb-7ddccd1834d4" xlink:to="loc_us-gaap_StockholdersEquity_d2a12e29-d92b-4833-803d-2e00de77afcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="exdx-20210331.xsd#UnauditedCondensedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_973582eb-2fee-4554-9496-4c7ba3a10a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_7c27b0f9-14f9-4151-81c7-9546b6fcc7bd" xlink:href="exdx-20210331.xsd#exdx_StockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_973582eb-2fee-4554-9496-4c7ba3a10a31" xlink:to="loc_exdx_StockIssuanceCosts_7c27b0f9-14f9-4151-81c7-9546b6fcc7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20210331.xsd#UnauditedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_121e3ec6-87bf-43b6-b8a8-993a0ccae14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_44356087-fdcb-4fd3-821f-64f0e0a58521" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_121e3ec6-87bf-43b6-b8a8-993a0ccae14f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_44356087-fdcb-4fd3-821f-64f0e0a58521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_776e7041-5c6a-4368-ac84-bed80ce1c5c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_44356087-fdcb-4fd3-821f-64f0e0a58521" xlink:to="loc_us-gaap_NetIncomeLoss_776e7041-5c6a-4368-ac84-bed80ce1c5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2eff6e24-a34a-42e5-8203-224f6fefc6fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_44356087-fdcb-4fd3-821f-64f0e0a58521" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2eff6e24-a34a-42e5-8203-224f6fefc6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_2f389fa4-06de-453e-84d5-177627d4f1de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2eff6e24-a34a-42e5-8203-224f6fefc6fb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_2f389fa4-06de-453e-84d5-177627d4f1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ab6b7863-24bc-4b4a-9493-f2f096c6b72a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2eff6e24-a34a-42e5-8203-224f6fefc6fb" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ab6b7863-24bc-4b4a-9493-f2f096c6b72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_441f168a-05d8-4997-b774-36a26f328753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2eff6e24-a34a-42e5-8203-224f6fefc6fb" xlink:to="loc_us-gaap_PaidInKindInterest_441f168a-05d8-4997-b774-36a26f328753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a706da3e-213e-4fa9-aa40-3bb4ba3b317e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2eff6e24-a34a-42e5-8203-224f6fefc6fb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a706da3e-213e-4fa9-aa40-3bb4ba3b317e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ad461323-d00a-45f3-b64e-b9c5e9985a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2eff6e24-a34a-42e5-8203-224f6fefc6fb" xlink:to="loc_us-gaap_ShareBasedCompensation_ad461323-d00a-45f3-b64e-b9c5e9985a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ffef0f3-7139-45da-ae20-1a1877171f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2eff6e24-a34a-42e5-8203-224f6fefc6fb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ffef0f3-7139-45da-ae20-1a1877171f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c02ee2b8-44c8-481c-8fd5-fde6faf244d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ffef0f3-7139-45da-ae20-1a1877171f80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c02ee2b8-44c8-481c-8fd5-fde6faf244d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_b138da80-268b-40b4-bce5-28359aab363c" xlink:href="exdx-20210331.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ffef0f3-7139-45da-ae20-1a1877171f80" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_b138da80-268b-40b4-bce5-28359aab363c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_939211e4-1783-4476-a214-55e3c0f52652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ffef0f3-7139-45da-ae20-1a1877171f80" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_939211e4-1783-4476-a214-55e3c0f52652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f5c6f2e1-f340-43b0-bc90-43159f05fae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ffef0f3-7139-45da-ae20-1a1877171f80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f5c6f2e1-f340-43b0-bc90-43159f05fae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_ba824233-5984-4e51-ad73-f4e81d1fc192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ffef0f3-7139-45da-ae20-1a1877171f80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_ba824233-5984-4e51-ad73-f4e81d1fc192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8dcdf479-43d9-4406-80f1-2a38156ed249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_44356087-fdcb-4fd3-821f-64f0e0a58521" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8dcdf479-43d9-4406-80f1-2a38156ed249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3b0156d3-b6e9-4ea7-b5b9-d77f6b493817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_121e3ec6-87bf-43b6-b8a8-993a0ccae14f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3b0156d3-b6e9-4ea7-b5b9-d77f6b493817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ab47797e-f59c-4da2-92fa-9b6583aa61ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3b0156d3-b6e9-4ea7-b5b9-d77f6b493817" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ab47797e-f59c-4da2-92fa-9b6583aa61ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23259b2b-bc9b-46ac-9858-81491c657f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3b0156d3-b6e9-4ea7-b5b9-d77f6b493817" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23259b2b-bc9b-46ac-9858-81491c657f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d028df20-feda-45b0-8247-0a3f9f2e7044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_121e3ec6-87bf-43b6-b8a8-993a0ccae14f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d028df20-feda-45b0-8247-0a3f9f2e7044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b0f1c0b5-c508-445c-a99c-e07462a8070e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d028df20-feda-45b0-8247-0a3f9f2e7044" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b0f1c0b5-c508-445c-a99c-e07462a8070e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_2e2f9bab-6108-4897-be89-c7e8df2869e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d028df20-feda-45b0-8247-0a3f9f2e7044" xlink:to="loc_us-gaap_ProceedsFromStockPlans_2e2f9bab-6108-4897-be89-c7e8df2869e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_6d8a6c4a-19d8-4a53-a9ad-311c2c76df4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d028df20-feda-45b0-8247-0a3f9f2e7044" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_6d8a6c4a-19d8-4a53-a9ad-311c2c76df4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_75bc876d-a213-4d75-a3d9-6b60f5006f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d028df20-feda-45b0-8247-0a3f9f2e7044" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_75bc876d-a213-4d75-a3d9-6b60f5006f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_90a2bf57-5afa-48e2-9a9d-9dfa7e7a39d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d028df20-feda-45b0-8247-0a3f9f2e7044" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_90a2bf57-5afa-48e2-9a9d-9dfa7e7a39d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66cb78aa-0abc-4a07-9f54-54215a3a15c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d028df20-feda-45b0-8247-0a3f9f2e7044" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66cb78aa-0abc-4a07-9f54-54215a3a15c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_22b9a3be-159e-462b-aa1d-f52b50240ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_121e3ec6-87bf-43b6-b8a8-993a0ccae14f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_22b9a3be-159e-462b-aa1d-f52b50240ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbe907be-ff8b-4283-bea8-afc77a393eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_121e3ec6-87bf-43b6-b8a8-993a0ccae14f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbe907be-ff8b-4283-bea8-afc77a393eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_efe39ba1-3c79-4ddf-af07-0c01676d4d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_121e3ec6-87bf-43b6-b8a8-993a0ccae14f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_efe39ba1-3c79-4ddf-af07-0c01676d4d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5c266dc8-9292-4862-a4aa-7c0a06cb88ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_121e3ec6-87bf-43b6-b8a8-993a0ccae14f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5c266dc8-9292-4862-a4aa-7c0a06cb88ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_538dd521-8377-45ca-9d64-3db0147eb098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5c266dc8-9292-4862-a4aa-7c0a06cb88ec" xlink:to="loc_us-gaap_InterestPaidNet_538dd521-8377-45ca-9d64-3db0147eb098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_60d4f9ef-7a74-42bf-820b-9772a1365392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_121e3ec6-87bf-43b6-b8a8-993a0ccae14f" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_60d4f9ef-7a74-42bf-820b-9772a1365392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderCapitalLease_c6ab48f6-7d2a-45be-b92f-e03615f67098" xlink:href="exdx-20210331.xsd#exdx_EquipmentPurchasedUnderCapitalLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_60d4f9ef-7a74-42bf-820b-9772a1365392" xlink:to="loc_exdx_EquipmentPurchasedUnderCapitalLease_c6ab48f6-7d2a-45be-b92f-e03615f67098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8893566c-831c-4a6d-b112-f631dca95ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_60d4f9ef-7a74-42bf-820b-9772a1365392" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8893566c-831c-4a6d-b112-f631dca95ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_d7c3c3df-9605-4bc0-946a-687a7047087b" xlink:href="exdx-20210331.xsd#exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_60d4f9ef-7a74-42bf-820b-9772a1365392" xlink:to="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_d7c3c3df-9605-4bc0-946a-687a7047087b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsReclassifiedToEquity_f7203237-d088-4c79-a64b-ce6c624eb3f1" xlink:href="exdx-20210331.xsd#exdx_DeferredOfferingCostsReclassifiedToEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_60d4f9ef-7a74-42bf-820b-9772a1365392" xlink:to="loc_exdx_DeferredOfferingCostsReclassifiedToEquity_f7203237-d088-4c79-a64b-ce6c624eb3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Organization" xlink:type="simple" xlink:href="exdx-20210331.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7fb5bfe-30d2-4c9e-bfde-662049d0fcbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_dcd960c2-fae6-4180-ae25-8049cc8dea81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7fb5bfe-30d2-4c9e-bfde-662049d0fcbb" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_dcd960c2-fae6-4180-ae25-8049cc8dea81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a310d9e3-fbc7-4e4d-898f-526ce00a9950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_930e065f-a09b-4ced-93fc-86799cf74cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a310d9e3-fbc7-4e4d-898f-526ce00a9950" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_930e065f-a09b-4ced-93fc-86799cf74cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9655ff1-21f3-4f26-a7d2-5e391d2378da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a310d9e3-fbc7-4e4d-898f-526ce00a9950" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9655ff1-21f3-4f26-a7d2-5e391d2378da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_77aa9447-dab4-4b17-83b4-bbb6ea447615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d13ff6ab-a49a-4470-871c-8ce89edb2fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_77aa9447-dab4-4b17-83b4-bbb6ea447615" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d13ff6ab-a49a-4470-871c-8ce89edb2fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f99b8504-19d1-44f7-8c1e-b45d137ea6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_702d6c81-041f-4202-9485-88a949016d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f99b8504-19d1-44f7-8c1e-b45d137ea6de" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_702d6c81-041f-4202-9485-88a949016d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3a95ed7e-cfd4-4920-81f7-7f5043e5b0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f99b8504-19d1-44f7-8c1e-b45d137ea6de" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3a95ed7e-cfd4-4920-81f7-7f5043e5b0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b3ebca0e-3cdf-4906-a8a0-b018cad78fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f99b8504-19d1-44f7-8c1e-b45d137ea6de" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b3ebca0e-3cdf-4906-a8a0-b018cad78fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8a1a329b-da7c-42a4-95a0-139b3c682f3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f99b8504-19d1-44f7-8c1e-b45d137ea6de" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8a1a329b-da7c-42a4-95a0-139b3c682f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9c0873be-2224-49f0-bf9b-96311d381eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f99b8504-19d1-44f7-8c1e-b45d137ea6de" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9c0873be-2224-49f0-bf9b-96311d381eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_7ca3a91e-bc3f-42c8-ba57-05e71fbd591c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f99b8504-19d1-44f7-8c1e-b45d137ea6de" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_7ca3a91e-bc3f-42c8-ba57-05e71fbd591c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_af5e0e6e-8396-4f2e-abaa-a5b9d70c6d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f99b8504-19d1-44f7-8c1e-b45d137ea6de" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_af5e0e6e-8396-4f2e-abaa-a5b9d70c6d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_292aa3ee-ab7e-4768-8d52-48efc51141a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f99b8504-19d1-44f7-8c1e-b45d137ea6de" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_292aa3ee-ab7e-4768-8d52-48efc51141a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_bfd13fd0-4642-4ca7-8696-1e24b2f2ecb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f99b8504-19d1-44f7-8c1e-b45d137ea6de" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_bfd13fd0-4642-4ca7-8696-1e24b2f2ecb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8ea5155d-5d6e-4a6f-9eca-25ea2a8d6467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f99b8504-19d1-44f7-8c1e-b45d137ea6de" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8ea5155d-5d6e-4a6f-9eca-25ea2a8d6467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16c3a14a-24ed-4b7b-b94b-049aafe87db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f99b8504-19d1-44f7-8c1e-b45d137ea6de" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16c3a14a-24ed-4b7b-b94b-049aafe87db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c1e2dade-fa89-4e25-b9c4-c39673d9f695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_48a7cda4-c4e5-46ff-9818-4b05e6afa587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1e2dade-fa89-4e25-b9c4-c39673d9f695" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_48a7cda4-c4e5-46ff-9818-4b05e6afa587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b058cfb4-56a8-4820-9ee0-b006aa3fbd81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1e2dade-fa89-4e25-b9c4-c39673d9f695" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b058cfb4-56a8-4820-9ee0-b006aa3fbd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_5521c59c-5528-4246-8cd3-4fd87797e75a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1e2dade-fa89-4e25-b9c4-c39673d9f695" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_5521c59c-5528-4246-8cd3-4fd87797e75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_14bf18cf-3034-4bd7-8a92-a782a2f733a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1e2dade-fa89-4e25-b9c4-c39673d9f695" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_14bf18cf-3034-4bd7-8a92-a782a2f733a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_050cd568-e110-4d8b-b543-200e6f920f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1e2dade-fa89-4e25-b9c4-c39673d9f695" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_050cd568-e110-4d8b-b543-200e6f920f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_017e61b2-8ff2-4307-a560-8c213fe08cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f333425b-7582-4765-9b65-3956f652aefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_017e61b2-8ff2-4307-a560-8c213fe08cbc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f333425b-7582-4765-9b65-3956f652aefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_df4419ea-3710-4486-880e-8991681a573e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f333425b-7582-4765-9b65-3956f652aefe" xlink:to="loc_srt_MajorCustomersAxis_df4419ea-3710-4486-880e-8991681a573e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_df4419ea-3710-4486-880e-8991681a573e" xlink:to="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_d7e40818-0109-4469-a0d0-bef9344bcf3d" xlink:href="exdx-20210331.xsd#exdx_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:to="loc_exdx_MedicareMember_d7e40818-0109-4469-a0d0-bef9344bcf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_8bb33029-5fc2-4be0-9365-35b1d4092dcd" xlink:href="exdx-20210331.xsd#exdx_BlueShieldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:to="loc_exdx_BlueShieldMember_8bb33029-5fc2-4be0-9365-35b1d4092dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_8d23804f-1624-45cb-846f-f18bd9f14630" xlink:href="exdx-20210331.xsd#exdx_MedicareAdvantageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:to="loc_exdx_MedicareAdvantageMember_8d23804f-1624-45cb-846f-f18bd9f14630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_8adf0725-2734-4c9d-b084-584774a36fb9" xlink:href="exdx-20210331.xsd#exdx_UnitedHealthcareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:to="loc_exdx_UnitedHealthcareMember_8adf0725-2734-4c9d-b084-584774a36fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_7ea270f6-2315-497c-8fd4-3229a7b515f9" xlink:href="exdx-20210331.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5e756043-1731-437a-87b6-44320c8ab9ee" xlink:to="loc_exdx_JanssenSIMPONIMember_7ea270f6-2315-497c-8fd4-3229a7b515f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_256a1389-b02a-4f5d-9ed7-ea3a4834cb73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f333425b-7582-4765-9b65-3956f652aefe" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_256a1389-b02a-4f5d-9ed7-ea3a4834cb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_786cb627-1c34-4fa4-b44f-1079a34c1972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_256a1389-b02a-4f5d-9ed7-ea3a4834cb73" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_786cb627-1c34-4fa4-b44f-1079a34c1972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6631eca1-9562-4625-89e3-ea7aa408c382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_786cb627-1c34-4fa4-b44f-1079a34c1972" xlink:to="loc_us-gaap_SalesRevenueNetMember_6631eca1-9562-4625-89e3-ea7aa408c382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember_54227168-2064-44f7-9666-dadc6baf64be" xlink:href="exdx-20210331.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_786cb627-1c34-4fa4-b44f-1079a34c1972" xlink:to="loc_exdx_ReceivableBenchmarkMember_54227168-2064-44f7-9666-dadc6baf64be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_edb2fcaf-5d18-4728-b1ee-a48f1ac92c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f333425b-7582-4765-9b65-3956f652aefe" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_edb2fcaf-5d18-4728-b1ee-a48f1ac92c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c65735ef-4b6b-4bd7-8dc0-d341fd39c367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_edb2fcaf-5d18-4728-b1ee-a48f1ac92c1b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c65735ef-4b6b-4bd7-8dc0-d341fd39c367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4fe7f5ea-0d1a-4550-8548-d63366e4e642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c65735ef-4b6b-4bd7-8dc0-d341fd39c367" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4fe7f5ea-0d1a-4550-8548-d63366e4e642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d6ee2c77-14a6-4497-b089-0fde024dbb63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f333425b-7582-4765-9b65-3956f652aefe" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d6ee2c77-14a6-4497-b089-0fde024dbb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_26fd5484-f184-4634-9405-9c3e5994c69d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d6ee2c77-14a6-4497-b089-0fde024dbb63" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_26fd5484-f184-4634-9405-9c3e5994c69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6f3375f3-8bd2-41f2-96d4-bb9e0c51f984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6f3375f3-8bd2-41f2-96d4-bb9e0c51f984" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_75fda264-2750-425d-90ab-597a2bbc18d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_75fda264-2750-425d-90ab-597a2bbc18d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_120244c4-2058-4ce7-8709-7dcf22878d44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_75fda264-2750-425d-90ab-597a2bbc18d7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_120244c4-2058-4ce7-8709-7dcf22878d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_805aa40e-ceba-4b30-b7cd-68e8077bd4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_120244c4-2058-4ce7-8709-7dcf22878d44" xlink:to="loc_us-gaap_SalesRevenueNetMember_805aa40e-ceba-4b30-b7cd-68e8077bd4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0132908a-3088-482d-8bbd-152cf08bf6ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0132908a-3088-482d-8bbd-152cf08bf6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_98adc483-e514-436b-b1dc-8eab51e00ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0132908a-3088-482d-8bbd-152cf08bf6ec" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_98adc483-e514-436b-b1dc-8eab51e00ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_873f7fbb-d37f-458c-82fb-4aa77b415e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_98adc483-e514-436b-b1dc-8eab51e00ec8" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_873f7fbb-d37f-458c-82fb-4aa77b415e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_e1d3875f-8bb3-4e9d-92e8-8e82fda207c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_98adc483-e514-436b-b1dc-8eab51e00ec8" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_e1d3875f-8bb3-4e9d-92e8-8e82fda207c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6ea3348c-9f9d-40e4-82ec-ed9b716c5ecc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_srt_ProductOrServiceAxis_6ea3348c-9f9d-40e4-82ec-ed9b716c5ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06b45fd1-5d6b-468b-a24b-678d47cb92fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6ea3348c-9f9d-40e4-82ec-ed9b716c5ecc" xlink:to="loc_srt_ProductsAndServicesDomain_06b45fd1-5d6b-468b-a24b-678d47cb92fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_a9d7bb4e-654e-4f04-8fa6-027e4dbf3e84" xlink:href="exdx-20210331.xsd#exdx_AVISECTDTestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06b45fd1-5d6b-468b-a24b-678d47cb92fb" xlink:to="loc_exdx_AVISECTDTestMember_a9d7bb4e-654e-4f04-8fa6-027e4dbf3e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_a840337d-6c8c-415b-9dca-133fd63c5df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06b45fd1-5d6b-468b-a24b-678d47cb92fb" xlink:to="loc_us-gaap_ShippingAndHandlingMember_a840337d-6c8c-415b-9dca-133fd63c5df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_02fa08d4-8060-4ae1-ac87-1769908adac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_02fa08d4-8060-4ae1-ac87-1769908adac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5db5c150-9448-45cd-b6d1-3fef7e70a66c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_02fa08d4-8060-4ae1-ac87-1769908adac3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5db5c150-9448-45cd-b6d1-3fef7e70a66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_2f35a7ac-d8b7-44c6-95e8-63ab14575298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5db5c150-9448-45cd-b6d1-3fef7e70a66c" xlink:to="loc_us-gaap_OtherAssetsMember_2f35a7ac-d8b7-44c6-95e8-63ab14575298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b765e289-991e-4c0f-bb05-f761aa5d72a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_srt_RangeAxis_b765e289-991e-4c0f-bb05-f761aa5d72a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f6dd7db-3165-4264-9093-9a502692c5f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b765e289-991e-4c0f-bb05-f761aa5d72a4" xlink:to="loc_srt_RangeMember_2f6dd7db-3165-4264-9093-9a502692c5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_329881fd-e2e8-4534-b762-ade77d1946e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2f6dd7db-3165-4264-9093-9a502692c5f3" xlink:to="loc_srt_MinimumMember_329881fd-e2e8-4534-b762-ade77d1946e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e1c2fdb3-9bd2-4736-9821-84a567dd38bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2f6dd7db-3165-4264-9093-9a502692c5f3" xlink:to="loc_srt_MaximumMember_e1c2fdb3-9bd2-4736-9821-84a567dd38bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_caa9c97a-24a8-4042-bd74-cc19cde553e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_srt_StatementScenarioAxis_caa9c97a-24a8-4042-bd74-cc19cde553e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a57b51f3-ac15-4de8-aa97-6abdcf47e9e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_caa9c97a-24a8-4042-bd74-cc19cde553e8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a57b51f3-ac15-4de8-aa97-6abdcf47e9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_26a99010-ff05-4111-a30b-370dd57d26cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a57b51f3-ac15-4de8-aa97-6abdcf47e9e7" xlink:to="loc_srt_ScenarioForecastMember_26a99010-ff05-4111-a30b-370dd57d26cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_495fc463-7712-4064-accb-65207424583d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_srt_CounterpartyNameAxis_495fc463-7712-4064-accb-65207424583d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bc5db9a-bec2-47dd-88d7-f97b5b16d8e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_495fc463-7712-4064-accb-65207424583d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bc5db9a-bec2-47dd-88d7-f97b5b16d8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_1017663a-2bfd-4e6c-8143-9edae7dbc394" xlink:href="exdx-20210331.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bc5db9a-bec2-47dd-88d7-f97b5b16d8e3" xlink:to="loc_exdx_JanssenSIMPONIMember_1017663a-2bfd-4e6c-8143-9edae7dbc394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e05cc84e-b9c4-45ba-b9b7-1ac828287531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_us-gaap_AwardTypeAxis_e05cc84e-b9c4-45ba-b9b7-1ac828287531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6564859-3e63-4d7d-94ae-df12f03daf23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e05cc84e-b9c4-45ba-b9b7-1ac828287531" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6564859-3e63-4d7d-94ae-df12f03daf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_42e1e797-85e9-4cf1-9925-7aa91a435539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6564859-3e63-4d7d-94ae-df12f03daf23" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_42e1e797-85e9-4cf1-9925-7aa91a435539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_0f9916b2-f404-4b5f-bc45-71197a9241e4" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_92016878-d1a8-4e91-9fc2-bbeb0dadde1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_92016878-d1a8-4e91-9fc2-bbeb0dadde1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_065c9814-3488-4a15-923b-7421bc7ff79e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_RestrictedCash_065c9814-3488-4a15-923b-7421bc7ff79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_26c9eb08-e08b-41b7-9792-2314cb3df74b" xlink:href="exdx-20210331.xsd#exdx_JointVentureQuarterlyPromotionFeePerPrescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_26c9eb08-e08b-41b7-9792-2314cb3df74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFee_75572ff6-b68b-4bde-b853-0bd71d5a8ba0" xlink:href="exdx-20210331.xsd#exdx_JointVentureQuarterlyPromotionFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFee_75572ff6-b68b-4bde-b853-0bd71d5a8ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_75e7b251-cd80-4651-8074-782c7fbd711d" xlink:href="exdx-20210331.xsd#exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_75e7b251-cd80-4651-8074-782c7fbd711d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPrescribedUnits_291fcf80-6dcd-4d36-9c58-56418a5188a0" xlink:href="exdx-20210331.xsd#exdx_JointVentureQuarterlyPrescribedUnits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_JointVentureQuarterlyPrescribedUnits_291fcf80-6dcd-4d36-9c58-56418a5188a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoPromotionAgreementRenewalTerm_c219f160-a824-4f92-ad7e-24bb8f82f684" xlink:href="exdx-20210331.xsd#exdx_CoPromotionAgreementRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_CoPromotionAgreementRenewalTerm_c219f160-a824-4f92-ad7e-24bb8f82f684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm_091afee8-c14d-42b3-b853-f6cee738c55a" xlink:href="exdx-20210331.xsd#exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm_091afee8-c14d-42b3-b853-f6cee738c55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement_ba3a97bf-92eb-4088-926b-55a1f7a20cf6" xlink:href="exdx-20210331.xsd#exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement_ba3a97bf-92eb-4088-926b-55a1f7a20cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3b3b3852-142d-4484-ace3-21d479a3d763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3b3b3852-142d-4484-ace3-21d479a3d763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_f4de2739-a2b3-47c7-b870-6ffbe383a0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_AdvertisingExpense_f4de2739-a2b3-47c7-b870-6ffbe383a0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_c25cfe6b-6400-418e-b470-8346e003c3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_CostOfRevenue_c25cfe6b-6400-418e-b470-8346e003c3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ed10c30c-1f15-4469-9bcd-ab815095469c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ed10c30c-1f15-4469-9bcd-ab815095469c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_deb5f4e6-afdc-4e0a-8edb-6489d28669fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_deb5f4e6-afdc-4e0a-8edb-6489d28669fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_52c21482-f7aa-4e97-bde6-5a4b22e25e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_5f7bde6c-b8dc-40aa-bbcd-b068dfc2edc1" xlink:to="loc_us-gaap_NumberOfOperatingSegments_52c21482-f7aa-4e97-bde6-5a4b22e25e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c042e7ed-0169-4b89-bcb4-07d9ebaebddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_57d4fa30-b5f0-4b9a-9562-a3ebc6519386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c042e7ed-0169-4b89-bcb4-07d9ebaebddb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_57d4fa30-b5f0-4b9a-9562-a3ebc6519386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a2ac9faf-e465-400a-b005-c83ad2c03306" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57d4fa30-b5f0-4b9a-9562-a3ebc6519386" xlink:to="loc_srt_MajorCustomersAxis_a2ac9faf-e465-400a-b005-c83ad2c03306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a2ac9faf-e465-400a-b005-c83ad2c03306" xlink:to="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember_6000cda1-d025-41b3-93aa-72c0c8be4c17" xlink:href="exdx-20210331.xsd#exdx_HealthcareInsurersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:to="loc_exdx_HealthcareInsurersMember_6000cda1-d025-41b3-93aa-72c0c8be4c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_b587e40a-bcd3-4437-8df4-6ae0f9d4c17c" xlink:href="exdx-20210331.xsd#exdx_Government1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:to="loc_exdx_Government1Member_b587e40a-bcd3-4437-8df4-6ae0f9d4c17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_f14029a2-4d12-4cab-bd62-d06e7273218e" xlink:href="exdx-20210331.xsd#exdx_ClientMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:to="loc_exdx_ClientMember_f14029a2-4d12-4cab-bd62-d06e7273218e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_f2f4e875-1654-47b6-8ea6-340faef45593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCustomerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:to="loc_us-gaap_OtherCustomerMember_f2f4e875-1654-47b6-8ea6-340faef45593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_f7cac0f5-3d3b-472f-a3a3-3d0be9c0274a" xlink:href="exdx-20210331.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b5875ec-9d86-4bde-9b77-e29e31f75f0f" xlink:to="loc_exdx_JanssenSIMPONIMember_f7cac0f5-3d3b-472f-a3a3-3d0be9c0274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b94a3103-c2e1-4641-b6b1-5f824af1b27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_57d4fa30-b5f0-4b9a-9562-a3ebc6519386" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b94a3103-c2e1-4641-b6b1-5f824af1b27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_625a6adf-b40c-42ef-b19c-259f68f0f3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b94a3103-c2e1-4641-b6b1-5f824af1b27b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_625a6adf-b40c-42ef-b19c-259f68f0f3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_76b55544-d56b-49ca-9c0a-d385b5f3ee6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_56fd7f58-e8ba-4e56-bb87-969da95bac36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76b55544-d56b-49ca-9c0a-d385b5f3ee6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_56fd7f58-e8ba-4e56-bb87-969da95bac36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_57229a76-a762-4c13-895d-185a6eb02d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76b55544-d56b-49ca-9c0a-d385b5f3ee6d" xlink:to="loc_us-gaap_RestrictedCash_57229a76-a762-4c13-895d-185a6eb02d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_260f4de2-5b3d-444e-9e47-fa755328e5e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76b55544-d56b-49ca-9c0a-d385b5f3ee6d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_260f4de2-5b3d-444e-9e47-fa755328e5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a1d5d024-7a32-4eb6-9997-e12d0fabb092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_61149811-358a-43bc-96c6-d86b1e81aef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1d5d024-7a32-4eb6-9997-e12d0fabb092" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_61149811-358a-43bc-96c6-d86b1e81aef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a3fef21a-dd60-4e64-a64e-7172872049d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_61149811-358a-43bc-96c6-d86b1e81aef5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a3fef21a-dd60-4e64-a64e-7172872049d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b128bcb9-afa2-401b-acde-78fc818a002c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a3fef21a-dd60-4e64-a64e-7172872049d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b128bcb9-afa2-401b-acde-78fc818a002c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_88ec831e-9eb9-4b2f-830e-0721bd31f88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b128bcb9-afa2-401b-acde-78fc818a002c" xlink:to="loc_us-gaap_WarrantMember_88ec831e-9eb9-4b2f-830e-0721bd31f88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_1d370a24-b700-49d1-ab1b-132d6de8de4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b128bcb9-afa2-401b-acde-78fc818a002c" xlink:to="loc_us-gaap_StockOptionMember_1d370a24-b700-49d1-ab1b-132d6de8de4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_885d7161-a6a7-4a95-b29a-7eb37c497c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b128bcb9-afa2-401b-acde-78fc818a002c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_885d7161-a6a7-4a95-b29a-7eb37c497c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e14bb96b-81e3-4031-917e-fae423efdd9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b128bcb9-afa2-401b-acde-78fc818a002c" xlink:to="loc_us-gaap_EmployeeStockMember_e14bb96b-81e3-4031-917e-fae423efdd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f6b77f1e-ce00-4107-a710-d866571ae6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_61149811-358a-43bc-96c6-d86b1e81aef5" xlink:to="loc_us-gaap_ClassOfStockLineItems_f6b77f1e-ce00-4107-a710-d866571ae6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46676862-f616-452f-ae3d-f838487030bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f6b77f1e-ce00-4107-a710-d866571ae6d1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46676862-f616-452f-ae3d-f838487030bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_863d844c-3ad6-43d0-86d4-2c896e2a7356" xlink:href="exdx-20210331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_54ba6dc9-a358-41df-9923-04c2b109e457" xlink:href="exdx-20210331.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_863d844c-3ad6-43d0-86d4-2c896e2a7356" xlink:to="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_54ba6dc9-a358-41df-9923-04c2b109e457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_aaccdaee-4dca-4d75-9b1b-96f11247195c" xlink:href="exdx-20210331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_82bc3876-5ed0-4cc3-be7c-ca3c09f6f49b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_aaccdaee-4dca-4d75-9b1b-96f11247195c" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_82bc3876-5ed0-4cc3-be7c-ca3c09f6f49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bfae3eb2-93b7-4df2-826e-2d206d4c517d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_aaccdaee-4dca-4d75-9b1b-96f11247195c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bfae3eb2-93b7-4df2-826e-2d206d4c517d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_14858446-117a-4352-a7ba-f0eb1861612c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_aaccdaee-4dca-4d75-9b1b-96f11247195c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_14858446-117a-4352-a7ba-f0eb1861612c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_7a7b6812-8083-4b8f-aaa9-5e81607b3273" xlink:href="exdx-20210331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_bb876ef1-5ac0-40a2-96b8-15f628a39c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_7a7b6812-8083-4b8f-aaa9-5e81607b3273" xlink:to="loc_us-gaap_OtherAssetsCurrent_bb876ef1-5ac0-40a2-96b8-15f628a39c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_1e07f109-95ff-465e-9ec6-6e981f11591a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_7a7b6812-8083-4b8f-aaa9-5e81607b3273" xlink:to="loc_us-gaap_PrepaidRoyalties_1e07f109-95ff-465e-9ec6-6e981f11591a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_ef6e88ad-989c-4f25-8e96-296338289c03" xlink:href="exdx-20210331.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_7a7b6812-8083-4b8f-aaa9-5e81607b3273" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_ef6e88ad-989c-4f25-8e96-296338289c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_fa82f66a-3dc3-490d-bcea-a0eedb7ca164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_7a7b6812-8083-4b8f-aaa9-5e81607b3273" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_fa82f66a-3dc3-490d-bcea-a0eedb7ca164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dbcff663-4d4f-46c4-8ba4-354b96efa0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_7a7b6812-8083-4b8f-aaa9-5e81607b3273" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dbcff663-4d4f-46c4-8ba4-354b96efa0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_0157e4c0-8e03-4445-aa95-dc927dc2eb80" xlink:href="exdx-20210331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f47ebcd8-bb94-48c5-8377-d8980cf6c630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_0157e4c0-8e03-4445-aa95-dc927dc2eb80" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f47ebcd8-bb94-48c5-8377-d8980cf6c630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_df9424e9-a23c-43f4-a4f5-7dcc73b4c325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f47ebcd8-bb94-48c5-8377-d8980cf6c630" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_df9424e9-a23c-43f4-a4f5-7dcc73b4c325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_df9424e9-a23c-43f4-a4f5-7dcc73b4c325" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5d52bd16-341b-4619-b019-4bd0a0f2bec5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5d52bd16-341b-4619-b019-4bd0a0f2bec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_f4d53f86-5b4c-49a8-82b0-b3b585dfda2b" xlink:href="exdx-20210331.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:to="loc_exdx_LaboratoryEquipmentMember_f4d53f86-5b4c-49a8-82b0-b3b585dfda2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_196b34a4-adbe-406b-ab1f-22b83d3b403e" xlink:href="exdx-20210331.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_196b34a4-adbe-406b-ab1f-22b83d3b403e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4caa131f-fe4d-42fa-9991-d1d2cdab653a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4caa131f-fe4d-42fa-9991-d1d2cdab653a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_a7f2e15f-3778-4cb3-bfd3-83604d12e19f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63aaa57f-5ded-4576-9a14-ee1029d30e5c" xlink:to="loc_us-gaap_ConstructionInProgressMember_a7f2e15f-3778-4cb3-bfd3-83604d12e19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_189ed879-714e-449b-a91b-d9557f6be94a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f47ebcd8-bb94-48c5-8377-d8980cf6c630" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_189ed879-714e-449b-a91b-d9557f6be94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a8f17e55-c602-45e0-8607-46f28c585368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_189ed879-714e-449b-a91b-d9557f6be94a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a8f17e55-c602-45e0-8607-46f28c585368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_31329079-dd87-429e-9799-8ccd08d97229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_189ed879-714e-449b-a91b-d9557f6be94a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_31329079-dd87-429e-9799-8ccd08d97229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c454ff7f-9729-4446-8e99-7e29aa5b39ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_189ed879-714e-449b-a91b-d9557f6be94a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c454ff7f-9729-4446-8e99-7e29aa5b39ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_b1ba317f-11d5-41d2-a033-0fc14a501397" xlink:href="exdx-20210331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_13702d2d-9f9e-433d-8cc6-78a2664ddd3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_b1ba317f-11d5-41d2-a033-0fc14a501397" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_13702d2d-9f9e-433d-8cc6-78a2664ddd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0290eb54-13c1-417d-9194-2a3b2af55e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_13702d2d-9f9e-433d-8cc6-78a2664ddd3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0290eb54-13c1-417d-9194-2a3b2af55e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4e7d229-1b14-4145-a541-590a87379c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0290eb54-13c1-417d-9194-2a3b2af55e38" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4e7d229-1b14-4145-a541-590a87379c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember_0581bc12-439d-49d6-9994-48b704dc5436" xlink:href="exdx-20210331.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4e7d229-1b14-4145-a541-590a87379c2a" xlink:to="loc_exdx_AssetsUnderCapitalLeaseMember_0581bc12-439d-49d6-9994-48b704dc5436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3c28a922-22f3-49f6-b7cd-600e212824aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_13702d2d-9f9e-433d-8cc6-78a2664ddd3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3c28a922-22f3-49f6-b7cd-600e212824aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ce576a5b-256a-42b1-a47a-f2b97a309f02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3c28a922-22f3-49f6-b7cd-600e212824aa" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ce576a5b-256a-42b1-a47a-f2b97a309f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_dc8f3236-ad7f-4b9f-88cd-8088b0180d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3c28a922-22f3-49f6-b7cd-600e212824aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_dc8f3236-ad7f-4b9f-88cd-8088b0180d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_1724d616-0442-46f2-94ac-428b24f685fc" xlink:href="exdx-20210331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_b56568ee-7a29-403d-b5dc-e71da102b2db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1724d616-0442-46f2-94ac-428b24f685fc" xlink:to="loc_us-gaap_AccruedSalariesCurrent_b56568ee-7a29-403d-b5dc-e71da102b2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_6789089f-a826-4a32-938c-84241f86d2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1724d616-0442-46f2-94ac-428b24f685fc" xlink:to="loc_us-gaap_InterestPayableCurrent_6789089f-a826-4a32-938c-84241f86d2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_94f896a4-8c1f-429e-9309-4c17a5452d73" xlink:href="exdx-20210331.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1724d616-0442-46f2-94ac-428b24f685fc" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_94f896a4-8c1f-429e-9309-4c17a5452d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_1fd7fe75-1eab-42e3-85c8-411307b9a6d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1724d616-0442-46f2-94ac-428b24f685fc" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_1fd7fe75-1eab-42e3-85c8-411307b9a6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_a8220a96-e3b9-4eb5-9496-71fcea0b2902" xlink:href="exdx-20210331.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1724d616-0442-46f2-94ac-428b24f685fc" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_a8220a96-e3b9-4eb5-9496-71fcea0b2902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_2fa79598-8218-4d62-a345-51354772c348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1724d616-0442-46f2-94ac-428b24f685fc" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_2fa79598-8218-4d62-a345-51354772c348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c18ac283-1f55-4a77-a9c6-812a15d2973c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1724d616-0442-46f2-94ac-428b24f685fc" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c18ac283-1f55-4a77-a9c6-812a15d2973c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a54525d4-c46a-4ded-b3c9-eb2546626a67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1724d616-0442-46f2-94ac-428b24f685fc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a54525d4-c46a-4ded-b3c9-eb2546626a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Borrowings" xlink:type="simple" xlink:href="exdx-20210331.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_121b0536-8f43-461f-9114-17d4e01ae034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_cae92ddb-1a22-467a-b1a1-e3364c4f3cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_121b0536-8f43-461f-9114-17d4e01ae034" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_cae92ddb-1a22-467a-b1a1-e3364c4f3cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3d3e162a-fa6c-4019-9498-647eb23b0618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4beed714-6eea-4f36-9015-197c487cc58a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3d3e162a-fa6c-4019-9498-647eb23b0618" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4beed714-6eea-4f36-9015-197c487cc58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0757efd7-2c70-4da5-a327-7cb552df7988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c9092b99-117c-4c6f-acac-66d0a0b5873d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0757efd7-2c70-4da5-a327-7cb552df7988" xlink:to="loc_us-gaap_DebtInstrumentTable_c9092b99-117c-4c6f-acac-66d0a0b5873d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7f99fba0-57d2-4e9c-bd18-21655bdefb02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c9092b99-117c-4c6f-acac-66d0a0b5873d" xlink:to="loc_us-gaap_DebtInstrumentAxis_7f99fba0-57d2-4e9c-bd18-21655bdefb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7a81553-5434-4164-b907-37face57be81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7f99fba0-57d2-4e9c-bd18-21655bdefb02" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7a81553-5434-4164-b907-37face57be81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_139b202d-1393-4561-9e4c-931f6ef0f6c2" xlink:href="exdx-20210331.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7a81553-5434-4164-b907-37face57be81" xlink:to="loc_exdx_Term2017Member_139b202d-1393-4561-9e4c-931f6ef0f6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_10461eb9-17dc-4b48-aad0-67f8943e2959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c9092b99-117c-4c6f-acac-66d0a0b5873d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_10461eb9-17dc-4b48-aad0-67f8943e2959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bec2f939-35ef-42b0-800b-b6e64bb19fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_10461eb9-17dc-4b48-aad0-67f8943e2959" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bec2f939-35ef-42b0-800b-b6e64bb19fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_f8405168-f4f3-4950-83cb-06e2a3192431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bec2f939-35ef-42b0-800b-b6e64bb19fea" xlink:to="loc_us-gaap_LoansPayableMember_f8405168-f4f3-4950-83cb-06e2a3192431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_65c161eb-97aa-4258-9c35-a8635ad17f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bec2f939-35ef-42b0-800b-b6e64bb19fea" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_65c161eb-97aa-4258-9c35-a8635ad17f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_bff274b5-cfad-420d-90e4-b6a3262288a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c9092b99-117c-4c6f-acac-66d0a0b5873d" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_bff274b5-cfad-420d-90e4-b6a3262288a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_7940e180-2637-489e-9293-e1c654681b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_bff274b5-cfad-420d-90e4-b6a3262288a0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_7940e180-2637-489e-9293-e1c654681b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_20d89637-6e3e-4e2d-814f-7917dd945ec9" xlink:href="exdx-20210331.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7940e180-2637-489e-9293-e1c654681b67" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_20d89637-6e3e-4e2d-814f-7917dd945ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember_d49d9448-4a3b-45ce-8cc1-883b9a63c4a9" xlink:href="exdx-20210331.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7940e180-2637-489e-9293-e1c654681b67" xlink:to="loc_exdx_CapitalRoyaltyPartnersIILPMember_d49d9448-4a3b-45ce-8cc1-883b9a63c4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c9092b99-117c-4c6f-acac-66d0a0b5873d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_611233b9-ec78-4e39-9cd2-04d034825820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_611233b9-ec78-4e39-9cd2-04d034825820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9cb5b8e7-87b2-40f4-a13d-4a8fdf83867b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9cb5b8e7-87b2-40f4-a13d-4a8fdf83867b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0fbb5d76-a4fe-4476-9d3a-afdd2faf4efb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0fbb5d76-a4fe-4476-9d3a-afdd2faf4efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_77e77e22-7502-4488-a20f-ce60a95fce6d" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_77e77e22-7502-4488-a20f-ce60a95fce6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5e8ded89-887c-444b-990e-fe8c81cee8fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_5e8ded89-887c-444b-990e-fe8c81cee8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_00248636-eddf-4687-819e-341ba31bec8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_DebtInstrumentTerm_00248636-eddf-4687-819e-341ba31bec8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_48096845-2aa9-4d7c-b28b-a76e026742e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_48096845-2aa9-4d7c-b28b-a76e026742e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_2833e15f-5756-441d-9ff9-d9211af1da31" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_2833e15f-5756-441d-9ff9-d9211af1da31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_8c6bc9fe-640b-4da2-a2c6-5db48712d016" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_8c6bc9fe-640b-4da2-a2c6-5db48712d016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_6bf78129-b8b8-43d1-af09-d8956fdcf9d3" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_6bf78129-b8b8-43d1-af09-d8956fdcf9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_cb0969c5-63eb-429b-8d71-3f036d4ea44f" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_cb0969c5-63eb-429b-8d71-3f036d4ea44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_21331193-32c5-4318-b920-545d41e605c0" xlink:href="exdx-20210331.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b3f27fa-7ef0-4c50-8ef6-8058e1451feb" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_21331193-32c5-4318-b920-545d41e605c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_191b6c61-849b-4a10-b189-9e1fe9e2d13d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_819796dd-17d9-481f-a33b-791d6506573d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_191b6c61-849b-4a10-b189-9e1fe9e2d13d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_819796dd-17d9-481f-a33b-791d6506573d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_da07d9ba-84c2-4bf7-9cf8-a31c179491b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_191b6c61-849b-4a10-b189-9e1fe9e2d13d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_da07d9ba-84c2-4bf7-9cf8-a31c179491b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_30551250-7c36-4c0e-bb65-c2d58a10b247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_191b6c61-849b-4a10-b189-9e1fe9e2d13d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_30551250-7c36-4c0e-bb65-c2d58a10b247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6f3e22f0-6d72-41f9-b26d-dcbebdbfcc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_191b6c61-849b-4a10-b189-9e1fe9e2d13d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6f3e22f0-6d72-41f9-b26d-dcbebdbfcc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3f90ec68-08c1-4dd3-891c-6ca3e9873d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_191b6c61-849b-4a10-b189-9e1fe9e2d13d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3f90ec68-08c1-4dd3-891c-6ca3e9873d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_6b43d9e1-1e84-44cc-bebf-76db38e7e637" xlink:href="exdx-20210331.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_191b6c61-849b-4a10-b189-9e1fe9e2d13d" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_6b43d9e1-1e84-44cc-bebf-76db38e7e637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_95e5bd4d-7ef8-4e5a-8f47-a1b8af14b000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_191b6c61-849b-4a10-b189-9e1fe9e2d13d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_95e5bd4d-7ef8-4e5a-8f47-a1b8af14b000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_cfbe3616-8de1-4c6c-8a9e-dd5791546dfb" xlink:href="exdx-20210331.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_191b6c61-849b-4a10-b189-9e1fe9e2d13d" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_cfbe3616-8de1-4c6c-8a9e-dd5791546dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c09b5fec-4c54-4395-9ff5-4118f0abd319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_191b6c61-849b-4a10-b189-9e1fe9e2d13d" xlink:to="loc_us-gaap_LongTermDebt_c09b5fec-4c54-4395-9ff5-4118f0abd319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="exdx-20210331.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e2fe282e-e01e-480d-97a3-d76f16931947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9de38c0a-531b-4fe5-97cc-bf158b4cc256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e2fe282e-e01e-480d-97a3-d76f16931947" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9de38c0a-531b-4fe5-97cc-bf158b4cc256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_08da8625-bd84-405f-9c00-41b336efce9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_08da8625-bd84-405f-9c00-41b336efce9c" xlink:to="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_329604b1-50ce-4b61-9e5d-a73f863e66bb" xlink:href="exdx-20210331.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:to="loc_exdx_RentalPropertyByTypeAxis_329604b1-50ce-4b61-9e5d-a73f863e66bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_4d0cfa54-051d-440b-9127-1c496c449c4d" xlink:href="exdx-20210331.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeAxis_329604b1-50ce-4b61-9e5d-a73f863e66bb" xlink:to="loc_exdx_RentalPropertyByTypeDomain_4d0cfa54-051d-440b-9127-1c496c449c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_2bb8735a-91c2-42cd-a08a-2de7beda21df" xlink:href="exdx-20210331.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_4d0cfa54-051d-440b-9127-1c496c449c4d" xlink:to="loc_exdx_OfficeAndLaboratoryMember_2bb8735a-91c2-42cd-a08a-2de7beda21df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_41d841c3-6d10-443c-ae9d-3f1dfe108865" xlink:href="exdx-20210331.xsd#exdx_OfficeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_4d0cfa54-051d-440b-9127-1c496c449c4d" xlink:to="loc_exdx_OfficeMember_41d841c3-6d10-443c-ae9d-3f1dfe108865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e77a7157-f86a-4df8-89ce-1c4d33f2134f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:to="loc_srt_CounterpartyNameAxis_e77a7157-f86a-4df8-89ce-1c4d33f2134f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a7b2319-9faf-4ce8-b5b0-23c9b8460a09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e77a7157-f86a-4df8-89ce-1c4d33f2134f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a7b2319-9faf-4ce8-b5b0-23c9b8460a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_888a5d90-8af5-48ce-a5c6-2141d50b062d" xlink:href="exdx-20210331.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a7b2319-9faf-4ce8-b5b0-23c9b8460a09" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_888a5d90-8af5-48ce-a5c6-2141d50b062d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_6f0e348b-f499-4169-a27f-699ff9d1beb4" xlink:href="exdx-20210331.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a7b2319-9faf-4ce8-b5b0-23c9b8460a09" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_6f0e348b-f499-4169-a27f-699ff9d1beb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a4c656d3-49d5-4005-88e7-0470cb8733b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:to="loc_srt_RangeAxis_a4c656d3-49d5-4005-88e7-0470cb8733b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eef99c26-135d-4199-a8f4-b08bbfe00d95" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a4c656d3-49d5-4005-88e7-0470cb8733b7" xlink:to="loc_srt_RangeMember_eef99c26-135d-4199-a8f4-b08bbfe00d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_01d0950b-d1ab-4db2-bb0b-323e3909c516" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eef99c26-135d-4199-a8f4-b08bbfe00d95" xlink:to="loc_srt_MinimumMember_01d0950b-d1ab-4db2-bb0b-323e3909c516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0cc2c0db-07e9-4497-8f89-8a43297390b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eef99c26-135d-4199-a8f4-b08bbfe00d95" xlink:to="loc_srt_MaximumMember_0cc2c0db-07e9-4497-8f89-8a43297390b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_285fa607-f0fb-4fee-ac5a-cfe11e7050b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_285fa607-f0fb-4fee-ac5a-cfe11e7050b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6d4e3062-522d-47d3-8547-762ff63ddafa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_285fa607-f0fb-4fee-ac5a-cfe11e7050b4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6d4e3062-522d-47d3-8547-762ff63ddafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_bf03a504-ff64-430b-8640-9a2556ceb37a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6d4e3062-522d-47d3-8547-762ff63ddafa" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_bf03a504-ff64-430b-8640-9a2556ceb37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4e79dddf-d7de-47a1-b22f-f981e3c790b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4e79dddf-d7de-47a1-b22f-f981e3c790b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_93013d02-ba49-4f80-9300-39ef9a50b199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4e79dddf-d7de-47a1-b22f-f981e3c790b1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_93013d02-ba49-4f80-9300-39ef9a50b199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_79b23381-d8c5-4b8c-a5eb-ba2b44c21e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_93013d02-ba49-4f80-9300-39ef9a50b199" xlink:to="loc_us-gaap_SubsequentEventMember_79b23381-d8c5-4b8c-a5eb-ba2b44c21e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2f6ab89e-bd05-4f9d-9de4-12c76fcbc895" xlink:to="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeasesRenewalTerm_0feceb8a-72e2-41a7-8ed4-60b4d8ad820c" xlink:href="exdx-20210331.xsd#exdx_OperatingLeasesRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_OperatingLeasesRenewalTerm_0feceb8a-72e2-41a7-8ed4-60b4d8ad820c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_fd812f31-2a5b-40bc-9739-61e0dfa29664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_us-gaap_LeaseAndRentalExpense_fd812f31-2a5b-40bc-9739-61e0dfa29664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation_20071798-d95c-4d7b-ac9c-a4c04f312ad6" xlink:href="exdx-20210331.xsd#exdx_MilestoneObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_MilestoneObligation_20071798-d95c-4d7b-ac9c-a4c04f312ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneContingencyFairValueDisclosure_75734cca-b25a-46d3-a181-c9cdb5aed3fd" xlink:href="exdx-20210331.xsd#exdx_MilestoneContingencyFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_MilestoneContingencyFairValueDisclosure_75734cca-b25a-46d3-a181-c9cdb5aed3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_18bf6cc6-2ab9-48a6-b9ce-e08e323aa1fd" xlink:href="exdx-20210331.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_18bf6cc6-2ab9-48a6-b9ce-e08e323aa1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_f329bbf1-d2f9-4fe4-846b-2f485a1f7a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_f329bbf1-d2f9-4fe4-846b-2f485a1f7a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_3e6bf6e8-ce70-4943-bf4f-ae77e0408882" xlink:href="exdx-20210331.xsd#exdx_AdvancePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_AdvancePayment_3e6bf6e8-ce70-4943-bf4f-ae77e0408882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementInitialLicenseFee_442f4d76-c9bd-40cd-9341-c00b7c3b8efe" xlink:href="exdx-20210331.xsd#exdx_LicenseAgreementInitialLicenseFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_LicenseAgreementInitialLicenseFee_442f4d76-c9bd-40cd-9341-c00b7c3b8efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0ec6075c-604b-48aa-afcf-0e634ee1ec9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0ec6075c-604b-48aa-afcf-0e634ee1ec9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_527a8a52-f113-447c-a506-7043e6756fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_527a8a52-f113-447c-a506-7043e6756fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_6238f988-330a-42d4-85bb-f19dd2adda6e" xlink:href="exdx-20210331.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_6238f988-330a-42d4-85bb-f19dd2adda6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_2ea82a67-226b-4701-afc0-271f75d55f89" xlink:href="exdx-20210331.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f1a9d651-2b03-4319-8d06-71b832761662" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_2ea82a67-226b-4701-afc0-271f75d55f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exdx-20210331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_044dc5fe-0845-4f58-acb2-e2f54a741a76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_9eda5d8e-7087-4368-a846-987996c0edad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_044dc5fe-0845-4f58-acb2-e2f54a741a76" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_9eda5d8e-7087-4368-a846-987996c0edad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d40cf53d-9188-450b-8018-798aedd17d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ae7c8ff3-4cde-41e0-a0ea-376ad7770d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d40cf53d-9188-450b-8018-798aedd17d69" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ae7c8ff3-4cde-41e0-a0ea-376ad7770d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_34f45e14-087d-4eda-9503-40f5d9cde3f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3cab5e24-fce2-4f59-8cd8-3954d1f392b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_34f45e14-087d-4eda-9503-40f5d9cde3f7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3cab5e24-fce2-4f59-8cd8-3954d1f392b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ba99eb9-a88f-486c-95b6-545d00bebcd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3cab5e24-fce2-4f59-8cd8-3954d1f392b5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ba99eb9-a88f-486c-95b6-545d00bebcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c93e455e-2cb7-42a6-8306-682bcd43bff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ba99eb9-a88f-486c-95b6-545d00bebcd5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c93e455e-2cb7-42a6-8306-682bcd43bff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7ee753b5-0f63-48d8-959d-9bf89e09e7e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c93e455e-2cb7-42a6-8306-682bcd43bff0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7ee753b5-0f63-48d8-959d-9bf89e09e7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbfbc2c-934f-404b-b426-77cca6de233e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3cab5e24-fce2-4f59-8cd8-3954d1f392b5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbfbc2c-934f-404b-b426-77cca6de233e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbcd4ab5-8b0f-45d0-8747-f281127446cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0cbfbc2c-934f-404b-b426-77cca6de233e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbcd4ab5-8b0f-45d0-8747-f281127446cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_983e2cba-2db8-46de-82ed-aad9aa76a704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbcd4ab5-8b0f-45d0-8747-f281127446cc" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_983e2cba-2db8-46de-82ed-aad9aa76a704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_725fc744-1634-4e3a-b970-b2c4842b5f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbcd4ab5-8b0f-45d0-8747-f281127446cc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_725fc744-1634-4e3a-b970-b2c4842b5f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9e3d663d-3cdc-4d1b-91bb-f73366eb6236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbcd4ab5-8b0f-45d0-8747-f281127446cc" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9e3d663d-3cdc-4d1b-91bb-f73366eb6236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d4addde0-6b35-4429-b7b1-f1d54a3d8a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3cab5e24-fce2-4f59-8cd8-3954d1f392b5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d4addde0-6b35-4429-b7b1-f1d54a3d8a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4d7b57c-96dd-43ac-9199-628987a13767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d4addde0-6b35-4429-b7b1-f1d54a3d8a0a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4d7b57c-96dd-43ac-9199-628987a13767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_450ddaa7-2295-4710-b105-3f7e20f0b87f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4d7b57c-96dd-43ac-9199-628987a13767" xlink:to="loc_us-gaap_MoneyMarketFundsMember_450ddaa7-2295-4710-b105-3f7e20f0b87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_929f446f-7e57-41d0-9f8c-59e7e4b6be80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3cab5e24-fce2-4f59-8cd8-3954d1f392b5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_929f446f-7e57-41d0-9f8c-59e7e4b6be80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_c4a91a2a-184f-4dd8-bfa5-8fea3cee9bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_929f446f-7e57-41d0-9f8c-59e7e4b6be80" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_c4a91a2a-184f-4dd8-bfa5-8fea3cee9bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8d197903-7a58-4c7c-ab98-528c41989a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c4a91a2a-184f-4dd8-bfa5-8fea3cee9bff" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8d197903-7a58-4c7c-ab98-528c41989a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5a40350b-7557-4a8b-be53-8135cc9e8707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f95933b8-d2ff-4b05-8a88-6892c5977c60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5a40350b-7557-4a8b-be53-8135cc9e8707" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f95933b8-d2ff-4b05-8a88-6892c5977c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a52a6bac-f14a-4416-a44c-6d3f00fe723f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_de2a82ff-0ff9-4386-9d2b-e7f65c14d299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a52a6bac-f14a-4416-a44c-6d3f00fe723f" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_de2a82ff-0ff9-4386-9d2b-e7f65c14d299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_53e7aee2-e21c-4dd4-8364-c4d2d08562a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_10bddc64-29ca-4c56-a467-135ad1627665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_53e7aee2-e21c-4dd4-8364-c4d2d08562a9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_10bddc64-29ca-4c56-a467-135ad1627665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_861e6b9e-81f8-4f3a-be26-d65c29a17438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10bddc64-29ca-4c56-a467-135ad1627665" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_861e6b9e-81f8-4f3a-be26-d65c29a17438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_413fb7f0-3107-45ec-92d4-e7f3af3c7681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_861e6b9e-81f8-4f3a-be26-d65c29a17438" xlink:to="loc_us-gaap_EquityComponentDomain_413fb7f0-3107-45ec-92d4-e7f3af3c7681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1c988cef-0d05-45a0-b40e-57bb3dfacacd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_413fb7f0-3107-45ec-92d4-e7f3af3c7681" xlink:to="loc_us-gaap_CommonStockMember_1c988cef-0d05-45a0-b40e-57bb3dfacacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e48394ed-df39-4087-82ec-bcd9e460c346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10bddc64-29ca-4c56-a467-135ad1627665" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e48394ed-df39-4087-82ec-bcd9e460c346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b4a969a8-097d-4d27-aa63-fdd1714ca462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e48394ed-df39-4087-82ec-bcd9e460c346" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b4a969a8-097d-4d27-aa63-fdd1714ca462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_a23c9d05-6b8b-4781-9933-804011d11458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b4a969a8-097d-4d27-aa63-fdd1714ca462" xlink:to="loc_us-gaap_IPOMember_a23c9d05-6b8b-4781-9933-804011d11458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d437dd2d-c8b9-48ad-8a63-d805a9960bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10bddc64-29ca-4c56-a467-135ad1627665" xlink:to="loc_us-gaap_ClassOfStockLineItems_d437dd2d-c8b9-48ad-8a63-d805a9960bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9cf38510-42dc-48d9-aa8d-17010c286c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d437dd2d-c8b9-48ad-8a63-d805a9960bd2" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9cf38510-42dc-48d9-aa8d-17010c286c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_546b3656-5d95-46a4-8dd5-8cce77a16ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d437dd2d-c8b9-48ad-8a63-d805a9960bd2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_546b3656-5d95-46a4-8dd5-8cce77a16ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6946a51e-8a59-4afc-b26d-0433ce54147c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d437dd2d-c8b9-48ad-8a63-d805a9960bd2" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6946a51e-8a59-4afc-b26d-0433ce54147c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_46a15ab9-4e52-44b3-9fe5-998b8a8fe4d2" xlink:href="exdx-20210331.xsd#exdx_StockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d437dd2d-c8b9-48ad-8a63-d805a9960bd2" xlink:to="loc_exdx_StockIssuanceCosts_46a15ab9-4e52-44b3-9fe5-998b8a8fe4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b8be623a-3771-4baf-86b3-c9dd6113abf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ad5c3372-10e6-4360-9406-190f0b865109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b8be623a-3771-4baf-86b3-c9dd6113abf8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ad5c3372-10e6-4360-9406-190f0b865109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5fb4063c-c274-4189-ae6b-5988f0fef2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ad5c3372-10e6-4360-9406-190f0b865109" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5fb4063c-c274-4189-ae6b-5988f0fef2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5fb4063c-c274-4189-ae6b-5988f0fef2ae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_aae82934-45b5-4f7e-88b0-525b1d9a50a9" xlink:href="exdx-20210331.xsd#exdx_ExpirationJan192026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:to="loc_exdx_ExpirationJan192026Member_aae82934-45b5-4f7e-88b0-525b1d9a50a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_c000e4e7-fe05-40a9-9c50-702d77502cad" xlink:href="exdx-20210331.xsd#exdx_ExpirationMar312026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:to="loc_exdx_ExpirationMar312026Member_c000e4e7-fe05-40a9-9c50-702d77502cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_cf18756f-6469-4081-a217-0afaee515b25" xlink:href="exdx-20210331.xsd#exdx_ExpirationApr12026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:to="loc_exdx_ExpirationApr12026Member_cf18756f-6469-4081-a217-0afaee515b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_f6c61bb3-53e3-41cd-81e2-3e3853cb04df" xlink:href="exdx-20210331.xsd#exdx_ExpirationSep72024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:to="loc_exdx_ExpirationSep72024Member_f6c61bb3-53e3-41cd-81e2-3e3853cb04df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_924b56f4-27fe-4d34-bfa4-2822282ce70d" xlink:href="exdx-20210331.xsd#exdx_ExpirationDec72025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d6d3a37-6016-4c84-a312-57f74f9f3a10" xlink:to="loc_exdx_ExpirationDec72025Member_924b56f4-27fe-4d34-bfa4-2822282ce70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ca59669e-dc28-4d97-a63e-43388343daec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ad5c3372-10e6-4360-9406-190f0b865109" xlink:to="loc_us-gaap_ClassOfStockLineItems_ca59669e-dc28-4d97-a63e-43388343daec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1b2b2bdf-9438-49fc-a9c1-46bac74f674e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca59669e-dc28-4d97-a63e-43388343daec" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1b2b2bdf-9438-49fc-a9c1-46bac74f674e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_583fcd17-f9d2-4e63-8075-05d9d4afd45b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca59669e-dc28-4d97-a63e-43388343daec" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_583fcd17-f9d2-4e63-8075-05d9d4afd45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd7035b1-27f6-4ecc-bef3-27876e0729ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7dcd5d37-fbce-4afb-8f61-6c098fb57287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd7035b1-27f6-4ecc-bef3-27876e0729ea" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7dcd5d37-fbce-4afb-8f61-6c098fb57287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48847cbc-2399-457a-8fe1-806422d8c9f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7e59c0d0-2654-4e1f-bed1-044266ce3687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48847cbc-2399-457a-8fe1-806422d8c9f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7e59c0d0-2654-4e1f-bed1-044266ce3687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9f683c56-89e5-47bb-8b9a-d4f635b7db3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48847cbc-2399-457a-8fe1-806422d8c9f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9f683c56-89e5-47bb-8b9a-d4f635b7db3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_52a583a7-5cba-4df2-b722-8c10357b6b40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48847cbc-2399-457a-8fe1-806422d8c9f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_52a583a7-5cba-4df2-b722-8c10357b6b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_910468ba-83dc-426c-9989-57f36ac766b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48847cbc-2399-457a-8fe1-806422d8c9f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_910468ba-83dc-426c-9989-57f36ac766b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4bdf046c-b7c1-4524-bf4e-14b4634d057e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48847cbc-2399-457a-8fe1-806422d8c9f9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4bdf046c-b7c1-4524-bf4e-14b4634d057e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a5c386d-c58a-4ed8-8965-c98ff8859b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45f5d055-43fa-40e1-bfd3-5198bd1d0268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a5c386d-c58a-4ed8-8965-c98ff8859b2b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45f5d055-43fa-40e1-bfd3-5198bd1d0268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4717a25d-b3cd-4e38-98ba-d5ce34ab04c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45f5d055-43fa-40e1-bfd3-5198bd1d0268" xlink:to="loc_us-gaap_PlanNameAxis_4717a25d-b3cd-4e38-98ba-d5ce34ab04c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2f49080a-ea75-425a-af41-5cd48e5dd910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4717a25d-b3cd-4e38-98ba-d5ce34ab04c0" xlink:to="loc_us-gaap_PlanNameDomain_2f49080a-ea75-425a-af41-5cd48e5dd910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_4f3a4454-f312-4780-aefa-b25b183520fa" xlink:href="exdx-20210331.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2f49080a-ea75-425a-af41-5cd48e5dd910" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_4f3a4454-f312-4780-aefa-b25b183520fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_072d08d1-93f4-4ac5-8b29-f7041c0998ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45f5d055-43fa-40e1-bfd3-5198bd1d0268" xlink:to="loc_us-gaap_AwardTypeAxis_072d08d1-93f4-4ac5-8b29-f7041c0998ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b329f750-c870-48a4-a206-405f2a37b546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_072d08d1-93f4-4ac5-8b29-f7041c0998ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b329f750-c870-48a4-a206-405f2a37b546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b42d5bb7-25cc-45d1-a05c-c030673dee55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b329f750-c870-48a4-a206-405f2a37b546" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b42d5bb7-25cc-45d1-a05c-c030673dee55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e914fc13-31b1-42da-8942-fe5651f3d4a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b329f750-c870-48a4-a206-405f2a37b546" xlink:to="loc_us-gaap_EmployeeStockMember_e914fc13-31b1-42da-8942-fe5651f3d4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_902a7dd8-d016-4911-9e17-aa4adbc8e4b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b329f750-c870-48a4-a206-405f2a37b546" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_902a7dd8-d016-4911-9e17-aa4adbc8e4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45f5d055-43fa-40e1-bfd3-5198bd1d0268" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_849e2e24-f906-4ce2-8672-a6cf004a3b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_849e2e24-f906-4ce2-8672-a6cf004a3b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_254faa9b-3981-495a-af2a-79937e12a70d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_254faa9b-3981-495a-af2a-79937e12a70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5d6e913-ed4a-4820-b95f-a0c3b04eea1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5d6e913-ed4a-4820-b95f-a0c3b04eea1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_51a25402-38b8-43d1-a6e7-a275ca4f7d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_51a25402-38b8-43d1-a6e7-a275ca4f7d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62e1c759-2aba-435b-9593-8ec7b33a6a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62e1c759-2aba-435b-9593-8ec7b33a6a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b08cc5e-1165-4068-bb41-790312cd4c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b08cc5e-1165-4068-bb41-790312cd4c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f73b8ea-4658-4ed7-ab4b-dc20a22a1591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f73b8ea-4658-4ed7-ab4b-dc20a22a1591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e24fe90-9c71-46a0-afaf-28df9ca3b16d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ef8a50a-8c86-4e3e-99dd-bc74e996c03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e24fe90-9c71-46a0-afaf-28df9ca3b16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00d9c0c0-646e-4cac-a0ef-2c712ebf3ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80b9feb-3449-40b0-8101-d47f7918e43d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00d9c0c0-646e-4cac-a0ef-2c712ebf3ab7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80b9feb-3449-40b0-8101-d47f7918e43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4629ecc3-ab74-49fa-b136-de8825066981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80b9feb-3449-40b0-8101-d47f7918e43d" xlink:to="loc_us-gaap_AwardTypeAxis_4629ecc3-ab74-49fa-b136-de8825066981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f451c903-72c7-468a-9a46-53749b2d42ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4629ecc3-ab74-49fa-b136-de8825066981" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f451c903-72c7-468a-9a46-53749b2d42ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9e3c74da-ff79-4cc4-b0ae-799e9b8e82ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f451c903-72c7-468a-9a46-53749b2d42ec" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9e3c74da-ff79-4cc4-b0ae-799e9b8e82ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80b9feb-3449-40b0-8101-d47f7918e43d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9cd8eaf2-a12e-4c5a-bd41-226c2d637933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9cd8eaf2-a12e-4c5a-bd41-226c2d637933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_334d3483-cc3c-4213-a848-b87432bd1808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_334d3483-cc3c-4213-a848-b87432bd1808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9f4aee95-0e41-4ec7-8f2b-f883146f3b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9f4aee95-0e41-4ec7-8f2b-f883146f3b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_dbcf561d-7fbc-48aa-9314-5fa99a1f2133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_dbcf561d-7fbc-48aa-9314-5fa99a1f2133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_113fbe25-8a49-4f00-9f13-f7cc7526e2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_113fbe25-8a49-4f00-9f13-f7cc7526e2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_84911549-fe43-4b50-9fb8-1a7aa61d0893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4d9a562b-51b4-4bfc-8742-17eebe4926cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_84911549-fe43-4b50-9fb8-1a7aa61d0893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e0078158-b6ab-44d3-8acc-9c218a55b048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e0078158-b6ab-44d3-8acc-9c218a55b048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5dceeda2-35e6-4da3-8bea-2e871e70a938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5dceeda2-35e6-4da3-8bea-2e871e70a938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b597449b-f7cd-4a84-8ee9-b33b5607fe48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b597449b-f7cd-4a84-8ee9-b33b5607fe48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5496591b-8bc1-48ae-9f0c-ded3c1da7149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5496591b-8bc1-48ae-9f0c-ded3c1da7149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_793274c3-96a4-49f6-b5de-fa4262b337be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_793274c3-96a4-49f6-b5de-fa4262b337be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0da8c531-ae29-4df7-aae1-04c8e2d0b8ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cad6d8c-0805-41d4-a5c3-9e63d4b37a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0da8c531-ae29-4df7-aae1-04c8e2d0b8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_26dbc36d-5d2b-419f-853f-db010effa121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_26dbc36d-5d2b-419f-853f-db010effa121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_357195ea-21b2-4287-8c7a-926fa14b4a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_357195ea-21b2-4287-8c7a-926fa14b4a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1d6885fb-76d6-4555-9431-f64119bf02be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1d6885fb-76d6-4555-9431-f64119bf02be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dd36fd5b-1fbb-4dea-8c71-744d8429e110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dd36fd5b-1fbb-4dea-8c71-744d8429e110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a9026350-60fc-439b-86c8-0e093478b5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a9026350-60fc-439b-86c8-0e093478b5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_fffcd094-a55b-41b3-8681-9b9ce043a322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_56bbc84f-6fc4-40f1-959a-da703f645181" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_fffcd094-a55b-41b3-8681-9b9ce043a322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d5452068-6b16-490c-a4a2-41eaa55f788a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d5452068-6b16-490c-a4a2-41eaa55f788a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_b4f01ba1-48de-4443-a9ac-613ad3170ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_b4f01ba1-48de-4443-a9ac-613ad3170ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_546d50d6-b9e4-409d-9f3d-2a28f6ea8b26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_546d50d6-b9e4-409d-9f3d-2a28f6ea8b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1d4b4aee-125a-42e5-a2ce-336d840a7330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7350f892-96f3-4dba-921a-0f7189f318ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1d4b4aee-125a-42e5-a2ce-336d840a7330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_190cd29e-5b52-43d2-910c-a7753a5b6d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0025d20-a46f-4b00-b33b-544e3d4420f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_190cd29e-5b52-43d2-910c-a7753a5b6d6d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0025d20-a46f-4b00-b33b-544e3d4420f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ef948970-d091-4704-86a2-c08b4faa4a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0025d20-a46f-4b00-b33b-544e3d4420f8" xlink:to="loc_us-gaap_AwardTypeAxis_ef948970-d091-4704-86a2-c08b4faa4a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_168e6aec-62b0-4d10-a300-d071bc810437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ef948970-d091-4704-86a2-c08b4faa4a84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_168e6aec-62b0-4d10-a300-d071bc810437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0f9c3dcb-4b92-47b9-b530-8ce0980e9bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_168e6aec-62b0-4d10-a300-d071bc810437" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0f9c3dcb-4b92-47b9-b530-8ce0980e9bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac9f7d2b-7bbd-487a-ae30-c7c0aa3d5b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0025d20-a46f-4b00-b33b-544e3d4420f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac9f7d2b-7bbd-487a-ae30-c7c0aa3d5b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac9f7d2b-7bbd-487a-ae30-c7c0aa3d5b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c4950569-f9b3-47bf-951f-bffac538504b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c4950569-f9b3-47bf-951f-bffac538504b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_988c7e09-cbc9-491d-b142-0d432531cd16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_988c7e09-cbc9-491d-b142-0d432531cd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b5cbdfd0-3442-4ee6-aa80-a08d6fbe1599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b5cbdfd0-3442-4ee6-aa80-a08d6fbe1599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1d9db37f-8b68-4de4-8d0b-4707daf9ddb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1d9db37f-8b68-4de4-8d0b-4707daf9ddb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_97fc83dd-ec0f-4d82-80da-90aec6769b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c062821d-8a59-4bbe-b3d9-6a286c3fdf18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_97fc83dd-ec0f-4d82-80da-90aec6769b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac9f7d2b-7bbd-487a-ae30-c7c0aa3d5b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a10e3710-281a-4616-8a80-cf3bfde7a7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a10e3710-281a-4616-8a80-cf3bfde7a7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e369fbe5-9a8b-4abe-8f88-823467ea97fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e369fbe5-9a8b-4abe-8f88-823467ea97fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ef57d1a5-6660-4657-a7f3-1c1dffc77c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ef57d1a5-6660-4657-a7f3-1c1dffc77c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3f360d86-3428-4515-bdf2-0fea91b4a6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3f360d86-3428-4515-bdf2-0fea91b4a6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8e039f3c-da4d-460d-a4cf-45869d945af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b8726e02-8734-4aab-95a9-b01656f8a49f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8e039f3c-da4d-460d-a4cf-45869d945af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_1c776417-6448-4795-8492-e65a8d2a9128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac9f7d2b-7bbd-487a-ae30-c7c0aa3d5b1c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_1c776417-6448-4795-8492-e65a8d2a9128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_671e2be1-949d-43ad-8427-4e35b98d05ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_1c776417-6448-4795-8492-e65a8d2a9128" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_671e2be1-949d-43ad-8427-4e35b98d05ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_439dd02f-2956-435c-b2e7-58eeb6e99f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1b3bfc5-09e2-462a-8768-d3f9abd05312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_439dd02f-2956-435c-b2e7-58eeb6e99f89" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1b3bfc5-09e2-462a-8768-d3f9abd05312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8e36805b-4608-4d82-9260-36149e3576d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1b3bfc5-09e2-462a-8768-d3f9abd05312" xlink:to="loc_us-gaap_AwardTypeAxis_8e36805b-4608-4d82-9260-36149e3576d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_341f3f0d-148e-48ef-8f6f-b0654c1263e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8e36805b-4608-4d82-9260-36149e3576d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_341f3f0d-148e-48ef-8f6f-b0654c1263e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_77567ccc-38b2-4b04-8891-95e43e4cd684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_341f3f0d-148e-48ef-8f6f-b0654c1263e1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_77567ccc-38b2-4b04-8891-95e43e4cd684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7fc244bb-3f36-4777-aa5e-b4d2bd1af333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_341f3f0d-148e-48ef-8f6f-b0654c1263e1" xlink:to="loc_us-gaap_EmployeeStockMember_7fc244bb-3f36-4777-aa5e-b4d2bd1af333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1b3bfc5-09e2-462a-8768-d3f9abd05312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dabc1a5b-3b55-4555-9b4a-381b8d01b87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dabc1a5b-3b55-4555-9b4a-381b8d01b87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_292319bd-2560-435f-a9d9-497fec1e97ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_292319bd-2560-435f-a9d9-497fec1e97ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_83f90c14-ea6f-4868-9524-69968342df13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_83f90c14-ea6f-4868-9524-69968342df13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5f87a0ce-c1db-4c85-b6a4-90e133e18c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5f87a0ce-c1db-4c85-b6a4-90e133e18c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_099b581b-a376-42a3-8c52-73cac9143b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_099b581b-a376-42a3-8c52-73cac9143b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4cf978ce-32f3-4a90-a20f-8309c9da7aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4cf978ce-32f3-4a90-a20f-8309c9da7aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5f508da9-9d3d-4f57-bfcd-57f48c757621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5f508da9-9d3d-4f57-bfcd-57f48c757621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fd79fda2-2c4e-4770-8667-c5f2453e275b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_185a5793-dadc-4c4c-b4b1-3998eb013f90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fd79fda2-2c4e-4770-8667-c5f2453e275b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20210331.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_699a9dcc-8541-4531-b40d-4d0242f86bce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05d98d30-dead-4e25-bb10-f4d039818fba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_699a9dcc-8541-4531-b40d-4d0242f86bce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05d98d30-dead-4e25-bb10-f4d039818fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_760662bd-0260-4728-9b2d-332c5eac5054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05d98d30-dead-4e25-bb10-f4d039818fba" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_760662bd-0260-4728-9b2d-332c5eac5054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_18ee7456-3714-437d-a15f-318f458e6d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_760662bd-0260-4728-9b2d-332c5eac5054" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_18ee7456-3714-437d-a15f-318f458e6d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d3d804ce-a4d2-4850-8365-ecd75c48f392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_18ee7456-3714-437d-a15f-318f458e6d3c" xlink:to="loc_us-gaap_CostOfSalesMember_d3d804ce-a4d2-4850-8365-ecd75c48f392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22a6879a-be32-40a4-b99b-ab08616f8cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_18ee7456-3714-437d-a15f-318f458e6d3c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_22a6879a-be32-40a4-b99b-ab08616f8cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9cfcfd34-2086-47e3-a047-b65e2a76fd0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_18ee7456-3714-437d-a15f-318f458e6d3c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9cfcfd34-2086-47e3-a047-b65e2a76fd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f7655c-f8d1-47d5-a1a4-ccec9a47e511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05d98d30-dead-4e25-bb10-f4d039818fba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f7655c-f8d1-47d5-a1a4-ccec9a47e511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4296aca2-7b28-48de-aa6c-55ef9f4b1cdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3f7655c-f8d1-47d5-a1a4-ccec9a47e511" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4296aca2-7b28-48de-aa6c-55ef9f4b1cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19" xlink:type="simple" xlink:href="exdx-20210331.xsd#Covid19"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Covid19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReorganizationsAbstract_57e11e8b-f696-4c74-86ff-115f5b029a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReorganizationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_9c6d9bda-ee36-421f-9907-4c7b4802b071" xlink:href="exdx-20210331.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReorganizationsAbstract_57e11e8b-f696-4c74-86ff-115f5b029a04" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_9c6d9bda-ee36-421f-9907-4c7b4802b071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19Details" xlink:type="simple" xlink:href="exdx-20210331.xsd#Covid19Details"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Covid19Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReorganizationsAbstract_a41cccad-8252-4ba7-b333-d1185a5f70c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReorganizationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_c1574774-6007-4d8c-bbfd-4a6428a0e9da" xlink:href="exdx-20210331.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReorganizationsAbstract_a41cccad-8252-4ba7-b333-d1185a5f70c6" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_c1574774-6007-4d8c-bbfd-4a6428a0e9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_5b7193fc-9f5e-4e2f-9651-90b6d8258a46" xlink:href="exdx-20210331.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReorganizationsAbstract_a41cccad-8252-4ba7-b333-d1185a5f70c6" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_5b7193fc-9f5e-4e2f-9651-90b6d8258a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>exdx-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:exdx="http://www.exagen.com/20210331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exdx-20210331.xsd" xlink:type="simple"/>
    <context id="ib3192990da444100b6eb7449a48628b2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ide9030e76ecf4a9fba67cf057c17afba_I20210507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-05-07</instant>
        </period>
    </context>
    <context id="idc581bdd73dd4021b430c6ee34ea7187_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i74dfc75aad9542dabc25c6d61005effa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7cbaa66b7be7474ab7a46aa220c8660a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34cf1017273f4604809f912f8b657925_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i339ea458049d4a5487ec4a446348117a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6378bff170144726a0783fd0bb36c1bb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7d7ae133aa7d4c2ca916c1a2f5aaeacb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i982e06fc73cd4df1b2177274c2d432e5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i57d8609b6a10413a832521fbe6add4c6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i89ffb13c1b9d4b6c8256e8e5e1dcd383_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6df3369140bd4cb9a9d5f8e91adac83e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie0bf96da109947f599efed58bc0f90d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib0c6212cfa0f4ad388b89fa71d8bc8c3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icce72bac87624a92bdbfc5d01d2d86c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1b221cae4dee43a2acc22fa21886929f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i504e33597e674687b5ef22eca9e130d4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i967f443c3ab8444dbe967bcd6f7b5174_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib9a4e45c10a54a7a992104de496d6574_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia14ddb9d17de4c8eb2f62cc86eb0451f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ieaa8db75f5344e35b666cc34a12c7d9e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3322be77d6de4025839cac63f86f0243_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5194501b750d4090955a5e16b78c217c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0fc61924d3f34ca4bab8516c11208885_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia7ac61c025c245af88e7397f61447e69_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i21d9452d5c4c42f9bb942373684d2e42_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i834f47585cfe4c7d8a215294b1923d36_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1f3ffd1dd835435c94a893df6356b1b1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i187e453a33374a7797711f58bcc14b7f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie8a62a0ccfd34fca91b61d270f96dbfd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i65a7a857be764806adc1eb00dcc35517_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id13f474ddf0d441ba77566815923f88a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i782e358e46694beb9624e9aa3ed858ea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i701b3c86d5b74909bf2e8bf593384649_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c299e56192b4127a3e3d90a1847d6f1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i023127e7d06344128078f124e3501be0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4184a1eb75de41ce9509149528c2c0aa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia721771017024f3f9f0c91f7b23abe19_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i14c0363cf9954703ba1f808170614d1e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iae6bedc762044534a4143ad3d0409cf0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1454a0a0df9044c6b9f918a3859fbdb2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i77ab1dd3b4a245ce9165116eabdb5ff9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i76abec2d56de47129071a1dd6c7b2acb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1509c8e8724f4915b96a65425f3d99ee_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i905e56813efc44a0997851f5274917d7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie2d9d310c7f94750b20d74e6de87c94a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1c286444d4974baf83c59a97267301ea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if67771cd955c4c85bf332d7c2b0097d8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1dd0a205cd3249ccb82b12ae5f6c2929_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="ic2ef52e13fcc4ac290fb3f3f17fc1d8e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib134284be93446ceb5f659fddbb92851_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic717b41edf9f4ff48d0b9b2e8087ccf9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i035a93a2bf2f4d91913f3d26706f1810_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3f2c6ac308c4ed4a5dac4b72e609986_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i00bf9e1bcaa041139ea4e7b5f25c4a6e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iccf1ab5f053e4f769295776a4596ca23_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4bc7c41756524ddd9cc16ef0ee800e1b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia8c4a64accf64f4e8d3c6f1c85c45656_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i545c29e8f1ac444a9fd4436eb738bd53_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie01b6015e94e40b18dbc9c1af60a487e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i51b7dc429b4b47a4a086f500297ae4f5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i83c36c4109874e448199eb8e55ebd4dc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id50b7c2e8d494f8c946e330ed5574198_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if8a1bd4a29ec4f84888bbc4981057e5b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib8a1d1023b6a4f4db7161e28f63e8578_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib430868217a64c48beccdf7a906cd385_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i56ebd098dbb0414199e0a1f304311104_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2ed20d5e060644a197e27c3b20c2b130_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ide582e20a1564092a1d4f74f3cce4c9c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9e1e4c97623d4b02a76aab4a8cd9dfc1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icc9a7f02a64d485784bba6b218e085da_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib68a12746a0a43778d411a0e71f850e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e89c10b517a40da817bf9dd7fadec65_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if96214d4c6e24fdb959ba168df6a8af4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i718a9b57c44f43859f8f20ce6569fbb6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i87b062212901454892bd5210a1dbcd07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4a67b72dfa84dba92b35b0b41b493e2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if0e64a9b4c5140059a5acbc43d92843a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84fefc5a1ec94437b3ba22e7b5a8b9da_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ieeea39a95a634c1f8fae5c44cf640d7a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea8e8125271042c2bd42020d228a5c4b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7261f22c88a04977b74b69ed970fe446_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49816a32de1a4847a965a660b298f0a0_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i79bb007a0e4b4e11ad37da79ccacc407_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:CapitalRoyaltyPartnersIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i9225dd725d3041c3897811c47544cbeb_D20181207-20181207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-07</startDate>
            <endDate>2018-12-07</endDate>
        </period>
    </context>
    <context id="ic99585e2b612446894f42dbc14e98bc3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i62c7962700564e34b08a1b062a8fb73a_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="ifd4d54f913db46d989b313ea1cf7787b_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i9517d690925b44e1b66094ac282a2fb8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6a1d3210812c4ec99a01bc62b58c261b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iffe724be62e54f5e98c97114c1b16b4c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibb1da3cc014a47988102c4a5fbfcdf4a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie5600c9592fb46b690a5bc52e4c34fc2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i786adb20b67b40bfb36498bdace13f68_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibef5d76e001f48ab9c9f255b50909153_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i51edebd2dc964c65960284e7a29563ad_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifc8c434620fc4d7fa5e5804d5459e9c8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9300102ead9949fa9aa89415fe805f2a_D20210401-20210511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-05-11</endDate>
        </period>
    </context>
    <context id="i526a9a0b5afe4cc1874bdb70a537e2e7_D20210401-20210511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-05-11</endDate>
        </period>
    </context>
    <context id="ibf438e067e0e490e8bd11c8a8dfb7428_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if7d19acf05fd481bbbf64336028dc9c3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7c9e78b389424e3ba420f778fc2889d9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4d467b35645c46a0bc2317ac4c2edca0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icf259d6549974c23a1e93dd4e55b13cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97ff3388db6d405984fbd5a85da92d27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f9e0cbbdb764f8195a783d55722eb00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98fb6a4c5e334327ad489b104eeff646_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2fe73e79f1c549a483f3917d929c8e40_D20201110-20201110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-10</startDate>
            <endDate>2020-11-10</endDate>
        </period>
    </context>
    <context id="icc1bb719e1074fdebd679404c35cd358_D20210325-20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="i74ff8c067c394119ba0c56e9d82ededc_I20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="i7c19a7a2bfad4edd8ddd7b2557ae3114_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i350d91760ddf4160af25d20cd8d9b448_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iafc3772ba3454fac8749b13340ee0e47_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaea87b8242ef4b51bfab54bca764763b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i246430710e7b464984f4d6c04203b925_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifb31a3a85da44447bf660e6e7ba47571_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2c847c7e24b747288c96c2df35a0d98f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9740e39188bc48939564a399602a85af_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i205b83f91058431aacdac5b60d121b3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f7571bc1a6842eea4966067cef12287_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if56d5f147a234f47a5c286cd55a8ab8d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i74e686b941754a318cfceeff5fffc858_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb431306073e41619a17523f2b2e4c23_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2b8c82dfa9c441afb9faca3a14a0e8c3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0c0b8637038f4e0485961f9c7baa5391_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2512bb71fe984f9f8a14d808494366bf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id44b1e4210bc4a58b1886b02e42edda2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i05daa2aed2c447f9b2aaf190a27f3d81_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i713b0e54a4ca43bfb3140d1b4aff6cd1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i414d38c16c134af097eb843d3bb15bc4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icbf102bb294e439ca5afd862c3fe6335_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="unit">
        <measure>exdx:unit</measure>
    </unit>
    <unit id="segment">
        <measure>exdx:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80L2ZyYWc6ZTAyNWI3YjgxMGE0NGU1OGFmOGY2NDYwOTdiYmY2NGYvdGFibGU6NGU1YTI1M2JkNDRkNDU1OGEzYjJkNDYyOGZiMjI3YjQvdGFibGVyYW5nZTo0ZTVhMjUzYmQ0NGQ0NTU4YTNiMmQ0NjI4ZmIyMjdiNF8zLTEtMS0xLTA_e717c702-7d49-4370-9d82-52afe57f170c">0001274737</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80L2ZyYWc6ZTAyNWI3YjgxMGE0NGU1OGFmOGY2NDYwOTdiYmY2NGYvdGFibGU6NGU1YTI1M2JkNDRkNDU1OGEzYjJkNDYyOGZiMjI3YjQvdGFibGVyYW5nZTo0ZTVhMjUzYmQ0NGQ0NTU4YTNiMmQ0NjI4ZmIyMjdiNF80LTEtMS0xLTA_b67796b5-53c0-404f-b322-d15cdeb645ea">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80L2ZyYWc6ZTAyNWI3YjgxMGE0NGU1OGFmOGY2NDYwOTdiYmY2NGYvdGFibGU6NGU1YTI1M2JkNDRkNDU1OGEzYjJkNDYyOGZiMjI3YjQvdGFibGVyYW5nZTo0ZTVhMjUzYmQ0NGQ0NTU4YTNiMmQ0NjI4ZmIyMjdiNF81LTEtMS0xLTA_d10c9814-b41f-46f0-851f-3b4cbd767535">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80L2ZyYWc6ZTAyNWI3YjgxMGE0NGU1OGFmOGY2NDYwOTdiYmY2NGYvdGFibGU6NGU1YTI1M2JkNDRkNDU1OGEzYjJkNDYyOGZiMjI3YjQvdGFibGVyYW5nZTo0ZTVhMjUzYmQ0NGQ0NTU4YTNiMmQ0NjI4ZmIyMjdiNF82LTEtMS0xLTA_80eb3699-770c-40b9-95f1-d168f20d9d51">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80L2ZyYWc6ZTAyNWI3YjgxMGE0NGU1OGFmOGY2NDYwOTdiYmY2NGYvdGFibGU6NGU1YTI1M2JkNDRkNDU1OGEzYjJkNDYyOGZiMjI3YjQvdGFibGVyYW5nZTo0ZTVhMjUzYmQ0NGQ0NTU4YTNiMmQ0NjI4ZmIyMjdiNF83LTEtMS0xLTA_747005f5-9958-4c8f-8db8-749b6b600710">false</dei:AmendmentFlag>
    <us-gaap:DebtInstrumentTerm
      contextRef="ifd4d54f913db46d989b313ea1cf7787b_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTExOQ_943420c3-685f-4155-98c0-99295e2c5baa">P24M</us-gaap:DebtInstrumentTerm>
    <dei:DocumentType
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M184NA_1f0b1f23-6999-4d7a-aeb7-9f9f7b89e010">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6ZWE1OWE5M2E5YTYwNDQ4MThmY2NlYzBkZWIzZTA1MzMvdGFibGVyYW5nZTplYTU5YTkzYTlhNjA0NDgxOGZjY2VjMGRlYjNlMDUzM18wLTAtMS0xLTA_690bc495-5a8a-4954-b7c0-10630a421ea3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6ZWE1OWE5M2E5YTYwNDQ4MThmY2NlYzBkZWIzZTA1MzMvdGFibGVyYW5nZTplYTU5YTkzYTlhNjA0NDgxOGZjY2VjMGRlYjNlMDUzM18xLTAtMS0xLTAvdGV4dHJlZ2lvbjphNjY3Y2YxNGI4NmU0MDFlODg5MGU1NDBiOGFjMzNlM18zNg_74c58d09-6108-4468-b8ea-69f1c6cbc7bb">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6ZWE1OWE5M2E5YTYwNDQ4MThmY2NlYzBkZWIzZTA1MzMvdGFibGVyYW5nZTplYTU5YTkzYTlhNjA0NDgxOGZjY2VjMGRlYjNlMDUzM18yLTAtMS0xLTA_dcb20ba0-d50f-49fc-9e92-d61cf8d0799c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M18xMzA_639943c5-53b2-46bb-812b-2901597e2e03">001-39049</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M18xMzQ_a996082c-c9a1-4112-b387-19c08b85ffa1">EXAGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MTkxYWFkZDYwMGJlNGQ5M2JmNzhjZTI5MmYxZDcwODEvdGFibGVyYW5nZToxOTFhYWRkNjAwYmU0ZDkzYmY3OGNlMjkyZjFkNzA4MV8wLTAtMS0xLTA_a0b54eeb-052b-4e13-9fa1-1e1c3f1e63f9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MTkxYWFkZDYwMGJlNGQ5M2JmNzhjZTI5MmYxZDcwODEvdGFibGVyYW5nZToxOTFhYWRkNjAwYmU0ZDkzYmY3OGNlMjkyZjFkNzA4MV8wLTYtMS0xLTA_003a185d-8978-4673-9805-32c1e140e6bb">20-0434866</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MTkxYWFkZDYwMGJlNGQ5M2JmNzhjZTI5MmYxZDcwODEvdGFibGVyYW5nZToxOTFhYWRkNjAwYmU0ZDkzYmY3OGNlMjkyZjFkNzA4MV8zLTEtMS0xLTA_353131e6-7ac9-4498-8586-1011d0e05ffa">1261 Liberty Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MTkxYWFkZDYwMGJlNGQ5M2JmNzhjZTI5MmYxZDcwODEvdGFibGVyYW5nZToxOTFhYWRkNjAwYmU0ZDkzYmY3OGNlMjkyZjFkNzA4MV80LTEtMS0xLTA_070cf835-2607-4ca3-9ca0-ae6e1908a1ed">Vista,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MTkxYWFkZDYwMGJlNGQ5M2JmNzhjZTI5MmYxZDcwODEvdGFibGVyYW5nZToxOTFhYWRkNjAwYmU0ZDkzYmY3OGNlMjkyZjFkNzA4MV80LTItMS0xLTA_e8177e15-9f1c-4628-8cb2-4d8b6762b838">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MTkxYWFkZDYwMGJlNGQ5M2JmNzhjZTI5MmYxZDcwODEvdGFibGVyYW5nZToxOTFhYWRkNjAwYmU0ZDkzYmY3OGNlMjkyZjFkNzA4MV80LTYtMS0xLTA_0147b121-72f5-4f9d-b62d-610daf4c8130">92081</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MzlmNjVmNDBiNzZiNDA5OGI2NjU5ZmYwYWM0YWE0MmEvdGFibGVyYW5nZTozOWY2NWY0MGI3NmI0MDk4YjY2NTlmZjBhYzRhYTQyYV8wLTAtMS0xLTA_e9964966-66d0-404f-81e3-ba0fee7b3ce9">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MzlmNjVmNDBiNzZiNDA5OGI2NjU5ZmYwYWM0YWE0MmEvdGFibGVyYW5nZTozOWY2NWY0MGI3NmI0MDk4YjY2NTlmZjBhYzRhYTQyYV8wLTEtMS0xLTA_f2531936-e76c-443e-b6ce-2c0d469e3b16">560-1501</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MzQ2MjRhZDk0M2ZjNGJkZGJlYjFhNzY0YzE2NzUxZjkvdGFibGVyYW5nZTozNDYyNGFkOTQzZmM0YmRkYmViMWE3NjRjMTY3NTFmOV8xLTAtMS0xLTA_48b5e9ec-0318-4d5a-90e8-9192ed835707">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MzQ2MjRhZDk0M2ZjNGJkZGJlYjFhNzY0YzE2NzUxZjkvdGFibGVyYW5nZTozNDYyNGFkOTQzZmM0YmRkYmViMWE3NjRjMTY3NTFmOV8xLTItMS0xLTA_d5657030-71be-482a-8c87-3669c53f48bf">XGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6MzQ2MjRhZDk0M2ZjNGJkZGJlYjFhNzY0YzE2NzUxZjkvdGFibGVyYW5nZTozNDYyNGFkOTQzZmM0YmRkYmViMWE3NjRjMTY3NTFmOV8xLTQtMS0xLTA_abd56325-f213-4dcc-ba85-49c41799423e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M182MDM_1b8b7f49-03a4-4b69-8451-7f6feedc40c9">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M185MDU_06495b7f-1656-4a94-bf1b-b14baa3ba892">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6Mzk1NGEzMzYzNGFjNDUxZTlhMDkwYTM3MDY2NDZkZDcvdGFibGVyYW5nZTozOTU0YTMzNjM0YWM0NTFlOWEwOTBhMzcwNjY0NmRkN18yLTAtMS0xLTA_0a395365-d1f7-4586-a01f-101a68730a42">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6Mzk1NGEzMzYzNGFjNDUxZTlhMDkwYTM3MDY2NDZkZDcvdGFibGVyYW5nZTozOTU0YTMzNjM0YWM0NTFlOWEwOTBhMzcwNjY0NmRkN18yLTQtMS0xLTA_130baf7e-3044-45df-b2c0-a790fb41fb9e">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGFibGU6Mzk1NGEzMzYzNGFjNDUxZTlhMDkwYTM3MDY2NDZkZDcvdGFibGVyYW5nZTozOTU0YTMzNjM0YWM0NTFlOWEwOTBhMzcwNjY0NmRkN180LTQtMS0xLTA_4152a543-9c56-4a33-8c0b-60555df009e1">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M18xNTM5_5e31cb8f-9ff1-417f-bd63-6a00d353610f">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M18xNjU5_a7e60e1b-6182-459e-9032-a6f2239d3b40">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ide9030e76ecf4a9fba67cf057c17afba_I20210507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xL2ZyYWc6OTI1NzM3NDZjMGViNDliMTlkNmYzNGNmMDRlZWY3NDMvdGV4dHJlZ2lvbjo5MjU3Mzc0NmMwZWI0OWIxOWQ2ZjM0Y2YwNGVlZjc0M18xNzQ2_fa8126a8-8141-4c81-a7b7-c5140a52c235"
      unitRef="shares">16928278</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNC00LTEtMS0w_035cceaa-a444-4370-b461-364bf972f22a"
      unitRef="usd">118050000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNC02LTEtMS0w_b950158c-c2df-4faf-a29b-fe0f5b5c9d28"
      unitRef="usd">57448000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNS00LTEtMS0w_5ed4fe2b-2e63-4c1d-8c70-6726c33f6516"
      unitRef="usd">8221000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNS02LTEtMS0w_e7dfe626-872a-42ef-ae1d-b9c4e78dd59c"
      unitRef="usd">8910000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNi00LTEtMS0w_1930151b-171e-4253-9c9e-879804c8be13"
      unitRef="usd">3098000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNi02LTEtMS0w_d9fc2edf-43ef-4075-ab82-bc019d23849c"
      unitRef="usd">4159000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNy00LTEtMS0w_476c5eed-39ce-4f3d-bc99-dda53d497bdc"
      unitRef="usd">129369000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfNy02LTEtMS0w_bcb29a03-9537-42aa-b6ee-25a1d2020a11"
      unitRef="usd">70517000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfOC00LTEtMS0w_48414c0e-7fb7-405f-a871-f01b080c3552"
      unitRef="usd">2378000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfOC02LTEtMS0w_ce495af6-ec56-424d-b5b7-a420fe482f6a"
      unitRef="usd">2102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfOS00LTEtMS0w_63f4a12a-6aab-4f45-858f-ea1d6b499353"
      unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfOS02LTEtMS0w_ec0f7ce8-06cf-4a1c-bb9b-0afad0c2b5b1"
      unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTAtNC0xLTEtMA_09c89d53-7089-480d-aedb-87dcce8fc43a"
      unitRef="usd">269000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTAtNi0xLTEtMA_30b7678c-3643-4f93-bc1e-80f74f9e9005"
      unitRef="usd">250000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTEtNC0xLTEtMA_40afe4cf-3382-46b6-a7b8-b8f7c1e13cf3"
      unitRef="usd">137522000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTEtNi0xLTEtMA_01f48b5f-773d-448f-9c97-ba314eefcf92"
      unitRef="usd">78375000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTQtNC0xLTEtMA_432c3b81-171f-4170-b4c9-7e3ad0fc860b"
      unitRef="usd">2170000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTQtNi0xLTEtMA_3536dbe1-853b-4aae-856d-4c2877e9a781"
      unitRef="usd">3014000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTUtNC0xLTEtMA_e192623e-d6a3-4a7a-be57-be86d6d7c52f"
      unitRef="usd">5714000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTUtNi0xLTEtMA_c7a284ef-12ac-4343-9fd9-95b8ea99d342"
      unitRef="usd">5757000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTctNC0xLTEtMA_785328a2-bf40-4cf3-bf35-cc689b61b5a4"
      unitRef="usd">7884000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTctNi0xLTEtMA_a14ea70d-5111-4f31-ae35-feb57157f576"
      unitRef="usd">8771000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTgtNC0xLTEtMA_20761bf6-c3b1-43c9-9f9e-519c81f993c9"
      unitRef="usd">26864000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMTgtNi0xLTEtMA_2159f3ad-9933-4348-9252-80676fd58226"
      unitRef="usd">26659000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjAtNC0xLTEtMA_ee95b45d-b272-40c5-aeeb-f2c44b90f5c5"
      unitRef="usd">158000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjAtNi0xLTEtMA_4a7cb1b3-4b98-406a-94e9-7038db9d4fe9"
      unitRef="usd">158000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjEtNC0xLTEtMA_e37605a4-5d02-4f56-aaf6-6c64793c4fb3"
      unitRef="usd">1146000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjEtNi0xLTEtMA_66ecb717-a151-45b3-80bd-f2ba98165f33"
      unitRef="usd">948000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjItNC0xLTEtMA_ea7033f7-e019-4683-85a3-5ca345a2dfaa"
      unitRef="usd">36052000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjItNi0xLTEtMA_980bdb73-bed9-45ea-8ff9-1c0cd6dbabe6"
      unitRef="usd">36536000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjMtNC0xLTEtMA_0476a057-413e-4b9e-9e45-3b24943014ed"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjMtNi0xLTEtMA_e2a677ac-06e5-4304-b08c-edfdd870efe8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzIx_b072b05a-9fe0-4016-98c6-ece7760de2c0"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzIx_f4ff17ec-bd43-4ddb-a5fd-5a651b4eefc1"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzM1_b736ce25-ca89-4c3e-a2f2-124e2e04fc2f"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzM1_d4834439-80a1-44fb-bb63-27c859b3697c"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzU3_1006d159-0cad-45c9-a97f-ba2b07778abb"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzU3_1327319c-c7d8-4b51-83c0-f3990e1d847d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzU3_3c4b2a3b-d842-4eed-9809-f5aad3ddd736"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjY2YWZkMzA4ZWFmMDQ2YzRhNWJiOTMzZTg2YTk2ZmIwXzU3_bb78c9a7-2e43-426b-9659-81a4c99d4203"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtNC0xLTEtMA_74c63ac8-4f8e-46df-a7a6-a7a9d4cd6a0a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjYtNi0xLTEtMA_feee8381-b6e1-4036-a861-a8348401204f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzE4_0fe55bd2-c2f4-4800-b66e-cd48c15dc9d5"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzE4_1ea3ce9f-7a15-428c-9a29-2e825af99e24"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzMy_668b541b-f843-4e17-9b39-3e2452d94686"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzMy_d54a13b9-ff81-48c9-8c94-3735ef5258af"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzgy_ede2dbd8-ec0e-4757-aa82-16ebdc4d4802"
      unitRef="shares">16925680</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzgy_f82ef43c-47e9-4b1f-be3a-77dc53993ed3"
      unitRef="shares">16925680</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzg5_144121db-23ff-459f-9512-fbe814a540ad"
      unitRef="shares">12652308</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdjMDM2ZWY2ZDFiOTQxZDNhODY4YzUwNTk5MGI5ZDJiXzg5_e11352c8-346c-4edc-bc09-97729922c23a"
      unitRef="shares">12652308</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctNC0xLTEtMA_c2c2745e-8c62-4f09-90cc-7fc62608e651"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjctNi0xLTEtMA_557919f9-3f5f-4318-9458-ce068ef4db81"
      unitRef="usd">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjgtNC0xLTEtMA_c91be3bb-30a4-45be-910f-10b2dff5e918"
      unitRef="usd">288951000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjgtNi0xLTEtMA_d64af3ee-c0cb-4cd0-bc3a-a0a63de8071b"
      unitRef="usd">223115000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjktNC0xLTEtMA_ba894114-d769-41de-abf6-6155531050ec"
      unitRef="usd">-187498000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMjktNi0xLTEtMA_d59cb93b-03c0-4ef4-966c-66ba05917062"
      unitRef="usd">-181289000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMzAtNC0xLTEtMA_5b4c7c48-3d1d-41c5-88b5-7a5c62559516"
      unitRef="usd">101470000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMzAtNi0xLTEtMA_23568b4b-6167-401e-bcbc-ac8a3d2e1b5b"
      unitRef="usd">41839000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMzEtNC0xLTEtMA_828e2a6a-26f5-4dbd-822e-98955cfabca5"
      unitRef="usd">137522000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xNi9mcmFnOjlkYTUwY2VkYTc2MzQ4NGM4MTZkNWEwZjc4NDgwMzdiL3RhYmxlOmY2ODdlYjk3OTNhNDQ0ZDRhMzkzYjQ1OTlkYmI2YTJkL3RhYmxlcmFuZ2U6ZjY4N2ViOTc5M2E0NDRkNGEzOTNiNDU5OWRiYjZhMmRfMzEtNi0xLTEtMA_d1419be9-e907-4119-892f-0763595ff650"
      unitRef="usd">78375000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMy0yLTEtMS0w_221a90dc-f389-433c-9c4a-9e48c0b1be97"
      unitRef="usd">10587000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMy00LTEtMS0w_49300834-081e-4bdf-a025-7b87cb876fcb"
      unitRef="usd">9584000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfNS0yLTEtMS0w_b0defe58-a964-443b-b986-1c0636030620"
      unitRef="usd">4711000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfNS00LTEtMS0w_1eadd5cb-305f-472e-8ec0-03d002bc5084"
      unitRef="usd">4545000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfNi0yLTEtMS0w_e5c80890-ba1b-4d4b-98c1-2ae0259440eb"
      unitRef="usd">10040000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfNi00LTEtMS0w_391961fa-b8c6-4533-97d8-de3900d54c84"
      unitRef="usd">9626000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfNy0yLTEtMS0w_98bbe8cc-e312-41bd-a94c-1e9a542a394d"
      unitRef="usd">1403000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfNy00LTEtMS0w_bc20b943-fc7e-4189-be73-6e54cebd1c8f"
      unitRef="usd">634000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTAtMi0xLTEtMA_39998fd9-5bd7-4fbc-b2ec-650f6b2b7aea"
      unitRef="usd">16154000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTAtNC0xLTEtMA_991a6d97-31a7-4f86-9f0b-3419185835e0"
      unitRef="usd">14805000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTEtMi0xLTEtMA_9ebdba5f-27a9-4da4-8211-c12815f8be13"
      unitRef="usd">-5567000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTEtNC0xLTEtMA_655f025c-13d7-4911-be5b-ad7e263ebf92"
      unitRef="usd">-5221000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTItMi0xLTEtMA_b34220b1-ee91-4570-874f-34b134211be8"
      unitRef="usd">645000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTItNC0xLTEtMA_be0097da-762b-4343-9de3-b7d4f21136ba"
      unitRef="usd">631000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTQtMi0xLTEtMA_55379f09-b07f-408c-8b68-1a3068937d96"
      unitRef="usd">3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTQtNC0xLTEtMA_027991b9-4b06-42e4-8a7e-224e44c0e20b"
      unitRef="usd">171000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTUtMi0xLTEtMA_4c7831ee-0abd-4862-a9e4-dfadbaf13d61"
      unitRef="usd">-6209000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTUtNC0xLTEtMA_641dcda2-1554-4a0d-b54a-cb3990bd8585"
      unitRef="usd">-5681000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTYtMi0xLTEtMA_36ae5d1a-0ebb-4311-9196-615822d3e8ec"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTYtNC0xLTEtMA_7b1fe556-34fe-4083-a5a4-5f5aed1e1619"
      unitRef="usd">-118000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTctMi0xLTEtMA_856e0317-479f-48e9-87bf-3adbd8ec92e3"
      unitRef="usd">-6209000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMTctNC0xLTEtMA_90bb43f7-707d-409b-bdcb-bcdb6bccabec"
      unitRef="usd">-5563000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMjEtMi0xLTEtMA_2e97007c-d247-4dd6-9ffa-11480f4ac4fe"
      unitRef="usdPerShare">-0.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMjEtNC0xLTEtMA_fdfe049b-57de-48aa-9c27-9d769d27950a"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMjItMi0xLTEtMA_fc8d6154-7d8b-4a79-9a44-3f8fd6f5f237"
      unitRef="shares">12943237</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8xOS9mcmFnOjIwMjgyMDRiOTQ0YzRjMjNhYTBmODg1ZTFmY2JjZGZiL3RhYmxlOmZkZGE2NWExMjQ1ZTRjZjViYjg4OWNiOGI3OGExMTU4L3RhYmxlcmFuZ2U6ZmRkYTY1YTEyNDVlNGNmNWJiODg5Y2I4Yjc4YTExNThfMjItNC0xLTEtMA_5e0fb54c-882d-4e91-a9c3-f2a5322af466"
      unitRef="shares">12595715</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7cbaa66b7be7474ab7a46aa220c8660a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMi0yLTEtMS0zNA_bf5ccd06-33f7-4c0e-a7cb-5a4689c050a1"
      unitRef="shares">12652308</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7cbaa66b7be7474ab7a46aa220c8660a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMi00LTEtMS0zNA_6fe012b2-c16a-4e21-8801-1bac39d49ca7"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34cf1017273f4604809f912f8b657925_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMi02LTEtMS0zNA_7d37ccb4-91a2-4b8c-934a-85e6e706797c"
      unitRef="usd">223115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i339ea458049d4a5487ec4a446348117a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMi04LTEtMS0zNA_1bf90445-b2b4-4f22-a643-f2ad391ead6c"
      unitRef="usd">-181289000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMi0xMC0xLTEtMzQ_85ced39d-9fa9-4fed-9cd3-31d8f9ac1f24"
      unitRef="usd">41839000</us-gaap:StockholdersEquity>
    <exdx:StockIssuanceCosts
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy0wLTEtMS0xNjg4L3RleHRyZWdpb246NjMyOTIxYjU4MjgxNDUwNDg5Y2ZhMThmYTQ2ZWEyMWJfMTA5OTUxMTYyNzg1MQ_d02ae006-3c56-4a50-a3a8-5ed290f635d0"
      unitRef="usd">4435000</exdx:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6378bff170144726a0783fd0bb36c1bb_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy0yLTEtMS0zNjc_920a5a87-b14e-4be7-a9a0-80270362234f"
      unitRef="shares">4255000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6378bff170144726a0783fd0bb36c1bb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy00LTEtMS0zNzE_d210a31b-8b50-418d-8565-a47deb0be9d1"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7d7ae133aa7d4c2ca916c1a2f5aaeacb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy02LTEtMS0zNzU_5b41726d-6003-423a-b2a5-f3dcbb437dd7"
      unitRef="usd">64705000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy0xMC0xLTEtNjU_b0881b39-9e3f-4cb1-b96d-0b6c7005d73b"
      unitRef="usd">64709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6378bff170144726a0783fd0bb36c1bb_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy0yLTEtMS0zNA_988e0e0e-61e3-4e13-83c5-6864a4f34df1"
      unitRef="shares">3381</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7d7ae133aa7d4c2ca916c1a2f5aaeacb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy02LTEtMS0zNA_673eae83-5774-45a0-8bc1-26b758f81113"
      unitRef="usd">44000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfMy0xMC0xLTEtMzQ_e539e9d6-6b30-48b3-bcc5-da7e21f53e13"
      unitRef="usd">44000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i6378bff170144726a0783fd0bb36c1bb_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNS0yLTEtMS0zNjc_664af82e-7b7e-4774-874e-c628ae9f4b5d"
      unitRef="shares">14991</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7d7ae133aa7d4c2ca916c1a2f5aaeacb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNS02LTEtMS0zNzU_501a67ae-a238-47a2-b202-3fb9f14c1644"
      unitRef="usd">175000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNS0xMC0xLTEtNjU_773840be-34a4-4c3b-aa24-d5d102da6b03"
      unitRef="usd">175000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7d7ae133aa7d4c2ca916c1a2f5aaeacb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNC02LTEtMS0zNA_6aa18692-9852-49aa-bbe7-449fca1ce86f"
      unitRef="usd">912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNC0xMC0xLTEtMzQ_740f18d1-a908-4736-ac84-35939c7d2317"
      unitRef="usd">912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i982e06fc73cd4df1b2177274c2d432e5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNi04LTEtMS0zNA_71cc7c63-7291-45eb-b204-c9d7b50a8a09"
      unitRef="usd">-6209000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNi0xMC0xLTEtMzQ_821de086-11a8-4fb7-b32e-a0107e509fe3"
      unitRef="usd">-6209000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i57d8609b6a10413a832521fbe6add4c6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNy0yLTEtMS0zNA_dc2468c3-b6ba-4cfa-8ce1-0ab50f2ed361"
      unitRef="shares">16925680</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i57d8609b6a10413a832521fbe6add4c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNy00LTEtMS0zNA_6629414f-2713-4e01-8c29-8eb755a453e5"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i89ffb13c1b9d4b6c8256e8e5e1dcd383_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNy02LTEtMS0zNA_83e6c2e1-e751-438b-9083-591165ead299"
      unitRef="usd">288951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6df3369140bd4cb9a9d5f8e91adac83e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNy04LTEtMS0zNA_c4e2bb4b-1e69-4e31-b15f-1b8835bb10ee"
      unitRef="usd">-187498000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjcxMzQ0NDlkM2UxZjQ5YTY4YmMzNjE4NWM5MGYyZmRjL3RhYmxlcmFuZ2U6NzEzNDQ0OWQzZTFmNDlhNjhiYzM2MTg1YzkwZjJmZGNfNy0xMC0xLTEtMzQ_e799f309-1677-4ef3-81cc-404b261cbdb9"
      unitRef="usd">101470000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie0bf96da109947f599efed58bc0f90d9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMi0yLTEtMS0w_0a59b7e2-6d59-495b-b519-35b94fc4eef4"
      unitRef="shares">12560990</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie0bf96da109947f599efed58bc0f90d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMi00LTEtMS0w_59b636c8-9a4e-4613-ba3a-1d79ce381e8e"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib0c6212cfa0f4ad388b89fa71d8bc8c3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMi02LTEtMS0w_29394b68-229d-4587-a48b-9c3de1845154"
      unitRef="usd">220248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icce72bac87624a92bdbfc5d01d2d86c1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMi04LTEtMS0w_004d66a5-c65c-4571-b047-a1e2d29c5b7a"
      unitRef="usd">-164602000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1b221cae4dee43a2acc22fa21886929f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMi0xMC0xLTEtMA_06d038c3-0586-4cb0-80d9-ed897f1ead97"
      unitRef="usd">55659000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i504e33597e674687b5ef22eca9e130d4_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMy0yLTEtMS0w_ba624ab7-a040-4ec3-940d-115336440f7d"
      unitRef="shares">43700</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i967f443c3ab8444dbe967bcd6f7b5174_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMy02LTEtMS0w_70899d7c-9ce1-4373-989e-089192325fee"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfMy0xMC0xLTEtMA_4fb32fc0-c4e4-4bf7-9891-e2aa18d35f5f"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i967f443c3ab8444dbe967bcd6f7b5174_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNC02LTEtMS0w_b38d59a1-a3fd-4792-a171-9f49befd2de6"
      unitRef="usd">431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNC0xMC0xLTEtMA_5a27c60e-7005-48ee-8099-2f76fa74a810"
      unitRef="usd">431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="i504e33597e674687b5ef22eca9e130d4_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNS0yLTEtMS0w_649d2a99-41bf-431e-be03-b53d81263e02"
      unitRef="shares">22366</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNS0xMC0xLTEtMA_fc0a65cf-6e5b-4535-a50e-671de1d0d289"
      unitRef="usd">0</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <us-gaap:NetIncomeLoss
      contextRef="ib9a4e45c10a54a7a992104de496d6574_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNi04LTEtMS0w_ec4db218-074e-4de8-8064-975a46831f87"
      unitRef="usd">-5563000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNi0xMC0xLTEtMA_92099b96-0fb1-4170-849f-b76fcd08dc51"
      unitRef="usd">-5563000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia14ddb9d17de4c8eb2f62cc86eb0451f_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNy0yLTEtMS0w_e7e97a79-5591-44fa-912e-b1a373814672"
      unitRef="shares">12627056</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia14ddb9d17de4c8eb2f62cc86eb0451f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNy00LTEtMS0w_0816f30d-78e1-4729-b97e-a82215b0e23d"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieaa8db75f5344e35b666cc34a12c7d9e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNy02LTEtMS0w_93852018-54eb-42e7-b538-a5fbe725b6ac"
      unitRef="usd">220689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3322be77d6de4025839cac63f86f0243_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNy04LTEtMS0w_ec2d7c80-65b2-4123-a2ea-ae305e5b99ed"
      unitRef="usd">-170165000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5194501b750d4090955a5e16b78c217c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yMi9mcmFnOjExOTg3MzI0NDlmZDRmNDc5NzRiZWZhM2Q3NGM4ZTJmL3RhYmxlOjUwZTdjOTU4Yzc2NzQzYzdhODk4ZDI2M2UyN2VlZDI0L3RhYmxlcmFuZ2U6NTBlN2M5NThjNzY3NDNjN2E4OThkMjYzZTI3ZWVkMjRfNy0xMC0xLTEtMA_7f9f26b5-0667-457d-ab49-cd37d9f2700a"
      unitRef="usd">50537000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNC02LTEtMS0w_1b05014e-7f82-48ca-a653-e5f2896f134e"
      unitRef="usd">-6209000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNC04LTEtMS0w_31b3f44d-9eee-4482-adce-d550407fda09"
      unitRef="usd">-5563000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNi02LTEtMS0w_4768c95d-ab6c-4363-866d-1a026114cfda"
      unitRef="usd">187000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNi04LTEtMS0w_51c98853-81a1-47af-9cc1-1445599ace48"
      unitRef="usd">126000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNy02LTEtMS0w_10828e28-e17b-4334-95b8-2576a957bace"
      unitRef="usd">73000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNy04LTEtMS0w_56032c2f-674b-4ad6-8a68-59122f4593df"
      unitRef="usd">65000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfOC02LTEtMS0w_5235202e-4880-4749-aa0e-a7644f4938a5"
      unitRef="usd">132000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfOC04LTEtMS0w_d54e4234-3f24-4172-afeb-21e4b3926c41"
      unitRef="usd">131000</us-gaap:PaidInKindInterest>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTAtNi0xLTEtMA_cca59a31-e245-4ce2-a674-bcaa7787d521"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTAtOC0xLTEtMA_d53db411-1ced-4e61-b2fc-c935a88c6cda"
      unitRef="usd">-117000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTItNi0xLTEtMA_750156fe-d990-40ed-9596-8b6f2b3102cd"
      unitRef="usd">912000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTItOC0xLTEtMA_d560f452-c347-4f3b-9808-3d2b22c10dbe"
      unitRef="usd">431000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTQtNi0xLTEtMA_55951b54-0889-40f3-9cef-fa925f538d8f"
      unitRef="usd">-689000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTQtOC0xLTEtMA_d5f7a26c-30eb-4618-96d4-a58f4d0453c3"
      unitRef="usd">128000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTUtNi0xLTEtMA_2cfaf22b-0167-4b50-ac0e-7a9219013edc"
      unitRef="usd">-1061000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTUtOC0xLTEtMA_edaf1938-cb87-417c-a801-b9507993218d"
      unitRef="usd">-367000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTYtNi0xLTEtMA_be2afbae-40cf-4e75-8948-986d61edebcd"
      unitRef="usd">48000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTYtOC0xLTEtMA_6bc263f7-40e2-42c9-8553-b6d6f4c218a0"
      unitRef="usd">14000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTctNi0xLTEtMA_85cf803e-d5eb-44af-a38c-7b5f2b010ee2"
      unitRef="usd">-792000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTctOC0xLTEtMA_b3784aef-7d7b-4a47-b712-29175236121a"
      unitRef="usd">1054000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTgtNi0xLTEtMA_835c65f4-ba97-4244-8b98-0dfc70edcaa0"
      unitRef="usd">-317000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMTgtOC0xLTEtMA_03ee8647-c45f-4ef5-bc1a-f64fcb0a9f58"
      unitRef="usd">347000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjAtNi0xLTEtMA_1acad6ea-3689-4a9f-9fce-502d27226686"
      unitRef="usd">-4312000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjAtOC0xLTEtMA_19f06527-7376-45f5-bb32-5b7bd0b16736"
      unitRef="usd">-3301000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjItNi0xLTEtMA_a75b88df-796d-41a9-9179-149b5ba78ec9"
      unitRef="usd">167000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjItOC0xLTEtMA_40f89807-0058-4bb2-8b1c-c9bcd30c5831"
      unitRef="usd">84000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjYtNi0xLTEtMA_2dc5bef9-7e49-4eca-8eb8-e1b3d915a131"
      unitRef="usd">-167000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjYtOC0xLTEtMA_9cfe026c-999c-4847-aad9-5cbe30ae4cce"
      unitRef="usd">-84000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjgtNi0xLTEtMA_0b6083f9-7b1e-4c1c-8815-fba8032ab33c"
      unitRef="usd">44000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjgtOC0xLTEtMA_b4188b8e-26af-47b5-8ecc-3898b82e115e"
      unitRef="usd">10000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjktNi0xLTEtMA_c080b5f3-f7cf-4865-b7f2-0beb8ed197aa"
      unitRef="usd">175000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMjktOC0xLTEtMA_5451f723-39db-4a55-be9b-e62cee38252b"
      unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMzEtNi0xLTEtMA_4b9fbc7e-bd33-4dda-9ada-b4449fc8ab33"
      unitRef="usd">96000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMzEtOC0xLTEtMA_ff04320c-842e-4f2c-82c1-a751ff8e5066"
      unitRef="usd">61000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMzUtNi0xLTEtODc_536dff7c-afab-41eb-9b72-4adc6ccfc086"
      unitRef="usd">69144000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMzUtOC0xLTEtODM_13d59ed8-07d8-4a94-b769-11996cb7ab29"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMzYtNi0xLTEtMjg3NA_6f064150-96f8-43ca-9e14-43df981bc850"
      unitRef="usd">4186000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfMzYtOC0xLTEtMjg3NA_565cbb06-5f05-4d75-bd46-319051cfea0c"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDAtNi0xLTEtMA_fac7f737-dc92-430b-adad-198ba73adaa2"
      unitRef="usd">65081000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDAtOC0xLTEtMA_3d7ccadd-f972-4d6e-88ab-76b11c6d31c9"
      unitRef="usd">-51000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDEtNi0xLTEtMA_1e7486e9-1e83-49f8-b224-b5e73b443fc7"
      unitRef="usd">60602000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDEtOC0xLTEtMA_f64794fa-6d30-483d-87d8-2d980e7b2cb0"
      unitRef="usd">-3436000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDItNi0xLTEtMA_0e9d638e-c4e6-4aa1-9515-bb8ab78906eb"
      unitRef="usd">57548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1b221cae4dee43a2acc22fa21886929f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDItOC0xLTEtMA_0ce85d3c-c9ee-45d5-a307-9dd887417632"
      unitRef="usd">72184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDMtNi0xLTEtMA_cd3d2894-429c-4ca3-bda3-5658285578d9"
      unitRef="usd">118150000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5194501b750d4090955a5e16b78c217c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDMtOC0xLTEtMA_6bd95658-b551-48c6-bbc5-2cee5956dfb7"
      unitRef="usd">68748000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDUtNi0xLTEtMA_38cd809d-bf93-4319-b3c0-b08f33ca707f"
      unitRef="usd">439000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDUtOC0xLTEtMA_68c06645-4c6d-41c6-ac1a-fa16900dc98c"
      unitRef="usd">432000</us-gaap:InterestPaidNet>
    <exdx:EquipmentPurchasedUnderCapitalLease
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDgtNi0xLTEtMA_704345b5-9931-4e1c-aff2-0e50f5bf72ce"
      unitRef="usd">384000</exdx:EquipmentPurchasedUnderCapitalLease>
    <exdx:EquipmentPurchasedUnderCapitalLease
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNDgtOC0xLTEtMA_9895dbdd-75f1-41e0-9682-82d98c6922d3"
      unitRef="usd">2000</exdx:EquipmentPurchasedUnderCapitalLease>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNTAtNi0xLTEtMA_5d8d26d2-21c2-46df-8b77-5d1881f4c1d9"
      unitRef="usd">44000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNTAtOC0xLTEtMA_61d45864-1e02-4978-bb8b-9165abcb09f2"
      unitRef="usd">37000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNTMtNi0xLTEtMA_194f9ac3-b2a7-435e-ae6f-31c075a80391"
      unitRef="usd">221000</exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities>
    <exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNTMtOC0xLTEtMA_0323d176-1c55-4890-aedc-fe6c800ceea3"
      unitRef="usd">0</exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities>
    <exdx:DeferredOfferingCostsReclassifiedToEquity
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNTUtNi0xLTEtMTU4Nw_bdf79530-42cc-4120-a227-e262a0b1ddba"
      unitRef="usd">28000</exdx:DeferredOfferingCostsReclassifiedToEquity>
    <exdx:DeferredOfferingCostsReclassifiedToEquity
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8yNS9mcmFnOmMwODc1ZmQxNGY3YzQxMzJiYTc0N2NlMTZmNjQ3ZDNhL3RhYmxlOjVkZmQyM2Y2ZjEzOTQ1MTk4ZjM1MjNiZmJhZWYxMjhjL3RhYmxlcmFuZ2U6NWRmZDIzZjZmMTM5NDUxOThmMzUyM2JmYmFlZjEyOGNfNTUtOC0xLTEtMTU4Nw_5ee876c2-30f4-4eb7-9323-a844635bcff6"
      unitRef="usd">0</exdx:DeferredOfferingCostsReclassifiedToEquity>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zMS9mcmFnOjM3YmRhZmYxMGQyMDQwMzU5YmVhMmIxZjc2ZGIzMWJmL3RleHRyZWdpb246MzdiZGFmZjEwZDIwNDAzNTliZWEyYjFmNzZkYjMxYmZfMjU2NA_2de3aee8-f286-4430-9d7b-da054a73db99">Organization&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exagen Inc. (the Company) is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At March&#160;31, 2021, the Company had cash and cash equivalents of $118.1 million and had an accumulated deficit of $187.5 million. Since inception, the Company has financed its operations primarily through a combination of equity financings of common stock and private placements of preferred securities, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zMS9mcmFnOjM3YmRhZmYxMGQyMDQwMzU5YmVhMmIxZjc2ZGIzMWJmL3RleHRyZWdpb246MzdiZGFmZjEwZDIwNDAzNTliZWEyYjFmNzZkYjMxYmZfMTAxMQ_ec4cc064-ed87-44af-92c4-3bd363f8a086"
      unitRef="usd">118100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zMS9mcmFnOjM3YmRhZmYxMGQyMDQwMzU5YmVhMmIxZjc2ZGIzMWJmL3RleHRyZWdpb246MzdiZGFmZjEwZDIwNDAzNTliZWEyYjFmNzZkYjMxYmZfMTA0OA_0ca11d32-ce75-4e89-a6b7-ee65c38589b8"
      unitRef="usd">-187500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzU_7117a360-13ab-4f6d-a2cf-ba999ad9d4b7">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed balance sheet as of March&#160;31, 2021, the condensed statements of operations and the condensed statements of stockholders' equity for the three months ended March&#160;31, 2021 and 2020 and cash flows for the three months ended March&#160;31, 2021 and 2020 and the related footnote disclosure are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments, necessary for the fair presentation of the Company's financial position as of March&#160;31, 2021 and its results of operations for the three month periods presented. The results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. These unaudited condensed financial statements should be read in conjunction with the Company&#x2019;s audited financial statements for the year ended December 31, 2020, included in its Annual Report on Form 10-K filed with the SEC on March 16, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill) and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2021 and 2020, approximately 81%, and 83%, respectively, of the Company's revenue was related to the AVISE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; CTD test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is dependent on key suppliers for certain laboratory materials. For the three months ended March&#160;31, 2021 and 2020, approximately 98% and 96%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay that is immaterial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $0.1 million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:16pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payors) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janssen Promotion Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the Company entered into a co-promotion agreement (the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States. The Company is responsible for the costs associated with its sales force over the course of such co-promotion. Janssen is responsible for all other aspects of the commercialization of SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company is entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for that quarter over a predetermined baseline. For quarter ended March&#160;31, 2020, the tiered promotion fee ranged from $750 to $1,250 per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020, the Janssen Agreement was amended (June Amended Janssen Agreement) to adjust the predetermined average baseline for the third and fourth quarters of 2020, and for each of the third and fourth quarters of 2020, the Company received a minimum promotion fee of $0.3&#160;million and the fee was capped at 5% above the adjusted predetermined baseline. In December 2020, the Janssen Agreement was further amended. The Janssen Agreement, as amended in June 2020 and December 2020 is collectively referred to as the Amended Janssen Agreement. In accordance with the Amended Janssen Agreement, the predetermined average baseline for prescribed units for the quarters ending December 31, 2020, March 31, 2021 and June 30, 2021, was adjusted to approximately 28,750 prescribed units per quarter, subject to adjustment under certain circumstances. For the first and second quarter of 2021, the Company will be entitled to an amended tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units. Pursuant to the Amended Janssen Agreement, for the first and second quarters of 2021, the Company will receive a minimum promotion fee of $0.3&#160;million and the fee will be capped at 10% above the adjusted predetermined baseline. The quarterly tiered promotion fee for the remaining term of the Janssen Promotion Agreement beginning on July 1, 2021 will revert to the terms set forth in the Janssen Agreement prior to amendment, with no minimum promotion fee and no cap on predetermined baseline units. In addition, during the term of the Janssen Agreement, the Company is restricted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from promoting any other biologic or Janus kinase inhibitor, or JAK inhibitor, used for treatment of indications covered by the agreement without first obtaining Janssen's written consent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Janssen Agreement expires on December 31, 2021, unless extended by the Company for an additional 12 months upon 180 days written notice prior to the end of the current term. If the Company elects to extend the term, the predetermined baseline for 2022 will be subject to future agreement by the Company and Janssen. Janssen may terminate the Amended Janssen Agreement at any time for any reason upon 30 days' notice to the Company, and the Company may terminate the Amended Janssen Agreement for any reason at the end of any calendar quarter upon 30 days' notice to Janssen. Either party may terminate the Amended Janssen Agreement in the event of the other party's default of any of its material obligations under the agreement if such default remains uncured for a specified period of time following receipt of written notice of such default.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's obligations relating to sales and co-promotion services for SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is a series of single performance obligations since Janssen simultaneously receives and consumes benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations is based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the agreement is cancelable. The Company recognized co-promotion revenue of approximately $0.3 million and no co-promotion revenue during the three months ended March&#160;31, 2021 and 2020, respectively. The related expenses for marketing SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are included in selling, general and administrative expenses and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.3 million and $0.4 million for the three months ended March&#160;31, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.5 million and $0.4 million for the three months ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the employee stock purchase plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest annually from the grant date in four equal installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy RSUs upon vesting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021, the Company awarded 185,000 RSUs to certain employees, all of which are outstanding and unvested as of March&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan and shares of the Company's common stock pursuant to Employee Stock Purchase Plan. For the three months ended March&#160;31, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;436,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,041,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,630,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,656,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,068,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Leases&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842). The new topic supersedes Topic 840,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;leasing arrangements. In July 2018, the FASB issued ASU 2018-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNjY_90d7cd5d-3be3-41d2-90a7-bbb829091868">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzY_b1476be1-4c5d-4389-9dbb-0d2e6cd37b4c">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0fc61924d3f34ca4bab8516c11208885_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfMy0yLTEtMS0w_4da1a9b8-d2c9-469e-89f1-3bf5eb00d633"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia7ac61c025c245af88e7397f61447e69_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfMy00LTEtMS0w_8150a560-d070-4b84-94bd-74b51c31000b"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i21d9452d5c4c42f9bb942373684d2e42_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfNS0yLTEtMS0w_960a8c97-6efb-404c-b4ce-c995cde701fa"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i834f47585cfe4c7d8a215294b1923d36_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfNS00LTEtMS0w_0e4bee87-687d-4a02-a64f-64bea083dcd9"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1f3ffd1dd835435c94a893df6356b1b1_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfNi0yLTEtMS0w_97b97cb8-8de5-4d01-92f5-3efb91003c75"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i187e453a33374a7797711f58bcc14b7f_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfNi00LTEtMS0w_d83e25fb-aa2c-48e5-8d70-b93ec8017a4f"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie8a62a0ccfd34fca91b61d270f96dbfd_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmU4YjdkYWE1YjllYTQwOTI5MjAwNzk3NGEyOTJjZWQ2L3RhYmxlcmFuZ2U6ZThiN2RhYTViOWVhNDA5MjkyMDA3OTc0YTI5MmNlZDZfNy00LTEtMS0w_7517399d-e073-42c8-bf7d-8aa00e9d2eb4"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i65a7a857be764806adc1eb00dcc35517_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjZjM2E5YWRlYjM4NjQzMzg4ZGM3NGM4MDZmNTJiZWI2L3RhYmxlcmFuZ2U6NmMzYTlhZGViMzg2NDMzODhkYzc0YzgwNmY1MmJlYjZfMy00LTEtMS0w_fd6a3d03-9aac-4ba8-8cf9-d8a0d2a6aff6"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id13f474ddf0d441ba77566815923f88a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjZjM2E5YWRlYjM4NjQzMzg4ZGM3NGM4MDZmNTJiZWI2L3RhYmxlcmFuZ2U6NmMzYTlhZGViMzg2NDMzODhkYzc0YzgwNmY1MmJlYjZfMy02LTEtMS0w_b8175739-2a10-406d-bb52-93b7dda74032"
      unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i782e358e46694beb9624e9aa3ed858ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjZjM2E5YWRlYjM4NjQzMzg4ZGM3NGM4MDZmNTJiZWI2L3RhYmxlcmFuZ2U6NmMzYTlhZGViMzg2NDMzODhkYzc0YzgwNmY1MmJlYjZfNS00LTEtMS0w_23830b58-c9c4-4e5f-aa62-fb8a41ba352c"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i701b3c86d5b74909bf2e8bf593384649_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjZjM2E5YWRlYjM4NjQzMzg4ZGM3NGM4MDZmNTJiZWI2L3RhYmxlcmFuZ2U6NmMzYTlhZGViMzg2NDMzODhkYzc0YzgwNmY1MmJlYjZfNS02LTEtMS0w_d2f679fe-3afe-4c1c-8e78-1a91f2b234fe"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2c299e56192b4127a3e3d90a1847d6f1_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzgzMw_e01a8157-3527-4c8a-871e-935ce0b51e9f"
      unitRef="number">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i023127e7d06344128078f124e3501be0_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0MQ_3bd1f408-a19e-4b2f-b41a-24682fbf5804"
      unitRef="number">0.83</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4184a1eb75de41ce9509149528c2c0aa_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfNDE4OQ_8fe99d3c-f322-461b-93d3-b04284df2377"
      unitRef="number">0.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia721771017024f3f9f0c91f7b23abe19_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfNDE5Ng_415559f4-4020-49cb-9187-04f3b62701bf"
      unitRef="number">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNjc_90656f09-e998-4907-9499-962ff859f771">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay that is immaterial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14c0363cf9954703ba1f808170614d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfMy0yLTEtMS0w_75097fc6-08b0-4aa7-b3df-ac8c042a50d3"
      unitRef="usd">6027000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae6bedc762044534a4143ad3d0409cf0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfMy00LTEtMS0w_df98076d-3141-4948-beb8-e381fc3ca3d3"
      unitRef="usd">6062000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1454a0a0df9044c6b9f918a3859fbdb2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNC0yLTEtMS0w_1127d739-6749-44e1-9efe-0fe20e3cb652"
      unitRef="usd">2009000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77ab1dd3b4a245ce9165116eabdb5ff9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNC00LTEtMS0w_09b0c4cd-8336-4f05-976e-a01d1b128067"
      unitRef="usd">2245000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76abec2d56de47129071a1dd6c7b2acb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNS0yLTEtMS0w_31186eb3-fd79-4f22-8bed-af56d0b000df"
      unitRef="usd">1965000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1509c8e8724f4915b96a65425f3d99ee_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNS00LTEtMS0w_fa1ad752-9a3e-4dae-a449-466d532487b0"
      unitRef="usd">1082000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i905e56813efc44a0997851f5274917d7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNi0yLTEtMS0w_ea142478-6092-4d22-a0d0-e318cfa41a0b"
      unitRef="usd">286000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2d9d310c7f94750b20d74e6de87c94a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNi00LTEtMS0w_30356c52-5f61-4380-bf54-33025dddea95"
      unitRef="usd">195000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c286444d4974baf83c59a97267301ea_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNy0yLTEtMS0w_27003074-c00d-4a71-a7df-8ac1955c4855"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if67771cd955c4c85bf332d7c2b0097d8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfNy00LTEtMS0w_d1124cd9-213f-4f43-99e8-9690c22d5787"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfOC0yLTEtMS0w_5304296b-dcfc-4396-a646-e94f5cb6643b"
      unitRef="usd">10587000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmM4OGU4NjcyOWJmZjRiOTZiMjliNTUyMmU4YzBjNDQwL3RhYmxlcmFuZ2U6Yzg4ZTg2NzI5YmZmNGI5NmIyOWI1NTIyZThjMGM0NDBfOC00LTEtMS0w_a55905c2-69e0-4efe-ad7d-abb0d46ee2d9"
      unitRef="usd">9584000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODE_9cb497cf-88fd-4f00-9727-3b597a7217f8">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODI_1c870f71-c410-49dc-8da3-db6bf8abc573">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="i1dd0a205cd3249ccb82b12ae5f6c2929_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfNjkwNA_5f79eb90-e190-4864-bd83-1301caa1f650"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzE_43e9fd3d-ca94-456c-958e-38e7f8a794ff">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzE_6bbca675-6309-4829-ba34-1cc7155eb9fc">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjgyMzcyY2ZmY2JjZTQxMjliYTkzODA2MDk2N2Q3ZTI1L3RhYmxlcmFuZ2U6ODIzNzJjZmZjYmNlNDEyOWJhOTM4MDYwOTY3ZDdlMjVfMi00LTEtMS0w_da686ddf-0303-4c7d-b69a-5d1988facbdc"
      unitRef="usd">118050000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjgyMzcyY2ZmY2JjZTQxMjliYTkzODA2MDk2N2Q3ZTI1L3RhYmxlcmFuZ2U6ODIzNzJjZmZjYmNlNDEyOWJhOTM4MDYwOTY3ZDdlMjVfMi02LTEtMS0w_0101872a-c397-44a7-849a-12c6edb8d167"
      unitRef="usd">57448000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjgyMzcyY2ZmY2JjZTQxMjliYTkzODA2MDk2N2Q3ZTI1L3RhYmxlcmFuZ2U6ODIzNzJjZmZjYmNlNDEyOWJhOTM4MDYwOTY3ZDdlMjVfMy00LTEtMS0w_07c8838d-858e-4960-b637-cbbb67dbc486"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjgyMzcyY2ZmY2JjZTQxMjliYTkzODA2MDk2N2Q3ZTI1L3RhYmxlcmFuZ2U6ODIzNzJjZmZjYmNlNDEyOWJhOTM4MDYwOTY3ZDdlMjVfMy02LTEtMS0w_2e45ffe3-4917-4db0-9018-fc147bc26094"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjgyMzcyY2ZmY2JjZTQxMjliYTkzODA2MDk2N2Q3ZTI1L3RhYmxlcmFuZ2U6ODIzNzJjZmZjYmNlNDEyOWJhOTM4MDYwOTY3ZDdlMjVfNC00LTEtMS0w_7c5ba74e-0d4e-4323-8d08-5f4bec860895"
      unitRef="usd">118150000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOjgyMzcyY2ZmY2JjZTQxMjliYTkzODA2MDk2N2Q3ZTI1L3RhYmxlcmFuZ2U6ODIzNzJjZmZjYmNlNDEyOWJhOTM4MDYwOTY3ZDdlMjVfNC02LTEtMS0w_623cb57f-019c-4a83-b658-45b6e62caec5"
      unitRef="usd">57548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzI_d7bb340f-d8cf-4422-8387-feb24945257c">&lt;div style="margin-top:16pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payors) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="ic2ef52e13fcc4ac290fb3f3f17fc1d8e_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTA1ODM_d2233032-ebc5-4e62-b7b2-76552d5111b7"
      unitRef="usd">750</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="ib134284be93446ceb5f659fddbb92851_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTA1ODk_b3670654-444e-4bdd-88eb-71fee2b24492"
      unitRef="usd">1250</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="ic717b41edf9f4ff48d0b9b2e8087ccf9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMTY4Mw_220ed7fc-6c3f-4498-bef1-4aa188b49e4e"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="i035a93a2bf2f4d91913f3d26706f1810_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMTY4Mw_a229be02-f156-47c2-aa9f-e62ba9e9927c"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzg_2f96277e-4afd-44b1-87df-145f58fd6a0f"
      unitRef="number">0.05</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="ic3f2c6ac308c4ed4a5dac4b72e609986_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzg_ec9f38e1-8745-4c37-bb03-1cf14ebafdd9"
      unitRef="number">0.05</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <exdx:JointVentureQuarterlyPrescribedUnits
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ2NA_8e59301d-0216-4ed1-98ac-a11bc8490ce4"
      unitRef="unit">28750</exdx:JointVentureQuarterlyPrescribedUnits>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i00bf9e1bcaa041139ea4e7b5f25c4a6e_I20210630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ3Mg_1fcae933-2b06-4cd3-a926-555ce1652be1"
      unitRef="usd">500</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="iccf1ab5f053e4f769295776a4596ca23_I20210331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ3Mg_76cb585f-9ecd-4244-b9f4-5dc445c311e7"
      unitRef="usd">500</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i4bc7c41756524ddd9cc16ef0ee800e1b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ3OA_853de476-e1fc-42b6-b574-ff9c00d92225"
      unitRef="usd">1000</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i4bc7c41756524ddd9cc16ef0ee800e1b_I20210630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ3OA_fa474880-2de2-4d8c-b0b6-7c99ba0501e9"
      unitRef="usd">1000</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="i00bf9e1bcaa041139ea4e7b5f25c4a6e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMTY1NA_01cd4c51-8bf0-446f-8d4c-223d779b940a"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="iccf1ab5f053e4f769295776a4596ca23_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMTY1NA_06e694a0-3649-4b46-adc5-acda84eb96a8"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ4Ng_2f56e5d8-798f-4539-bcbc-0e4fc630c670"
      unitRef="number">0.10</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="ia8c4a64accf64f4e8d3c6f1c85c45656_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ4Ng_dd2e8a34-c32f-402b-8ab0-86efa38f169c"
      unitRef="number">0.10</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <exdx:CoPromotionAgreementRenewalTerm
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMjA2Ng_b1e75479-72e2-48de-b24e-586ea45d5885">P12M</exdx:CoPromotionAgreementRenewalTerm>
    <exdx:CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMjA4MQ_983d33b9-fd50-40ff-a328-b5ea5b5e77ae">P180D</exdx:CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm>
    <exdx:CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjc0ODc3OTEwMjA5MA_eb8bc4bc-1011-421c-b541-aff0471bf084">P30D</exdx:CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i545c29e8f1ac444a9fd4436eb738bd53_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTI4OTI_bb71fe43-ace5-48ef-b58f-7357be984bba"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie01b6015e94e40b18dbc9c1af60a487e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTI5MDc_89f59b35-ad9b-4cdd-91f1-ba35bfb9b4d9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODM_8053057b-0bfc-4310-9f51-a606df2d2288">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODQ_e8c7200f-a10d-4390-b6af-2df29ed251a5">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.3 million and $0.4 million for the three months ended March&#160;31, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTM4MTQ_cc242423-377b-45f7-80b7-2e37ded103d4"
      unitRef="usd">300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTM4Mjk_20b262cb-87e1-4739-a6ed-19c2bbf125a5"
      unitRef="usd">400000</us-gaap:AdvertisingExpense>
    <us-gaap:CostOfRevenue
      contextRef="i51b7dc429b4b47a4a086f500297ae4f5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTQyODE_4c7a372d-654f-48e9-a114-cf1e36d759a9"
      unitRef="usd">500000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i83c36c4109874e448199eb8e55ebd4dc_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTA5OTUxMTY1NzAwMQ_2b342701-8973-4775-baf6-abe5881141d6"
      unitRef="usd">400000</us-gaap:CostOfRevenue>
    <us-gaap:EmployeeStockOwnershipPlanESOPPolicy
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODU_2567a114-7e95-44c8-a829-2d0a8cb6d6b2">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the employee stock purchase plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest annually from the grant date in four equal installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy RSUs upon vesting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021, the Company awarded 185,000 RSUs to certain employees, all of which are outstanding and unvested as of March&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.&lt;/span&gt;&lt;/div&gt;</us-gaap:EmployeeStockOwnershipPlanESOPPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMzg0ODI5MDcyNjQ5MA_4bcf1579-58be-4f76-b2a3-b87b9aa0412e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTA5OTUxMTY1OTQzNQ_98ff4cd0-3975-433f-b215-c37bd3d8c2d9"
      unitRef="shares">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzM_922fcba0-e03b-4220-8417-2d3529bc18b3">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzk_0615f730-f9eb-411e-976d-b6c1f1a6caac">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan and shares of the Company's common stock pursuant to Employee Stock Purchase Plan. For the three months ended March&#160;31, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwNzQ_a6b388a8-e439-4ccd-a1e4-6dc0ecaf9a6d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;436,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,041,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,630,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,656,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,068,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id50b7c2e8d494f8c946e330ed5574198_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNC0yLTEtMS0w_98706730-32d3-42b8-933f-2d216969c92c"
      unitRef="shares">426827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if8a1bd4a29ec4f84888bbc4981057e5b_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNC00LTEtMS0w_46fd5e16-4a7a-43f3-b7fb-aba2527a7c1d"
      unitRef="shares">436581</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib8a1d1023b6a4f4db7161e28f63e8578_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNS0yLTEtMS0w_7c658bc9-8c0c-4df3-8f5e-787c8c875643"
      unitRef="shares">2041580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib430868217a64c48beccdf7a906cd385_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNS00LTEtMS0w_843ec17d-788e-47eb-a915-f2c42e2f8cf3"
      unitRef="shares">1630014</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i56ebd098dbb0414199e0a1f304311104_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNi0yLTEtMS0yODA0_378f65ce-5daa-4087-a4e8-b7eb8c905918"
      unitRef="shares">185000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2ed20d5e060644a197e27c3b20c2b130_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNi00LTEtMS0yODA4_f1246f88-e7a5-4cda-894a-e9dad057048c"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide582e20a1564092a1d4f74f3cce4c9c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNi0yLTEtMS0zNTc_7ac6294c-bfd9-41f0-87c5-b277ae171857"
      unitRef="shares">2869</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9e1e4c97623d4b02a76aab4a8cd9dfc1_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNi00LTEtMS0zNTc_c1518fbe-c046-4775-a14a-69ff669c7dcb"
      unitRef="shares">2021</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNi0yLTEtMS0w_c05e3441-0e56-4df3-bfd4-fbd5516565ec"
      unitRef="shares">2656276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RhYmxlOmI5YjMzNjkzNTE4YzQ5ZWNhYzk4NWVmNjA5MDczOGYyL3RhYmxlcmFuZ2U6YjliMzM2OTM1MThjNDllY2FjOTg1ZWY2MDkwNzM4ZjJfNi00LTEtMS0w_eb7fdcd0-8b15-4aab-8d7d-48ff164d7e86"
      unitRef="shares">2068616</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODA_751f44ae-a349-4767-bf3f-82b2969341f1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMTgyNTY_3671274c-1011-497b-bf66-9d751106cbac"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNC9mcmFnOjMyMGRmM2FiYmI5ZjQxZTNhZTNhODc5ZDFjZDBmZDE4L3RleHRyZWdpb246MzIwZGYzYWJiYjlmNDFlM2FlM2E4NzlkMWNkMGZkMThfMjIwODY_6f6e6e08-ad81-4c8f-bc4a-f479bd238a1f">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Leases&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842). The new topic supersedes Topic 840,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;leasing arrangements. In July 2018, the FASB issued ASU 2018-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfNzcy_9835da39-427a-49b6-bdf0-3aa9f5a96c54">Other Financial Information&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for the three months ended March&#160;31, 2021 and 2020 was approximately $0.2 million and $0.1 million, respectively. At March&#160;31, 2021 and December 31, 2020, the gross book value of assets under capital lease was $1.6 million and $1.2 million, respectively, and is classified in "Laboratory equipment" in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capital lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfNzcz_087720dd-7422-4e3b-be10-6cd974876d28">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherAssetsCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfMS0yLTEtMS0w_73d53010-3b9b-4a0e-be96-6534e37ab94e"
      unitRef="usd">921000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfMS00LTEtMS0w_c827a5ad-f398-403d-8e65-0b74efd6c891"
      unitRef="usd">1203000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidRoyalties
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfMi0yLTEtMS0w_395d5d1f-ae3c-42c5-b4cf-66bf1389f901"
      unitRef="usd">65000</us-gaap:PrepaidRoyalties>
    <us-gaap:PrepaidRoyalties
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfMi00LTEtMS0w_11f38206-23d4-43d9-9436-50c49f2ac884"
      unitRef="usd">68000</us-gaap:PrepaidRoyalties>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfMy0yLTEtMS0w_c30cacd0-c71c-4618-8d4e-a94a0f86610a"
      unitRef="usd">1892000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfMy00LTEtMS0w_ccab32c6-aca7-4ceb-bd02-79fc2cf43392"
      unitRef="usd">2229000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfNC0yLTEtMS0w_22717133-a635-47b4-86cc-c301f9b5adf2"
      unitRef="usd">220000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfNC00LTEtMS0w_cab55dff-bd45-4b13-8302-63e1ecd6746b"
      unitRef="usd">659000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfNS0yLTEtMS0w_dff02f01-f806-4c50-94bf-759eec535831"
      unitRef="usd">3098000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmUwOWI3Mjg0NWNkNDQyYTJhNzllNmYzMzRmMTAwODRhL3RhYmxlcmFuZ2U6ZTA5YjcyODQ1Y2Q0NDJhMmE3OWU2ZjMzNGYxMDA4NGFfNS00LTEtMS0w_397bf31e-9d5b-4974-bf63-34b2c844892f"
      unitRef="usd">4159000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfNzc0_87d7500f-d5df-4422-95dd-c67987c016db">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icc9a7f02a64d485784bba6b218e085da_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfMS0yLTEtMS0w_4fca6b2c-f999-4971-8013-66b8eb47d04b"
      unitRef="usd">64000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib68a12746a0a43778d411a0e71f850e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfMS00LTEtMS0w_19983469-2925-411c-b20a-5e4aa5fb1809"
      unitRef="usd">64000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2e89c10b517a40da817bf9dd7fadec65_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfMi0yLTEtMS0w_a9169f0f-fdf8-40c5-a616-5c8557362d43"
      unitRef="usd">3148000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if96214d4c6e24fdb959ba168df6a8af4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfMi00LTEtMS0w_7928ff6d-f31e-4e02-b0bd-ae0106748794"
      unitRef="usd">2679000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i718a9b57c44f43859f8f20ce6569fbb6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfMy0yLTEtMS0w_dff5b519-78c7-4287-aabb-f3875b21a392"
      unitRef="usd">1079000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i87b062212901454892bd5210a1dbcd07_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfMy00LTEtMS0w_13a3f9b2-4f19-44ec-b482-88de4609fd60"
      unitRef="usd">927000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic4a67b72dfa84dba92b35b0b41b493e2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNC0yLTEtMS0w_14573c6d-287a-4b23-a693-59122b48f756"
      unitRef="usd">1073000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if0e64a9b4c5140059a5acbc43d92843a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNC00LTEtMS0w_45e43a9a-fa23-498c-9bb1-bb61438150b9"
      unitRef="usd">1072000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i84fefc5a1ec94437b3ba22e7b5a8b9da_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNS0yLTEtMS0w_5d798b85-c949-40f6-96f8-b7824ba3ee3c"
      unitRef="usd">142000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ieeea39a95a634c1f8fae5c44cf640d7a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNS00LTEtMS0w_8e8f451d-848a-460a-9fe7-3a66125aece8"
      unitRef="usd">301000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNi0yLTEtMS0w_1238e784-14a8-4dd5-b284-02a314f7bda0"
      unitRef="usd">5506000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNi00LTEtMS0w_6fe7d078-6e59-4c21-8e37-28dd94ba5e7b"
      unitRef="usd">5043000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNy0yLTEtMS0w_9d95108b-f648-4a98-907e-c38887e62317"
      unitRef="usd">3128000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfNy00LTEtMS0w_171f5cc6-dbb7-4d24-83db-34c1c672a444"
      unitRef="usd">2941000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfOC0yLTEtMS0w_0adb60f5-a5ea-438f-b02b-fc93f984fb84"
      unitRef="usd">2378000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOmNjZDU3ZTk2MzliMTRiMDM5NjE2MWZiOTA5OGRmZTBlL3RhYmxlcmFuZ2U6Y2NkNTdlOTYzOWIxNGIwMzk2MTYxZmI5MDk4ZGZlMGVfOC00LTEtMS0w_72e99bbe-6d39-44a5-b008-58c709dff7bb"
      unitRef="usd">2102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfMzU5_ba5a55ff-01ba-4469-9a28-d29398c26c0f"
      unitRef="usd">200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfMTA5OTUxMTYyODY1MQ_6d3bbb23-ddfe-4880-a046-33d2f23f7133"
      unitRef="usd">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iea8e8125271042c2bd42020d228a5c4b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfNTQy_a6cd3ef6-d299-47db-be7e-c4d55f4f3f2f"
      unitRef="usd">1600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7261f22c88a04977b74b69ed970fe446_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfNTU3_e506b70a-0a9f-4c30-9921-df5037366cfa"
      unitRef="usd">1200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RleHRyZWdpb246MGE2MjMzZmMyM2UwNDk2YjllZjYyZjc1YmU4NjYyMmZfNzcw_2bdbc174-1724-41ca-b077-1f2d04774f78">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capital lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfMS0yLTEtMS0w_3ae23467-0c69-454a-8cd8-9b85e6fba8c7"
      unitRef="usd">3318000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfMS00LTEtMS0w_1967a7cf-d363-4e85-add6-16eeb9cec522"
      unitRef="usd">3589000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfMy0yLTEtMS0w_f5cade37-a333-4cc3-a3d3-90c5ec6e4e41"
      unitRef="usd">148000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfMy00LTEtMS0w_15badcbb-b5ef-4198-982f-5a13b3ced5a7"
      unitRef="usd">147000</us-gaap:InterestPayableCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNC0yLTEtMS0w_e4a4e212-f01d-48f7-9d4a-fd72c4fbd48d"
      unitRef="usd">493000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNC00LTEtMS0w_d1055da1-5607-4b8a-9bc5-da5d291d4aa4"
      unitRef="usd">311000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNS0yLTEtMS0w_22b0d019-9204-4ca6-b99d-6e23335894be"
      unitRef="usd">188000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNS00LTEtMS0w_1e005c24-e6ff-4e54-b72e-d6ae87ae85e0"
      unitRef="usd">221000</us-gaap:AccruedRoyaltiesCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNi0yLTEtMS0w_7af06e42-540b-42dc-8346-8d8ecc395546"
      unitRef="usd">286000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNi00LTEtMS0w_4c8b8246-781a-4301-b95e-21754da9086a"
      unitRef="usd">228000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNy0yLTEtMS0w_cec2499e-0250-4a54-a872-2bf7fd1c52a0"
      unitRef="usd">394000</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfNy00LTEtMS0w_7774b049-bb27-4a38-a999-93d1dc46287e"
      unitRef="usd">308000</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfOC0yLTEtMS0w_f2f76493-5771-4a34-954b-f6118a1527e1"
      unitRef="usd">887000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfOC00LTEtMS0w_0cda0dec-1202-48bd-b9e4-dcf8700865d0"
      unitRef="usd">953000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfOS0yLTEtMS0w_d8a3f4f6-4e41-481a-af24-bd98cc6b57c7"
      unitRef="usd">5714000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i74dfc75aad9542dabc25c6d61005effa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV8zNy9mcmFnOjBhNjIzM2ZjMjNlMDQ5NmI5ZWY2MmY3NWJlODY2MjJmL3RhYmxlOjU2N2E4NjczYzU3YzRkZjA4ZDBhMmRjMTc1OTMxZTZhL3RhYmxlcmFuZ2U6NTY3YTg2NzNjNTdjNGRmMDhkMGEyZGMxNzU5MzFlNmFfOS00LTEtMS0w_620f8b91-690d-4a5d-b3ef-5c0c10905030"
      unitRef="usd">5757000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfNTQ4MA_347aef17-c653-449e-992e-fdc1fa4c8103">Borrowings&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $20.0 million, $17.8 million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $5.0 million under the 2017 Term Loan. At March&#160;31, 2021, no additional amounts remain available to borrow under the 2017 Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company executed the First Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the Loan Amendment is 8.5%, of which 2.0% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2022, after which interest accrues at an annual rate of 8.5%. The Company has estimated the effective interest rate of this loan to be approximately 10%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the Loan Amendment will be repaid in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTExOQ_943420c3-685f-4155-98c0-99295e2c5baa"&gt;twenty-four&lt;/span&gt; equal monthly installments commencing in December 2022. Upon repayment of the final installment under the Loan Amendment, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of Loan Amendment using the effective interest method. For each of the three months ended March&#160;31, 2021 and 2020, the Company issued PIK Loans totaling $0.1 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Amendment requires a prepayment premium of 3% of the aggregate outstanding principal. The prepayment premium decreases by 1% during each subsequent twelve-month period after November&#160;19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021, the Company was in compliance with all covenants of the Loan Amendment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon an event of default in any of the Loan Amendment covenants, the repayment of the Loan Amendment may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the Loan Amendment due beyond twelve months of the balance sheet date as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Future Minimum Payments on the Outstanding Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i49816a32de1a4847a965a660b298f0a0_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTk3_3db558e7-2597-48cb-b4b2-de9a057616a6"
      unitRef="usd">20000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i79bb007a0e4b4e11ad37da79ccacc407_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMjAx_e06f01ea-1c55-47d7-9ce8-0cbbe5492216"
      unitRef="usd">17800000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i9225dd725d3041c3897811c47544cbeb_D20181207-20181207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMzg1_79ff06f1-0bf9-442f-bdec-e23d10447471"
      unitRef="usd">5000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic99585e2b612446894f42dbc14e98bc3_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfNDIx_8863637a-a8e4-4cab-9753-3bce108608e2"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfNjgx_bf6506c9-7cc7-410e-817d-f90edb321aa7"
      unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <exdx:DebtInstrumentStatedInterestRatePaidInKind
      contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfNjk0_5e896f91-c28e-4dbf-9b15-93bb71bbfdee"
      unitRef="number">0.020</exdx:DebtInstrumentStatedInterestRatePaidInKind>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfODM2_bf6506c9-7cc7-410e-817d-f90edb321aa7"
      unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfOTI3_f43637e3-ad1e-430a-b48b-8a2016af0c4b"
      unitRef="number">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTI5Ng_02e0784f-5adf-49ce-860a-7de3085ff470"
      unitRef="usd">1000000.0</us-gaap:DebtInstrumentFeeAmount>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i9517d690925b44e1b66094ac282a2fb8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTUwMw_554116f6-c467-48c4-afc5-f5e9bf50f002"
      unitRef="usd">100000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i6a1d3210812c4ec99a01bc62b58c261b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTUwMw_d18da14a-9f71-4cd6-9c41-a2586b8689de"
      unitRef="usd">100000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTc3Mw_2a2ec724-e50b-4ef7-aa01-90aec6d1f970"
      unitRef="number">0.03</exdx:DebtInstrumentPrepaymentPremiumPercentage>
    <exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction
      contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTg1Mg_1fb3b944-7f0a-4489-b66a-02fef41696cb"
      unitRef="number">0.01</exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction>
    <exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance
      contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMzQ5NQ_6c948477-bd79-4998-99bc-8bba9e16c963"
      unitRef="usd">2000000.0</exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance>
    <exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease
      contextRef="i62c7962700564e34b08a1b062a8fb73a_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfNDg5Ng_852abd0a-cc3a-4ec2-84de-a29e8c2240f0"
      unitRef="number">0.040</exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfNTQ4MQ_d86e3352-aa46-42c6-a6f5-4b8dfecd2e6c">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfMS0yLTEtMS0w_b397554c-684a-4b34-a2e2-a60095e58a53"
      unitRef="usd">1326000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfMi0yLTEtMS0w_66628342-8c6f-4265-8f0e-9559df380fb2"
      unitRef="usd">2996000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfMy0yLTEtMS0w_a44a8f3e-6aba-4d65-b759-7463a0cb81b2"
      unitRef="usd">15619000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfNC0yLTEtMS0w_27c20f67-0044-40dc-9f1b-a16eead9964a"
      unitRef="usd">14280000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfNS0yLTEtMS0yNTc4_7814d569-b24c-4a37-b521-b627dcd7e2d1"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <exdx:LongTermDebtIncludingUndiscountedInterest
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfNi0yLTEtMS0w_db18bd09-04a8-4017-8c3e-8e9a414ebb48"
      unitRef="usd">34221000</exdx:LongTermDebtIncludingUndiscountedInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfOC0yLTEtMS0w_920e3a47-ec44-4442-bb17-74498e12fed0"
      unitRef="usd">273000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <exdx:LongTermDebtUndiscountedInterestAmount
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfOS0yLTEtMS0w_7645a47c-bfe2-4b56-b061-f5598688f453"
      unitRef="usd">7084000</exdx:LongTermDebtUndiscountedInterestAmount>
    <us-gaap:LongTermDebt
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RhYmxlOjQyNjg4M2QyODJkZjQyY2RiMDliNGYwNTMwYzM1MGRjL3RhYmxlcmFuZ2U6NDI2ODgzZDI4MmRmNDJjZGIwOWI0ZjA1MzBjMzUwZGNfMTAtMi0xLTEtMA_489c370f-5364-436e-acb6-acdf40261967"
      unitRef="usd">26864000</us-gaap:LongTermDebt>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMzYzMw_27f1cb5b-a54e-4184-8b38-1a3ee0a8608b">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the Company leases office and laboratory space in Vista, California, under leases that expire in January 2026, with an option to extend a portion of the lease for an additional 5-year period. In addition, the Company also leases additional office space in Vista, California, under a lease that expires in January 2026 with an option to extend the lease for an additional 5-year period. The Company's lease payments under each of these leases are subject to escalation clauses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2021 and 2020, rent expense was $0.2 million and $0.1 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. As of March&#160;31, 2021 and December 31, 2020, the remaining milestone obligation is for an additional $2.0 million payment due to Prometheus Laboratories, Inc. (Prometheus) for which the fair value was determined to be zero at March&#160;31, 2021 and December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company has ongoing royalty payment obligations on net sales of products which incorporate certain acquired technologies of 2.5%. Future royalties payable under these arrangements are limited to the lesser of an aggregate of $1.2 million (including an upfront payment of $100,000) or the total royalties earned through January 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments on net sales of products which incorporate licensed technology, as defined, ranging from 2.0% to 3.0%. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the first quarter of 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute, or AHN, to obtain an exclusive license to AHN's patent rights in certain inventions, or the AGN Patent Rights, in May 2021, pursuant to which the Company is required to pay AHN an initial license fee of $0.4 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $4.1 million and $6.0 million for the years ended December 31, 2021 and 2022, respectively, with a 15% annual increase thereafter through the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the first quarter 2021, the Company entered into a master research collaboration agreement with AHN in May 2021, pursuant to which the Company is required to pay AGN a collaboration fee of $0.4 million for each year during the initial term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payors and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or of which of the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <exdx:OperatingLeasesRenewalTerm
      contextRef="iffe724be62e54f5e98c97114c1b16b4c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMjM5_f964e250-c145-4eb8-8b2d-c4f4cf995fbb">P5Y</exdx:OperatingLeasesRenewalTerm>
    <exdx:OperatingLeasesRenewalTerm
      contextRef="ibb1da3cc014a47988102c4a5fbfcdf4a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfNDM0_162a6d84-7de6-4e4a-9ae0-ddc63804e643">P5Y</exdx:OperatingLeasesRenewalTerm>
    <us-gaap:LeaseAndRentalExpense
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfNTk4_40a3450c-e923-4cda-b409-8282c1976096"
      unitRef="usd">200000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfNjEz_d9ae15bc-5a88-4da3-9809-5d91e3137f5a"
      unitRef="usd">100000</us-gaap:LeaseAndRentalExpense>
    <exdx:MilestoneObligation
      contextRef="ie5600c9592fb46b690a5bc52e4c34fc2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTI4OQ_1a6257fe-0bbe-42b0-90dd-26582d644243"
      unitRef="usd">2000000.0</exdx:MilestoneObligation>
    <exdx:MilestoneObligation
      contextRef="i786adb20b67b40bfb36498bdace13f68_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTI4OQ_e91c1ca7-dbb5-4704-9396-a468011d7b37"
      unitRef="usd">2000000.0</exdx:MilestoneObligation>
    <exdx:MilestoneContingencyFairValueDisclosure
      contextRef="i786adb20b67b40bfb36498bdace13f68_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTM5Ng_033fddd0-6a8f-4f5d-8676-da1392becae0"
      unitRef="usd">0</exdx:MilestoneContingencyFairValueDisclosure>
    <exdx:MilestoneContingencyFairValueDisclosure
      contextRef="ie5600c9592fb46b690a5bc52e4c34fc2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTM5Ng_06794f50-4920-47d6-80d8-a8258d4ca6a3"
      unitRef="usd">0</exdx:MilestoneContingencyFairValueDisclosure>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="ibef5d76e001f48ab9c9f255b50909153_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTU2NA_71611ece-7799-4cb0-9e5a-e8dbd058063a"
      unitRef="number">0.025</exdx:RoyaltyObligationPercentageOfSales>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="i786adb20b67b40bfb36498bdace13f68_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTA5OTUxMTYzMTUzMA_8caa87de-d54c-47e1-b6a8-2807dc78a9a9"
      unitRef="usd">1200000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <exdx:AdvancePayment
      contextRef="i786adb20b67b40bfb36498bdace13f68_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTcxMw_c0ddbcd1-0e3e-49b7-bfb5-7110c8761625"
      unitRef="usd">100000</exdx:AdvancePayment>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i51edebd2dc964c65960284e7a29563ad_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMjExNQ_4864b859-fcc8-466b-8e18-f6854a2d1eba"
      unitRef="number">0.020</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="ifc8c434620fc4d7fa5e5804d5459e9c8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMjEyMQ_d73b761b-a9b9-41f9-8899-a73111a732bf"
      unitRef="number">0.030</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:LicenseAgreementInitialLicenseFee
      contextRef="i9300102ead9949fa9aa89415fe805f2a_D20210401-20210511"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTA5OTUxMTYzMjM4NQ_3a2163de-9f9a-4285-a3c3-cc7f93a49860"
      unitRef="usd">400000</exdx:LicenseAgreementInitialLicenseFee>
    <us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMjQzMw_fba91400-4ba0-4425-899e-8b0038bbc7b6"
      unitRef="usd">4100000</us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMjQ0OA_ab964233-0aac-4a77-a072-be2c17db0de5"
      unitRef="usd">6000000.0</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTA5OTUxMTYzMTU1NQ_71455018-afd7-42bd-80b4-1ff61a4849b3"
      unitRef="number">0.15</exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage>
    <exdx:CollaborationAgreementAnnualCollaborationFee
      contextRef="i526a9a0b5afe4cc1874bdb70a537e2e7_D20210401-20210511"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80My9mcmFnOmY5MmNkZTczZGU0MjQyODE5MDNlYWNiZjdiYTgyZDU5L3RleHRyZWdpb246ZjkyY2RlNzNkZTQyNDI4MTkwM2VhY2JmN2JhODJkNTlfMTA5OTUxMTYzMzE2OQ_266254dd-0047-48e7-b8e2-2c3d50ec6ba6"
      unitRef="usd">400000</exdx:CollaborationAgreementAnnualCollaborationFee>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RleHRyZWdpb246YTM5NjZhZjU2YWVlNDcxOWE3NTZiZTA2NzE1YWFjNTFfMzAw_0be4c285-55d7-4ce8-b565-48439228dd2d">Fair Value MeasurementsThe following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair value of the Company's money market funds is based on quoted market prices.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RleHRyZWdpb246YTM5NjZhZjU2YWVlNDcxOWE3NTZiZTA2NzE1YWFjNTFfMzAx_6127e6ba-ca73-43b2-891e-3341a3166b7d">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibf438e067e0e490e8bd11c8a8dfb7428_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOjA3YTI1YWE5MGVjYzRhNTI4MTRiNDRkZTE1MzNkNDJmL3RhYmxlcmFuZ2U6MDdhMjVhYTkwZWNjNGE1MjgxNGI0NGRlMTUzM2Q0MmZfMy0yLTEtMS0w_475bdecd-fc91-49ab-b36d-e18a2ac04c8e"
      unitRef="usd">107983000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if7d19acf05fd481bbbf64336028dc9c3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOjA3YTI1YWE5MGVjYzRhNTI4MTRiNDRkZTE1MzNkNDJmL3RhYmxlcmFuZ2U6MDdhMjVhYTkwZWNjNGE1MjgxNGI0NGRlMTUzM2Q0MmZfMy00LTEtMS0w_d5cc4d1d-43a6-4f39-9631-c42882e531fa"
      unitRef="usd">107983000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7c9e78b389424e3ba420f778fc2889d9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOjA3YTI1YWE5MGVjYzRhNTI4MTRiNDRkZTE1MzNkNDJmL3RhYmxlcmFuZ2U6MDdhMjVhYTkwZWNjNGE1MjgxNGI0NGRlMTUzM2Q0MmZfMy02LTEtMS0w_1407035c-b2b6-41c1-8fcd-833bae9d59cb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4d467b35645c46a0bc2317ac4c2edca0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOjA3YTI1YWE5MGVjYzRhNTI4MTRiNDRkZTE1MzNkNDJmL3RhYmxlcmFuZ2U6MDdhMjVhYTkwZWNjNGE1MjgxNGI0NGRlMTUzM2Q0MmZfMy04LTEtMS0w_3c1a2eee-3e6e-45ef-89ee-febe813944c0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icf259d6549974c23a1e93dd4e55b13cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOmIxZTdjMTA1OTIwMTQ4ZTQ4NDZmMmNjNjE3ZjgyNjZkL3RhYmxlcmFuZ2U6YjFlN2MxMDU5MjAxNDhlNDg0NmYyY2M2MTdmODI2NmRfMy0yLTEtMS0w_adbc33f7-3072-4873-9c85-48bc50657913"
      unitRef="usd">34507000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i97ff3388db6d405984fbd5a85da92d27_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOmIxZTdjMTA1OTIwMTQ4ZTQ4NDZmMmNjNjE3ZjgyNjZkL3RhYmxlcmFuZ2U6YjFlN2MxMDU5MjAxNDhlNDg0NmYyY2M2MTdmODI2NmRfMy00LTEtMS0w_19c50990-ba83-4810-b183-0b632b6b539c"
      unitRef="usd">34507000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8f9e0cbbdb764f8195a783d55722eb00_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOmIxZTdjMTA1OTIwMTQ4ZTQ4NDZmMmNjNjE3ZjgyNjZkL3RhYmxlcmFuZ2U6YjFlN2MxMDU5MjAxNDhlNDg0NmYyY2M2MTdmODI2NmRfMy02LTEtMS0w_eae0f768-cd52-474f-8974-97d0bf2c2501"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i98fb6a4c5e334327ad489b104eeff646_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80Ni9mcmFnOmEzOTY2YWY1NmFlZTQ3MTlhNzU2YmUwNjcxNWFhYzUxL3RhYmxlOmIxZTdjMTA1OTIwMTQ4ZTQ4NDZmMmNjNjE3ZjgyNjZkL3RhYmxlcmFuZ2U6YjFlN2MxMDU5MjAxNDhlNDg0NmYyY2M2MTdmODI2NmRfMy04LTEtMS0w_37645b10-695b-4941-8692-2ba04843d3d0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTI3OQ_db252bda-9b1a-424e-b2e4-e6fa2f70b6e7">Stockholders' Equity&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 10, 2020, the Company filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2021, the Company completed a public offering of 4,255,000 shares of its common stock at a public offering price of $16.25 per share. Net proceeds from the offering were approximately $64.7 million, after deducting underwriting discounts and commissions and offering expenses of $4.4 million. The shares were registered pursuant to the Company's Shelf Registration Statement discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Outstanding Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following equity classified warrants to purchase common stock were outstanding as of March&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252,798&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2fe73e79f1c549a483f3917d929c8e40_D20201110-20201110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTA5OTUxMTYzMTYxNw_d00382a8-5cff-4744-9a1e-0cd76d82f0f1"
      unitRef="shares">150000000.0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icc1bb719e1074fdebd679404c35cd358_D20210325-20210325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTA5OTUxMTYyOTE4MA_f7d98627-33b9-4097-95bc-2b75ab5e099d"
      unitRef="shares">4255000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i74ff8c067c394119ba0c56e9d82ededc_I20210325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTA5OTUxMTYyOTI0MQ_7e970ac4-e740-4d38-b062-ee683707a45d"
      unitRef="usdPerShare">16.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="icc1bb719e1074fdebd679404c35cd358_D20210325-20210325"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTA5OTUxMTYyOTM3Mg_29c4a772-dad7-4fca-a1e6-16e7ca00c306"
      unitRef="usd">64700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <exdx:StockIssuanceCosts
      contextRef="i74ff8c067c394119ba0c56e9d82ededc_I20210325"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTA5OTUxMTYyOTQ1Nw_458feb86-cc3a-4a96-97aa-cd188c9fd87f"
      unitRef="usd">4400000</exdx:StockIssuanceCosts>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RleHRyZWdpb246YjAyMTU3Y2FlYzAxNDNiZmJmNDlhMzVlNzFmNGNlNTdfMTI4MA_a3ea7015-e7d5-4819-b4d1-8e392bd900be">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following equity classified warrants to purchase common stock were outstanding as of March&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252,798&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7c19a7a2bfad4edd8ddd7b2557ae3114_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfMS0xLTEtMS0w_de775313-c111-4a84-978f-44d600cae211"
      unitRef="shares">252798</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7c19a7a2bfad4edd8ddd7b2557ae3114_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfMS0zLTEtMS0w_bfbd14e6-dbce-48d3-9e05-1f2907920246"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i350d91760ddf4160af25d20cd8d9b448_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfMi0xLTEtMS0w_0dc2c0d7-0218-449b-bade-54af48c40765"
      unitRef="shares">69176</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i350d91760ddf4160af25d20cd8d9b448_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfMi0zLTEtMS0w_743315f8-4e5a-4062-af55-410f7f7f0cbb"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="iafc3772ba3454fac8749b13340ee0e47_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfMy0xLTEtMS0w_010c2b7c-4c4e-4cc1-8ef4-0dd183a93eeb"
      unitRef="shares">131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iafc3772ba3454fac8749b13340ee0e47_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfMy0zLTEtMS0w_7856f4b2-b98e-43c5-8f11-b07decfc3ad6"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="iaea87b8242ef4b51bfab54bca764763b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfNC0xLTEtMS0w_dcb9689e-9c09-44d8-822f-61e914bc9f69"
      unitRef="shares">83778</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iaea87b8242ef4b51bfab54bca764763b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfNC0zLTEtMS0w_a280ce6b-60c4-4310-beba-e58107db8d62"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i246430710e7b464984f4d6c04203b925_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfNS0xLTEtMS0w_218a5081-de0b-46ea-a530-7b5f0d953ca3"
      unitRef="shares">20944</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i246430710e7b464984f4d6c04203b925_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfNS0zLTEtMS0w_e5f6e16f-67b8-4462-ad34-cd3e85e44813"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="idc581bdd73dd4021b430c6ee34ea7187_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81Mi9mcmFnOmIwMjE1N2NhZWMwMTQzYmZiZjQ5YTM1ZTcxZjRjZTU3L3RhYmxlOjNjOTM2ZjBhMDY5YzQxYWZiMGQ3ZjFlZDE4MGI2MzgyL3RhYmxlcmFuZ2U6M2M5MzZmMGEwNjljNDFhZmIwZDdmMWVkMTgwYjYzODJfNi0xLTEtMS0w_73105143-f060-4e4a-8757-c23c8d9d7d98"
      unitRef="shares">426827</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTc4NA_fa9ea043-5d29-436b-96e2-d3d61df66949">Stock Option Plan&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Incentive Award Plan (the 2019 Plan). Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant. As of March&#160;31, 2021, 1,391,215 shares remained available for future awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the Employee Stock Purchase Plan (the ESPP). The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. As of March&#160;31, 2021, 345,493 shares remained available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,041,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,041,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;665,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. As of March&#160;31, 2021, total unrecognized compensation cost related to option awards was $8.8 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.6&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the quarter ended March&#160;31, 2021, the Company awarded 185,000 RSUs at a weighted-average grant date fair value per share of $18.20 to certain employees, all of which are outstanding and unvested as of March&#160;31, 2021. As of March&#160;31, 2021, total unrecognized compensation cost related to restricted stock units was $3.3 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47%-50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6%-1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense for the ESPP was immaterial for the three months ended March&#160;31, 2021 and 2020. As of March&#160;31, 2021, total unrecognized compensation cost related to stock purchase rights granted under the ESPP $0.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ifb31a3a85da44447bf660e6e7ba47571_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfNzQx_b913a2f4-f582-42a7-8f34-9fc0c57ab8df">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifb31a3a85da44447bf660e6e7ba47571_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfODc2_14ce64d1-e543-4272-b5bf-8ae1999f8b60">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i2c847c7e24b747288c96c2df35a0d98f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfOTEz_d48a02ea-cefd-4692-9c9d-50ac867b93e3"
      unitRef="shares">1391215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i9740e39188bc48939564a399602a85af_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMTMxMw_76dccde2-aaeb-4a88-8748-9f325c7ea362"
      unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9740e39188bc48939564a399602a85af_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMTQ0NQ_9e7c2b4d-e910-43de-ba1b-a41e57f8192c"
      unitRef="shares">345493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTc4MQ_8ecbee46-4e5b-443e-9c0f-326bdb3013c9">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,041,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,041,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;665,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i205b83f91058431aacdac5b60d121b3b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMS0yLTEtMS0w_96d8d1e8-3f51-4bb2-9c1f-d2476d8e34c8"
      unitRef="shares">1975761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i205b83f91058431aacdac5b60d121b3b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMS00LTEtMS0w_5576bbe0-a72a-4fd3-99c0-c8d475a2b915"
      unitRef="usdPerShare">11.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9f7571bc1a6842eea4966067cef12287_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMS02LTEtMS0w_224a9f41-996a-4ece-9e8a-dbb21854436f">P8Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i205b83f91058431aacdac5b60d121b3b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMS04LTEtMS0w_3206487d-759d-4874-95e8-9c9bfc4ab6a1"
      unitRef="usd">6750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMi0yLTEtMS0w_e484f961-9220-4f23-8574-e8de45b1ecf0"
      unitRef="shares">88750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMi00LTEtMS0w_9499c7fe-be4b-44fb-b239-0f0af987abae"
      unitRef="usdPerShare">18.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMy0yLTEtMS0w_7e2f50e8-e3aa-4a81-8fcc-03e4a3e479f4"
      unitRef="shares">3381</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfMy00LTEtMS0w_e5aba6a7-65ed-42aa-9171-e99857fcddd3"
      unitRef="usdPerShare">12.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNC0yLTEtMS0w_d7e107c0-92eb-48c0-8d54-0c1015c9eff0"
      unitRef="shares">17197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNC00LTEtMS0w_e84e36b1-740d-4d1b-8851-270a50f64062"
      unitRef="usdPerShare">12.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNS0yLTEtMS0w_8c0f8cb6-c665-4031-a96f-5ff875cde974"
      unitRef="shares">2353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNS00LTEtMS0w_04827d84-a76b-40c1-a757-48453f89eac8"
      unitRef="usdPerShare">29.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNi0yLTEtMS0w_89316ac6-8b74-496f-a9f4-d2f2c3931466"
      unitRef="shares">2041580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNi00LTEtMS0w_e011913e-a458-4f09-9269-ff35fa019859"
      unitRef="usdPerShare">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNi02LTEtMS0w_33f8ce3d-c9d3-43ee-9f0d-2749d941e26f">P8Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNi04LTEtMS0w_b2d01d7f-2720-4fcb-bec5-c7a8b6fb96cb"
      unitRef="usd">13247000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNy0yLTEtMS0w_89e97478-1999-4f59-a814-bdfd2551de22"
      unitRef="shares">2041580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNy00LTEtMS0w_5e545ca2-1387-4025-90d4-1aebff2e8c25"
      unitRef="usdPerShare">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNy02LTEtMS0w_4e46c56c-d252-4688-bf41-0c9e931e7cba">P8Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfNy04LTEtMS0w_06e2efd0-c89d-434d-afe9-e7a51b4159b8"
      unitRef="usd">13247000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfOC0yLTEtMS0w_54aaac00-f66e-40d7-9f1c-d1870b4bb70c"
      unitRef="shares">665878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfOC00LTEtMS0w_6edf2094-c831-4914-8fb1-aa71bef76279"
      unitRef="usdPerShare">9.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfOC02LTEtMS0w_4a6d734e-552c-4b75-a2af-7a93ca650bae">P8Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjg1MDQ2MjY4MWIwMzQ5MjRhMjg1ZTIzZjkzZDQ0NjEyL3RhYmxlcmFuZ2U6ODUwNDYyNjgxYjAzNDkyNGEyODVlMjNmOTNkNDQ2MTJfOC04LTEtMS0w_eb4f8fa5-d6ef-4405-b779-7935963f64a2"
      unitRef="usd">6013000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if56d5f147a234f47a5c286cd55a8ab8d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMzI3Mg_ab3ee84b-bac9-4fcf-92b2-63a552662759"
      unitRef="usd">8800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMzQxNQ_be73fedc-702f-4c4a-aea5-f7c2b8af116b">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMzg0ODI5MDcwMjM0OA_3973ff7a-6d1c-4887-963d-d8543d7cd4b3">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i74e686b941754a318cfceeff5fffc858_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMS0yLTEtMS03NjU_f3c587c2-9dba-48d5-8917-8c2ce48606ef"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i74e686b941754a318cfceeff5fffc858_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMS00LTEtMS03NjU_fcc375f0-44f1-4881-b987-1f8d0f2f4cec"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i74e686b941754a318cfceeff5fffc858_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMS04LTEtMS03NjU_9a9ee1ff-6f85-4a2f-9c9d-031ffc4c0d08"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMi0yLTEtMS03NjU_904a54f2-d14f-4cb4-8923-593bd4f4dd61"
      unitRef="shares">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMi00LTEtMS03NjU_03cff8af-12a5-4e3b-8e07-aadaabccb266"
      unitRef="usdPerShare">18.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMy0yLTEtMS03NjU_38c91d0d-f126-4611-80d1-c19502105f25"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfMy00LTEtMS03NjU_e4a16b62-909f-49f0-8de1-5687c58bc5d8"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfNC0yLTEtMS03NjU_f63b08f8-27d2-4879-99b0-49984f2d7641"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfNC00LTEtMS03NjU_3fb0466c-8134-47db-9139-65e7913a3653"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idb431306073e41619a17523f2b2e4c23_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfNi0yLTEtMS03NjU_562725a7-a4c4-43ba-a36a-4c62fce04cc3"
      unitRef="shares">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idb431306073e41619a17523f2b2e4c23_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfNi00LTEtMS03NjU_3bc11ab8-97af-4775-ac3d-05376f1c003a"
      unitRef="usdPerShare">18.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="idb431306073e41619a17523f2b2e4c23_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjkyYmQ3MTE0ZTU0MzQ0MGNhNjNmMTNlZmI0ODA0YWUxL3RhYmxlcmFuZ2U6OTJiZDcxMTRlNTQzNDQwY2E2M2YxM2VmYjQ4MDRhZTFfNi04LTEtMS03NjU_3f5c75d1-f5c0-44f2-b5d3-a75afb1ed12f"
      unitRef="usd">3238000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMjk2OA_98ff4cd0-3975-433f-b215-c37bd3d8c2d9"
      unitRef="shares">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzNDk3MQ_ff8b4432-e123-4904-bd69-885b76847dfb"
      unitRef="usdPerShare">18.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="idb431306073e41619a17523f2b2e4c23_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMzc4MQ_705395b1-edca-4d85-b235-66220f6ae053"
      unitRef="usd">3300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie39b84825f574994abaa8d85a16bf48d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzMzkyMg_646e612b-89f5-42fb-a6c0-7ce92b2be490">P3Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTc4Mg_fca7cf0d-f412-4b39-901a-81f3a3ad8147">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47%-50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6%-1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfMi0yLTEtMS0wL3RleHRyZWdpb246NDIxZjgxMGJlOTMwNDk2Mjg1Yjk3MDZmNDBiODdhMjlfNA_082724a6-b20c-4689-84ac-125b1e352831"
      unitRef="number">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfMi00LTEtMS0wL3RleHRyZWdpb246NzI4NGFiMGUxNDZlNGRlYWE3MTk1Y2YzNDM1ZjNhNTZfMTA5OTUxMTYyNzc4Mw_3cb4e51e-5607-4fb8-adce-77b5efaf93ec"
      unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfMi00LTEtMS0wL3RleHRyZWdpb246NzI4NGFiMGUxNDZlNGRlYWE3MTk1Y2YzNDM1ZjNhNTZfMTA5OTUxMTYyNzc5MA_7d5b1576-d299-42d8-8ad7-14f2c4e8372e"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfMy0yLTEtMS0wL3RleHRyZWdpb246MjcxZGZmMWUyNTljNDg0NjkwNGFhYjE2MmY1NTc5ZDdfNA_9c689ee8-09f0-4678-b3a7-3a3ac78aedbe"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfMy00LTEtMS0wL3RleHRyZWdpb246YTBiMzNkZTc0YjBhNDE5Mzk0OGIxNTNjNTMxN2ZlZmZfMTA5OTUxMTYyNzc4Mg_9c5d4460-2b55-46e9-a5a4-bea94c13e6ba"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfMy00LTEtMS0wL3RleHRyZWdpb246YTBiMzNkZTc0YjBhNDE5Mzk0OGIxNTNjNTMxN2ZlZmZfMTA5OTUxMTYyNzc4OA_db5920dd-a7be-487d-acea-b9c149de88aa"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfNC0yLTEtMS0w_86d5fc86-d79d-414c-aac9-ac490f5ed907"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfNC00LTEtMS0w_ed537c13-0a53-4bfe-a9ae-f5b6a8dcf2df"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3636c80610a2496b91acc3a427ed857c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfNS0yLTEtMS0wL3RleHRyZWdpb246MTNiZmNhNDhlNGIwNDIzY2JiZjI4MzFjZmNhODZmNTZfNA_3465b02d-da1f-474b-a291-54f7da9b4281">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iee5a6beb4c2442e6948f35138fe7e604_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjY5ZTQwZTI1YzQ2NzQ4ODhiZjBiYjJlOTVjNTA3NmI3L3RhYmxlcmFuZ2U6NjllNDBlMjVjNDY3NDg4OGJmMGJiMmU5NWM1MDc2YjdfNS00LTEtMS0wL3RleHRyZWdpb246NGQxNTAxZDcwN2IzNGQxZWFiODk5MWQ0MDI3MTViYTNfMTA5OTUxMTYyNzc4Ng_ccc9c390-c76e-4754-a7d0-36013592baea">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMzg0ODI5MDcwMjM0Nw_15f1e12b-96f9-4df1-a4d8-565a8916a281">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2b8c82dfa9c441afb9faca3a14a0e8c3_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfMi0yLTEtMS02MjY_39e25baa-9029-44f5-864e-e7b17895609a"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0c0b8637038f4e0485961f9c7baa5391_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfMi00LTEtMS02MjY_da077daf-0f22-4092-886e-31d2475c2456"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2b8c82dfa9c441afb9faca3a14a0e8c3_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfMy0yLTEtMS02MjY_8f92c356-523f-44dc-b1db-c108d318289d"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0c0b8637038f4e0485961f9c7baa5391_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfMy00LTEtMS02MjY_476c8ea7-2f7a-43c9-9526-6b757f9f8c2a"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2b8c82dfa9c441afb9faca3a14a0e8c3_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfNC0yLTEtMS02MjY_a8175f21-b4d7-4b3d-9da6-6b52e44a4ffc"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0c0b8637038f4e0485961f9c7baa5391_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfNC00LTEtMS02MjY_c966a320-9bf5-434e-a467-f5acac4c2526"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2b8c82dfa9c441afb9faca3a14a0e8c3_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfNS0yLTEtMS02MjY_2c5d3432-7b8c-4839-a8c0-cd41d3efbb80">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0c0b8637038f4e0485961f9c7baa5391_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOmQ3YjZmM2ZhOGZiZTQyMmNhZjdkZmJlYjJjYjJmNDEyL3RhYmxlcmFuZ2U6ZDdiNmYzZmE4ZmJlNDIyY2FmN2RmYmViMmNiMmY0MTJfNS00LTEtMS02MjY_a7a0851a-7c13-418f-be66-bacefc2647c8">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i9740e39188bc48939564a399602a85af_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzNDI4NA_19158832-3fca-4bb4-9b8b-2da468919867"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2b8c82dfa9c441afb9faca3a14a0e8c3_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTA5OTUxMTYzNDQyMw_21bfdb75-4451-4662-9403-f2e25b65a58e">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RleHRyZWdpb246NmI4ZTU5NThlYzUxNDk0NWJkNDU0MWVlY2JjMDdmMDVfMTc4Mw_79a90f1a-aded-4467-b53e-28fbda39eb53">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2512bb71fe984f9f8a14d808494366bf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfMi0yLTEtMS0w_e56033c3-717d-4146-91af-0e5121add8f9"
      unitRef="usd">11000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id44b1e4210bc4a58b1886b02e42edda2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfMi00LTEtMS0w_823005bc-f500-44cd-9df0-9bddd38643b5"
      unitRef="usd">6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i05daa2aed2c447f9b2aaf190a27f3d81_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfMy0yLTEtMS0w_ebe05368-5f80-4604-9f52-cacfd14727eb"
      unitRef="usd">791000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i713b0e54a4ca43bfb3140d1b4aff6cd1_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfMy00LTEtMS0w_19416b2a-031d-4731-9d29-a32a0310bf1e"
      unitRef="usd">422000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i414d38c16c134af097eb843d3bb15bc4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfNC0yLTEtMS0w_8bb13fbd-dfe1-4b87-a9cc-a8793cf8bed5"
      unitRef="usd">110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icbf102bb294e439ca5afd862c3fe6335_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfNC00LTEtMS0w_d23d5647-9406-4f4c-ac5e-a33dcc796af4"
      unitRef="usd">3000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfNS0yLTEtMS0w_6f040a2b-2946-47bf-984f-816d4f86ab9d"
      unitRef="usd">912000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV81NS9mcmFnOjZiOGU1OTU4ZWM1MTQ5NDViZDQ1NDFlZWNiYzA3ZjA1L3RhYmxlOjJjYjVkNzJlODVlMTQ3Y2I4YTc2N2NkNDRmYWY5Njg2L3RhYmxlcmFuZ2U6MmNiNWQ3MmU4NWUxNDdjYjhhNzY3Y2Q0NGZhZjk2ODZfNS00LTEtMS0w_035304f2-d093-4382-b373-baf79d2ff0f3"
      unitRef="usd">431000</us-gaap:AllocatedShareBasedCompensationExpense>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock
      contextRef="ib3192990da444100b6eb7449a48628b2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV82MS9mcmFnOjU0ZTJjY2M0MTY5NzQ2NTZhYTM0ZmNiNmU4YTc5NDI2L3RleHRyZWdpb246NTRlMmNjYzQxNjk3NDY1NmFhMzRmY2I2ZThhNzk0MjZfNjg3Nw_bf6ca7ed-8afc-49ba-9ed4-c5d2cc6ccf10">COVID-19&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, due to the worldwide COVID-19 pandemic, the Company experienced a reduction in patient test volumes, delays in patient enrollment in ongoing and planned clinical studies, and delays in the procurement of its testing supplies. In response to the pandemic, the Company has curtailed non-essential employee travel, equipped employees with the ability to work remotely with the exception of clinical laboratory employees, and reduced marketing spend and employee headcount. The full extent to which the COVID-19 pandemic will directly or indirectly continue to impact the Company's business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional and international markets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. The CARES Act did not have a material impact on the Company's effective tax rate or income tax provision for the three months ended March 31, 2020. Under the Tax Cuts and Jobs Act (TCJA), NOLs generated post TCJA were allowed to be carried forward indefinitely but were only allowed to offset 80% of taxable income. As a result of the CARES Act and the change to permit NOLs generated in taxable years 2018, 2019 and 2020 to offset 100% of taxable income, the Company released valuation allowance &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;against its deferred tax assets in the amount of $0.1 million. The release of valuation allowance resulted in a discrete tax benefit of $0.1&#160;million in the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law. It provides additional COVID-19 focused relief and extends certain provisions of the CARES Act. At this time, the Company does not believe that the Consolidated Appropriations Act, 2021 has a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance
      contextRef="i5194501b750d4090955a5e16b78c217c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV82MS9mcmFnOjU0ZTJjY2M0MTY5NzQ2NTZhYTM0ZmNiNmU4YTc5NDI2L3RleHRyZWdpb246NTRlMmNjYzQxNjk3NDY1NmFhMzRmY2I2ZThhNzk0MjZfNTA1Nw_b50afc7a-af0c-4e71-b6fb-9ffa9823e911"
      unitRef="usd">100000</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit
      contextRef="i6e93a80658024513a0e5ed41e7162c6e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV82MS9mcmFnOjU0ZTJjY2M0MTY5NzQ2NTZhYTM0ZmNiNmU4YTc5NDI2L3RleHRyZWdpb246NTRlMmNjYzQxNjk3NDY1NmFhMzRmY2I2ZThhNzk0MjZfNTE0Mg_cf3c654f-5275-47e7-9711-f47b195ef73d"
      unitRef="usd">100000</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279177338024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 07, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXAGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0434866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1261 Liberty Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vista,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">560-1501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,928,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001274737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279254340328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 118,050<span></span>
</td>
<td class="nump">$ 57,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">8,221<span></span>
</td>
<td class="nump">8,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,098<span></span>
</td>
<td class="nump">4,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">129,369<span></span>
</td>
<td class="nump">70,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,378<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,506<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">137,522<span></span>
</td>
<td class="nump">78,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,170<span></span>
</td>
<td class="nump">3,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">5,714<span></span>
</td>
<td class="nump">5,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,884<span></span>
</td>
<td class="nump">8,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">26,864<span></span>
</td>
<td class="nump">26,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">36,052<span></span>
</td>
<td class="nump">36,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at March&#160;31, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized at March&#160;31, 2021 and December 31, 2020; 16,925,680 and 12,652,308 shares issued and outstanding at March&#160;31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">288,951<span></span>
</td>
<td class="nump">223,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(187,498)<span></span>
</td>
<td class="num">(181,289)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">101,470<span></span>
</td>
<td class="nump">41,839<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 137,522<span></span>
</td>
<td class="nump">$ 78,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279179073912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">16,925,680<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">16,925,680<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279254380280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 10,587<span></span>
</td>
<td class="nump">$ 9,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="nump">4,711<span></span>
</td>
<td class="nump">4,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">10,040<span></span>
</td>
<td class="nump">9,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">16,154<span></span>
</td>
<td class="nump">14,805<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,567)<span></span>
</td>
<td class="num">(5,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(645)<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(6,209)<span></span>
</td>
<td class="num">(5,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,209)<span></span>
</td>
<td class="num">$ (5,563)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (USD per share)</a></td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of shares used to compute net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">12,943,237<span></span>
</td>
<td class="nump">12,595,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279177532088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 55,659<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 220,248<span></span>
</td>
<td class="num">$ (164,602)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Net exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet', window );">Net exercise of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,563)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,627,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 50,537<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">220,689<span></span>
</td>
<td class="num">(170,165)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">12,652,308<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 41,839<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">223,115<span></span>
</td>
<td class="num">(181,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock in public offering, net of issuance costs of $4,435 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock in public offering, net of issuance costs of $4,435</a></td>
<td class="nump">64,709<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">64,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,209)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">16,925,680<span></span>
</td>
<td class="nump">16,925,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 101,470<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 288,951<span></span>
</td>
<td class="num">$ (187,498)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279173558728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 4,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279174032024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,209)<span></span>
</td>
<td class="num">$ (5,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">912<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">689<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(792)<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(317)<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,312)<span></span>
</td>
<td class="num">(3,301)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from common stock issued under Employee Stock Purchase Pan</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payment on capital lease obligations</a></td>
<td class="num">(96)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock in public offering, gross</a></td>
<td class="nump">69,144<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs related to public offering</a></td>
<td class="num">(4,186)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">65,081<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">60,602<span></span>
</td>
<td class="num">(3,436)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">57,548<span></span>
</td>
<td class="nump">72,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">118,150<span></span>
</td>
<td class="nump">68,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_EquipmentPurchasedUnderCapitalLease', window );">Equipment purchased under capital lease obligations</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Costs incurred, but not paid, in connection with capital expenditures</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities', window );">Issuance costs included in accounts payable and accrued liabilities</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DeferredOfferingCostsReclassifiedToEquity', window );">Deferred offering costs reclassified to equity</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Included within Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredOfferingCostsReclassifiedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Reclassified to Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredOfferingCostsReclassifiedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_EquipmentPurchasedUnderCapitalLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equipment Purchased Under Capital Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_EquipmentPurchasedUnderCapitalLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expense and Current Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279173110408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exagen Inc. (the Company) is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At March&#160;31, 2021, the Company had cash and cash equivalents of $118.1 million and had an accumulated deficit of $187.5 million. Since inception, the Company has financed its operations primarily through a combination of equity financings of common stock and private placements of preferred securities, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279173076296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed balance sheet as of March&#160;31, 2021, the condensed statements of operations and the condensed statements of stockholders' equity for the three months ended March&#160;31, 2021 and 2020 and cash flows for the three months ended March&#160;31, 2021 and 2020 and the related footnote disclosure are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments, necessary for the fair presentation of the Company's financial position as of March&#160;31, 2021 and its results of operations for the three month periods presented. The results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December 31, 2020, included in its Annual Report on Form 10-K filed with the SEC on March 16, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill) and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, approximately 81%, and 83%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on key suppliers for certain laboratory materials. For the three months ended March&#160;31, 2021 and 2020, approximately 98% and 96%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,062&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay that is immaterial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $0.1 million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payors) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Promotion Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a co-promotion agreement (the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. The Company is responsible for the costs associated with its sales force over the course of such co-promotion. Janssen is responsible for all other aspects of the commercialization of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company is entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over a predetermined baseline. For quarter ended March&#160;31, 2020, the tiered promotion fee ranged from $750 to $1,250 per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020, the Janssen Agreement was amended (June Amended Janssen Agreement) to adjust the predetermined average baseline for the third and fourth quarters of 2020, and for each of the third and fourth quarters of 2020, the Company received a minimum promotion fee of $0.3&#160;million and the fee was capped at 5% above the adjusted predetermined baseline. In December 2020, the Janssen Agreement was further amended. The Janssen Agreement, as amended in June 2020 and December 2020 is collectively referred to as the Amended Janssen Agreement. In accordance with the Amended Janssen Agreement, the predetermined average baseline for prescribed units for the quarters ending December 31, 2020, March 31, 2021 and June 30, 2021, was adjusted to approximately 28,750 prescribed units per quarter, subject to adjustment under certain circumstances. For the first and second quarter of 2021, the Company will be entitled to an amended tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units. Pursuant to the Amended Janssen Agreement, for the first and second quarters of 2021, the Company will receive a minimum promotion fee of $0.3&#160;million and the fee will be capped at 10% above the adjusted predetermined baseline. The quarterly tiered promotion fee for the remaining term of the Janssen Promotion Agreement beginning on July 1, 2021 will revert to the terms set forth in the Janssen Agreement prior to amendment, with no minimum promotion fee and no cap on predetermined baseline units. In addition, during the term of the Janssen Agreement, the Company is restricted </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from promoting any other biologic or Janus kinase inhibitor, or JAK inhibitor, used for treatment of indications covered by the agreement without first obtaining Janssen's written consent. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Janssen Agreement expires on December 31, 2021, unless extended by the Company for an additional 12 months upon 180 days written notice prior to the end of the current term. If the Company elects to extend the term, the predetermined baseline for 2022 will be subject to future agreement by the Company and Janssen. Janssen may terminate the Amended Janssen Agreement at any time for any reason upon 30 days' notice to the Company, and the Company may terminate the Amended Janssen Agreement for any reason at the end of any calendar quarter upon 30 days' notice to Janssen. Either party may terminate the Amended Janssen Agreement in the event of the other party's default of any of its material obligations under the agreement if such default remains uncured for a specified period of time following receipt of written notice of such default.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations relating to sales and co-promotion services for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a series of single performance obligations since Janssen simultaneously receives and consumes benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations is based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the agreement is cancelable. The Company recognized co-promotion revenue of approximately $0.3 million and no co-promotion revenue during the three months ended March&#160;31, 2021 and 2020, respectively. The related expenses for marketing SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are included in selling, general and administrative expenses and are expensed as incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.3 million and $0.4 million for the three months ended March&#160;31, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.5 million and $0.4 million for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the employee stock purchase plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest annually from the grant date in four equal installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy RSUs upon vesting. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, the Company awarded 185,000 RSUs to certain employees, all of which are outstanding and unvested as of March&#160;31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan and shares of the Company's common stock pursuant to Employee Stock Purchase Plan. For the three months ended March&#160;31, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.669%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,041,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,630,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,656,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,068,616&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279171490360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial Information<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,506&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,043&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended March&#160;31, 2021 and 2020 was approximately $0.2 million and $0.1 million, respectively. At March&#160;31, 2021 and December 31, 2020, the gross book value of assets under capital lease was $1.6 million and $1.2 million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,714&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279259327672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Term Loan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $20.0 million, $17.8 million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $5.0 million under the 2017 Term Loan. At March&#160;31, 2021, no additional amounts remain available to borrow under the 2017 Term Loan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company executed the First Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the Loan Amendment is 8.5%, of which 2.0% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2022, after which interest accrues at an annual rate of 8.5%. The Company has estimated the effective interest rate of this loan to be approximately 10%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the Loan Amendment will be repaid in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZmUxOTFmMzJiNTQ0Mjk5NjA5NmFhNjdmNWUyNzhhL3NlYzpkZmZlMTkxZjMyYjU0NDI5OTYwOTZhYTY3ZjVlMjc4YV80MC9mcmFnOmQxN2FiZDRhODA5OTQ0YjFhYjk3ODZjZmY2ZGY0ZGE0L3RleHRyZWdpb246ZDE3YWJkNGE4MDk5NDRiMWFiOTc4NmNmZjZkZjRkYTRfMTExOQ_943420c3-685f-4155-98c0-99295e2c5baa">twenty-four</span> equal monthly installments commencing in December 2022. Upon repayment of the final installment under the Loan Amendment, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of Loan Amendment using the effective interest method. For each of the three months ended March&#160;31, 2021 and 2020, the Company issued PIK Loans totaling $0.1 million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Amendment requires a prepayment premium of 3% of the aggregate outstanding principal. The prepayment premium decreases by 1% during each subsequent twelve-month period after November&#160;19, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the Company was in compliance with all covenants of the Loan Amendment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the Loan Amendment covenants, the repayment of the Loan Amendment may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Minimum Payments on the Outstanding Borrowings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,084)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,864&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279173110408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the Company leases office and laboratory space in Vista, California, under leases that expire in January 2026, with an option to extend a portion of the lease for an additional 5-year period. In addition, the Company also leases additional office space in Vista, California, under a lease that expires in January 2026 with an option to extend the lease for an additional 5-year period. The Company's lease payments under each of these leases are subject to escalation clauses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, rent expense was $0.2 million and $0.1 million, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. As of March&#160;31, 2021 and December 31, 2020, the remaining milestone obligation is for an additional $2.0 million payment due to Prometheus Laboratories, Inc. (Prometheus) for which the fair value was determined to be zero at March&#160;31, 2021 and December 31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has ongoing royalty payment obligations on net sales of products which incorporate certain acquired technologies of 2.5%. Future royalties payable under these arrangements are limited to the lesser of an aggregate of $1.2 million (including an upfront payment of $100,000) or the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments on net sales of products which incorporate licensed technology, as defined, ranging from 2.0% to 3.0%. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the first quarter of 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute, or AHN, to obtain an exclusive license to AHN's patent rights in certain inventions, or the AGN Patent Rights, in May 2021, pursuant to which the Company is required to pay AHN an initial license fee of $0.4 million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $4.1 million and $6.0 million for the years ended December 31, 2021 and 2022, respectively, with a 15% annual increase thereafter through the year ended December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the first quarter 2021, the Company entered into a master research collaboration agreement with AHN in May 2021, pursuant to which the Company is required to pay AGN a collaboration fee of $0.4 million for each year during the initial term of the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payors and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or of which of the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279173108360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value MeasurementsThe following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The fair value of the Company's money market funds is based on quoted market prices.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279171745016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2020, the Company filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company completed a public offering of 4,255,000 shares of its common stock at a public offering price of $16.25 per share. Net proceeds from the offering were approximately $64.7 million, after deducting underwriting discounts and commissions and offering expenses of $4.4 million. The shares were registered pursuant to the Company's Shelf Registration Statement discussed above. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Warrants</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of March&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252,798</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,176</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279171692664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option Plan</a></td>
<td class="text">Stock Option Plan<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Incentive Award Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Incentive Award Plan (the 2019 Plan). Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant. As of March&#160;31, 2021, 1,391,215 shares remained available for future awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the Employee Stock Purchase Plan (the ESPP). The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. As of March&#160;31, 2021, 345,493 shares remained available for issuance under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,041,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,041,580&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">665,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. As of March&#160;31, 2021, total unrecognized compensation cost related to option awards was $8.8 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.6&#160;years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March&#160;31, 2021, the Company awarded 185,000 RSUs at a weighted-average grant date fair value per share of $18.20 to certain employees, all of which are outstanding and unvested as of March&#160;31, 2021. As of March&#160;31, 2021, total unrecognized compensation cost related to restricted stock units was $3.3 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.9 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47%-50%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6%-1.7%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for the ESPP was immaterial for the three months ended March&#160;31, 2021 and 2020. As of March&#160;31, 2021, total unrecognized compensation cost related to stock purchase rights granted under the ESPP $0.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.4 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279171713128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Covid-19<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReorganizationsAbstract', window );"><strong>Reorganizations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock', window );">Covid-19</a></td>
<td class="text">COVID-19<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, due to the worldwide COVID-19 pandemic, the Company experienced a reduction in patient test volumes, delays in patient enrollment in ongoing and planned clinical studies, and delays in the procurement of its testing supplies. In response to the pandemic, the Company has curtailed non-essential employee travel, equipped employees with the ability to work remotely with the exception of clinical laboratory employees, and reduced marketing spend and employee headcount. The full extent to which the COVID-19 pandemic will directly or indirectly continue to impact the Company's business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional and international markets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. The CARES Act did not have a material impact on the Company's effective tax rate or income tax provision for the three months ended March 31, 2020. Under the Tax Cuts and Jobs Act (TCJA), NOLs generated post TCJA were allowed to be carried forward indefinitely but were only allowed to offset 80% of taxable income. As a result of the CARES Act and the change to permit NOLs generated in taxable years 2018, 2019 and 2020 to offset 100% of taxable income, the Company released valuation allowance </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">against its deferred tax assets in the amount of $0.1 million. The release of valuation allowance resulted in a discrete tax benefit of $0.1&#160;million in the first quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law. It provides additional COVID-19 focused relief and extends certain provisions of the CARES Act. At this time, the Company does not believe that the Consolidated Appropriations Act, 2021 has a material impact on its financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReorganizationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReorganizationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279254244952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risk and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payors) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.3 million and $0.4 million for the three months ended March&#160;31, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the employee stock purchase plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest annually from the grant date in four equal installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy RSUs upon vesting. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, the Company awarded 185,000 RSUs to certain employees, all of which are outstanding and unvested as of March&#160;31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan and shares of the Company's common stock pursuant to Employee Stock Purchase Plan. For the three months ended March&#160;31, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted; Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279174211176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</a></td>
<td class="text">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,062&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay that is immaterial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.669%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,041,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,630,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,656,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,068,616&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279277455720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid expenses table</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,506&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,043&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,714&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279171667976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,084)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,864&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279171724568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</a></td>
<td class="text">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279171423544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of March&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252,798</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,176</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279169107160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,041,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,041,580&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">665,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions, Stock Options</a></td>
<td class="text">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47%-50%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6%-1.7%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions, Employee Stock Purchase Plan</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279173110088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 118,050<span></span>
</td>
<td class="nump">$ 57,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 187,498<span></span>
</td>
<td class="nump">$ 181,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279177472408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Major Payers (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember', window );">United Healthcare | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI) | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_BlueShieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_BlueShieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=exdx_ReceivableBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=exdx_ReceivableBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_UnitedHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279169870648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>unit </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline', window );">Joint venture quarterly promotion fee cap</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPrescribedUnits', window );">Joint venture, number of units prescribed quarterly | unit</a></td>
<td class="nump">28,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoPromotionAgreementRenewalTerm', window );">Co-promotion agreement, renewal term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm', window );">Co-Promotion Agreement, Period Before Current Expiration To Extend Term</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement', window );">Co-promotion, number of days' noticed required to give to terminate agreement</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 10,587,000<span></span>
</td>
<td class="nump">$ 9,584,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares) | shares</a></td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline', window );">Joint venture quarterly promotion fee cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription', window );">Joint venture, quarterly promotion fee per prescription</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFee', window );">Joint venture, quarterly promotion fee</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription', window );">Joint venture, quarterly promotion fee per prescription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFee', window );">Joint venture, quarterly promotion fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription', window );">Joint venture, quarterly promotion fee per prescription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription', window );">Joint venture, quarterly promotion fee per prescription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Product Concentration Risk | AVISE CTD Test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Supplier Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-Promotion Agreement, Number Of Days' Notice To Terminate Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-Promotion Agreement, Period Before Current Expiration To Extend Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoPromotionAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-Promotion Agreement, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoPromotionAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPrescribedUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Prescribed Units</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPrescribedUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPromotionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Promotion Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPromotionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Promotion Fee Per Prescription</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPromotionFeePerPrescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exdx_AVISECTDTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exdx_AVISECTDTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279324977320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 10,587<span></span>
</td>
<td class="nump">$ 9,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_HealthcareInsurersMember', window );">Healthcare insurers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">6,027<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_Government1Member', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,009<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_ClientMember', window );">Client</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_HealthcareInsurersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_HealthcareInsurersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_Government1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_Government1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_ClientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_ClientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=us-gaap_OtherCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279256433416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 118,050<span></span>
</td>
<td class="nump">$ 57,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">$ 118,150<span></span>
</td>
<td class="nump">$ 57,548<span></span>
</td>
<td class="nump">$ 68,748<span></span>
</td>
<td class="nump">$ 72,184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279174022376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">2,656,276<span></span>
</td>
<td class="nump">2,068,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">426,827<span></span>
</td>
<td class="nump">436,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">2,041,580<span></span>
</td>
<td class="nump">1,630,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">185,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">2,869<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279169004632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Prepaid expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Diagnostic&#160;testing&#160;supplies</a></td>
<td class="nump">$ 921<span></span>
</td>
<td class="nump">$ 1,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRoyalties', window );">Prepaid product royalties</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PrepaidMaintenanceAndInsuranceContracts', window );">Prepaid maintenance and insurance contracts</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">2,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid and other current assets</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">$ 3,098<span></span>
</td>
<td class="nump">$ 4,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidMaintenanceAndInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Maintenance and Insurance Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidMaintenanceAndInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279177555064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Property and equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 5,506<span></span>
</td>
<td class="nump">$ 5,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,128)<span></span>
</td>
<td class="num">(2,941)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,378<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture&#160;and&#160;fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,148<span></span>
</td>
<td class="nump">2,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279177163000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember', window );">Assets under capital lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279254143816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accrued and other current liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</a></td>
<td class="nump">$ 3,318<span></span>
</td>
<td class="nump">$ 3,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AccruedPurchaseGoodsAndServicesCurrent', window );">Accrued purchases of goods and services</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AccruedLiabilitiesClinicalStudyCurrent', window );">Accrued clinical study activity</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations, current portion</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 5,714<span></span>
</td>
<td class="nump">$ 5,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedLiabilitiesClinicalStudyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Clinical Study, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedLiabilitiesClinicalStudyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedPurchaseGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Purchase, Goods and Services, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedPurchaseGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121569800&amp;loc=d3e45023-112735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279256364952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2018</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan payable | Capital Royalty Partners II LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Loan repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Loan payable | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Term loan borrowings</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Term loan, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Term loan, fee incurred upon payment of final installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentage', window );">Term loan, prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction', window );">Term loan, annual reduction in prepayment penalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance', window );">Term loan covenant, minimum unrestricted cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease', window );">Term loan covenant, increase to interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Paid in-kind note | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPaidInKindLoansIssued', window );">Term loan, paid in-kind loans issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPaidInKindLoansIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Paid In Kind Loans Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPaidInKindLoansIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage, Annual Reduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentStatedInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Stated Interest Rate, Paid In-Kind</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentStatedInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_CapitalRoyaltyPartnersIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_CapitalRoyaltyPartnersIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279177480616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Future minimum payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021 (remaining)</a></td>
<td class="nump">$ 1,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">2,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">15,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">14,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LongTermDebtIncludingUndiscountedInterest', window );">Total</a></td>
<td class="nump">34,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="num">(273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LongTermDebtUndiscountedInterestAmount', window );">Interest</a></td>
<td class="num">(7,084)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">$ 26,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtIncludingUndiscountedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Including Undiscounted Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtIncludingUndiscountedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtUndiscountedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Undiscounted Interest Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtUndiscountedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279256327368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 11, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating lease, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear', window );">Purchase obligation, to be paid remainder of fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase obligation, due in year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage', window );">Annual increase in purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Licensing Agreements | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LicenseAgreementInitialLicenseFee', window );">Initial license fee</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_MilestoneObligation', window );">Remaining milestone obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_MilestoneContingencyFairValueDisclosure', window );">Remaining milestone obligation, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Future minimum royalty commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdvancePayment', window );">Advance royalties payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember', window );">Allegheny Health Network Research Institute | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CollaborationAgreementAnnualCollaborationFee', window );">Collaboration fee</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember', window );">Office and Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeasesRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeMember', window );">Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeasesRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdvancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdvancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementAnnualCollaborationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Annual Collaboration Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementAnnualCollaborationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LicenseAgreementInitialLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Initial License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LicenseAgreementInitialLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_MilestoneContingencyFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Contingency, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_MilestoneContingencyFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_MilestoneObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_MilestoneObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Annual Increase In Commitment, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RoyaltyObligationPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Percentage of Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RoyaltyObligationPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_OfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279173277496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - Money market funds, included in cash and cash equivalents - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">$ 107,983<span></span>
</td>
<td class="nump">$ 34,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">107,983<span></span>
</td>
<td class="nump">34,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279277338744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Nov. 10, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Estimated offering expenses for aggregate expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Initial public offering (in shares)</a></td>
<td class="nump">4,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in public offering, price per share (in dollars per share)</a></td>
<td class="nump">$ 16.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from public offering, net</a></td>
<td class="nump">$ 64,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Estimated offering expenses for aggregate expenses</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279177105176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">426,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member', window );">Warrant expiration January 19, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">252,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member', window );">Warrant expiration March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">69,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member', window );">Warrant expiration April 1, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member', window );">Warrant expiration September 7, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">83,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member', window );">Warrant expiration December 7, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">20,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279177103336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost | $</a></td>
<td class="nump">$ 8.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares that remain available for future awards (in shares) | shares</a></td>
<td class="nump">345,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee payroll deduction percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost | $</a></td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares) | shares</a></td>
<td class="nump">185,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares that remain available for future awards (in shares) | shares</a></td>
<td class="nump">1,391,215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279258468984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock Option Activity (Details) - Stock options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, December 31, 2020 (in shares)</a></td>
<td class="nump">1,975,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">88,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(3,381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(17,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(2,353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, March&#160;31, 2021 (in shares)</a></td>
<td class="nump">2,041,580<span></span>
</td>
<td class="nump">1,975,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, December 31, 2020, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 11.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">18.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">12.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">12.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">29.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, March&#160;31, 2021, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="nump">$ 11.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 6 months 14 days<span></span>
</td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 13,247<span></span>
</td>
<td class="nump">$ 6,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">13,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 6,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, March&#160;31, 2021 (in shares)</a></td>
<td class="nump">2,041,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable, March&#160;31, 2021 (in Shares)</a></td>
<td class="nump">665,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, March&#160;31, 2021, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options exercised, March&#160;31, 2021, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 9.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279177543096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Restricted Stock Units (Details) - Restricted stock units - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, December 31, 2020 (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards released (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards canceled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, March&#160;31, 2021 (in shares)</a></td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, December&#160;31, 2020 (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">18.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Awards released/ Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Awards canceled/Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, March&#160;31, 2021 (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18.20<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,238<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279177523080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279253973944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 912<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279173115288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Covid-19 (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReorganizationsAbstract', window );"><strong>Reorganizations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance', window );">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit', window );">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, income tax benefit</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReorganizationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReorganizationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M==IP*1O*$.UW^FX?6]>7SN_BAKVWUYLP,47])X>*ARTY:^3:;8>V773+H2P
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M9%X_IIP!:BL OV^E-.\O]E*JO81<_P-02P,$%     @ 4XFK4@#0?6*Q @
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M[NZ<>WR[PC/M8"R^Y_0H+ZZ1EK+A_*>^>4SO'$\3T8)NE0Y!X-^!KFA1Z$C
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M5&@#^'W'N3K=Z 6ZS['E_U!+ P04    " !3B:M2#-2SG T%  !;%0  &
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M;>N6RWXN#,0V[)'/.X^) 1LZ<#BB'11I'(I?7Y(07"OJO-E1L]YIM+E&W)\
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M>XP35^6R5(.YB4$)EZU7Y?P9))N\N51\.N@9HE(OF<X 0 7EBEZ1_T)RTJV
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MR5J6%#MA16<@X5$4JO=L7!)77O:NA\MB/8(+=DEY.P'4 1K$<8S=6S'&V@9
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MC(II5@3.QI6VX^H-+HN7#6(I2%5P,,,EPJ< NQ9(QV;IMDIO 0!!U.)1'I
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MA-Z_AN^O@1O;<F2Y, "U/#)U'^= PQ_$$P"J[QEY!$R2?YDG)3%5%[C?6?>
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MES4AM8$%\'[C?1INV,#X)?/JOU!+ P04    " !3B:M2+\E6B+D"  !4!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R]54UOVS ,_2N$-^P#"&K'
M3M<L2P(D[8H-6("B[;K#L(-BT[%067(E.6[^_2C9\5)LS0X#=K$HBGQ\E$AZ
MVBA];PI$"X^ED&86%-96DS T:8$E,R>J0DDGN=(EL[35F]!4&EGFG4H1QE'T
M+BP9E\%\ZG57>CY5M15<XI4&4Y<ET[LE"M7,@F&P5USS36&=(IQ/*[;!&[1?
MJRM-N[!'R7B)TG E06,^"Q;#R7+D[+W!'<?&',C@,EDK=>\VG[-9$#E"*#"U
M#H'1LL5S%,(!$8V'#C/H0SK'0WF/?NESIUS6S."Y$M]X9HM9, X@PYS5PEZK
MYA-V^9PZO%0)X[_0M+;)*("T-E:5G3,Q*+EL5_;8W<.!PSAZQB'N'&+/NPWD
M65XPR^93K1K0SIK0G.!3]=Y$CDOW*#=6TRDG/SN_9%S#'1,UP@J9J372C5LS
M#2V!.Y,P[8"6+5#\#% "*R5M8>"CS#![ZA\2J9Y9O&>VC(\"KI@^@60X@#B*
MAT?PDC[3Q.,E?\_T@IM4*)>L@>^+M;&:BN/'D1BC/L;(QQC]^VT>!7*M.#$5
M2W$64*\9U%L,GD._+1!R):B]N-R 96N!8- :4FI;@*7C<U563.Y>DXY+)E/.
M!'!)>=<>@6R8A08U0MD"9T"*W,7;^GBN?Z@'TUIK%X3Z@!NJ5%MPZ0,<F!8<
M-=-IL8,W_E#5ALG,O)W RJG[)X5;98G&%]RB@&&WQMV:P,*X'":NJG!'%:_O
M:4+E-2$-B'HJ:JHR$B!EI@ *T KX4'.BX9-Z"</H;/!^G#R17KT8Q\/XPX%T
M@2F6:]1[9M%_8):,!J?1V:'P.Z\_U6-XT.DEZHV?9P9254O;-GVO[4?FHIT4
MO\S;>4NOL:$: ($YN48G9Z<!Z':&M1NK*C\WULK2%/)B06,?M3.@\UPIN]^X
M /V/9/X34$L#!!0    ( %.)JU)WZZ$+^@,  #P)   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$T+GAM;*56;6_;-A#^*P<C0#= TYOEEP2.@23-L!9H&\3=
M^F'8!UHZ640H426I.OGW.Y*28@>U@6%?)-V1]_!YCG>D5GNIGG2%:."Y%HV^
MGE3&M%=1I/,*:Z9#V6)#(Z54-3-DJEVD6X6L<$&UB-(XGD<UX\UDO7*^![5>
MR<X(WN"# MW5-5,OMRCD_GJ23 ;'(]]5QCJB]:IE.]R@^;-]4&1%(TK!:VPT
MEPTH+*\G-\G5;6;GNPE_<=SK@V^P2K92/EGC0W$]B2TA%)@;B\#H]0/O4 @+
M1#2^]YB3<4D;>/@]H/_NM).6+=-X)\4W7ICJ>K*<0($EZX1YE/L_L-<SLWBY
M%-H]8>_GIK1BWFDCZSZ8[)HW_LV>^SP<!"SC$P%I'Y ZWGXAQ_(],VR]4G(/
MRLXF-/OAI+IH(L<;NRD;HVB44YQ9;XS,GRHI"E3Z'=Q_[[AY646&D.UXE/<H
MMQXE/8$RA4^R,96&^Z; XC@^(D8CK72@=9N>!?S$5 C3)( T3I,S>--1YM3A
M34_@>6'P]\U6&T65\,\9S&S$S!QF]C]3]]]1X$[6-96L&X,O#7R6/[#>HH(D
M=BFAIZG03FM9\P(E%U@ HR;9<:O/U;LVS""UCP$R; 7#YK<I_&+C-A6*$AX/
M9V^&V;\&D--JBC<[MX8L2V<$4"I9@Z&.!"/=.Z!!Z%IK7B2S.(RI0(6P:.3/
MO01M)01 !P;!*&+9.PK<&M"8=XH;CCJ /5.*-48#:PKH&FZLK^)Y=98M;#%G
MQ B)I>MO*_8U6Y<^6Z'-(944@:4S7U/'"22RK4#CDMAV6\'S4;?5D@7I;!;$
M<0RZ8@JU]1'!(XW S$^"6\5SFT-*T#Q,9] 2*X<1PF<Z<5LE<\1"][D]2#?L
M42&PEF8\<SI\4+S Q3P+%T.. V"E(33JMXZ44T1'O:?V-I]D%%SGLAOR:8ER
M;0]2;X^KX#.=[MHKNLC";$ /X2N1Z=4Z*KZVT&YAVRG=T5ZY.GC-XCM]?JLL
MI4YKF^0M[1!M2F>H2)O"$ODV;+]=MY2"+@O'S_=#+ABQ+SG%CG5"BQ.1O*(C
M^7@C'%UY@,V</+__PYER15R=N/MG5#DGC >W51^TE48?!=&FP9;W.IQ]=[3.
MP"2=I<'B<@D7D(3+##ZRIJ/[K:^^9/[&D<Y/P,PO@V0Q]QB'9 GAB/NI^&2:
M^. ;JCH!0^R!=3)T.0T6BR4D63A-88.M\?VS<!"+MYXT.Y6(.+C,LA[F/>:'
M*,LW#FJ&+)T'RW3QLZ,X.KC1:E0[=V_;AJ.2]I?;Z!U_#6[\C?@ZW?]74.YV
MG.I>8$FA<;B834#YN]H;1K;N?MQ*0[>M^ZSH]P:5G4#CI91F,.P"XP_3^E]0
M2P,$%     @ 4XFK4DW?1N^E!P  )Q4  !D   !X;"]W;W)K<VAE971S+W-H
M965T,34N>&ULM5C;<N.X$?T5E&(GXRJ:XD4W.[:K[)E),@^;==DSNP^I/$ D
M)*&&)+@ *%GY^IP&2)D:6<IN=O9%(HE&H_OTZ0MYLU'ZJUD)8=E+653F=K"R
MMKX>#DVV$B4WH:I%A96%TB6WN-7+H:FUX+G;5!;#)(HFPY++:G!WXYX]ZKL;
MU=A"5N)1,].4)=?;!U&HS>T@'G0/GN1R9>G!\.ZFYDOQ+.R7^E'C;KC3DLM2
M5$:JBFFQN!W<Q]</(Y)W C])L3&]:T:>S)7Z2C>?\MM!1 :)0F26-'#\K<5[
M412D"&;\TNH<[(ZDC?WK3OO?G._P9<Z->*^*GV5N5[>#V8#E8L&;PCZIS3]$
MZ\^8]&6J,.Z7;;SL*!VPK#%6E>UF6%#*RO_SEQ:'WH99=&1#TFY(G-W^(&?E
M!V[YW8U6&Z9)&MKHPKGJ=L,X65%0GJW&JL0^>_=L5?:5_5@[B!X+7MT,+=32
MXC!K53QX%<D1%2G[055V9=C'*A?Y_OXAS-G9E'0V/20G%?[ =<C2.&!)E,0G
M]*4['U.G+SWFXXIK<4FQR]DCWX)2EMUKS:NE<-?_NI\;J\&/?Y\X;+0[;.0.
M&_T>0$^JH#R\-C7/Q.T B6:$7HO!H5Z@$U^Q3U4&%T!L=K_A.O<KGRKV+&HK
MRKG03BQ@=B78>U76O-K^Q; '1;)JP3Y(C?10VC">*^S( \:K_!MI0T>O5)$+
MDJMKK=8D2$+';7BW6Z;;BY!] 3LTVWL:L,U*9BLF7FK889C<MSO9MQNTW[(E
MPF:]14PY,$S0WI)E(I/<(:0I&[$$M5;+#)YYJ<,GK*FD-<YMA=,TX^2$85;!
MGERN9=[PPL!2Q4 C,JABHJP+M14"!ZC%0F8 )F"5JBZ[!9;O@%6:9; 250*6
M&P*][Q-6Z733S(W,)==2F)!]AD#K'%N*2FA>%-L6)69Q_E9P"L7"MHCFW K2
M[-$A5\A4\2)T)@V?%X*\(4'Q8HGQ:V @\I#]A']9+9DT#%<0E*@D.9MOG?!;
M+(%JV3=JH1K=FK/0JCRT)F3WSFDD-2+=977 XB"]BH,D'C-#Z6D0%^HA.)VO
MN2R<T>@Y;-'8!K[XH(2>.Q\[E'U2/#90C>P^2?[O1OF3ASO6?WQ^?+SP4:1+
M-A<9+X']8B%<#V+@I\?)X^R$-GQG4(?_J7SMJ:^%+HE#-==69K)V-$.\Z\ZR
M3)4ECO1LMRNMFN4*TENMB@(=+&\R3S7H;VK:F43G+4^E9J*02TG1@!J, L;E
MU[&HIJ-Q,+I*_T=,I3$-1]% ZG4U@3P)6;_(F?;.)X)OW])N>WM>\=E5%"*G
MP2B#4^P*P&/FN&;_;!P78.[/KDF+_+)W=;]<:K$DRO[86"0!<KY:!NR#R#R%
M6N<B,/9J.@ZFDYB=L3@.9S&;A5.ZF033<<3^3FR'J[.9NX7,+,2NCSX)L? N
M#=)9?$$K27@U8I@J%D+2EG?Q-(BOINU2/,$F2G4L)$$Z3NEY<A5&LWT+][%G
M21"-XF \B[R6: +SQB.Z28-D-'6Y3I$ UU%)A"N B#65@M^LJXM0K\(<Z)A,
MQL%L.L.FJW"<0 &T$%91G#KNR@IE&,-=QM:\: 1%+N-%UA3<F6E\BD@DC1;$
ME;FP&R%\YBPXB.FW[==3<&&/[5UFMX8*5J/T[S;MM9%CE+;*\@*L0^*I927_
M ^/ZF8 ;8T%T;S8 [?CJNPBE]=DLG&%V*PH\[UH>5=Q>%.:"]?2CV* -M=E#
M]7G3L95C!;.RBQHM(/>E<I4A"2>^#H?LZ;7#^13ZXCK<TUN-[WOGU:_.IC__
M:9;$R5]!B<.K>X_=LLVH>#8.HN@UI=IE8"[<3'=4049%IGA3XE0F?7O>&0/K
MTQG[T&C"G"#ZI4&QA3N"1MY#RO0:O.-!SXFGYR\H],#],*B^>[ONV2,X0NS+
M*0%]YBT"8S!S6+"C/XJ@(9.,)YC;\.JDRX2F6K=%X VF?R_^'YFO7"*D8?J'
M)T(:7G6)X-A_^>!(\KYO,^HKKL4W_>;S0679C7-[E<+Y0N>6SN?&=*Q8H*&J
MC4,;':YLI>%5+BPUZ4J\4;WV5;><OX8Q&N?VWZP.BG3DVDN+W5HA K*@3)Z-
MSMEH>GXY1AM_DN;KY8)4H=X*B@W31+ HG)WC9W)^&8?3<\P5F'-!9K:5HGC-
ME^Y_=PJYP=[)=@*]8!/J2N[GY%CT^2@X&]@$!'WP=_7_M3JWKVU[C*,10G!
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;+U;;6\;MY;^*X2QP-J
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M66GHTTK43,X$<9P8PB.K'!Q$V*8AYD>ZGXV(G*7"G3K0HX?<X:-M4F]_OB$
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M!@"3-JX^R!YXZLP]IYN1:7Q6\AC/5[$O?K7\^GQ]D526=D@JXAL,;(8'IJ!
M@AYA%^D=2F4MNG')2Z/!A_4F%X3V\*?!#@\5F",]9CZJ<Y\XS]L>)*8!?_@*
M)ZO8Y0/62<\NWL\H)8DND 356[-V/5V>AB&_D@V0JR61C[KDAXX+Q/.;U8<+
M?F^^O)ZIGPTWDLY_M1V2S\OGUQ=B3-)_X&>^I^:Y*3$J#5KF]V:I_>[D,]L6
M6(O4MX^=[8:@-][#TTBE6VQTJ]MX;8B94>KOD< U392N'=$,\F!T^RA?R=0U
MGY+(;PB$6L16U'"CC77YT>PG,"^I@2;FE$HT1AI7GK7[4U^S9E\>T>SJ W\S
MOX(.WB!XZ=B'Y_RQH3,JDP\0LT)5:I3)&195SIHN:$(9B(<\GGH9J%I0EI/B
MJ1M-]T)R_TQ.FJ-;DW%$+<DYQ0Z#=%?)0M^J7[7;\KG^1,(D%%4N<6]8-8I(
M-TXHRPF7A<=6Z:".R)L.Z7A+QZ9T+)D61*-R1(8=LBDDFN5;G+E-FGQY CLY
MA&0-<VR%H2BC2:6T3BWO(:*&YK?X\A0N18F0;=M7)3L0-[[Z=0U[#=NMA->Z
M3$B2"&L#!.1;5'J#(%?? R^8VUV]F+'VHP\A\V9B>,2'KI?SY8MDA=+4=-K(
M[>.D&X@9[4F1RL*@")Y'08D%R3T6BYU[.C#:&^T^*QZU6"1D":":+]W5]?5"
MW?@3*8#R5&H&1'LG\)UFEX/LP#N?;#KYC2($J]5/NF6DNTIB#('5D.\'ON;:
M<"@:@H#@;#IH&:>:<0<T=[+:P.U"BC>2X(G@2D?TJNB;OH[G,-+/I#>+^-B4
MK &ZLD :9G_FG8KWZ^(C%7Q\F$VM#3(9]73+2GY^$%M7@I#QTBM?XN:)^"["
M1)%<.SC'%YBX&*)P&%W8D#T 5D L$TH=-O)&U]@3TXU%Y) /!WW;+PNY+Z)Y
M%"/9QZBV>Q)KOYE?(4^MI)>]3_*-YJ3(0&%H0>=^U9_@#D,&RR'N3&/IMDSN
M''XJ3*Q)8SLTG;G%N^;Q^M[-ZHWZ^OF27#K>8K.IK1[+ 3FWB(E)VGV$W6.%
MDQGR#10^[H-?5"C;]42"D4Q\59K:[A$S@_XT*AEFDX0)GS-\$$Z#QFDRG71C
M>JH@"=?YD&E\#4K @)!C'JP<?U%+0\X7#S!B-G;.OP!:Q[!U#)2&0PA+9WR3
MT9^#J^74TQ.WG@H'?YZB2\3&"0R75?D98O<%,7&LX+H<_72.,)5_($@SP:WE
M5W3Y:?X1XHW\]&X8+K]@?*<)DCU"?H-7EXNO7YS)85_Z ";'/\1;VQ!LPW_2
M)0+C: "^WU@;T@=:(/\T\_7_ %!+ P04    " !3B:M2CN A<&@%  ":#@
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MZ2.-H_@=W&]MF%>4S6"0.@C']-\'Y^5F%;I"F8J3N E .6\@V%11;5":BE
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M&V.Z&73-QJK*#Y>ELC2JO%C0OP&U,Z#S7"F[V[@ W=]F^@=02P,$%     @
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M:?&=J@&)PTL2!5%X )Z=AL\@[^'!6[B/8GO%4:\X<O7B3RB^))D46G)6M -
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M:V.%U=6.RAXO5CVBAAXQN!%<+Q2XY#&--^7;QOIJ".AU"!?(J_"&R!. X3%
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MZPVU&5&UZ6JB^-;VH357NJO98:Y?-A &H/<SSM5A8EI;\U;&_P%02P,$%
M  @ 4XFK4@YZ/+TS P  ?PL  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&ULO5;?;YLP$/Y7+)Y::2T8 J%5$BE).VW2*D6-MCY,>W#!!*O&9K9IVO]^
MMB&0GV@OR4O ]MUW]]T7'S=:<_$F<XP5^"@HDV,G5ZJ\=UV9Y+A \I:7F.F3
MC(L"*;T4*U>6 J/4.A74]3TO<@M$F#,9V;V%F(QXI2AA>"& K(H"B<\9IGP]
M=J"SV7@FJUR9#7<R*M$*+['Z62Z$7KDM2DH*S"3A# B<C9TIO)_#R#A8BU\$
MK^76.S!47CE_,XOOZ=CQ3$:8XD09"*0?[WB.*35(.H^_#:C3QC2.V^\;]*^6
MO";SBB2><_I"4I6/G=@!*<Y01=4S7W_##:'0X"6<2OL+UK7M,'1 4DG%B\99
M9U 05C_11U.(+0=XRL%O'/Q]A\$)AZ!Q""S1.C-+ZP$I-!D)O@;"6&LT\V)K
M8[TU&\*,C$LE]"G1?FJRK.4#/ -+LF(D(PEB"DR3A%=,$;8""TY)0K $-V")
MDTH09197#U@A0N6UWI8Y$EB.7*7S,:ANTL2>U;']$[$#\,29RB5X9"E.=_U=
MS:,EXV_(S/Q>P"<D;D$ OP#?\^&1?.;_[^[UI!.TM0TL7G ";TZ1E+:RBB=O
MX/</?0Z^*US(/SWH@Q9]8-$')]"G6IZ;E-#*W ,@.VGP1T(K75"0"5Z A!=E
MI9"],U>$-6)='U.KCA?:>.;ZOT_\*(S\831RW[>K>,3.B^((=G8[A,*64-A+
MZ 4)H?][$B@.RDHDN;Z=)OU"9RY-!7N*%K4QHC-(,FS1AQ>69'A0ZH$?Q?YP
M3Y$C9D$4QO"X('%+)^ZE,]^J/>"ER5?V5.FNA;T[@P;0ZSJ:=V$5FH"[__@!
M#&-O3X<CAC */ \.CBL!M]HT["7UC*42)%$Z^UJ/BA'5IP;T.VC_''IT71 &
ME]8C."QS''K>@1R'=MX)(;JN"_O;[F-14OZ)<2-#VZA*BEA?N;HN",-SR-%U
M0!A=6H[H\'K$T=V^&$>L[&=Z1P]W:Y0IL%C9"4\".XW4@T"[VTZ14SL[[>W/
MS'1I1Z0.IAY-]6=^19@$%&<:TKLULYRHI[UZH7AI!Z97KO3X95]S/2%C80ST
M><:YVBQ,@';FGOP#4$L#!!0    ( %.)JU*"4*!)I0(  % '   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;)V5WV_:,!#'_Q4KJZ96VII?)$ 'D5I0
MU3Y,0^VZ/4Q[,,E!K#IV9CO0_O>SG1!1$E"W%^*S[WO^W/FP)ULNGF4.H-!+
M09F<.KE2Y97KRC2' LM+7@+3*RLN"JRT*=:N+ 7@S(H*Z@:>%[L%)LQ))G9N
M(9()KQ0E#!8"R:HHL'B] <JW4\=W=A,/9)TK,^$FDQ*OX1'44[D0VG+;*!DI
M@$G"&1*PFCK7_M5L:/RMPP\"6[DW1B:3)>?/QKC/IHYG@(!"JDP$K#\;F &E
M)I#&^-/$=-HMC7!_O(M^:W/7N2RQA!FG/TFF\JDS<E &*UQ1]<"W=]#D$YEX
M*:?2_J)MX^LY**VDXD4CU@0%8?47OS1UV!/X@R."H!$$[Q6$C2"TB=9D-JTY
M5CB9"+Y%PGCK:&9@:V/5.AO"S"D^*J%7B=:IY)O*0:!;PC!+":;HGM6=84K\
M&2T$E)AD"%YTUTB0Z'P."A,J+_3BT^,<G9]=H#-$&/J>\TIBELF)JS26">ZF
M#<)-C1 <0?B*Q24*_4\H\ *_1SX[+9]#VLJ]MW)7%Z.M2-!6)+#QPO^HR*_K
MI51"M][O$QN%[4:AW6AP#)S@->-2D?3C!S_VOBC08[:N#5F5)2706\XZ;&S#
MFG_I)AF;PFWV:];U\0,O;)W>  ]:X,%)X%TWE()G5:J0X*^8JB.0=:AH#R".
M#AA[7$;]A%%+&+V+T%Q?"LP) M)-J1M45L):*6?V 'N9HPZ0/QH'!]1=IR (
MQOW<<<L=G^2N>ZYLZ TQMS-I)00PA;"4T(\<]]!X!\1=GS@Z CQL@8?O*O2_
MH X[+1EZX]$!:]=IX'=@W;W[SKPU^@99ZR-&%%9:YET.=:ZBOK]K0_'27H%+
MKO2%:H>Y?O) & >]ON)<[0QSJ[:/:/(74$L#!!0    ( %.)JU+/K;V+?@,
M %8-   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;+U776_3,!3]*U9
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M/WJ2!76RH$@6[DEVJ2Q0GW62W<5D&2TJHKGG]&8V&.!HXM^T^>HPPF%0&ST
M&M9 PUZ@Y]R88WCTEGF:)\SR%3PQH![0.>4S"<!9JK05OXN#+NQE@D$+UF%
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M)C/@Z)X4N$@(INBAJ+>&+O$G=),DO((4X2)%S%@F%>=02$0)7A!*) &!SN]
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M =<&ZOF2,;F;Z$;;?EC-_@)02P,$%     @ 4XFK4GST/_O^ P   P\  !D
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M]:8]2##E968?U.Y7K <T<GRQRDSU'W;[OI-A#^+26)778%*0"[G_Y5_J1!P
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M2W=6\I9#%$#\#(+E)LVOAT7;P[;0]AJT/2_:AT(E<X1)Y"3C,V9U[808229
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MOW< >^"#SIA"#;R JX(;?4B+-/Z>R95F1:J'OB%UUH:?U$I.*R71%B5?F>I
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M=)U-UW".K\F=&!2%&>)=0(2$!9I@XK$W'*6RWN$$<;?ZFGM$F6[\=-'LIR-
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MTKOLX><BRPZEG&A1V$M^(32V#':88E<'TAC@_E((O9V8 ^H^<?0/4$L#!!0
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M:'*3&;:U>PK1^ !W7FE-1\,7Z!_7_#=02P,$%     @ 4XFK4H?3JY$; P
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M-T^[QK4JFZ,_Z_ZES3\!4$L! A0#%     @ 4XFK4@=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !3
MB:M2+VDFS.X    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " !3B:M2F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %.)JU+MN6>T
M0P4  /$5   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " !3B:M23!5RRE<%  "0%   &
M@(&&#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 4XFK
M4@#0?6*Q @  =@D  !@              ("!$Q,  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( %.)JU)]]!?"$00  )H-   8
M      " @?H5  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" !3B:M2#-2SG T%  !;%0  &               @(%!&@  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 4XFK4J:5DM0+ @   @0  !@
M             ("!A!\  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( %.)JU)-]2^=T08  $H;   8              " @<4A  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !3B:M2^5O% K$%  #-
M#   &               @(',*   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ 4XFK4M= .:5B'@  !EP  !@              ("!LRX
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( %.)JU*4*3CE
MD00  !$+   9              " @4M-  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ 4XFK4H)'A%QJ"0  \!8  !D
M ("!$U(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !3
MB:M2FKED0EH(  #5%   &0              @(&T6P  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %.)JU(OR5:(N0(  %0&   9
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M970Q-RYX;6Q02P$"% ,4    " !3B:M2CN A<&@%  ":#@  &0
M    @(%GC0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M %.)JU*5P>>2)P0  'X*   9              " @0:3  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ 4XFK4KOQ-8[U @  ( 8  !D
M             ("!9)<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " !3B:M2PHN,.MP"  !Y!@  &0              @(&0F@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( %.)JU*I?0 6P0(
M $$&   9              " @:.=  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ 4XFK4I[I4<L]!0  4PX  !D              ("!
MFZ   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !3B:M2
MOP6TJDD"   ]!0  &0              @($/I@  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( %.)JU)"Q0<@:P,  &P.   9
M      " @8^H  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ 4XFK4CG2$]Y-!@  :Q\  !D              ("!,:P  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !3B:M2]0$L43$#  #("P
M&0              @(&UL@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( %.)JU)@+3E]D0(  #<'   9              " @1VV  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 4XFK4@YZ/+TS
M P  ?PL  !D              ("!Y;@  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " !3B:M2@E"@2:4"  !0!P  &0
M@(%/O   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( %.)
MJU+/K;V+?@,  %8-   9              " @2N_  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ 4XFK4EWSG,7# @  O@<  !D
M         ("!X,(  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " !3B:M2Q![IJ1@#  !D"0  &0              @(':Q0  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( %.)JU)\]#_[_@,   ,/
M   9              " @2G)  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ 4XFK4M %+3RW @  H@<  !D              ("!7LT
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !3B:M28T'<
M_M@$  #M%   &0              @(%,T   >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( %.)JU*O*C6WE0(  -\(   9
M  " @5O5  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M4XFK4E6*=;(* P  4PD  !D              ("!)]@  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " !3B:M2,Q0'/F0#  "!#P  &0
M            @(%HVP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( %.)JU(%3JMY0P0  'D0   9              " @0/?  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 4XFK4N^VLN[I!
MB!4  !D              ("!?>,  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " !3B:M2R0Z2)-0#  !##@  &0              @(&=
MZ   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( %.)JU*#
M^04:AP,  %@/   9              " @:CL  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ 4XFK4A_J]KS_ @  ,PH  !D
M     ("!9O   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %.)JU*X-L3<J0$  "X;   :
M          "  5?^  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( %.)JU)3V2LIL@$  %,;   3              "  3@  0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     U #4 :@X  !L" 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>136</ContextCount>
  <ElementCount>323</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Unaudited Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofOperations</Role>
      <ShortName>Unaudited Condensed Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Unaudited Condensed Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity</Role>
      <ShortName>Unaudited Condensed Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Unaudited Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedStatementsofCashFlows</Role>
      <ShortName>Unaudited Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117104 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Stock Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlan</Role>
      <ShortName>Stock Option Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137109 - Disclosure - Covid-19</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Covid19</Role>
      <ShortName>Covid-19</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies - (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Other Financial Information - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/OtherFinancialInformation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Borrowings - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Borrowings</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2324304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Stock Option Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanTables</Role>
      <ShortName>Stock Option Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockOptionPlan</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OrganizationDetails</Role>
      <ShortName>Organization - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Organization</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Other Financial Information - Prepaid expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails</Role>
      <ShortName>Other Financial Information - Prepaid expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Other Financial Information - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails</Role>
      <ShortName>Other Financial Information - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Other Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails</Role>
      <ShortName>Other Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Other Financial Information - Accrued and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails</Role>
      <ShortName>Other Financial Information - Accrued and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Borrowings - Future minimum payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails</Role>
      <ShortName>Borrowings - Future minimum payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Commitment and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stock Option Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanNarrativeDetails</Role>
      <ShortName>Stock Option Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails</Role>
      <ShortName>Stock Option Plan - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails</Role>
      <ShortName>Stock Option Plan - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails</Role>
      <ShortName>Stock Option Plan - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Option Plan - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exdx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Covid-19 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Covid19Details</Role>
      <ShortName>Covid-19 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Covid19</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exdx-20210331.htm">exdx-20210331.htm</File>
    <File>exdx-20210331.xsd</File>
    <File>exdx-20210331_cal.xml</File>
    <File>exdx-20210331_def.xml</File>
    <File>exdx-20210331_lab.xml</File>
    <File>exdx-20210331_pre.xml</File>
    <File>xgn311-33121.htm</File>
    <File>xgn312-33121.htm</File>
    <File>xgn321-33121.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exdx-20210331.htm": {
   "axisCustom": 1,
   "axisStandard": 24,
   "contextCount": 136,
   "dts": {
    "calculationLink": {
     "local": [
      "exdx-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exdx-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "exdx-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exdx-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exdx-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exdx-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 422,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 6
   },
   "keyCustom": 37,
   "keyStandard": 286,
   "memberCustom": 26,
   "memberStandard": 34,
   "nsprefix": "exdx",
   "nsuri": "http://www.exagen.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.exagen.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Other Financial Information",
     "role": "http://www.exagen.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117104 - Disclosure - Borrowings",
     "role": "http://www.exagen.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Commitment and Contingencies",
     "role": "http://www.exagen.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - Fair Value Measurements",
     "role": "http://www.exagen.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Stockholders' Equity",
     "role": "http://www.exagen.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Stock Option Plan",
     "role": "http://www.exagen.com/role/StockOptionPlan",
     "shortName": "Stock Option Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137109 - Disclosure - Covid-19",
     "role": "http://www.exagen.com/role/Covid19",
     "shortName": "Covid-19",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies - (Policies)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies - (Tables)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Other Financial Information - (Tables)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Balance Sheets",
     "role": "http://www.exagen.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Borrowings - (Tables)",
     "role": "http://www.exagen.com/role/BorrowingsTables",
     "shortName": "Borrowings - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exagen.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.exagen.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Stock Option Plan (Tables)",
     "role": "http://www.exagen.com/role/StockOptionPlanTables",
     "shortName": "Stock Option Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization - (Details)",
     "role": "http://www.exagen.com/role/OrganizationDetails",
     "shortName": "Organization - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "i0fc61924d3f34ca4bab8516c11208885_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "i0fc61924d3f34ca4bab8516c11208885_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
     "shortName": "Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "i14c0363cf9954703ba1f808170614d1e_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Other Financial Information - Prepaid expenses (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails",
     "shortName": "Other Financial Information - Prepaid expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Other Financial Information - Property and equipment (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails",
     "shortName": "Other Financial Information - Property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Other Financial Information - Narrative (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
     "shortName": "Other Financial Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Other Financial Information - Accrued and other current liabilities (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails",
     "shortName": "Other Financial Information - Accrued and other current liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "i79bb007a0e4b4e11ad37da79ccacc407_D20170901-20170930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Borrowings - Narrative (Details)",
     "role": "http://www.exagen.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "i79bb007a0e4b4e11ad37da79ccacc407_D20170901-20170930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Borrowings - Future minimum payments (Details)",
     "role": "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails",
     "shortName": "Borrowings - Future minimum payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Commitment and Contingencies - Narrative (Details)",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
     "shortName": "Commitment and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ibf438e067e0e490e8bd11c8a8dfb7428_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exagen.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ibf438e067e0e490e8bd11c8a8dfb7428_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "exdx:StockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "icc1bb719e1074fdebd679404c35cd358_D20210325-20210325",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.exagen.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Unaudited Condensed Statements of Operations",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations",
     "shortName": "Unaudited Condensed Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "if56d5f147a234f47a5c286cd55a8ab8d_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stock Option Plan - Narrative (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
     "shortName": "Stock Option Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "if56d5f147a234f47a5c286cd55a8ab8d_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "i205b83f91058431aacdac5b60d121b3b_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stock Option Plan - Stock Option Activity (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
     "shortName": "Stock Option Plan - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "i3636c80610a2496b91acc3a427ed857c_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "i74e686b941754a318cfceeff5fffc858_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
     "shortName": "Stock Option Plan - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "i74e686b941754a318cfceeff5fffc858_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EmployeeStockOwnershipPlanESOPPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
     "shortName": "Stock Option Plan - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "i3636c80610a2496b91acc3a427ed857c_D20210101-20210331",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
     "shortName": "Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "i5194501b750d4090955a5e16b78c217c_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Covid-19 (Details)",
     "role": "http://www.exagen.com/role/Covid19Details",
     "shortName": "Covid-19 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "i5194501b750d4090955a5e16b78c217c_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ie0bf96da109947f599efed58bc0f90d9_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Unaudited Condensed Statements of Stockholders' Equity",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity",
     "shortName": "Unaudited Condensed Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ie0bf96da109947f599efed58bc0f90d9_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "idc581bdd73dd4021b430c6ee34ea7187_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "exdx:StockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical",
     "shortName": "Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Unaudited Statements of Cash Flows",
     "role": "http://www.exagen.com/role/UnauditedStatementsofCashFlows",
     "shortName": "Unaudited Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.exagen.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210331.htm",
      "contextRef": "ib3192990da444100b6eb7449a48628b2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 63,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exdx_AVISECTDTestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVISE CTD Test",
        "label": "AVISE CTD Test [Member]",
        "terseLabel": "AVISE CTD Test"
       }
      }
     },
     "localname": "AVISECTDTestMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AccruedLiabilitiesClinicalStudyCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Clinical Study, Current",
        "label": "Accrued Liabilities, Clinical Study, Current",
        "terseLabel": "Accrued clinical study activity"
       }
      }
     },
     "localname": "AccruedLiabilitiesClinicalStudyCurrent",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AccruedPurchaseGoodsAndServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Purchase, Goods and Services, Current",
        "label": "Accrued Purchase, Goods and Services, Current",
        "terseLabel": "Accrued purchases of goods and services"
       }
      }
     },
     "localname": "AccruedPurchaseGoodsAndServicesCurrent",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdvancePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance Payment",
        "label": "Advance Payment",
        "terseLabel": "Advance royalties payment"
       }
      }
     },
     "localname": "AdvancePayment",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AlleghenyHealthNetworkResearchInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allegheny Health Network Research Institute",
        "label": "Allegheny Health Network Research Institute [Member]",
        "terseLabel": "Allegheny Health Network Research Institute"
       }
      }
     },
     "localname": "AlleghenyHealthNetworkResearchInstituteMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AssetsUnderCapitalLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Under Capital Lease",
        "label": "Assets Under Capital Lease [Member]",
        "terseLabel": "Assets under capital lease"
       }
      }
     },
     "localname": "AssetsUnderCapitalLeaseMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_BlueShieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blue Shield",
        "label": "Blue Shield [Member]",
        "terseLabel": "Blue Shield"
       }
      }
     },
     "localname": "BlueShieldMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CapitalRoyaltyPartnersIILPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Royalty Partners II LP",
        "label": "Capital Royalty Partners II LP [Member]",
        "terseLabel": "Capital Royalty Partners II LP"
       }
      }
     },
     "localname": "CapitalRoyaltyPartnersIILPMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ClientMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Client",
        "label": "Client [Member]",
        "terseLabel": "Client"
       }
      }
     },
     "localname": "ClientMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-Promotion Agreement, Number Of Days' Notice To Terminate Agreement",
        "label": "Co-Promotion Agreement, Number Of Days' Notice To Terminate Agreement",
        "terseLabel": "Co-promotion, number of days' noticed required to give to terminate agreement"
       }
      }
     },
     "localname": "CoPromotionAgreementNumberOfDaysNoticeToTerminateAgreement",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-Promotion Agreement, Period Before Current Expiration To Extend Term",
        "label": "Co-Promotion Agreement, Period Before Current Expiration To Extend Term",
        "terseLabel": "Co-Promotion Agreement, Period Before Current Expiration To Extend Term"
       }
      }
     },
     "localname": "CoPromotionAgreementPeriodBeforeCurrentExpirationToExtendTerm",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_CoPromotionAgreementRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-Promotion Agreement, Renewal Term",
        "label": "Co-Promotion Agreement, Renewal Term",
        "terseLabel": "Co-promotion agreement, renewal term"
       }
      }
     },
     "localname": "CoPromotionAgreementRenewalTerm",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_CollaborationAgreementAnnualCollaborationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Annual Collaboration Fee",
        "label": "Collaboration Agreement, Annual Collaboration Fee",
        "terseLabel": "Collaboration fee"
       }
      }
     },
     "localname": "CollaborationAgreementAnnualCollaborationFee",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit",
        "terseLabel": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, income tax benefit"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure [Text Block]",
        "terseLabel": "Covid-19"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/Covid19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "label": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "terseLabel": "Term loan covenant, minimum unrestricted cash balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "label": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "terseLabel": "Term loan covenant, increase to interest rate"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentPaidInKindLoansIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Paid In Kind Loans Issued",
        "label": "Debt Instrument, Paid In Kind Loans Issued",
        "terseLabel": "Term loan, paid in-kind loans issued"
       }
      }
     },
     "localname": "DebtInstrumentPaidInKindLoansIssued",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage",
        "label": "Debt Instrument, Prepayment Premium Percentage",
        "terseLabel": "Term loan, prepayment premium percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "label": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "terseLabel": "Term loan, annual reduction in prepayment penalty percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentageAnnualReduction",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentStatedInterestRatePaidInKind": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "label": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "terseLabel": "Term loan, paid in-kind, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentStatedInterestRatePaidInKind",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Included within Current Liabilities",
        "label": "Deferred Offering Costs Included within Current Liabilities",
        "terseLabel": "Issuance costs included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedWithinCurrentLiabilities",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DeferredOfferingCostsReclassifiedToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Reclassified to Equity",
        "label": "Deferred Offering Costs Reclassified to Equity",
        "terseLabel": "Deferred offering costs reclassified to equity"
       }
      }
     },
     "localname": "DeferredOfferingCostsReclassifiedToEquity",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_EquipmentPurchasedUnderCapitalLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment Purchased Under Capital Lease",
        "label": "Equipment Purchased Under Capital Lease",
        "terseLabel": "Equipment purchased under capital lease obligations"
       }
      }
     },
     "localname": "EquipmentPurchasedUnderCapitalLease",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ExpirationApr12026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Apr 1, 2026",
        "label": "Expiration Apr 1, 2026 [Member]",
        "terseLabel": "Warrant expiration April 1, 2026"
       }
      }
     },
     "localname": "ExpirationApr12026Member",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationDec72025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Dec 7, 2025",
        "label": "Expiration Dec 7, 2025 [Member]",
        "terseLabel": "Warrant expiration December 7, 2025"
       }
      }
     },
     "localname": "ExpirationDec72025Member",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationJan192026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Jan 19, 2026",
        "label": "Expiration Jan 19, 2026 [Member]",
        "terseLabel": "Warrant expiration January 19, 2026"
       }
      }
     },
     "localname": "ExpirationJan192026Member",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationMar312026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Mar 31, 2026",
        "label": "Expiration Mar 31, 2026 [Member]",
        "terseLabel": "Warrant expiration March 31, 2026"
       }
      }
     },
     "localname": "ExpirationMar312026Member",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationSep72024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Sep 7, 2024",
        "label": "Expiration Sep 7, 2024 [Member]",
        "terseLabel": "Warrant expiration September 7, 2024"
       }
      }
     },
     "localname": "ExpirationSep72024Member",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_Government1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government1",
        "label": "Government1 [Member]",
        "terseLabel": "Government"
       }
      }
     },
     "localname": "Government1Member",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_HealthcareInsurersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Insurers",
        "label": "Healthcare Insurers [Member]",
        "terseLabel": "Healthcare insurers"
       }
      }
     },
     "localname": "HealthcareInsurersMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncentiveAwardPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Award Plan, 2019",
        "label": "Incentive Award Plan, 2019 [Member]",
        "terseLabel": "2019 Incentive Award Plan"
       }
      }
     },
     "localname": "IncentiveAwardPlan2019Member",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "label": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_InnovatusLifeSciencesLendingFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Life Sciences Lending Fund",
        "label": "Innovatus Life Sciences Lending Fund [Member]",
        "terseLabel": "Innovatus Life Sciences Lending Fund"
       }
      }
     },
     "localname": "InnovatusLifeSciencesLendingFundMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_JanssenSIMPONIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen (SIMPONI)",
        "label": "Janssen (SIMPONI) [Member]",
        "terseLabel": "Janssen (SIMPONI)"
       }
      }
     },
     "localname": "JanssenSIMPONIMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_JointVentureQuarterlyPrescribedUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Prescribed Units",
        "label": "Joint Venture, Quarterly Prescribed Units",
        "terseLabel": "Joint venture, number of units prescribed quarterly"
       }
      }
     },
     "localname": "JointVentureQuarterlyPrescribedUnits",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exdx_JointVentureQuarterlyPromotionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Promotion Fee",
        "label": "Joint Venture, Quarterly Promotion Fee",
        "terseLabel": "Joint venture, quarterly promotion fee"
       }
      }
     },
     "localname": "JointVentureQuarterlyPromotionFee",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline",
        "label": "Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline",
        "terseLabel": "Joint venture quarterly promotion fee cap"
       }
      }
     },
     "localname": "JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_JointVentureQuarterlyPromotionFeePerPrescription": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Promotion Fee Per Prescription",
        "label": "Joint Venture, Quarterly Promotion Fee Per Prescription",
        "terseLabel": "Joint venture, quarterly promotion fee per prescription"
       }
      }
     },
     "localname": "JointVentureQuarterlyPromotionFeePerPrescription",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_LicenseAgreementInitialLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Initial License Fee",
        "label": "License Agreement, Initial License Fee",
        "terseLabel": "Initial license fee"
       }
      }
     },
     "localname": "LicenseAgreementInitialLicenseFee",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LongTermDebtIncludingUndiscountedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Including Undiscounted Interest",
        "label": "Long-term Debt, Including Undiscounted Interest",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtIncludingUndiscountedInterest",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LongTermDebtUndiscountedInterestAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Undiscounted Interest Amount",
        "label": "Long-term Debt, Undiscounted Interest Amount",
        "negatedLabel": "Interest"
       }
      }
     },
     "localname": "LongTermDebtUndiscountedInterestAmount",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_MedicareAdvantageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Advantage",
        "label": "Medicare Advantage [Member]",
        "terseLabel": "Medicare Advantage"
       }
      }
     },
     "localname": "MedicareAdvantageMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_MilestoneContingencyFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Contingency, Fair Value Disclosure",
        "label": "Milestone Contingency, Fair Value Disclosure",
        "terseLabel": "Remaining milestone obligation, fair value"
       }
      }
     },
     "localname": "MilestoneContingencyFairValueDisclosure",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_MilestoneObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Obligation",
        "label": "Milestone Obligation",
        "terseLabel": "Remaining milestone obligation"
       }
      }
     },
     "localname": "MilestoneObligation",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory",
        "label": "Office and Laboratory [Member]",
        "terseLabel": "Office and Laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office",
        "label": "Office [Member]",
        "terseLabel": "Office"
       }
      }
     },
     "localname": "OfficeMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OperatingLeasesRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Renewal Term",
        "label": "Operating Leases, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "OperatingLeasesRenewalTerm",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.exagen.com/20210331",
     "xbrltype": "stringItemType"
    },
    "exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities",
        "label": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_PrepaidMaintenanceAndInsuranceContracts": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Maintenance and Insurance Contracts",
        "label": "Prepaid Maintenance and Insurance Contracts",
        "terseLabel": "Prepaid maintenance and insurance contracts"
       }
      }
     },
     "localname": "PrepaidMaintenanceAndInsuranceContracts",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_PrometheusLaboratoriesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prometheus Laboratories, Inc.",
        "label": "Prometheus Laboratories, Inc. [Member]",
        "terseLabel": "Prometheus Laboratories"
       }
      }
     },
     "localname": "PrometheusLaboratoriesIncMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, Annual Increase In Commitment, Percentage",
        "label": "Purchase Obligation, Annual Increase In Commitment, Percentage",
        "terseLabel": "Annual increase in purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligationAnnualIncreaseInCommitmentPercentage",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_ReceivableBenchmarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable Benchmark",
        "label": "Receivable Benchmark [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivableBenchmarkMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_RentalPropertyByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental Property, by Type",
        "label": "Rental Property, by Type [Axis]",
        "terseLabel": "Rental Property, by Type [Axis]"
       }
      }
     },
     "localname": "RentalPropertyByTypeAxis",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exdx_RentalPropertyByTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental Property, by Type",
        "label": "Rental Property, by Type [Domain]",
        "terseLabel": "Rental Property, by Type [Domain]"
       }
      }
     },
     "localname": "RentalPropertyByTypeDomain",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_RoyaltyObligationPercentageOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation, Percentage of Sales",
        "label": "Royalty Obligation, Percentage of Sales",
        "terseLabel": "Royalty obligation, percent of net sales"
       }
      }
     },
     "localname": "RoyaltyObligationPercentageOfSales",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs",
        "label": "Stock Issuance Costs",
        "terseLabel": "Estimated offering expenses for aggregate expenses",
        "verboseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "terseLabel": "Net exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Value, Warrants Exercised, Net",
        "terseLabel": "Net exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_Term2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term 2017",
        "label": "Term 2017 [Member]",
        "terseLabel": "2017 Term loan"
       }
      }
     },
     "localname": "Term2017Member",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_UnitedHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Healthcare",
        "label": "United Healthcare [Member]",
        "terseLabel": "United Healthcare"
       }
      }
     },
     "localname": "UnitedHealthcareMember",
     "nsuri": "http://www.exagen.com/20210331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r45",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r141",
      "r199",
      "r202",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r216",
      "r218",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r343",
      "r370",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r216",
      "r218",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r343",
      "r370",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r141",
      "r199",
      "r202",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r139",
      "r199",
      "r200",
      "r344",
      "r368",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r139",
      "r199",
      "r200",
      "r344",
      "r368",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r207",
      "r216",
      "r218",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r343",
      "r370",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r207",
      "r216",
      "r218",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r343",
      "r370",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r170",
      "r217",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r19",
      "r142",
      "r143"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r34"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r34"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued\u00a0payroll\u00a0and\u00a0related\u00a0expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29",
      "r163"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r254"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r219",
      "r221",
      "r257",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising and Marketing Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r221",
      "r247",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r67",
      "r307"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r81",
      "r122",
      "r131",
      "r137",
      "r147",
      "r277",
      "r279",
      "r295",
      "r348",
      "r358"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r44",
      "r81",
      "r147",
      "r277",
      "r279",
      "r295"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r222",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Costs incurred, but not paid, in connection with capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r14",
      "r309",
      "r310"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.",
        "label": "Capital Lease Obligations, Current",
        "terseLabel": "Capital lease obligations, current portion"
       }
      }
     },
     "localname": "CapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r27",
      "r69"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds, included in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r70",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r63",
      "r69",
      "r75"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r296"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r196",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants issued to purchase redeemable convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r169",
      "r352",
      "r364"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized at March\u00a031, 2021 and December 31, 2020; 16,925,680 and 12,652,308 shares issued and outstanding at March\u00a031, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r112",
      "r113",
      "r141",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r112",
      "r113",
      "r141",
      "r292",
      "r293",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r112",
      "r113",
      "r141",
      "r292",
      "r293",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r108",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risk and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r112",
      "r113",
      "r141",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r112",
      "r113",
      "r141",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r52",
      "r344"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r53",
      "r81",
      "r147",
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r110",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r349",
      "r350",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Term loan, fee incurred upon payment of final installment"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r36",
      "r183",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Term loan, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Term loan, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r38",
      "r84",
      "r189",
      "r192",
      "r193",
      "r194",
      "r305",
      "r306",
      "r308",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r181",
      "r307"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid expenses table"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r67",
      "r82",
      "r269",
      "r273",
      "r274",
      "r275"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r67",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Option Plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock options, unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock options, cost not yet recognized, remaining weighted average vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPolicy": {
     "auth_ref": [
      "r76",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.",
        "label": "Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r105",
      "r148",
      "r188",
      "r195",
      "r251",
      "r252",
      "r253",
      "r270",
      "r271",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r286",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r285",
      "r286",
      "r288",
      "r289",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r208",
      "r209",
      "r214",
      "r215",
      "r286",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r208",
      "r209",
      "r214",
      "r215",
      "r286",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r286",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r145",
      "r146",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture\u00a0and\u00a0fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r160",
      "r161",
      "r347"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r98",
      "r99",
      "r121",
      "r268",
      "r272",
      "r276",
      "r366"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r48",
      "r119",
      "r304",
      "r307",
      "r354"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r62",
      "r64",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest expense"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r34"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating lease, rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r81",
      "r132",
      "r147",
      "r278",
      "r279",
      "r280",
      "r295"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r81",
      "r147",
      "r295",
      "r351",
      "r362"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r81",
      "r147",
      "r278",
      "r279",
      "r280",
      "r295"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r32",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loan payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r182",
      "r350",
      "r359"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total borrowings, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r85",
      "r179"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 4.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r85",
      "r179"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 5.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r85",
      "r179"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 3.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r85",
      "r179"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 2.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 1.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r38",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds, included in cash and cash equivalents"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r65",
      "r68"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r46",
      "r47",
      "r49",
      "r68",
      "r81",
      "r90",
      "r93",
      "r94",
      "r95",
      "r96",
      "r98",
      "r99",
      "r101",
      "r122",
      "r130",
      "r133",
      "r136",
      "r138",
      "r147",
      "r295",
      "r353",
      "r365"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncement, Early Adoption [Line Items]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementEarlyAdoptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementEarlyAdoptionTable": {
     "auth_ref": [
      "r92",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the financial statement line items and the effect of the guidance on financial statement line items by guidance implemented if the entity elects earlier application.",
        "label": "New Accounting Pronouncement, Early Adoption [Table]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementEarlyAdoptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted; Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r122",
      "r130",
      "r133",
      "r136",
      "r138"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r86",
      "r100",
      "r115",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r34"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Diagnostic\u00a0testing\u00a0supplies"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r282",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCustomerMember": {
     "auth_ref": [
      "r367",
      "r369",
      "r371",
      "r372",
      "r376",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer classified as other.",
        "label": "Other Customer [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r6",
      "r159"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentInKindPIKNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured.",
        "label": "Payment in Kind (PIK) Note [Member]",
        "terseLabel": "Paid in-kind note"
       }
      }
     },
     "localname": "PaymentInKindPIKNoteMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of issuance costs related to public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r222",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at March\u00a031, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRoyalties": {
     "auth_ref": [
      "r4",
      "r6",
      "r158",
      "r159"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Royalties",
        "terseLabel": "Prepaid product royalties"
       }
      }
     },
     "localname": "PrepaidRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock in public offering, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Term loan borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r58",
      "r250"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from common stock issued under Employee Stock Purchase Pan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r29",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r28",
      "r162"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment",
        "verboseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r164",
      "r363"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Purchase obligation, due in year one"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.",
        "label": "Purchase Obligation, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Purchase obligation, to be paid remainder of fiscal year"
       }
      }
     },
     "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReorganizationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reorganizations [Abstract]"
       }
      }
     },
     "localname": "ReorganizationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedLabel": "Principal payment on capital lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "terseLabel": "Loan repayment"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r263",
      "r384"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r76",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r75",
      "r346",
      "r360"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r195",
      "r254",
      "r361",
      "r380",
      "r381"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r148",
      "r251",
      "r252",
      "r253",
      "r270",
      "r271",
      "r377",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r117",
      "r118",
      "r129",
      "r134",
      "r135",
      "r139",
      "r140",
      "r141",
      "r198",
      "r199",
      "r344"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Future minimum royalty commitment"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Proceeds from public offering, net"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Initial public offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Shares issued in public offering, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r112",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r221",
      "r246",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Non-cash Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r29",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r11",
      "r75",
      "r346",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r222",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r226",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions, Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions, Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r41",
      "r79",
      "r106",
      "r107",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r196",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r109",
      "r112",
      "r113",
      "r114",
      "r292",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration of Risk, by Risk Factor and Significant Payer"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Awards canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards canceled/Weighted-Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, March\u00a031, 2021 (in shares)",
        "periodStartLabel": "Outstanding, December 31, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Outstanding, December\u00a031, 2020 (in dollars per share)",
        "terseLabel": "Outstanding, March\u00a031, 2021 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Awards released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards released/ Weighted-Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee payroll deduction percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares that remain available for future awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r228",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, March\u00a031, 2021 (in shares)",
        "periodStartLabel": "Outstanding, December 31, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, March\u00a031, 2021, Weighted Average Exercise Price (in dollars per share)",
        "periodStartLabel": "Outstanding, December 31, 2020, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options exercisable, March\u00a031, 2021 (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, March\u00a031, 2021, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, March\u00a031, 2021 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, March\u00a031, 2021, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r220",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock options, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r241",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r42",
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r105",
      "r148",
      "r188",
      "r195",
      "r251",
      "r252",
      "r253",
      "r270",
      "r271",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r105",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r17",
      "r18",
      "r188",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Issuance of stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r188",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock in public offering, net of issuance costs of $4,435 (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r188",
      "r195",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r188",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r188",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock in public offering, net of issuance costs of $4,435"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r188",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r81",
      "r144",
      "r147",
      "r295"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r195",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r303",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r303",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r303",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash items:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]",
        "terseLabel": "Supplier Concentration Risk"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r145",
      "r146",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121569800&loc=d3e45023-112735"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121616839&loc=d3e45280-112737"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121638524&loc=SL117422543-158416"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=d3e14931-158439"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782768-158439"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884803&loc=SL65671395-207642"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=SL117422267-158473"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r385": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r386": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r387": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r388": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r389": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r391": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(5)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001274737-21-000044-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001274737-21-000044-xbrl.zip
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MX3@25,U'%6=Y,2'DND;,GO4M'?OO1J='OWQH=[S5+\_KF)'91(++)X-8<4!
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MAR@DI;%4*J(8IYJHE,P?(44OB [,B3 P9$:2H!!DDD94U]9IRTST(Q!&9DB
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M;C?EK*1A?+VE&Y?=+.<"-RB2D&60YIK.V?7=?N.NZU["2X$ECM3BX@LI\:5
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M+R8^<QY96XPDL 4/[+RUS<*FF_]5PNR38';[%@'2T9,D00 /D0*4RPBS3!/
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M:[P$PXR"././PT\I\#\!QO7T2O_7N<K;+=MN^J0%)2@_"90WQ]F7\L89S0+
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M( &H4 %0Z160P@1 M(MNM;<*>_*VXFHECKU-')M)R+#$L9?@V/A"4V@,)4$
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M U^3$.?),'%RD5XS)2@F"@D>+.(TR'2U22$CH@V2 OF,JW(2%NK!^7 :8&R
M<;. <1%?(6.4@DQ)7X!*B*E03#OC"A95$3'E[&YD;+(=/CU$3OOVJ9=.850(
M2Q$GE"%#@T$F,"R"L%J'I#9*O$4*\0 _88..#3IN%CHN (Z":"XP <41>XXU
MUD(8$4AAI7*42->HC2N B=-G)S+J2 LK$"X*F7+ >F0LU\AY!FI^I!)C\^*E
MP%N"R0W0&YM*Q1O9LB'K1K9LR+J1+1NR;F3+AJP;V;(AZT:V;,BZD2T;LFYD
MRX:L&]FR(>M&MFS(NI$M&[)N9,N&K!O9LB'K1K9LR+J1+1NR;F3+AJP;V;(A
MZT:V;,BZD2T;LFYDRX:L&]DRD_5?0V/; ?[UY9>7_X8?XS<ZIG]<=JOK<73V
MUJP+W6'HOUCNQ=#<S2\I07OI[K\J2M-5T<.3T#(N%18RW8NR>]SJ]H8I(T ?
M_MQME3# X[YIM\Y,?YC26@]/PB"T8MDU70>#@4&;8<AYXJ\N%5Y?@/ISG&Y+
M 8,\ZPUR'OA?^J%MAN67\.MYZ8<GXYNK4R_6]PWQY!5C![WV:'CW*P]8W,.R
M _,^".>M=[V.Z=ZQS 1_ZP)N7E4VNQK3/]-HJSNO,0:B2634"LZIU@76A3&%
MC")0J<PG*EZ,7SKICV=P9HX#LOU@/B,388*_F/:YN1B\^-<LTP''U0.BO%KW
MZTM6+<S+?]L^O'K+:)>SJO>Q[(VUO)&E@E95J&'*W=9>UVW?R6-30E8\GHS-
M.>#6AZX9^7(8?.O]E7@DX7EE!B>MW]N]\[N%Y7E'_E/9!0GOC: //_CY,08Y
MIY31N:1L]C9S!N )=N1+R3"2MCD;A%_&O_PZ!O"RF_O++_U:LT\-.$E:KB=F
M23.N'D\$:1M7PE3OZ/67Z\?;^=%X)YEY)N6V4.K.QWB;?.<SKMB\;Z[%QKK(
MHJIM)>GSKNE"8^5S]?H-C7'!]$+/D2+QMGB#>V9R9[Z@Q^ ^/<]"5@CWE$MY
M>[*FPY-^"*U]:'<R:+WN>MA=<LZF%B-;,PO<\,R:8-LM+>^,I;DEG&85F91B
M2N9)&S;/-.<@ZVQ@TLVN-F Y<2/;:RW;^@%,OZ14[2N6=3!;03%90:W8[W5:
MO;/0-\/D>DA!BE_ T@^#7QXU=_NZ\,YRY_KT?:Q[ULQ'*"\P;WK,56&\^\VR
M[Z_?LAK;T<() U8]\'^AM.>,:*HU]H9S#J_;(EC)N39<%519FE,HDW$*9;+)
M*90/WM=I #K[YV]V'3GJO/UZ\,=']O'R[=?TO8^'#A_0 ^COJ'-P^I8=[1Z<
M3-( _ W?>GNQ3S_2H]/7EV\.WQ+X+H?ODOW3@_*H\^?)T3\?O^Z?GIS>2 /P
M#\QK=^_RZ/2HLW^X+PYVTQQ/8(X?H+\_.Q\[O[>ASXLW?QS,EF$F%@M,>$ R
M*HJX<@:90C 41*1*%Y$P#N):;%%\,W?4PHE1UBC!28,[JX\[3>KV=<.=24HF
M1BR+G'ND0PB(<P ?XUU 7@C,L8S>8/WPQ.VK5^UJQ530J?+<K6&OU0\@8*YL
MAU:WUDW37]/O+ME:HT'PK;+;&%J-H;6D\MI/S.Z[X0Q8O,SUY5NFZUNFTX/Q
M7.8__,AFV%7+'[.DYA(LF.OU#P;#-_&/7L\/=KK^?>A_*5T8O.^U_30+PJ.=
M*09LM(E%M(ERRHKALE!.BY3 K'"(LX(A510>$8-I00AWH$^\>$G4LO*8K9 A
M\X-+[A)L@$9RGUQR)W: ($XK)4!>B4D9_4U$VCF"".=":&U<X"J5-%E6+9,5
M,@5654F:9NQTV<P'.VR!WN!@2L.L->6_E(/!*!5]@B48#!^W1.XF*$]K5D+O
M.96G:09\$W^OK@AWCQ,R)TS>K5FQ\;XLA+K3-0,(5E0%JE @TH*^Q#C2PBI$
MA2R,%A+8%QA</KB.2E/N<L5D=>GJ4B.KCR.K4QI2@1EU-*)"<I!5XPND3*&0
MT(32R(5F/KYX>4O>^N>3U2<]KI^Z3EZ_CU+C7XC*@O]TI_F]+LI>TA3JT@^#
M82M\/0O=0;@6$]%XEWXT&W7I"M)?IO1[W?]7=N%GQ6L-O"X KV^F#\ %90)6
M/2"N% 8#E&MD8%=$1A:<1ZZ9,B*5E*,K9( VKJ.5U(4:L7RH6$ZT'B]XX!3L
M$A8I3X6]*3(Q6$1)X)9I6CA.DEB2%1++)BK[V5L^M6ONZ0%N-\30[^=S^'0+
MI34T7T/C??MQ+?HE*)?3=Y\N0[_GP8JYOK>-V:ZZ^W1HOKZNC)O?0C?$LMGH
M%MGH]@]WA@?E51TFYXS0AA$40 U!W 78ZL#61]89(Z627E"2 EX4)?37%;+R
M&X_<RMUB;&3V,67VS:1VFA?,6TX((BYXQ$-!D*71(:>9,$JYPN4+!^3FA8/Y
M+R\^G4-NM??US6BYX3?K<FE&9$VZ(9IR  '.-)?J?FS_RM+=GN]/3#_\EECL
MU12'-=O80MO8WK3J*04FHH@!>: 3XACV,BUT@90M(@7Z8>K\BY>:-,[/31/.
MI3L_&^%<BG#.Z)@%CEQ0Y!B7B$=FD598(>:II=01["WL-GR=7*#K?C7NU8GI
M'H=!BH$Q@T$8#O)UN'9I;-ENHF!6(H)EU:)@F%PY+MYQU9V<%.X5RB\I<=U6
M"O)J=/4?5AU89@C_K%ZPUW7] &K!;JC^W>N.V>_=%?<U6L)"6L+;:15>""V(
M%1QAI32H\)$A[4($-M)41,&45^EZF+H9OM^H\"LHLT_L.6YD]=%E=4:CC]+0
MPB&&@T6\( KIPG-DA(K<8RZ88RG816U4R/NJJD%_]<.9*?WXFF:ER_>&)Z'?
M<J-^/Z1@EZSD-SK]9IW.K6IJH_#5?[T%@VL^K0_O=KK^5<6=;Q*K[F0.;4!Y
M(5#^,*U 41=-I-0B3 J)N!48&8<#DJ! $8T)"]X!*&_AXL&.EN;P?<7$>_EG
M[XT,/YD,3RE6P9M(-%/(6273;5&'@*P$62VPU)I1HOR+EZQX</S_Z@7)K*IV
ME3G[(0I4XUA:681]XN20WS)2,ZL=]+JUUM[ Z7? Z<=IE<@&:J(U 7'L(N)!
M"J0T!V-5%;X@P0>;CH7YBIBIC3=I7;Q)C: N0U"G])[".EJP*-/5#8HX=1HI
M(1BR(*>1.U![# ;;A:^&H&ZX/^GJ6.W,7"1/:>,VVBR[\KE28L_KH_^K8KL&
M3Q?"4S>M^"CAHL(LI:%-#GIN(C),.22MB-0"N4*@+UY*??,^W+-<ZVZ<0"OB
M!)H[>W0CO<N6WBEMR#*IN D129^R&ADND96$(JJ)%)05A!*3/;GBID+4^($>
M3ROJCX*_Y7!MZMI<XR#Z<>W.)U:5$C/^9\)Y.UV?K=(WXY3F4\\:+%X(BX]G
M-"DF7"$B1]9H,$\IYTA9K1#VT4D<O#/),F4/"I!K?$B;ITDU$ORL$CRE38$9
M%%0!.I3C(CF!HT#6$8-BP:.SV.@H%$@P7Z6<VDV<Z[.WW/ (D(-Y:J$TGK_Y
MG EW%C)=F\UQ'<KDI3*I?_5[7TH?_&\7'P8I(<359KESQ;3-7KG(7GDZD\*%
M&&=\$0QB1;J$#WLCTM$%)##U5%):%*IX\9)OL5LB:1?V',XG-6OD4_RQ8."Y
MJM8U,/ X,#"E,A,=@:Y4(LED@4!M!I79,HJ$E=9C2PK)  ;8%L,WKY*N& RL
M>\7E^2J&E]TO8;"40G:;YHQ<[ER?OH_-+-?XUZCO3DR*5>G%UED_V1[#B^Q:
M#_\=E6>ICF-C>VS60>:SWK7\RUSDVJ"'O1T'#-8/?]4\]U?;=(<[7?]ZS':-
MVK"0VC"3A<=(897R$4E=>,2)T4@3J1'AV@IKI I.OWA);KF]WMPZ6%]A?83T
MXXVP/I*P3NGX'$>E%98(8Z$0MY8B94G*_&B=9]@)!71ZJ1YRY;))_+A)+1L2
M/'O+A@3/WG+#TY_>.!:ZS;/0.!;FNQGQ8_F#'^_^TQU.W[TQ:S9.W^]4"&>"
MY:AWPH:HD0Q<(QZ<02K85%K3,J^),"0IA ^SWA82C#6Z _5C2?KC9?IO)/W1
M)'W*]-,N!IS2-VFM'>**2V2,UT@X&Q@V@;M4-?=!IM^3"/JZ^\;G.]N)XUJT
M#S[;V33O^'+GNK;I65?,A #PACG[FGO#U]!WY2"D@YY!JJW0ZITE+&F,B!_W
M>O7RCW=JEOL=."X7\'A3\=CKFOE\HRTLI"W,1$  >;!BR2ZP)"#NB$-*$8&B
M!1V046,9<R]>\@>'HC51$"LFILL_V&G$=,EB.ATTRHE25@5$"Q,1EU: ^>X<
M8DK#GVD@1, 61/ *B>FZZ^_SZ#^NU^GTNK7J4PX&*8049A3ZK=>=LW;O(H16
M%H76^$I,ZR_S?<6F-DV[WZ#C])72C=(I>N,^60QI/\_4.<4*6Q$9BC)E%5.%
M0%9&BK -@+^>:&E2>+X4*Q2<W]QU61&-:)X:Q8W(+D5DIY0C =2*DC+$M$\9
M-02(;- 6!2!;"$Q10>TJEB9N#OR?O>6F.NG*KBO/3#LE>4M7Z5J ?,Z<E4/X
M4SN%J+=Z%@9F&E_=!CH!GO4N]KM0L]S@3?Q/KWM\&/J=5Q7G_2<QWIL)WS5;
MWB);WN7K:2V56QVMDP%9SQCBWAND#?RP0$8=G4I^NQ<O=='D+=D@85VZRZX1
MUL<3UBG]-$;,&<4.*4X#XI'";]019"3HK5$%@8OBQ<M;"G>L8O[;U=[&-Z-E
M0X)G;]F0X-E;_@@'",.3D,\-3-?E2Q2S!PK=UMD(MF '3R)\K'N\U8(9#YK,
M/3^NDW()!MO<Z3BF/95[-9.^B:\RBV;/9:,4+J043@JZP1@_"5;X&%,-J&@L
M BW>(FTE1=QX5S@7'4[9> J]11Y^^Z(Y:U@Q,7Z&LX9&@I<AP6.S[LWN_B?"
MO-#!*X0E_.!&<V1EH1$A6A?.2F.I7L-SAW5U>H]=W7&B4;G>8#AH]4/;#(-O
M#7O7]:G&]?WC>M.>5).Z<K-EU!U#\:O$G@T$+P3!4U%MI\?L8.=3$7'!B<!(
M%Q%0F#F#=" <?O-1*V*=$CAE-22J\8:ONORNH ;52.[R)/?*)UY)KBB$LQ87
M2$0L$/=2(.MY@0"8L2 N!H/=TO2GQD.^22T;$CQ[RX8$S]ZR(<&SMVQ(\.PM
M?Y1:#F=UWH26O6C]5&?P^?G6 /+F?&@^Q_+Z)_9847_''9D^?A_S:I/IX[ML
MJ(/=F7H.T3@9)9/(.TT19]@BXXU'1"MK)(/?#7WQLA!;6-V\6_1][N?5R.W3
M5'58E]P^C<0_7.*G;A(R+YT#OD11IY-B7P2DE+%(%I805WA&4@YFT=1M>#Y-
M[<1TCT.ZNI-TMJU*<TMI[[\ SW>'@YP&OQ\&PW[ITIE4>MZ<0LWGQ5Y_K%Y1
M=2TA=_K?ZPF?OKMBT?1@I^MG_S#5\B]8B9Z_60/3M4>))J^_5B+QS@S#ZQB#
M:_)Z+[8!S,1]P$X-] \:D: 8XCHJ9"GER(H@F>6<12=!Y<-;!;Y9P^O[/.:K
MH?(UZ1Q70.5K &4S &4Z-J7@4O-H$"B/&''%/%+I-A/U6N$@+74V5<#>XFP)
MI^<KIE2NQ7WQ5W.KD5LM&X[+;C?Y E/AI2Q&C2OPA[UC*GFJ8B]2\E?!J3?6
M40$V8@$="9BR^;27 )_0YU(<&]A>"+9GBC'AH'W!5$".AP)Q8PC2@J1"CLI8
MJ30&:^'%2R&W!%<K=/.TN3R^#,$FH/(39P+W(7!FJ'&.TF@H4:H FS$FP2:Z
M$>RU$>PI?0R[H(1GJ5)3"(@++Y!A6"+MO5*2$UDP^N*EI%ODE@S>S97RY].]
M OSQ85K7AGCTOML(F,L"OXTKGAZL_V=IEL^-2:_WUN2=4,1Z+YGW'%-B.<.N
M"('Q8"11,NN<S^BL;+:FA;:F_9G,B)YYJC1'G*;"$LXP9#W\$(505 DAE4\%
M0(G:(F)9B6CGEIMG]C\VH/<#@YX@F@M,K!080$]C+801@11@B#E*I*L,[0;T
MU@;TIO3QPGJ=  Y9(0CBRA5@8SN!4F9) 4]\M.G 16W)AQO:3X5YZ^XHO;VR
MSOO1V5D[I& =TVZ!;NK:O<&H7V75&!?=:97=2N2 .DV5G3GG.L6/##C.]T:V
M'6XPY'/7X/F.46ZNT=HZ,X 9P.K \,.0;-56^'H6NH/06*8/B))<4SUL@U2M
MI><KW:OEXR\0F(/0'"4OIBI]F+8/F7)>8>V1C9HA#I1"ECF,+%:1,6<DEO'%
M2\[T"H5R/I'YUR#+RB/+TI.K-LCR,&29-L*4PT7!!>*N\(@3,,*,(P88A10:
M8^^T2D7*V+*NO*V1D?68,K6PG04KC[*M50Y#IREC^I3FSW.5,5V7Q5_GEIMI
MIR8'Y5G.V'56%T<;UTYK*E4TQNLFJIA+,U[#5__UEROY&=<6]!^2]$SG[V]T
MSH5TSIG"N!)SQH452&M&$ \D)6I-=>""P%'8**D#\60/OX736+,-U*RN-=M
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MC2N*?/-S=R$$H=FUNE0QN',?OUTPIK@O[=-CIIP'WQYC]/?NCE/XV_H)- H
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MV!1GIC\)B>W[O*0YC5'N=]0.X^*2Q\G6S"M5JPCOK\R0W.+U5W>2;(^TSW5
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M4$>J588%&59DZ/;&ZYSIES:,\5YR[V*N+@#769?+RRNE!]BG[!K810$5RNX
M5.B\G]52D*9Z&Q+#EF^S>C8ZJS=#P-H FUD%WM!O7N(K8V]0'G?+"- #7==J
MVNW0?8L]-IT'^G&ML5>@QNYT??KG]429;2RQ-[M[GXA3$D=)D..I2KWV#BEO
M&/*VL%$9ZX1DZV.))1)OM=+/UNMILP64K'? QL!<2;C3\Y45Y;&9,[8>8/0
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M].QG 'H!E=*6< 5TTX,+V-QNON_>M=FPV>Y[-<3ASKDI,7Y9)T7HI!AJ+^[
M6G72$NT/]IMWG%SUM+5 MK</@U76@7-#8-89$9PY4 #!P%^+5( O%*D2SUYD
MRY7@OQKIK^6^EK*M28YCMGWB;25L0:KJ4\VU2J56NT@CX\VTI#\)7D:O#&DB
MZ*^ZR3NJCFFN,I8ZF,%#C9/N9H/IL\"]\1#FC7NC9FPUA0+64Z!7,G-RO9PY
MMC)5SVY]HJAY3!6LX;4 '+579EIX=JAJXKEPNG#:::T^3(N?+"#38/XK;G6N
M]"'\K^DAG=E)JV(H#.8&UQS>F9ZEQ,G:'*&YY<FY='H=#YZG[8L;21?PA#S^
MI=&/$F+UWLCTPV!<]B9%X,W*],OQ:2('Z(>8ZD?2&=\K#O)M#F-5>8[Z%#>N
M;M6BOB;B "5*[:_/L?4M/&S4+>-%$_=?]R;=F6.[5TI=JG[.^-3),;WJ;# >
M]9[8WQJ19C]+/9[K7J^X3X6/JR=M0=^Q'A;^W$,&@OF3BG.D##/BW3!2(,+,
M56NMLG$DA71<!Q69<6!\C8Y>B SM;Z:LE]DWJK66]8M.HWH-PVP.4/\#*/MR
M7(X&8"%>?:U;"&^#Q,#_^7WS]>GN+NSOBKW]W4-K\22*R(AQ04*D$2+86A5)
MD<G"!JV$M6;YED)K=O-@A64/E-F<,AFT"():IKQUVC$3<PI.5Q'2LM-FV:\<
M55K86DK^5W]\>CX A0O]C4A\ETA@%OE0Z2BUS20Q7ELL?/)$L\BP':RTT6HK
ML/"V/[@J$4LQ8C;Q>0R8T\2HUQUZK&I$J^)1/+O<%,-6R)0L&=R'K!K]LC:P
M%4<3?LO&U-[.U%8<%2C\55$R# B9)[8:KHJT!L9C#KP<#=,+3:<\?3:<_"%Q
ML73[*:KT"Z[<CV:\*P/*SW;?[X"T]09GIU5R 8=5D=\]-1T^V3W' Z>*RHP"
M@A-JL:8I8Y2 5D,(E=/<1^XY5^JVG'<_D[GC.LZ[:IWKBOG)2J\E;<?+I30.
MP]E7\--70.*A[I=NXE.[3J<JWJ1*6[=:=CQ*5R(M3*][VJVJYK?0QX/8M!]Z
M9!$CM^J;$2#![KG/I'(WD38&+C 3RB>X>&L2)\)M$_*T"PC7SLYZB4,M>=.]
M4<4[4X[27Y:],?(EX47CL\8)1PJY=!M,6N*E*4<PJ 90(&ITZ6[,ZQ\'XV=&
M/6S8K\:C;B]-UC=(:'XL[FS[A.@8H*35WO!L[NV\.PS*%>"O16(8]8 Y&ON'
MF$@X (X.GDMFY./!G)DUKI@')SY&6O)'!#UFX4VFWM(ML >\KE2M>/U#*NT_
M#YCBO7,L^)TG=Z[&@C/+5_L#3]BO;XOV_KM#Y[B _\U(5H!C(&0L"&X_$QZR
M MQ F%0O;A'JK;*L>="94327BG(A669HD,$+%@J68^>S6\1ZFV6]:5E//A]R
M:CE,IB40.S,BBDR#EQ<\8=IQ:R/C$F 7EE5<OZQ3@H;OB,^V)G'!G0.+.K6-
MAQA3_JF"%QA'0J42J;0J)L=!; W.:CJZ;[D":VMA/AQWS\X://T?^*?W&*S+
MQ"E%H2EG7^&X>85%&:@L1&)AKE("=UOGFM\8IA=-U-W3CLP6W@FNK;"B,,)0
ME4=)*=>%"2+*6YB:V_<D@#??BW42Z@DCU;N+O9U7A\(5)BNX)[D4$7.-&L]_
M"N(B"UGN"ZF-1J2Z>J;[S@9(92[+'7@46A4B"*&8UL&J(&6P7GBW6K)QL]BW
M(CZ"L7S\FDK6+[?/V^\.N<T$+V"*E2XRL%"%A  TYL38()4""6 ^_QD6ZJ?F
MIEZ=GO4&%R%\P(![[QR,'X+EVY[IO_JP]_8))Z<^'G*9%TGQBZ E$<(I8A37
M$"A2HYS-?6[Y8B&D*URT5@:168;M<ZTJLN E]9X&P>FM&SBL@=E/&9@_4P;F
MY4P&9BUM_M+-P')IYFA"+CJ;8C+51BA6$]7Z4)EQWT4R921BGCLQ=S0T,"*?
M=BXG3-K1=(<5>78Y93\=AO\;0Q@PFK0<F"U#0-^B^N+?QN4X,2_CW[XT#1/2
ME;]7'-SHA>(+D[2/.L/#/?W:M!F-+P7.R-03.1L#[AAT6Z=%%,U+UI<WE[3.
M0.U;O[WZ\/;M[ZW47B9M^LX44E5LX?B(/WL&9N^#.Q[T0DG:$.W ,'_[\T/[
M]_K;$]DX7GTZ\*'7D+NG^<#"T%/3-T?5QB[,^JGY'"8D"*8LQZ=G30W#D:FI
MUEO5V8Z*YQD9K[]6!PJK"BYTT+\8D"3;P\UO[)DTNJBF%U<\ABY6=S4])FK"
M](JKI.:[7D_6<%QBF-6EDXK>ZV!XAKE/>#-\^\%XRNT^ET\=79&4^7H")-7%
M>A"4AZT9+O@![A+U8"IG_IC.!>#4#[OE9Q+1TG43RS/VC9C2"%>O!1%>P]4R
M_X#D,U>+7%%=]=RX-T-)C^,K$PM_JMZI*AGJS;7EWUMQP"2EF7"7+U8;S)YI
MJ*>TNZ#<'Y]_@*\9IG*)B]9%-_12=!!BQ$+!NH(AE1#!<Q(25*-*Q/98:U7=
M@B^UVC&E>Z:%^<:6\X=C4(4$[[/HOCU,A*VHEW]>3"]Y6[5:V49U>@UB]!^4
MHNVIGKZJEW:GGH/WL!R;X]S542<L%106@@=9:"*5#00/J!++34; /; Z'4CF
MX Q<AN'5W>JMAE&IL6_8AJB/YXAP[7L&8]S4#*?K)R)8UH$N-@](H)Y,FQ^T
MRD$3U&*5<QE"ZN915;ZN+_[- U?BW)PY;539L%0V-&^L9HUU*QGK*;*XWJ"L
M:J'J.K_KX7#)<^:[):"]AC_U*PN>#I@L7-_M)T[0%AB_=,:^!">L5Z4.9@J0
M4V^&00^,=!I![59.'(<)458]S$6R]A(=CWXX;Y6HMF55]9<*NUKO/WRLB^UK
MWV+Q*,EB,FIS9FM!#/7ZG]GZYAFLA5"%RL *;HM@62X*YC35CLO,"Z]=843-
M)7+U>[X9XJP-=NRL6M(S?Z@Q.8_AAJ*Q2M$6Z\8R;9507$99"*V%L<8HKZ1A
MN456WGLA=_MN(U[YQ[N 1,-Q J(]+,W>/S;]O<JBOT'T*G?[U:F8IVO+9])$
M>_OO+CMX^"5&X3PEF2XD$5D6P98S25Q66)]YY3C6G3$EEY*S5%B,+4OJ:&<2
M<&XUW0>K2 D#E<%XE+ID-:GK<1_QNPI<X,(E$GR[,X)K8,5OL+?S5MQ>W&2V
ML?1XF;%.;9"PH4B:.S3"2[9?YBW<C\VSX;L.PS&H*%C(78C;3NO*KTU11N>R
M?:@YC\X:2@+-+!&<4Z($*PCWF>3:.J9L]GAR9W.+W?I[4*[K3MGL,$&UZG1/
MK"A6\9A#W0T&<:K*J*2NI18U,IW@19<L]3-MZF=-'8%OU2TD)Z22LTU,J[^
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M7KU.+)'85P&YT.&_6XG-W$Q?ZFS^I9(U0]ISWYB6UQ.;-#,5'Y#X*G59^7.
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M26K<9EI_6R\W97NZOCLSRPL_]P+^@+V59U;Y6KS<0.4J4#E;5Z'!NC&J+(&
M&!P:HQ71M C$94JI(N1@WHI4C<FO5F/^OC[1UT:Y5U3NG^#=;)3[891[IC"C
M8%$ZEQ-O;0'1"A=$9=X23(6YO.!(^('EGUI<S:^LD7+_<JF5Y>0:6ZU^^)[,
MRKR/^EBYO[[S>-XCI?CZI7),G;#![%4P>V^V?H4:;W,:)8$HU1"1J4@LY>"?
M.9U%K42T*F%V5JS*BKBF%%X;.-O V3JXJQLXNS\XFSF!Q(/6U@:2^PQK@XT$
M.*.*2.4*JGV,A;4(9XRNNOF^IG!V1T9"_!TEOML?IVAHC@BNUAK!GQ=(/78V
M*+MXS1_# -%5]TN8,H[]:YY!KIX=.KW%6)B(\>CZ6ZXP%=T>$6Y)W78[ CHV
M962J)FSFW^/AU'@<!6*'P7PF)L)@_S"]<W-1/OOO>2*];I\LS.'BZU]/^SCA
M3YQ=G@H%K%0RSY2BX&B)D&OC6!$B5]1%7E ;UX?.;^>FY&DK5"RMB)6)UF]T
M/ RA=0I//2Y;H>^#;R6RK$HA&\:L]!R$W=:Y*5OF[&PX^ K .@J]B];_6X54
MXB[\DS,@+Q>1_#;9A@FBYX\3T>_,3-F^_"@/K9%&RA@)91:<3&2,T(8KXKG.
MM'(\=Q2$ESZ_BLDM$,E>(T2KK'(>=&84S:6B7$B6&1ID\(*%@N4<(I.TRK19
M9;I9Y>];9;3E^Q^_@GV^@.>Q]KM#,,#68CF\]S$0 :A%#!4YR3+/(\\B]KC!
M-;^:"FK6?*LU#.59<&AR>A?/6]NC:V'A"KG<5@*6(]S7;-G!X'/KB^F- _*(
M5OTE0'0\-ITP9TA[V^KAN96$*ZO(6# J*,8E+Q@5W''K!7ZWYUP9Z82])NB]
M(EJWW)=]:D(%X[\X-+GS68@Y8@4X=(6WQ ;<,! >$$7$+"+W-'M^M?[ASM!1
M\)Q%SIU2(+"Z*, ZV%P'KPL: X#7-<[_9EEONZP?L\,@:6X+:@@U.A+A,DJT
MYHSX*&E69'GN(K;(O,$BS*/#5M6?MFRY'BAX-W8#=JMM/5O&=O.LE<B#P>](
M!+UPQ9?P_%KN[>L<U&LHN]>!>'CUP?P0GO!MYX;C4/7XJ1KWU4S\K;^[QG9[
M76R?_3-IPS^XX^#'O; 7ZZ'-C&,?9>$)TX>?'X+YLA!0",(*+HA@SD#H7!0$
ML-!3410B%FI=Z<-G16V^G51ONL0;-O$-F_B&37S#)OY+T&EOV,2?))OX[7HS
MU>:P4HTS<S$$\[! +)YRN<TE=4)NO5C&UV(_[<>V!ENW?;3'V#.QEO4/IF>&
MX.3]4LV^3C[R#G\%;KJ[/+C\F!U<OO_\Z61;?-KY\[A]^OZDO>_8WG[[ZR?X
MWL4=M Z,XV#_B'<N.R>=?7_2>?/^M+US_!G"@HM/;]I?.Y<?9?OR=0_><9Y^
M/#.!9R(O""R4)D(*0Y3SBFBK9,BC-<JE"LV,W7.;Q%^E"^(ZDI#_;!C[E3#L
MYY2N;C#LNS%LEI<\+TSA(O%9GA$1E"0@CSEA8'JL=L%)SA'#I+KGAH7K3DV^
M[)9?[\J5G?J8_N=Q./6M+D9@H;Q-Z>XWW_1.QQ26S-;#'%-8(W=U'L]WZR5Z
M:RXP ;?!\SO@^>RIH2B=\7BBTF09X+ES&?SD,Z*IDP$62 3!D%#ENSW2Y4#P
M0YW.C4;^&.=KHY'WKY$S'I:TQCMKB85E((+A.3[%(Y&&939SP4M3H$9^-P?K
M#]?()Y<5;)V-A^[8E*'$C;"CP<"7%1%\&'[INA^3!'Q<QQ_7SJ\(7_W7)DA\
M6Z_>&URX[;[_4"_;!M)6A[0Y)M<@C B<<1(I\P296XGVPI#H"^Y$M%XH_^R%
MT*MR.&Q.)Z^[>GZOD[%1SQ^FGE./PS,JI3>,R)P61%AEB+9.$F^DYYJ!IAKQ
M[$7&?DGJMD>>LA@.+DQOKMIK$R&MBV^QD(-^WRS5!K#N %BS&VF<6^HITT1S
M*HAP)B=6:T_RP+,LDTH+"^K/U"9I\:NIY'TE+38J>2\J.9.U"+ "C@L2\AB)
M"%(06_! ?&Z"*N#_9:#/7G#^W3[$)FMQ[SZ$@X]P%/"E8W_1PG7YTAU=;+(5
M:^=1S(9#,Q7V+^L%_(#KMX&R.T#9+#-L82+-@^!$"FH)6!E'L!4W45X%YS(M
MI<@!RM2JO+";;,6ZJ^=]9BLVZGFOZCG3JL8IJSCH8Z$8TNI0!LZ_#(2S0@IO
M-%6Y04_COFKHUMS3>!39BI=SAX$'%L:03G676Y/31&=XUON.]*^;F.EGI#'J
M14R-"/>F2[@!M#L VFP)A@L0-VD=".62$F$@=#*JX(3;6$3/G.3(1)]IL?:A
MTT8S'R:;L=',^]3,&<JKHA"6"DVLY05H9J:(T5H3G7GFG<BY*@+VM%G_/./3
M26I4Q^%-G=KH+3D.OXF7ULVS2&NV)&[:X-?*^#7'0!IY+'*!+7.+@B%^"0*&
M!AGB&5.&25X$]NR%4NO?SGNCF0_C66PT\SXU<^I94.<-A8DG#-:!"&4]L3H(
MXEU4!:4JEQY\?BW7OR+JZ20Q;L6$\B/R%]^Z[Y$3*]_W"<K[GY7';0M^WDGQ
MC87X/@LQ6^/BE<FBB#G!$SA@(9@A)G)!K-?*N=S* @^+RZV"W5=>:%UYF#=X
MN<'+Q^$[;_#R9^/E3*=(3J.RFI%<4X]9=/"HLQ")=-0QJJFD6>KG6LC[.CBU
MKGAYG[SU-Q)RUA(:8V":Q8Q;*037.J<Z-R8OH@R\4.90T&=7"/]NI/C\7O[/
ME5@/EQ-L=@:CT!+/6S^8-G,GV-%.MW2]03D>K@M')FV_K'7_]-W7#G_=_;3S
M_GAO!VFHW]&#D]?'!R>?L[V=3R>?3@_XIS<']-.;5W21(_/3SJOLX)^_/G?>
MO!+M'1C;SOMN^Y_7W;U])SJGG5.X&S#A_>>#_??(1BS:VX>9*$R(K" NEQF!
MB0Q(7!M(](Y%(YR"*:R@&D0T^&T$6HI$_28:YT0402O%L$1'F2!,%AC+%UDU
M_QP,AXF8LKPJ_[/BMK1)P+>_;'YP15"*,YW[:+PPVJK,62>4C)P*):S_J22?
MZ3G+&&:7,V2"@2M:^V%XVOI[8/I75?_G#/K&(>[V6Q_"V:@BJ\/Q5LSD+P>G
M,(2+5O@:W!C;S9K6"-^C!^_1,D?#$)"IN/4;7CO_EK^WSKNCX]9NOS_X8D;C
MLO5W-X;6!]<-?1?@M]!'Q&Z]!E/0VMUJ_?VV]=ODVM]36L F\0JKD6(+K5AN
M,NX# ^@ )="Y-'E.+=<J4D,11U@!)@QQ!'\ 0[; CKU*:QP7@B]?#P>GNV4Y
M-O!F>_'O0?\(9P'A:%W(LW\Z"L&XLL/,6RE5* B7NH"HRUEBA>7$!VVH+')8
M**S]H\_I#>S9*S&B:VLI+0P-P@H $>.SPIM".X<P0XO[7/SWX<Q<H/"7FR6O
MEOQD^^MAH'FD+!C"G)1(@U\0[8(BU%D;I-"< [*_8,7SJ[N\$Q[\06R='W?=
M<>IST#T]#;Y;=4\9EP &HT%KB%,_"T__50) =<L1 DI"I@0]39U4=2[AHO76
M#$?],"Q;N[NMOY^_?5Y1L8_*EHD1 @?XCO)Y:Z\_:=)0.;(%\G8R-0^'$VA"
M% 37$U\ OFD5686ID-X7\$]&!0/+IPO%F!,%^'W.!IMD50$X%Z3Y80-4/T!J
M+X_88:%C!,%EA-J(W;AX)!;W$P+//*-"%*)@$.[<@%-UGXZK9O"Z=B!;K15D
MQ6DM%00 -F=<B%QI<)DXLJ"CXV1=]HU60+N=UW/" CZ"0X$YAY"J#/WOD!;Z
MQ*0%QO+U4*D\R[/"$*-".C!GB2[ R<ZL"XRJG*K G[WH#ZX*RPQ4F%,(@@%[
MAN'4= %$OIAN+S&G [Y5Z'*]2*VK ]D9?)GXC_H:_Q'_^+H[+$>M;3">/GF/
M\,KXY[^33PF8_ &N'78!L;>7.)CIJLF]OS]O[<,G#==8:P@HWL)>*KU>/8T8
MGLQ,Y?SMV(GC6CT$#8&76>S7Q%VA<PZ!KLQ%R(2ERC!+<VY4M$66\ED0P+-Y
MSR)IX-5H=;=?0B2% VEX?][#^#^,D/'X;1@BB;4Y"A-M(_RIJ=O)T==#&W-)
M<Z=)X1QXD8P&HECA2=0T>)MQ9I#"1SV75_3M7UM37^(GKW(ZO#"_Q-6RSB[T
M6].%W_^WV_=/>8D_TT,9E,ZC9L1Q%8CP-A)MF20ZL[9@UD8? @0*2^SOOU"#
MSV > 0+(YV[?-SUST-RE-EI3R)T$KF7KM[>[_YN@ $)-@.%N;]J9"^X!&\JW
M6JEQ8BT]$WRI2N' 91PEUZ_?'\.#*]")&R197S';VVGS[T&2RLPTUNP8 A.8
MXM35L3)I(<:JQ=.B*<(6+B"B*2I!TQX6.D+^#)GAMY>85\U[;(0&A&9_-SN,
M IV]D!'C6< 34H98H2Q1!J8Z-Y$Z82&B70)-X/HO4*$B6/EQ2$[.6<7P5[43
MQ<9@XWXOE.6\U]2#Q2A1;C#@19@C4YBK'ED)YF \*D>FRJB=#;M]USU#'Q,;
MFBX.8=!?Y@>==]%A"BFT3F#:FG,=,6(@W:_DN.M]Z/_Q9"2@O?_JZ]Z[0RTR
MP:G+2*XDL@A*,$W*I59P&L(R)ZTQSUZ,SF$F+T@<C(>UAXZ]W& =ZB6&685%
MZO52T@CT^A1^<+ABW6G.(=F>YZV/9[!,PR;#-&D$U44S-O.4:_W:>>>[BV'&
M_XV[PRI]@K(TG[>((2'52GU+[X1$*V4MYE'J=0C;*69ZNJF*_5W9.3JD/-!"
M">2P]"",VH$5RP&5"A\R"O(914&Q)>'UR0K$#)")Z<E!E! ;4!01+L*HPHO!
M%#2:3L@0X-6MD$/E7BW R+C$AUQC$$_#Z'C@G[=>#X:M8,"KJL5ZQ;;*B[)=
M(KQ-_#D0<-R5@5&LE(R3X ?DFFHNK1"!V3RG6AAP1[GAT:I;=^%=XO=/O?PT
MP-TTX"<LQ!_/V^>'4@K&\I@3ART\A'*"F.@DB3)H&R6-E/*5ZDQRPSQX<%0Q
M[D1P6AO*K,NYE=BWF=E;=\O>K.#M5M SY0T3ANB(QR&<SXEV@A'#I<JMRI7V
M87G?Y!MP:2TS6_M7W:7:G$(<".[6Q$S#CZ?=\>D#A(++A'8RKK?5L#8>/<JN
MRT!V =2#P^ZA02(I28@%,8 71%,37.Y9U&A"KQX7^%=CLLS1T3 <I0!OF>==
M.>5+) ,6;Q@2I;'].:'?G65D.Z4VW@<_=G,=XY^@R!RQ]M$ABS:S6@A21/"U
MA%":@)-@".4Q1,%RG3L, Y>(C!\/43B2QU..;0G0D9+>YZ'W)9#D]K3. )D&
MODXY-6GTRO_!3#KZ'.N9]5^"C=C<&MN\PJN (W8)SAG(NH'@!9/^H"*#E-HO
MFQS_-#;NI^D!91K!L"!<PAQ^K6_3?5Y3EF%4;L'5KC?V5?0T"CT,E#'4.JM[
MF5<:B!N[&&R@&^I@5OL&(Z_ZF<LA'3XRHSD/<]0]Q41-[.+FC/D:X,MQRV:$
MVS;(2MZ:Z#]ZJ$?H(O?3$R'".^MU<?=LYH[F=,O%S,D7B.C&P^HZ&/^7KD?L
M@)M'K?Y@U(U=5SGI,.ZR>]1/?TB/'YX-4I(I?,&(LFHM'L?#?K<\;AF8'/3C
M,68$4$I\9'!M%7OB]CB,A4G:\N8BS4CLHH*W+H(9H@^>+@%L:V$ .QV"*9O-
MFM+!1$_@$+^L!6Y]]?G1 &<#T,O!5*11-4_#^:S>N>R"#,)WS3U_?65\N21=
M*S.@ZUU8%1![;/U>M7GOP1^20 ]QO<:PV#!;IV -QAB7PSP,01% T'":6]@)
M,X52LRAA3=DM*\G&%M$)2%Q%CQ]-M[I^,/EN' _H0@JWX;+)L$$6+S#5X]+W
M=N-6(PXE1.074X&X_1.71&3E;'H!9VFJ\MCA&D1E?JF7ULLVRUNOAN#/"VP*
M?38HTY/_2+U!846FO:#_-5\%6%<3T^DMQI:#WGAT_2U7>LC>7M1NV53[=D+'
M^,($S?Q[/)QVP#T*Q()+\9DDV_&'Z9W#^CW[[WGE <U9F,/%U[^^5OB&$LZU
M*LF\<3;!L R&@-$I7^_!!ZHJA/H!+5)5[0#&!W0<RQ/3AG3$ND049V< 36-O
M< [W59^[B]91Z(=A>E@$H&ZAS6DHF$"I\<)^\)6F7A<Y7,&,B8D U*Q,!0)&
MTD58P.XIN(^]+MSL&^/1W(!M,<!Y1",Z[#H<5!JS-;VDI3\ML7>MF_FRQHF7
M$X/8KE[HX\R@7\*8_ZR&_'1#Z\MWLO/N,'<:2U<+8GVAB=#8M$9;1Y2U1@<&
M'^?9\NW0222]MH:TCV'3O!6M?9XMK(D!@U/Y!VB1CLJM2DT:]R$9(/0@*_M7
M9<:G%<:@Y2?@!Z+Z-CH4OKIP5FOFO+)=H'/5PN,=@S(I27-+XV&&_A&@:VM&
M(2VF-W&/!CP[BV""STUNCP.]K"Q,Y9J.A[/VK]M'R D^W8O)3[@@)?N3.[3H
MX38N[%9*U,/2P=ST 9_JC9OIA:ZN;RQ' _<9GWMJ/B?/\;AKNU4.]PNH5W+Y
MEF+1M'Z[7H(:E>"BY%+BV #+S+A7;Q -'+X9N@QS2S7L'AV%(;SY;]W?JZ!E
M=JKK)Y3-SOS,ID9RE5)2?[(=-MW1F([N_#CT<=\,OV#F&\#Q2@,J*YSN#F%6
MT1=WX;?R]^I-W&#<\RT,N6$A;"_Y/9C+3BB9*DE+?#E<]19NR**,P\J!"U\V
M*>RK\]Z(P=8,[K<JF:R6? M_NW);X_?C#DSE1*7BTQG^OF4OG]YYV;3: %(8
M<%;!H_E27_EER87IH4>#E*QRQZ9?RS1H*SB9.-+?EMV%3H4[#M7<+E%:?-]&
M89;ZQO5J3U=Q,-R:U5"3'- Z\MVJ1.F\6R:$F&Y[UA.%\VFQ\5-H5=I;+Q6(
M^>F5;UI/\+NN#'1VTE/!<W\F<*S<% R$OQ&^KFGJ-.UC+H,3%)LI^"W@TN1=
MJ]FYL@^Z<'D=SQCG0J_RRJI0. G%&<RD2\@R7YC1;'@#6*>,G%^/C%SC*G4&
M_:FW-%N@L5N/=Z?.)#[=Q%QGYPBW0Y7DQGIJB'.9(2(X3I3P@1BN@W*<"QKI
MLQ=B:>U85?J%<C*1R[**BY^WMGOH<QP=?U/\'/PV+WXUCC?X.&N9%MP0&WH8
M69?3N^M$S[1H"/Z+C@I8:)O$V$P0P$\*C$*9,@(>]VB7IWQ2+4H*@8ZPUF1V
M#%C,- RQ5QM%5)JZ-GGY^V(!BPT7 ]2PE)UHMF[KRYNXHSP.$%ZE01I\ASZI
M&5X>#)]7/+7W>CQ""U7'*JVW]7&?QK+OS63^9T]"+IQ\_($'7C^ @?;C7MB+
M;?!_J]3*?*'^/HK,DSX)^^[0JSQDF>3$&)$3P5U.3!XEMN;RX.!Y'G*W>+)U
M7>SG=M*JI7Y#K*2S20U,=Z2:8VF+.7*T(%M8?3.W9W6;(GDS3"H<![W>X+P$
M-Q,58#"&%_/E[W_<_6CY+1-F_%93-4\[D [G3]. B3H@[4J<E>&/YH=_-X?[
MN_WTO'33O^OUKG.'F"Q;9,K"%&'U\32/]IQ6N;2:J*O^YOKCY^FC!2J$ZC/%
MG_,LN_9C^IS=\3.97?^E-]UYTV"9>*ZRXE:/_09KV3>9!K_KTB4\,E4R]T=2
MIQ3?XD)( I)TN=6H\1Q+QF.CD%6WXHI)M5N_5<><8)2__PCFV&_=M]X41+>;
MQ]M3$*W\TC^58>AV;[M>C&RS+M74U9H] ?ZV*?UXGP0=)GXOODY;J@?!#->%
MB.BN+EA-1/3NHG-R)-K\W<7>SE_@9KV[..#@?NWTNITW!^>=_?;YP66;M=^\
M/[E"1+2SR_=VCBX_[>R*-KQC9^>ODT]O=L_W_MFEGTZV6?ORSY/VY<?S3V\Z
ML3U+W&8S74@I',F5@.C.9@("NP"^7$ZIED$J([-G+]A6QN^K@= /YQEZ;'R>
MMX9Y_B/H.A]74X-?'-QV^QT8V7Z*^MLIZ-\@VRK(-ML8+<\AS,\$)\KE$<+2
M7!(5:2!:2NUCIFBT'-1J2^OO1K9[;(CPR_JHV::CP2\/7NB*[9\/-IBU"F;-
M-E<R0A@5LT!R8\$;\X!9MI":%"+/#'465ALPB\FMG.DUXEK_93TNL?&XG@9H
MX0FY#6RM %N=V<XMO'"<QKP@E I!!/6.Z,@L,0S6U7CPL(0!V!);7%W=)=SX
M6O<.6W+C:ZTI;%V&X<";\OB[$>OU8+S)>JT$6-.LUT5GWXG#0C'A9:Z)Y<)A
MNZF"6,D9L3DOO/-%X)[AKI?BC/_[UW.V*JW4:P=?^WB\_*'=KFMSE!MD6\DA
M2P58L]BVV^R8?^S[;NFP#&9*V;7!LU7P;#;7Y2U3UE--*,2/X("Q@B@'8:0*
MV@@F@K5"/7N1@0/&KYZ@_*Y^ M]0D0=VS=85Y/X.9?G'#W72[OJ,^[0N6;%V
M$_\1< E;MU\VQY0:%*JXBFLR5GCS<O1#FJ/]BK'_;P_0@W6^J'=F57?J]:S/
MVV_W?;JT7MB7N*Z=L+$TJUB:N2:MFM.0&5&0X##4%X(3:\'<8&6E"HS'@*T@
M>7&5V^%*8<HC"O'7%<X:SVD3[Z\35*WN%B_SAA?(V#9(=0NDFJUL*7(A :@<
ML3%P(JS,B:4Y(U%*K7*EHL#*EF*+JJLM"6^/59O ?J7 ?J8<>BN=#L<C2[7H
ME\D'2U[9CW?$?O&NB_==\OC(NRX^IIS)LI3PQ@JLLJ.^OSUJ=^G79 FV#X72
M+BMH)#++P6/-\D",LSG\XR,L7<YT7H#'FF^I_-?I3?N@'12S1]I!4?[P#HHO
M!Z>GW8HP "+3EVGVCY"D.)1KV%BQ::IZ>B#;IYW/G_;=Y:<W'^$[4']?R?8.
M//.?3O?3B>\>[!]=?-KY**\<)SOYC#K>ZUSB_:#_J+_[G\_;_#_'!_ROTP[_
MZQBQH+/?B^U+T'[<3([,66F)D2(0P90@RF:*,).%0 VV?[&+O0NE$L(($,G"
M,$%EKJW@7%B52Z%"IOGB\;.9=4A.Q]Q*W*'7XK>_?WZ\SKHB1JX<!>GAAAH>
M=$C[Y%2S0MKUZ+6X7%7^3OR*:WD:_H;3?+,'<GL50^0 Z8@JKOB>L<CT-AA>
MM&"T+A$X_*=;CLQ6ZR72IPV&_:[9J@_PU;<G_HOP]0SYR>#ROPQ(!-P/7Y=O
MU;0"_=8@<:,@TP(H-=*^F=899JJ:0\BA>EHZ-3A/&7X3$@$"%R!>(>=!"F3T
M54X7C G'+,NM<$N1:+$_E1\/+]+1B9F8=*_BV^@?58O\/O3#N>FA%_+4L.BD
M+0\CZ&/@DA+'A"0B6 5(Q,'8BRA<U%I&"YHJ%_&")(Z_BG?C>6MWNJKS4@@>
MX:"1I9EUKZ7RVV)H:M&9D<-R41"OE\.[BIZUS)O,.<H \ KL*DNY$P:F(J(_
M93:B][VBU]EITT.6<Y-[,'V%#SF('M) FT")]R[/%!4A1R_K&Z*W/T>/4ZUV
M4U!2"]$,37P9)M((B#9#)(.FLU<9.]<S8[AB/0E@D/;^3G3WR)DP8>!'BIA5
MZ-SNY!4NXW6;Q'VX". =OD>>X-ZK:ECKP]CVL[5A_[,X%-1D0E)'@N894J%C
MBQBJB>**.Z8+C$"0"IU?WSX25WLEEKZ@,Z-H+A7E0K+,T""#%RP4H)H0Z=^Z
M8<%F69<NZ\FKRT,/D,:D=40:I8@ NT*T@F657K.0L0PB2K.<X7[:O1B,WEG5
M!Z-W\7 <32NZT-M3.CN2.%:1O;;F+>XN^M8;YM9%YM9L88+6D+EUK0*\;[45
MA>'W0X6(R5],%$53$6TB%>P3C136OFN.^H-RU'5E8D\LZVM>7IP-D8#QS^Z@
MK+K0;X'WZYZC4\H!*:]2L2TV39H0WM7\2#7Q7$5N5O$-UE?4%,^( Z$<#?H@
M7>?(5U@S*?N$]^.SFDFHHD9/#:&&%6\3@&[B1T3:)V3@1U+*@>LF3:SGH%O.
M3D+-=SXS*\E_KQA@\/OJ(:=1UH1I2.14N5DEC&D(WPOP +"?J,P;,CUDCKHN
M;$UO,>E<5?^5-J1M->'#= X6&@Y==>Q7,8!!YI0Z+36/5N0VU]0 5$L>A,M$
M=#QEN"GC5^W>[;8_V\VH]R:#?K+6L+V_*_;>'3*3<UG$0*BU@0AN*0&_TA,.
M7@CWN1 \I59OOX:%RHVW''S2 OPE&VV6"ZVLA]"293%7U^Q2;-;P[FL8-'/,
MF8)X:R41!15$9SHG1N2*,N8+FQ7+J86O]UT;>CS$$T#*M\,!=OH*X[+U=Y.W
MZB+Q70+;WZ8?_YX@H&JPFF#0=(>M+Z8WKJ(<'[#)&!)IUXTS?[ADW;)/^KQL
M37.S%Z_A!?Z#XY\FR]>G4_I/E[=V:E:79=%[3TEN5"0B2D]47N3$&Y9I;H,S
M@:Z$&7?#_<W*WO_*YH6&]:1$: [_%#XGBGI%C.)2>>%,;L :X(&B6T")64J.
MN]R_6,_LSK5Y5*37'/2KEBC#P87IC2ZF%-@SW,\@]EAP@JY?\K=JSZ^<=*">
M]GN9^*&N\4^#.^[#ZQUUJWM7X[&U =2RR .E+ IEK'8Z<BFMI!JB 9DM!\ML
M3FG>5V\V-;333E)[\0.^TQH1U?YTA?G(.]N'!<L9 V$F1:$U$0[=IR -"<I;
M3Z6B>6;0]"[M/EUSD58"A*M\A2^]!/=_.$1Z[WK?$"[O=4^[-=-YE5 ORZK#
M.?K=TQ9FJS6(N+O7-I]QJD7FS=C J$<AE+.[SVO6Z?6G2PR6K'S\VMX_N 3I
MN6QO'RIGC"I\(![9L$01\"2@480K6GA7**.-QJZO-^08?YOR@6+#D+,X'%3$
M^PVY\4^0@EN7GV[[+UAA5Y/N/F%CZ[ZVSP\=Q%G6>49HR"#TTK8@,.62%(Q1
MIXJ<062&3<CI%MBVJ^6BK6;K(=4X3D$DF&%RKX^'B>FZV9JK#*U8/Y[F:W;\
M)UF+[4G68BU]A/T%MZ!*M\S:[XL4$HW+M+6*W2&FR2RXJ,1LS(RCT>#Z-,,R
MV3Z;I*[L16,<)G-3M2@JW1 LOV]!B/8E(%=PZC0RGF2!YNZH^AUA4[ZF05WB
M$5[NUJSDRRR9@]D>2ELM-&GX):G1TFJ.C63!!^NY=SH7+I<ZIUR)4!BN)1A;
M?T,4N'%M;EF'\.IKY]VA4+FP2FH2G5-$Y+DE*C!%P Y(8;AGP9KE685_H0RO
MMJK1*2<RD7,:G?!%-$@#20781:F#=C?%]IM5O>VJ7B!Q>I%9,"V6&&W!8651
M$Z7 =35%QAB#?[F-SUYDRU;U>>O]Q,@D]G#GAMBF/77RJ:T.!G?#@$T)4JNB
MJI9^IC_BI*^+<Q5FUDTEZRX'D]X&>,NT$<]Z1H<?9OJ^#F9R_G771WR%JW5@
M:1,KS0VVRTF]K'KC$KOL7$'H:E-@N]<+1S##%ZW_"3#YQZU.&)T/AI];[\$
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M+CRUD3LN*=O4*FS@X8X>A(HV-\+)D&4BXX7Q0FG+J,#@.Q?Y!A[6$AYF:A4
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MQIW02H0?F[Z5,,!I6)1/Q-P47F@#5(O#U'< I[$]U^D/TMH'Z9VXFLC4W(#
M6M OV9I+YK#>=/9$8?F:!1.8SUPKL"T1Q/ 1:\"RU$\LYEAN'#E>#]BV3<RT
M@PD=.^2>%=IF*JS89+[@)O=<RPQB+[/2R',3[CY[X5B#B/4&@0<!;-]PGGK
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MV6]D]459Q@G>5AH<)T'51') 0]=Y.@6(!2,M#&!4.*"Q(497P^)68"''(LM
MQRWA$YP>4_]@I/7"%B6>@VHZG%"1DFY]:/P5WUY-XRI/<U[FHI)EAM3DC',Q
M%B4?#F_5*MW)LC/@V=RESDC LUD0 [>PA ^'E#. (?9"EMV"C4!PR?-T6MX
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M Y@!?J;7%W?6R*:3*1;J)+G\:,6-[X,87VDX(/'V:UV=;!XYWJG(J@<S9R_
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MWW\X/?SRX?+3%[C?.KY\-1= >7+P]\WQP=GM\>7YY[/+_2^@'=X>__'J]N0
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M4$4XR<*BK3-Q47R%2+]K&9J[S%@+5NOI6*I<W_63T/)MBSN Q "><VPUS9Q
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M1,]>1'N>LT7^SCXZZNE;L9:?_-Z*]4UGOV7%XGX:N$R8GN<D)HL#S^0.S\R
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M^WY-)["7;<\/[.8%GQ@ YHP+H%\8S!1H#C<([L['R7":RH9C1(7X;GSU6-S
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MKDM\*L4'0$Y9C.@E2$1C4587^56%.P?C'!62?3:UHVL3?PYTA'>06Z)<DK=
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M:0U5_LFK3S";VME$#)_N:6K#M[GMY**HT'%5)64>2P[]&MYH'!X.#$*Q]OY
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M !8UJ1RI%08-^RVO>+LOUT$C!JVC ^"A]3W7FDN'G.=H&!9)!E)T\;]>'GQ
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M:PHS0I);QR+?, (@#!5[WK*ZH_^EWXU5=P,(>XI*)H:]2N#5+]YJB]=0G,A
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MIG64%)Z"Y>^@^#IQKKJ%[U!7HS0_)5W$=3&\)IJ_2TG86GOAE2CQ6*)=2VO
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M29G+):^7)U-9YBBF)A5N+?*7L?A795Q0":[V7<#I+IKTT.9[77Q1XA?RW"#
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MQ?AL+UB1P]'97)')T?18RUBQ@AC_R;;#/;LCK(F5\$K:E^B# $QW#<)EC Z
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MI0X#=]"Q[)S*%@B"\X!$3U2&^W&.AA*X"3CV$%D0#@B]]#',=HP@'DW<%)7
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M-!7/?E0K/H?K=HL"W9981E\JW*,1UQ:!JU9X+5W1W"+WB[M;^(A(=L K&)W
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MV'D !L,+FT=\C(B1$7(Z>!CZB(-*$RP(='(73%89Z0&2@[8@0,8/*XS_<4"
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MY&\DYTBMWR T5!!\-1"\GI]!OX[&K_1PKK/%]9?H@(Q)R3BQ6BDB)!B$J\0
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MV95GY^7W$6/24PZ>6#"Z$,:)CQE(]I%FGJTQDCTXI;%]OJ.JX!R,CE:"KH^
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MRKZ4Z$I'"]]^Z9[-6\]@.GU=YH=E7S< BZ4)KHC:I'I^"QQW#)S@C"9 :YP
MM+E)GM%:-'NG4)$"\_#L8C;\A%_5M]BQQKS8T3[_>#%;;FW]#),1*7SZ!B?S
MD\O%1?,#;:VSGERL8@6M J;.VZ@R*UYY[1U7O%-)W?:I5WV@/T+?RKUY=2LK
MZ^!F;-$B*WW ?'&&2\W\^&6NI\4VJA5"!R^( <8#TRJ2QV&3K<J) CUIIY@F
M^2R;,1WJ1*)_MO2EZ&.?0O3$_A^_K'_ 8E>O]@:1 EC.M6$,UL1HJY$YX:1W
MDFMR?$]P:KM+IF.=D_1&NWXGO][,WR#/:CVR:^E 7?"U3%:]#^"1$D]/A1&=
MF+JG.8]!NRBDCRD&!J7NLW$1&22*_9TO%)!YX%PV:3-V'+K=ERKZ4-FVC14;
ML.R?4%,AK^[^\9B\(H<F("'2D9Q/KS@R[J2(68GB?1-*W4!Q^%B@7R.-^])P
M"_>^+OJ+NW0ORX>R<AQD;013?=B0!8-(\@DEL\WH,^HV5RVO(GED9M]/TP=/
M%_?>9"<L0;+@F(9@6)0!F,.H7-+!)0\M:'!BZ>)-*=&?!1J<F/U\_O%L_ 5Q
M#NVJV9".,=C(O$!%PBK!@G#("J"6"DO.H<G<L ;+(Z/"OMK>>'C6X\'+_(#O
MQ7 $HS2$LY>C,IZ<S]VG7;;*-S]L[\WPCCA7MKN#*=H6%X2741<4(1:7:*R1
M29//V0TZ(>Y%G_/H>Z<#B/L>V4ZWZS"O'AD%'A%"S"!!IV1#"EIG*WD 8>@'
MFS5\&WTO>GXSP8\PS/BYU@'M=?"S[2O:V:&+3"MV@:QB] ZT=%(KK;QTV9=@
M1; 0?9&;[7*_=#W9:?P1)[,O0*#_^V+XL6Y/MC'6YO>TM%A'Z5;,IKFSR3D;
M>;!:R1 @IF"$L@"T]"B\RVR;W[CW%7KS)]?ZN-FS4?[Y\O%?]\B%#YB]"Q0M
MURL_=*!5,M!2F8,QKMB(834#H[=K].Z!UL/]@>O?\+?)>#H=@"^T>AO#DN7D
M'ACDS%M.GITMTB?CC;)--JWOAG5X/ZIGCJRY1K O*[3HCI'2Q?G%&9#/_Q-^
MG""-S'DK=*1Y:Z[V47YV/I[,AO]S8Z3>$F:@YG=PDHHR*8II&9 %%P+S*67N
M<W!2-BGG[4N 1\>[HUBVP;; 1F"_XFR0M-&EN$*(9" %Z9K/1]@<4F0*)JJ
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M>K'LC16U)QVV.+.K@)Z-\MLZ9,Y^7MQY.BC9"UD4"5J[:VH>$PM.!68%\EQ
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MLBD*-)'6'54( 0KNO35;V/&1F6X')?4X!*>3&3G]%[7]ST<@R6I-^7R:0>?
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MZ9$2K+N;=1K\VL94+7GU<O3Q8C:=:T LU_7@%9+/4+N[1%_O#D#F)>9Z 7@
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M<6 Q:\$D22*S52XH=>(T7TCR@!C>(\7:L7X'?IQ2.=+:3):_3<;3Z4"IV@W
M*Y:2HN!0DL</7GL62<U*QBP\;Y/DT;\L3Z0_ 8ZT. "XO!4.\T\7DZOJP$4%
MU34W='K9PC0/0M& & SC2,-38W+,%U)H\5X)30MH=&T:@FX-]8FT[2W<XE[
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M7KMFWH=Z'3UJA3IEVZ8\X+'?T[*5P3O?T[*-M1KDG-P =@FI)*EUC*P6I-<
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M-I;M]+B[^GS\:9C%RF52W79,+__JWKN@:S&L[&R&XI'6>^ BAUJ-'RF$L-:
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MUJL/WAO,N#[SI9P=^+@7/]!-KY;%:O;1^,_M<21-$VU)<LA#D4&4:M>349E
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MABN#<9C2;8<<#%6N;6ND9RO1=BAM5UFV(U=?M(=<:HUE3B+7-5&B+,E$1F#
MLQ@B0A-(J<)0<D&$"))494[ZXO@P4],7+4IP7\-T#%<Z3J735OP%!(VS#5^"
M!N$ *=#=' RP^[X_TG/LO)^0]L2N^ZFK>Q9#VBKI^ M=-75F/\K[VGPI3=R"
M=L;S>SI_N_B;I-IJ*:2<91@KS+B"2G!M3 11!*F)& B00@SQ5++ JLOF93"F
MICSTJX8<ZR?UH]].H0Q/ZL *IZH.^[FM#FL292LAGJZ 00LJN![K,EU$E]?:
M3?V0C%O?Z2*V#FI 7?:T45I!-)UE/M/O=:"I2>VK/<#Y?/G-5,B=A;&4F10(
M<BPP1!QK;XLQ"GF,(\PY%4C89^(-@7!J&O.BRO=70&PWLJ)-79;'5FI 6[$'
M;6E@\5YTZ^M)S/; JOS"B5[WWC)-M]H"/&N!P?54)GK07A9^)_Q'Z&WA8>*'
M;GUA/RF>6V%8##SEUACVO%W8*L-AH'XNU$>YHOE"BM>T6)B.$-I/>[A[F-.5
M%'KPG.<FT2NA*.$4QK$V#E#,N0E#2" 23+M-+(P1<\H1.3_DU!;Z+81FU380
MW3PE"Y8%BW 6J!1&/-765Z9B2*(HA;$44:QB3"/M.BWDK;EG5)Y)S?/VT#\V
MTW;^I]^W=& #I04+6K3@IVTF&\ >^P_8L^/3M;08=50WTIZ%?9?1X<[>YVCB
M@:]>&D$6J[HYQ\>\_+V)ED0D90E),NWF4:UMPBR"F&8AQ"''D8@RP=/$\3RM
M8[BIZ?,&+=B!"PQ>Y^.R+I*MC\T\43?\\=D)U@8(3;5CQ?.!6M>(8Q^L64A_
MY(#-YJZ1(]*:*(&MHH'O'ZK/PY0N#T620OU'K'40CB$-&8="4A$H$D@5AB/6
M 3V%T^4+?.:BGF"GGN>XX6<GIYESHB*I"&1<6[<HSF*(8Q9"D@5)@%4H QDT
MT_QZ86G:3F"26ZPC3?&I,IL3F62[I>Y9IVW@U=%#U. Z+G!GYFM))Q :>&X2
M)A$#>!+DCQ'L=XYC;U%]9P>ZM/#(NGYD4]A$J\M-JY1?)#7]7\6'Q4>SYU7H
MX37"O*RJ"6R:*U.*DYC&,4Q2$1@O)8$LC2*H,,)<BCAERJG$D%=T4W-J6N%,
M8;Y-Q=LK\"9?T 7/Z7PK'!FT(@)ST 368H)*SKYU3GQ,N>5"\EP3.?0B<F(.
MF]I+)AUP2[R=6=R;PZ:\"K!IC7Y!I16/] ]3CL4'P&>JV>*1V].%77P.TF_)
M:(.7/\GB,>?R^(JV+E=<Y]E4#>"V__WELER]7Z[^)E<:Z?)VD?^G%#/*(AZ@
M((-9Q!!$2:*7#\Y3R G*9(Q)D"6AR_(Q&-+)+26[=6$>%L4:JHE"W]BV7 OC
MMEH,-]MV*\<DYG!$5V3M8FQ,PJVZ^:WG8032OUV!)[D"&YGTPG-GHC;]K1R#
MT^]S%1D.[*@KRN"<[Z\NPP_HMM*4Q6KV"_V/Y;JA6WG]/2]G#&4,8Q3"D* 8
M(HD%)+%>**B4,2-"Q21 -LO#\<=/3:=O^@<:=):U#$\PUZUJ+^=CZ' N2RJL
MM5NWQ!TJ2=^XI8[TW_95T8DGCZ(_NJ5J/_HS5_4(;ETW<G]G4JG+CW(AO]&Y
M";"=)9G".,4$1DHH4QN#0!*:,N5496'&19 FW#I$]?0X4_MVUTA!E5U^!8H:
M*]"#WSE$#78PV_U)>^1KX&][0U6-TD3LU5Q]]L:50YRD'\Y&BG;LR9U;D.)Y
M1CI##3MN'R]@\+P,.V%_%I?W[BE;QP=6#EO=LDR@D*(TQ7H%R1*(<, A9DB:
M^J<\"Y 4,G-R>H^,,37UN(98YT9?@?\>_"D(0G!/BRJ>7OX3"(.K(*C^WYR8
M ?JP^KHL:B]GL6Q_VZ15+PNPW.R, [HZ>OYFMN,.CEZ=&]0>S*!MV,A%\S)X
MK$@[)9_J*6DV,M]6_'KM.GN*!<]=9@^&&;NK["DYCW21/7EI#VOLFO-"3UE;
M4^ ORZ4PNX2-;[?NHHQ2%622I9!CIIVIC"M(<:!@S"@/)*%9G%I5.'08<VIJ
MJ$$-[AO8I=G%OS78*TU1-N@=;!!+[BUL-_^,#JQ 6C);Q%?@+VLF6]3G4[A[
M4^I@XOFG=B1SSP_%;M:?&UF=EJ#EH\:S"MUDV[$0'6_MW_5KN:@K;]#B0U%5
MK!/5 G$CBVJ7;B85H03% D998K(0LA@2GD60$I8@+F4@A5/U?(LQIZ;&;UJK
MT4L;8QO2[0P^SU0.O<=6%RMJK#_#J;:I:\BU+6A*GM7!4'[;A%E2Y+M=V+EA
M1V\;9LG#L?9AMK?V4T-5^;"M0^;W6J9FU>4B8U3Q! H5,H@2Q;7V"6,8A3B)
M*.:(""??]?104U,Z=77 Q7(!&X!@OH'MIG$Z^+53-'Y8&WJ?KR)L"V5UJLE]
ME_0YSX5/1=(QVJCZX[S4^VK#XHZ>];W$?SR4=3O#S\MK(7)C$]/Y#<W%V\5+
M>I^OZ+S22FS_@/&C_/M#7N:K]ABR+D_8'"::"^K=%A:B).6<0"I)"A$A#+(@
M(Y")S)PO)%0*IV) 0P.>FN:JEHHFV& [-L2Q]MC0TVRG^J8T>4,[V#=O7UX=
MCT;?#A5YN^"%V;4&2MMO59C(EDP>2Z>-1+S7(FQ#8QZWG-M(,W!0&&ZL<7OL
M?7XTFS#SMO?=BZ?/^AFOEG<T7\P")01) @QEDB&H7>,4$JS]YB2E)!94,!P'
MUON=I\>9FK:OD8)-9T?V! Q:\*7&:QE7<HY=BQU-/YP-K&1'HLMAM](/;2/M
M4)ZBS]-FY'DN.C<@.VX?;]/QO P[&XT6E_>M(_,H%P_2U/8U/<=-.ZV_YJNO
M;5#0Z^]\_F#.4DV8N?Z?J6@SBTB2! AQ*-+4=,6B'.),*I@&8212*FE$G+IB
M]< P/?U:B>!:\\2=>SM[>&!&!]>^%?JZW'>+'WS3 H!6@BNPE@&T0IAJ73XK
MI?2FT&_I%'<8(]=2Z<W387&5_H_JV?JOS:)I,F;,VOBFT/:I7/"G9I&. QS%
M5$90)6$&$14A)#(+3)_BB.($L\@M&\5BS*EIMRVD8 W5T19RH=Q.R7DF<F"E
MUI-#]]Z ]JQX;1)H,>RXW0+M>3AH&^AP:P_OU)0;WJ3TU@[SO^<+\6Y)%V4=
M:#63H4(*<Z)-+*7=5*$=5B*#&&H'-0LD5I1%]FZJQ8!3TSA5_>VYQG<%[C5>
MD"_@[QIQ]:LVVL_!![.AW,)W]4SDP!K'H-W*'3>GN9K)MPM@((,*\[FXOGY,
M.KBUGAD=R;_UP*R;Q^M 4Z?K:_.<\7Q@!ZEVG&&7^_J>7CUJ/SLOM;'Y^KO9
MN)0SKE"2F>R5*#")*Q))B),T@)PEB/"095'JU'#Q<(BIZ> MA$#6$%T/APY8
MM#W.N82;H0]@MFAY?8:6'N<IIR3W>P)R,,K(9Q:GI#P\93AY9<_6,_E"?E O
M"RGRU1O*S;'W4Y4;*3%3E&88QB@C$)E6"H3P!*9$A6&<<J*D4[7D4P--[2M_
M)ZM6=._U)4XIIF<)M?O4?= T\ ?OP)![^Y<SXGMM\')JK'%;N)R1^*!)R[GK
M>WA@6I7D=9G-3_(^,PV4FLJODO! A2*&/)8,(B(32)CD,. I#542IQ&WSU,]
M-<K4-,!?J0D<6)DUOL$+-.!5G1Z55=E1E@VFNLFU<+!\4#:P-GB]PU++S_E*
MN@Y$.?A//@@;R6DZ3IPG!^D<#YU>T<F;QW.%SN'?\7_.7GQ!I>"#:(W#FH3,
MN=/P]>UM4;4A>+M8%?FBS'E=NHJ5U2;_+,R0T+J60!JK&*(TDI!(',$X")4*
M8B80=<I>>#9)IJ;:QVN)OB8&K)EI\@6^M.0X&I;/]SK:6:X_Q$LV\&+X@[Q?
M_6KM/N?<>J_)^RS"C%^[]SGG[&B-WV<%U#??<*\/P8TLS"_HK0QG84A4F(42
M"L&H]I 8,ZD^'"9IF@@>HS@A3@VZNP:;VFK:0#/IX2M3]@P4?:)^.NFU6WI\
MD3;PZG#8<.0*;)#Z3!\\3X??O,&.\49.&#PO^6&FH,4]8WL0:X^F#@:?B2R6
M48@DC!+3NTXB!EF82:@R'"#*"8VYU?FW=V13TTE[)5^W]G#J=A=CV=S[$SBT
M#7W!M/P -O%F%F^Z9W%$R_8$X].P5/?!_2"6YPE._5F2IP;HL6G^OY?Y8O6;
M?O)#(?_/ RVT=IL_W6@REN;Y;Z2<I5QA'@74E)Y@6FG' A)$]$3C+(X2'JO
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M-R?57,OTVW*N'Z/]NR>SXL]$2K(()P@23 E$1/^$0YI"+"7)A,A2(9WRD$;
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MOOAU(>G+I9 S11-!$T)@$*G4M):/($,BA3$A2J4!D@&U2K#=?_#D3"%3^-^
M P:=G;XY(*M;FUQ"P=!&C)WTUGK@E*B;K[QL/_-2\C_=+A]_UK?47[C^8?_#
M/GC<*)_M*2':C_+DO_>(NS.'8 _Z/5]_O_I;_K14JV^TD&TY?QY%"G,!,X9"
MB(),ZB\QPC"*,:),B2@1PCK0[OQXD_M &\0;HZ!:O,H&M$- EP77W1_R  P.
M[J0TY+W>(:_%VZ=LD 6+#G%P?MD<*?#M#*N>@MOLJ>F,9K-XS'CA:_8R[<2K
M.=S60P>?: F_O%N:U^B-- =W38?X^_J-%DG 589@DJ04(K.1Q*A0, OUSXC@
M.)3V#59<1Y^:?J[P@\=:@"OP]U8$X]'5,@ E9144<+\EAH/&<9X?"RT^).L#
MZ_2:\-]:PM?HP1H^T/BK4(&;D0AW4/A#$C^2^O<] 6[+0E\".Q<)YX>.MV3T
ME7=G >G]$'<O^E7S$M8AU:\7XI4)8!4\)2Q1,>29J5>5\@Q24[\N180C@1.>
MI8&M.WUTA*DM"RW()B, O#:U";K"2"V)/.]J7TS/P/K;F1DG[[M3^@O<\.//
M'<T?[Q1KVS'OOK!GT9F\I+>WA=D4U[KA@VH* N^UWQ0\09D,,Q@D6$ 4XA!B
M81*:*6$ISC*4"*>04*M1)_?9[X"N.Z96L!TKQ5@Q;K>)[YW'H?7#*0H'[4_J
MQ)+7VBU6 X];H<6%BX,Z+$XW^U=(LS!&84H0A6F2*H@$C2#%@L,X8C$)>("9
MB'SIH1]&_33?CF/5W$Z>+]<^/Y#2&4G3C*U@IJ-7^JB3"[6("<E<-2&9IKE>
M$ZZC<!(R03%4/$@@2K#4=DPB89(B4VL39TA9N2K=PTQ-<U3!R:M-<'+= -(I
M*NH,KW;ZXG*V!M84_8CJ%<!]F@??D=E'1AH]Y/JTM,=BJ3NN]IFC/4M9Q*((
M21C(0&I?1B60()-B'2N%9!2+,' JM'U\F*EI@RI_I\F:Y5LX?>1%7Y3,/"%%
M<#2S>)/'>07>ZW??U$?R7GB[FYKALWZGD*I[2C><N7KPE+./TN@B_>@/ZDU>
M<CHWN3TS%0FAHCB "A,,48H%I#+AD(2$!IA'*8KP0%EG1P%-3=^8'7GP4U%!
MS1>WCHFS%T^/O6DR%NEC&#%'4]'6R(T/5&.OTM.>)36MD\9GRDX[CFFJ"6J=
M#%Z0H];]W!ZQE\M'65A65#RX?D(?5H7+:SW#D])>$E.X\[SQ@@J/B;$357CT
M@AXA+=?SN;S]*A=/_R;I?/7UO5Q]6Q:_?Y2E?DOY5U,F.E\]K-IXK2B3J>"Q
MA!QE(40\Y) E#$$>I 2G$LG8+B?<?>BIK<-K\*!&#QKXH,4/U@(XQ%.XS4;W
MQS\LQP-K!P=Z^X0FNO'L$+0R&-\C1:SX>*W=HE1Z,=89HN+VQ/'B4WI)NA.<
MTN\)?3TYNBBUMVZVCYOO@-$LDBG&$'.6010&!.* I3"0"0F58#0*G%HK'@XQ
M-2UO$(+[&J&KIW5 GZWO= DI@WM#&AQHT)U7O#T\GE/"^_5A#D89V2LY)>6A
MGW'RRLOW9V:2AU0J12!5*H((A3$DDA*(5!3&BH0D8>ELM5S1N?M>B].7O!YB
MN#?WLQD#L&51++_EB]OR"BSDRGCN;<^BLHK,K]H87=*Y:(=@]]V227WKV\<W
MP^QJ#+U#\7R[#38[!Q=^R^LZAZ9OSWQ9/NC9=VRUT/6(";V*6_5'MX .T@S!
MAA&?;VOG>*.^O3:2[[_-5O?TV)4P7T@4A%EC.9$$*4XR!B.)!$095A 3PDU"
M#981)33!J?6VP^ZSIV9Q&F2@VF^>Z[7?P:7=H\QB;Z _$0-_[I7X%1$]7/L]
M'AQ\]_Y\C.2<KWGQY'H?%[C3M]Z[93SG^3C6'>_XQ"7]%M>/4L.DB_P_>[4P
M.G'WA+ZQ/82#K*5G6/"YC)X::M05](R\^XOGN<O[O;@O#=;%JN[X\S$O?W_Q
M]$(N^-<[6OQ^_3TO9RPD5"5! G$6)1#]?^K>=<EM'%L3?15&S,3LZHC$#$F
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MOZ8^0KT&39@,4Q5"0%F$ (H3!C#E"<AD1#A5"=*K>Y<9]KJHN<V$GVEN\M[
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M^R4O_OE-/Z=)$.110G%*04J)7F-000 6A ((,::1"D4:61VY6,B:VY[X2-7
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M9U2Y >N<3F7Y^-?-I7+#H#>1RO%Q0XK5_/W#UW=OOKW])HMM?<*013016"J
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MRV?<UF>\K]C88$;-K.F+LHSW;J4')&AL"*K:WHT5977OX)=\%12EJ99L>^L
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MYN"7!H>_E'4F*BB"!HLRDC:HT/!8Z?E51M%KW>AI+9BV"O6KC,Y93>O7T6+
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MHAGMABB7+Q@0-/U;OI3%=KV29D>OGRA7_&5?;.K@9%_(A&<JS# 0 F* ".6
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MR$P'Z:7M$P+WEN^$!MX^&@[A:B/ ^ SS\2R]G:8W>!F/0A9!)+P]>3:X 2>
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MPF*WMW!S9/!.!BFX(8HZ0Z0+BG@&C$0>1$X^ZV2J/,4_3M*PP<BCP*LG>32
MK%N;&#EF(,;$"'.>E98WC+@8&0%.M5;*N;RMN4.OUM.P4<MC1P)VXG@#UE,I
M&APOSU;93=/T>C8M'7!@&LM6I,Y:4[RPF2^X-YX2JUDBE*,#&EC0GM7).'N<
MIF'F,1P53'U)I %-] 2'=,Y..!^(S3SA,7&"!&%*OHIV7$-D.6RI"^\C9?R@
MJ'COE7Q'A59/\F@ 69^OUEUM:9V-&0+ES'I#4BD[D=E'XGAP)$AK5:E5,Z)*
MN'(++4/GY_<CYH<)9P?QO '8W"J17]/OH^*IN J22H'T6W0:%/+#.6&B%UG0
M.B'N^X0,_217!3 '<;L!M)RDM'J5])//?HQ^YVM_/D:[:P3":IO $Z4MWL+:
M1A(@2!)B- ITY,EN:7730U![.SW#^OZ5L-,'[QN T!=8^O$4TEL_GZ(9MSB)
M\>+L8E*&4K^!/([CY<@ZI-Q%16+0R"7I(GJ7BA.MG B22V]B%1?M>=*&]?HK
M :MGB32 L8>,&BD9)=4B$A&EPE-B!/%"6>(@4L$,<SI5R;]_2,JPWG\E#!W(
M\0;<_N?<C9$7@H%)DC!&2ZNI ,33,IS)^IRD2BJZ*G'NYP@;9F+:4-&DPV73
M&]:.4&3_>26#4UB.(UHU=S9P2,7]W8^M5G[_!/7'K,7W-#"1RNPLU&!$*FZ)
M=1+U&C?"FN2]3%5RVX]1BW_7 UV/^/B4U\W.D/TK)^.J$.K->!$GL\4%_M7-
MJ52EP7O&X[*J>C$>=;XWJ83TN?9"2D.WS%/H.T*P,]U#1Q-Z1MW3<86Z4FW
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MSJ:SNZ"_OE=]8DPG3T!X()*K0)PQD>B05:;&<L.JU#T]3=:P-5!5=$Y_8FC
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M>]WH&W9"2S4XUI!. S&&JUKK4GU=NFXK85-2G!$KC$'G(GKT3[4D(@7*I(%
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MSAO<VV2VRN/:-"E?[VWD(K6FU"%QSHN"SGA<,N[0:<%8$I:!KQ0M>Y:V@0?
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M2Q=Q^5CXV!J130Z!)&$RD<KB1G@.1'J/RE<R!:[*C)VGR6H,5?M*?U9-% T
M:S5&>OSXPP24ILUH?993)X@$AX8G!XN<PEVA24I-U%7,JJ?I:BP]HB=H]2F,
M@:O+-J?DT_PKS'^,XUJ9:_!"2#P1+B/I:"Y*/!L0"207#--10>QB6G4J+-M&
MP+!)$-7MJ%[XW@9N%B?3M-G!8G.PJ X2O6!6NDJB.M4V$,]E(+JX*R8&AUJV
M9_ \I&*X(K7#!?L0)0=R>>C\O)-_?__U[>MO;[[!XLH/]2Z9$"00K? 7F?'L
MV.PUH=R 3"$+N/^&\$ABWL//'ESTATIKUA_K6C!<3L?GYZA(D2G_ZJ<)?^S[
MU4:L1%F:1'3$DX$65R N14^8$#EI$57*57(/'J5HN#K'?I'3+^L;P- K/_%X
M!7\]!5A^*#]=1++R.GGV%!E!+-4437=@Q$=K"#/:%6\T^5@%0H\1-&S:RM$"
M0+W(HU%<7165I: B4Y0X*6TI!DTD:#R&(D,V8*C7NDIT\7&2AO72^Q%Y!QSM
MP?\&D/1I>0KSD\4"EHN-BN59*&]\),D&0Z2,FCB%/J 6/C"IC.*N2O3P 27M
MX68?$<_ZY/? OM,7/_V^]@N"T0JX=<25>4DR4E3"@2J2C6;>JV2X[_+*VLE7
MNEYUV#YY1_&N]^-P"["X1K-.R:2  M2*R/*B[*@3Q'E%N78\JDZV<7=@#.T[
M[2FQ^S+?@WU#-P ;3\=G%V<;P@5J*<MR(E#BA5()29 ?G/@$QB3FI(8NK^/=
M>G_=7GE@R>\CMUD?3!Q:^O[G+<*!19Y3P/VNLN.,P#O,<D:L]$J;E(0-N3?I
MWUYY.,^W%^GOS<2!I?\5>;RZ^KY&F/KY>+92@-%[%_%Z(UR6ENU4<A*2D21&
MYF("I01TL1P[H6 K!<-.K3R*@7 XYX>&SH;NWZ>+<XCC/(:T,:N]*EU*LD W
MK#0P2:@"<5N&:!]2S-* @RZ9HMW@\Q@5PUTG/4AVUC>;&\'*N]D<HK\.)'/M
MT4-GE.2,YI5D##UW05'[&IJ2,HGKV-MMLYV$ 5'2CURW(.4 )@\,D]=%Y\(<
MF;>\+-V65@='.I6CU((8P_ V+27_/L9 M.+42"Z5[30>OA-(MA$P['#;H]Q%
M!_-]:+\5SB_F\=0OX.3['%;<N;^ES=FR(:H4G"<!2JM%-,:(M<F0[/#,!::3
MA?Z\VJY4#:>$#A?\K+84AGXZWMJBC5%FM!9XF0=T\B3H2"R3HC10\H#^0Q2N
MV^/QWAWNZCC"=23X;,>[7=C90*C]Y \_3S=-)*B*T4I83]20*B!37#"$^6@Y
M_M<H467NV!TJAIV'?;1GO_TYWP!L5D-07N'A2F5,"DP7&_G,2P!B-97TU>7-
MSWSVE^5[JQW?;'N:R@#Z6P<Q:*6E58X(0(TMDTG$20\D9<8S%<EG7BF%H?_-
M#%PSNC^V'F0]#"SH!L!^,XCMZW(6_U9:W2Z^?/W]JHD)!P8&?1JKP!$9,R/.
M<=0!Z.@P+P5ZPU6RT)^D:ECX#0^:62T)-@#'CC?4A^L^&"J;D(HA$FR*: 1[
M//^AO ]3;5..'%*L<JOO2F@GT+H7?_%7E5\#^'RR=8KCE&EK+$FLA [!X5DK
MDP)"@$"33PG8<>H,FVEC4Q<.N[2UV44V#>#L[GS4$=4J.G2UB)"E9LXS11P7
M@:";ST(T.1M795C873)>1-%J/U@Z@/^#!T)FX^GRWY$M%W/X7Q=^CA\[N41^
MG<T*>]X!X+'XC+*+\_&*82.NH\-#8 E0&XAD:#T[XWAI:R]C$"D;>:\,X[$@
MR8XKOXCBG</P5%\BS<-M9)0R/&=-0LE)E\A#Y* 2A(9D6%+>!M]MY,RS2[V(
MI.IC &HGGC>/H-?^_!S2R5EA[<V=?A)F/U9.%GYHV3"8P!4C,5E*I,:O+#62
M&,M1/Y==LVXCK?J@YD7D31X#AWU+KE&HKE1W@+3RO4?<L1PS[D4G9*),):TH
M*DO0Q6?6*V;M8?KNSFHO(@.G'M3VY_S04'H]NSXHUX\X7V *?_C)-YB?C2)G
M+C--B;=EQE@NH^:3 <)E"#9;GG7'NL=G%GH1S^8] *A/?K>('52OXUEZ!7DV
MA]<7\\+\MS_/QVMO^-OL[:K9YVJGU#&? 2R)3.(IX4&L;8.L(X 1-BKE]T96
M9S)>Q$M8)=S5D56+J/QX4:+0G_(;?[GXB'\5X=NL;&P\]<N;Q^M1\,([$W)I
M?H'F:FD,Y+@.!'?'LO&<QJSWAF0W&EY$@+82'BM(J8D8VJJEW3O<[NO9=-55
M]J_CY>E5X_ZW/^/D(I6BY\4"\'_IF_\Y$@'_:Q4G3/)4QD*7G!H0A+,DRQR<
M9.ITN=^#UFZ17?JB$7LL43: UI/T ^;+\0)W@7<!3!<PRC(!-\(17_2^--$@
M[PQ:MSD'$%9XFJIT:GI(2C>L_7T\(QPHB :@]'JV6%Z/#$##5L4,J*:UI.A?
M,PLD2"3>"JD!5X\"JKSAWZ&B&X#^/MX.]F=_ ]AY-KWAL>R&=WX\_W<_N0#4
MP1=G*W8NRODI;RAOQC_&"4W:+VA.C" Q&@6-A.62-B^U(ZZPU@?+%'4*OU'E
ME;3ZSKIA_&6_9[0)DY=\;M[^U\5X>?E^NEC.+U;I0ZN&!=]._?33FCM_P8]8
M+MY/UT[C*$%068(F/A>I ?7$0BKJQ;K$K=8N5WD*/M8&NYVBE_V(TS1H&CA,
M5_[HIW,H,9'I]Z_P?;7-D>*1,VDY07_3ES0.M,20^T1Y&3@'KL!6F</Y*$7=
MX/JRWWKZ%<M+'AIU=RS7[,K(JSY"ZIEUCS90:I?]UQ\O%:GD8"#A>47K0(8R
M(ST&2:A)#H*'D%(595!OO-23XP2523+[,H=!9?0D2E7/:N2V%Q"B5LP)6R4<
M\!11S8Z/V@4;'6<O[BZ%P5N&_.=L?A4C6ZS*)3SWT66?"<C2.(.B(1 H521:
MX1./J)9H%PQU[!MR?_DF9RKN(=99;SP>&"&E!.%3OK.'JY9K05FC(!*7K%XG
M$+E@# 'N0+!LD$N]E?P_2L5P%9:'BG76-X^'?MS[5_"3Y6E$QJ'7<3''#]T4
MF&A*:4R>D41Y:5M0VND(- (-LB3: #(R\YP1].0*PX&@)\G-^F;CT%CXR^P'
MS*?%\F<;Z@L[0)83$9,@4HHR2#M+HCW0[%(A/G8"P8./'J[?5 7I'\:XH<7^
M>C)&RC>$9R8I=YX3F4KS@>@#>GQX7R:JP7 C.+//^CX//G68A/!*PMZ;70T$
M8%;AI"M&7&V!9PG("L*TDD2:H,L$%$V$I-E#EDJY*D_C6V@9)L^[?YSTQ>ZA
M-</69A'91!]I5D0D$7 #/*,Q[07^D09PD7(CNZ69[=U[H_>H6R5-<3#[&M 8
MSPZL#TYZ@9(ED0,C4DM&@@Z,J&RY])D%;JH$:YXC;-BBMMY]TBKR: !?^V0
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MG5?*UU?EB(L19 W6^D2<=9'(S!6QX#3A3@MA.7Z3=E.<'1=LVL[9!RW5N-V
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M^6RQ&'F;F0&E2-24X\&$4B) #7H4F2/GK!*Z2@^<I\EJU*W;$P1=,;:[1!K
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M^!7F/\;QYE@XF:W37J*_P_+F413-PS(3T:"SK7CJV">EVWI-5_OO@YA:O&Y
M!6UV==WNXFH;K,Q8!:,( Q_*1&I!K(JEGR83U 3G=:I2BO$(/4V7^?=PD1W$
M_T:TT*T67Z_QY\;13[XN+]+EU990GW+JG28@ROP8" K9A'\T+$?P-'!W/YCP
MM!9Z9KVFZ_8/U4)]\KH!+70[@/LI3,;?5]RZ/@P\>^.4*U4F#(] TIQX(151
M3"AI#(]"5GD'?)JL3@#3+PA@%:31 +;672T>'IO-;B*S/G(K",M*H;EG#/$N
M:F(9]TPE[HRH4MKZ-%F=L&5>(+9ZE$8#V'I\(RM33R5)HBRQV5*5$$1T! )7
M4FNNO:X2S3P,4?8%(JH?&;29K_=J-I_/_BAC._8)0][ZUSW$$Q^CI:<AUF\@
M+&_:8-\@@[- E4 -D*4H=<B9.,8D829)H,P#%55B(=O).?S1[?:GWO3 C1X<
M3RD0YGG!O_$D,,_0>A-:1IE%#)6ZMV^E9]BGM1Z0\/ Y[7"^M]E[^.94[C\<
MXL%G]*HM*HQ_> 8I(@E@FGN2O8YE4IPKSH\ENA1N<1&H9E7<A3HZXR:_X3>_
MW$QY^I0_S*;?O\'\K*QYKZ&V# #)X,G0 'CM93PRCC)%F#-16A.CJC.C<E="
MF]0RNV#G\53="I)J7?WT44'PQ*?UJI*JU@@\ S!JE(&<#.'14#1*O4+OF1MB
M8E"*IVR<?4'*J7SJ^U7Y]$V>5734\>!<:>B/1RCJ3'Q$8U[KTCHF*&M$E:*E
M+;0TJ6)V0< V0^80?C?@,]_=PBIKV&3G<O"4*)/0# ,724C,$LZT4B%!#K72
MS.Z3,CQ@#I+NDVC9F=7-@>76-&!OO&5*":*D*&G#6I+@J"'"9%_RX@+8*H-O
M'R.H)>#L+N@G<;,GUX=^E2HV%Z?,7/4>$BZ@3!/!+]!]5)H1!S(2)UC6D&G6
ML=OKT]W/;4GN^PIJU@_7&E 7Q=9>7MG:5S4IC$K-(+@2*4 -&J0EWB=*M,G6
M20'<J2J%_]N(&3:=M._[Y6!V-PB9JVGS$'EVPA&AH*1Q!$HLI8$$#5J&P%R&
M.OV]MI(SK)8Y7,S/X&8/GC>!'#]=;)+'KAHC6DD5TY9DN4K&5K@#$0.A91JN
M8(Y+4<4J>4A*6XC91\ /,',0MQO "Q)?U.[[Z;^-I^GS^W_[.%M>[42KR,II
M(L[X4LFA+'%1H%]HM5 ^,3Q34 ,WCY,T[$55 3\]<;\!''T83^%3?HT+CY?O
M?"R/GI<KE1QRYD8&16+VI0TB3<110,M/>\$UY];Z*O,('B-HV$XQO1L[?;"]
M4?A\* '/^>:4&2<I,$L)U\(0:4L&*T?K'UC42FK+0IW4A><(&_A*ZT7\'3"U
MMRR&=KC?3Z>S'WYYL?@PSO UCF$:85%V,YY^?W<Q31MMBPRRKNQ&@P B 9U+
MRV0FQJ$EF9Q4$.^Y8X\XXMW6:P\U^PMX5I?;0P-HDW>XSH6^_.SGRRE^\/OW
M'SYO-I.D0Y+1TY!>!")5A%+!S8BUHF1$BRA]-^@\M]+ UD\UT/3*X0;NLKMW
M_(?KHE@3!"KE[(F!3/&>+YX!9(W6HK+ I&(9JN73;*%GV,[<=5\5]F-Z ]CY
M/)]%@+1XAPQ[OUA<E)F==U_K1YHQ+DH"/<32_!G0\W Q<4)EHD):=!1X%8/Z
M>=):"COOB8"'M>A]BJ,!@'V!\[7/>2\)9.1B4,&"(=8$3B0M X&80-O1VYRR
M%5:;*MKI,8):"DKW Z9>6-\ A.[RYJI@]8M?PM=EZ4#[&>:QR.H[C&@.026C
MRVRITO6T=,!/PA.?4^+99PGY"%?>4R2V% [H!V:5Q#.T'7YW6^NMW-[<9S].
MZSC:R!C _W%.C"K-Q*6UQ'.:201-O5,9?T^=+/+N:[9D3!T&HYK,;EIYO<T9
M8LF_NW5 %-@$Z*NBJU$L4BD#<8X"R6"C96@:V%PE!+X3E<,.0CFN"CM42,TA
ML!@!(TJYM%IH BF5@=8630&&_G,9<^<%"Q#M$:[)0LHPY:/'P]+.[&X.,.\
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M=@0G,$,(V8=@3;"LR6.D9\[4"=B&1\)3F-M3+)TB3%S%&T*71)P ;J0"A3)
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M/Y1E"P$%BW7BW4K3H@K>^." ^?HP. L+(1@)I8Y/X"H1TYHLLWGY:..O1AH
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M 5%S'87>$A-WOZ&+2Y)6D-B#F?T@XA-^LT2$6A-13#(\4H2O)4IRK"F#XRB
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MM30;T]+'7AI.N4T6'D%'+>J"6E((7M,=:[4,.IK<9M'6J>RE0<:$SD1B4*:
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M;30'SZ+))" 7E#D0?N^?;=S,M$/T[B6\]NYV_8OZCUJ6_M__Z_\#4$L#!!0
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M+].VVT_)#YTVARI1NOVJ[O[M4TLEYD.93-H_'VG)DY_+!IZO&*%E[)N-_*^
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M],-%S^MB0UFN,Z"4<1HPBI1FS@"7B$"V#=). K.@A6=(6>P"299G#U!;9!#
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MX>#,A5M1WG46]?+"RSNK;JZY '=_+M.\SW$O+ONK^=?!W8OI)W\!4$L#!!0
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MH+8&E0[#UC2B>'2P-%7R6B!Z!Q.780BZ9RX XTP0E1>H:+)867-W\@6#I4-
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M,#(Q,#,S,5]D968N>&UL4$L! A0#%     @ 4XFK4LTM]<)QP   W4$( !4
M             ( !,/@! &5X9'@M,C R,3 S,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( %.)JU+B/,PQ;'   )0O!0 5              "  =2X @!E>&1X+3(P
M,C$P,S,Q7W!R92YX;6Q02P$"% ,4    " !3B:M21G_%.) (   @+P  $
M            @ %S*0, >&=N,S$Q+3,S,3(Q+FAT;5!+ 0(4 Q0    ( %.)
MJU(#@6EB>P@  /,N   0              "  3$R P!X9VXS,3(M,S,Q,C$N
M:'1M4$L! A0#%     @ 4XFK4DDG+<!%!@  024  !               ( !
JVCH# 'AG;C,R,2TS,S$R,2YH=&U02P4&      D "0!$ @  34$#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
